UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 10-Q

 

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended December 31, 20222023

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 001-38496

 

Canopy Growth Corporation

(Exact name of registrant as specified in its charter)

 

Canada

N/A

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer
Identification No.)

1 Hershey Drive

Smiths Falls, Ontario

K7A 0A8

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (855) 558-9333

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Common shares, no par value

 

CGC

 

NASDAQ Global Select Market

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

Accelerated filer

 

 

 

 

Non-accelerated filer

Smaller reporting company

 

 

 

 

 

 

 

Emerging growth company

 

 

 

 

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

As of February 7, 2023,2024, there were 494,894,04791,114,604 common shares of the registrant issued and outstanding.

 

 


 

Table of Contents

 

Page

PART I.

FINANCIAL INFORMATION

Item 1.

Financial Statements

1

Condensed Interim Consolidated Balance Sheets

1

Condensed Interim Consolidated Statements of Operations and Comprehensive (Loss) IncomeLoss

2

Condensed Interim Consolidated Statements of Shareholders’ Equity

3

Condensed Interim Consolidated Statements of Cash Flows

57

Notes to the Condensed Interim Consolidated Financial Statements

79

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

3938

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

7473

Item 4.

Controls and Procedures

7675

PART II.

OTHER INFORMATION

Item 1.

Legal Proceedings

77

Item 1A.

Risk Factors

7778

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

8179

Item 3.

Defaults Upon Senior Securities

8179

Item 4.

Mine Safety Disclosures

8179

Item 5.

Other Information

8179

Item 6.

Exhibits

8280

Signatures

8481

 

Unless otherwise noted or the context indicates otherwise, references in this Quarterly Report on Form 10-Q (“Quarterly Report”) to the “Company”,“Company,” “Canopy Growth”, “we”,Growth,” “we,” “us” and “our” refer to Canopy Growth Corporation and its direct and indirect wholly-owned subsidiaries and, if applicable, its joint ventures and investments accounted for by the equity method;subsidiaries; the term “cannabis” means the plant of any species or subspecies of genus Cannabis and any part of that plant, including all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers; and the term “U.S. hemp” has the meaning given to the term “hemp” in the U.S. Agricultural Improvement Act of 2018 (the “2018 Farm Bill”), including hemp-derived cannabidiol (“CBD”).

 

This Quarterly Report contains references to our trademarks and trade names and to trademarks and trade names belonging to other entities. Solely for convenience, trademarks and trade names referred to in this Quarterly Report may appear without the ® or ™ symbols, but such references are not intended to indicate, in any way, that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend our use or display of other companies’ trademarks or trade names to imply a relationship with, or endorsement or sponsorship of us or our business by, any other companies.

 

All currency amounts in this Quarterly Report are stated in Canadian dollars, which is our reporting currency, unless otherwise noted. All references to “dollars” or “CDN$” are to Canadian dollars and all references to “US$” are to U.S. dollars.

 

i


 

PART I—FINANCIAL INFORMATION

Item 1. Financial Statements.

CANOPY GROWTH CORPORATION

CONDENSED INTERIM CONSOLIDATED BALANCE SHEETS

(in thousands of Canadian dollars, except number of shares and per share data, unaudited)

 

December 31,
2022

 

 

March 31,
2022

 

 

December 31,
2023

 

 

March 31,
2023

 

ASSETS

ASSETS

 

ASSETS

 

Current assets:

 

 

 

 

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

598,131

 

 

$

776,005

 

 

$

142,745

 

 

$

667,693

 

Short-term investments

 

 

191,119

 

 

 

595,651

 

 

 

43,436

 

 

 

105,526

 

Restricted short-term investments

 

 

12,932

 

 

 

12,216

 

 

 

7,275

 

 

 

11,765

 

Amounts receivable, net

 

 

104,640

 

 

 

96,443

 

 

 

63,924

 

 

 

68,459

 

Inventory

 

 

213,937

 

 

 

204,387

 

 

 

86,917

 

 

 

83,230

 

Assets of discontinued operations

 

 

29,401

 

 

 

116,291

 

Prepaid expenses and other assets

 

 

52,151

 

 

 

52,700

 

 

 

23,582

 

 

 

24,290

 

Total current assets

 

 

1,172,910

 

 

 

1,737,402

 

 

 

397,280

 

 

 

1,077,254

 

Other financial assets

 

 

598,387

 

 

 

800,328

 

 

 

392,324

 

 

 

568,292

 

Property, plant and equipment

 

 

874,029

 

 

 

942,780

 

 

 

340,479

 

 

 

471,271

 

Intangible assets

 

 

213,530

 

 

 

252,695

 

 

 

119,072

 

 

 

160,750

 

Goodwill

 

 

142,076

 

 

 

1,866,503

 

 

 

85,237

 

 

 

85,563

 

Noncurrent assets of discontinued operations

 

 

-

 

 

 

56,569

 

Other assets

 

 

19,223

 

 

 

15,342

 

 

 

25,359

 

 

 

19,996

 

Total assets

 

$

3,020,155

 

 

$

5,615,050

 

 

$

1,359,751

 

 

$

2,439,695

 

 

 

 

 

 

 

 

 

 

 

 

 

LIABILITIES AND SHAREHOLDERS' EQUITY

LIABILITIES AND SHAREHOLDERS' EQUITY

 

LIABILITIES AND SHAREHOLDERS' EQUITY

 

Current liabilities:

 

 

 

 

 

 

 

 

 

 

 

 

Accounts payable

 

$

63,139

 

 

$

64,270

 

 

$

25,837

 

 

$

31,835

 

Other accrued expenses and liabilities

 

 

75,985

 

 

 

75,278

 

 

 

49,775

 

 

 

53,743

 

Current portion of long-term debt

 

 

455,483

 

 

 

9,296

 

Current portion of long-term debt and convertible debentures

 

 

91,336

 

 

 

556,890

 

Liabilities of discontinued operations

 

 

-

 

 

 

67,624

 

Other liabilities

 

 

84,134

 

 

 

64,054

 

 

 

54,397

 

 

 

93,750

 

Total current liabilities

 

 

678,741

 

 

 

212,898

 

 

 

221,345

 

 

 

803,842

 

Long-term debt

 

 

750,118

 

 

 

1,491,695

 

 

 

520,738

 

 

 

749,991

 

Deferred income tax liabilities

 

 

8,988

 

 

 

15,991

 

Liability arising from Acreage Arrangement

 

 

-

 

 

 

47,000

 

Warrant derivative liability

 

 

668

 

 

 

26,920

 

Noncurrent liabilities of discontinued operations

 

 

-

 

 

 

3,417

 

Other liabilities

 

 

141,891

 

 

 

190,049

 

 

 

73,005

 

 

 

122,423

 

Total liabilities

 

 

1,580,406

 

 

 

1,984,553

 

 

 

815,088

 

 

 

1,679,673

 

Commitments and contingencies

 

 

 

 

 

 

 

 

 

 

 

 

Redeemable noncontrolling interest

 

 

11,408

 

 

 

36,200

 

Canopy Growth Corporation shareholders' equity:

 

 

 

 

 

 

 

 

 

 

 

 

Common shares - $nil par value; Authorized - unlimited number of shares;
Issued -
494,891,390 shares and 394,422,604 shares, respectively

 

 

7,867,310

 

 

 

7,482,809

 

Common shares - $nil par value; Authorized - unlimited number of shares;
Issued and outstanding -
82,931,963 shares and 51,730,555 shares, respectively1

 

 

8,219,747

 

 

 

7,938,571

 

Additional paid-in capital

 

 

2,510,086

 

 

 

2,519,766

 

 

 

2,578,519

 

 

 

2,506,485

 

Accumulated other comprehensive loss

 

 

(14,248

)

 

 

(42,282

)

 

 

(16,049

)

 

 

(13,860

)

Deficit

 

 

(8,937,603

)

 

 

(6,370,337

)

 

 

(10,237,693

)

 

 

(9,672,761

)

Total Canopy Growth Corporation shareholders' equity

 

 

1,425,545

 

 

 

3,589,956

 

 

 

544,524

 

 

 

758,435

 

Noncontrolling interests

 

 

2,796

 

 

 

4,341

 

 

 

139

 

 

 

1,587

 

Total shareholders' equity

 

 

1,428,341

 

 

 

3,594,297

 

 

 

544,663

 

 

 

760,022

 

Total liabilities and shareholders' equity

 

$

3,020,155

 

 

$

5,615,050

 

 

$

1,359,751

 

 

$

2,439,695

 

1 Prior year share amounts have been retrospectively adjusted to reflect the Share Consolidation (as defined below), which became effective on December 15, 2023. See Note 2 for details.

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

1


 

CANOPY GROWTH CORPORATION

CONDENSED INTERIM CONSOLIDATED STATEMENTS OF

OPERATIONS AND COMPREHENSIVE (LOSS) INCOMELOSS

(in thousands of Canadian dollars, except number of shares and per share data, unaudited)

 

 

Three months ended December 31,

 

 

Nine months ended December 31,

 

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

 

 

 

 

 

(As Restated)

 

 

 

 

 

(As Restated)

 

Revenue

 

$

90,061

 

 

$

96,986

 

 

$

260,781

 

 

$

302,397

 

Excise taxes

 

 

11,556

 

 

 

12,136

 

 

 

36,423

 

 

 

37,379

 

Net revenue

 

 

78,505

 

 

 

84,850

 

 

 

224,358

 

 

 

265,018

 

Cost of goods sold

 

 

50,279

 

 

 

79,622

 

 

 

158,944

 

 

 

264,226

 

Gross margin

 

 

28,226

 

 

 

5,228

 

 

 

65,414

 

 

 

792

 

Operating expenses

 

 

 

 

 

 

 

 

 

 

 

 

Selling, general and administrative expenses

 

 

54,436

 

 

 

89,604

 

 

 

174,810

 

 

 

271,425

 

Share-based compensation

 

 

3,693

 

 

 

6,055

 

 

 

10,127

 

 

 

20,893

 

Loss on asset impairment and restructuring

 

 

30,413

 

 

 

22,259

 

 

 

2,452

 

 

 

1,794,212

 

Total operating expenses

 

 

88,542

 

 

 

117,918

 

 

 

187,389

 

 

 

2,086,530

 

Operating loss from continuing operations

 

 

(60,316

)

 

 

(112,690

)

 

 

(121,975

)

 

 

(2,085,738

)

Other income (expense), net

 

 

(171,037

)

 

 

(115,490

)

 

 

(253,270

)

 

 

(396,074

)

Loss from continuing operations before income taxes

 

 

(231,353

)

 

 

(228,180

)

 

 

(375,245

)

 

 

(2,481,812

)

Income tax recovery (expense)

 

 

1,077

 

 

 

1,336

 

 

 

(13,762

)

 

 

(10,633

)

Net loss from continuing operations

 

 

(230,276

)

 

 

(226,844

)

 

 

(389,007

)

 

 

(2,492,445

)

Discontinued operations, net of income tax

 

 

13,479

 

 

 

(37,532

)

 

 

(194,451

)

 

 

(169,492

)

Net loss

 

 

(216,797

)

 

 

(264,376

)

 

 

(583,458

)

 

 

(2,661,937

)

Net loss from continuing operations attributable to
   noncontrolling interests and redeemable noncontrolling
   interest

 

 

-

 

 

 

(542

)

 

 

-

 

 

 

(1,336

)

Discontinued operations attributable to noncontrolling
   interests and redeemable noncontrolling interest

 

 

-

 

 

 

(4,369

)

 

 

(18,526

)

 

 

(22,523

)

Net loss attributable to Canopy Growth Corporation

 

$

(216,797

)

 

$

(259,465

)

 

$

(564,932

)

 

$

(2,638,078

)

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic and diluted loss per share1

 

 

 

 

 

 

 

 

 

 

 

 

Continuing operations

 

$

(2.78

)

 

$

(4.66

)

 

$

(5.56

)

 

$

(54.96

)

Discontinued operations

 

 

0.16

 

 

 

(0.68

)

 

 

(2.52

)

 

 

(3.24

)

Basic and diluted loss per share

 

$

(2.62

)

 

$

(5.34

)

 

$

(8.08

)

 

$

(58.20

)

Basic and diluted weighted average common shares
   outstanding
1

 

 

82,919,190

 

 

 

48,611,260

 

 

 

69,918,744

 

 

 

45,323,788

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Comprehensive income (loss):

 

 

 

 

 

 

 

 

 

 

 

 

Net loss from continuing operations

 

$

(230,276

)

 

$

(226,844

)

 

$

(389,007

)

 

$

(2,492,445

)

Other comprehensive income (loss), net of income tax

 

 

 

 

 

 

 

 

 

 

 

 

Fair value changes of own credit risk of financial liabilities

 

 

(1,354

)

 

 

4,538

 

 

 

(13,824

)

 

 

32,847

 

Foreign currency translation

 

 

10,104

 

 

 

14,921

 

 

 

575

 

 

 

24,694

 

Total other comprehensive income (loss), net of income tax

 

 

8,750

 

 

 

19,459

 

 

 

(13,249

)

 

 

57,541

 

Comprehensive loss from continuing operations

 

 

(221,526

)

 

 

(207,385

)

 

 

(402,256

)

 

 

(2,434,904

)

Comprehensive income (loss) from discontinued operations

 

 

13,479

 

 

 

(37,532

)

 

 

(194,451

)

 

 

(169,492

)

Comprehensive loss

 

 

(208,047

)

 

 

(244,917

)

 

 

(596,707

)

 

 

(2,604,396

)

Comprehensive loss from continuing operations
   attributable to noncontrolling interests and
   redeemable noncontrolling interest

 

 

-

 

 

 

(542

)

 

 

-

 

 

 

(1,336

)

Comprehensive loss from discontinued operations
   attributable to noncontrolling interests and redeemable
   noncontrolling interest

 

 

-

 

 

 

(4,369

)

 

 

(18,526

)

 

 

(22,523

)

Comprehensive loss attributable to Canopy Growth
   Corporation

 

$

(208,047

)

 

$

(240,006

)

 

$

(578,181

)

 

$

(2,580,537

)

1

 

 

Three months ended December 31,

 

 

Nine months ended December 31,

 

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

 

Revenue

 

$

113,349

 

 

$

155,024

 

 

$

366,570

 

 

$

456,095

 

 

Excise taxes

 

 

12,136

 

 

 

14,052

 

 

 

37,379

 

 

 

47,540

 

 

Net revenue

 

 

101,213

 

 

 

140,972

 

 

 

329,191

 

 

 

408,555

 

 

Cost of goods sold

 

 

103,654

 

 

 

130,882

 

 

 

329,203

 

 

 

442,367

 

 

Gross margin

 

 

(2,441

)

 

 

10,090

 

 

 

(12

)

 

 

(33,812

)

 

Operating expenses

 

��

 

 

 

 

 

 

 

 

 

 

 

Selling, general and administrative expenses

 

 

122,636

 

 

 

116,835

 

 

 

351,891

 

 

 

355,165

 

 

Share-based compensation

 

 

6,428

 

 

 

6,777

 

 

 

21,725

 

 

 

35,856

 

 

Asset impairment and restructuring costs

 

 

22,259

 

 

 

36,439

 

 

 

1,794,212

 

 

 

128,198

 

 

Total operating expenses

 

 

151,323

 

 

 

160,051

 

 

 

2,167,828

 

 

 

519,219

 

 

Operating loss

 

 

(153,764

)

 

 

(149,961

)

 

 

(2,167,840

)

 

 

(553,031

)

 

Loss from equity method investments

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(100

)

 

Other income (expense), net

 

 

(113,340

)

 

 

34,282

 

 

 

(406,762

)

 

 

810,769

 

 

(Loss) income before income taxes

 

 

(267,104

)

 

 

(115,679

)

 

 

(2,574,602

)

 

 

257,638

 

 

Income tax recovery (expense)

 

 

382

 

 

 

183

 

 

 

(11,587

)

 

 

490

 

 

Net (loss) income

 

 

(266,722

)

 

 

(115,496

)

 

 

(2,586,189

)

 

 

258,128

 

 

Net loss attributable to noncontrolling interests and
   redeemable noncontrolling interest

 

 

(5,139

)

 

 

(6,571

)

 

 

(19,652

)

 

 

(14,307

)

 

Net (loss) income attributable to Canopy Growth
   Corporation

 

$

(261,583

)

 

$

(108,925

)

 

$

(2,566,537

)

 

$

272,435

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic (loss) earnings per share

 

$

(0.54

)

 

$

(0.28

)

 

$

(5.66

)

 

$

0.70

 

 

Basic weighted average common shares outstanding

 

 

486,112,598

 

 

 

393,818,282

 

 

 

453,237,882

 

 

 

390,423,083

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Diluted (loss) earnings per share

 

$

(0.54

)

 

$

(0.28

)

 

$

(5.66

)

 

$

0.43

 

 

Diluted weighted average common shares outstanding

 

 

486,112,598

 

 

 

393,818,282

 

 

 

453,237,882

 

 

 

410,986,802

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Comprehensive (loss) income:

 

 

 

 

 

 

 

 

 

 

 

 

 

Net (loss) income

 

$

(266,722

)

 

$

(115,496

)

 

$

(2,586,189

)

 

$

258,128

 

 

Other comprehensive income (loss), net of income tax
   effect

 

 

 

 

 

 

 

 

 

 

 

 

 

Fair value changes of own credit risk of financial liabilities

 

 

4,538

 

 

 

16,200

 

 

 

32,847

 

 

 

26,280

 

 

Foreign currency translation

 

 

14,921

 

 

 

(15,479

)

 

 

24,694

 

 

 

(18,767

)

 

Total other comprehensive income, net of income tax effect

 

 

19,459

 

 

 

721

 

 

 

57,541

 

 

 

7,513

 

 

Comprehensive (loss) income

 

 

(247,263

)

 

 

(114,775

)

 

 

(2,528,648

)

 

 

265,641

 

 

Comprehensive loss attributable to noncontrolling interests
   and redeemable noncontrolling interest

 

 

(5,139

)

 

 

(6,571

)

 

 

(19,652

)

 

 

(14,307

)

 

Comprehensive (loss) income attributable to Canopy Growth
   Corporation

 

$

(242,124

)

 

$

(108,204

)

 

$

(2,508,996

)

 

$

279,948

 

 

Prior year share and per share amounts have been retrospectively adjusted to reflect the Share Consolidation, which became effective on December 15, 2023. See Note 2 for details.

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

2


 

CANOPY GROWTH CORPORATION

CONDENSED INTERIM CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY

(in thousands of Canadian dollars, unaudited)

 

 

 

 

 

 

Additional paid-in capital

 

 

Accumulated

 

 

 

 

 

 

 

 

 

 

 

 

Common shares

 

 

Share-based reserve

 

 

Warrants

 

 

Ownership changes

 

 

Redeemable noncontrolling interest

 

 

other comprehensive income (loss)

 

 

Deficit

 

 

Noncontrolling interests

 

 

Total

 

Balance at March 31, 2022

 

$

7,482,809

 

 

$

492,041

 

 

$

2,581,788

 

 

$

(509,723

)

 

$

(44,340

)

 

$

(42,282

)

 

$

(6,370,337

)

 

$

4,341

 

 

$

3,594,297

 

Cumulative effect from adoption
   of ASU 2020-06

 

 

-

 

 

 

4,452

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(729

)

 

 

-

 

 

 

3,723

 

Other issuances of common
   shares and warrants

 

 

82,231

 

 

 

(1,732

)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

80,499

 

Exercise of Omnibus Plan stock
   options

 

 

1,506

 

 

 

(1,236

)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

270

 

Share-based compensation

 

 

-

 

 

 

20,892

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

20,892

 

Issuance and vesting of
   restricted share units and
   performance share units

 

 

8,993

 

 

 

(8,993

)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Changes in redeemable
   noncontrolling interest

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

6,983

 

 

 

-

 

 

 

-

 

 

 

17,808

 

 

 

24,791

 

Ownership changes relating to
   noncontrolling interests, net

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

1,851

 

 

 

1,851

 

Redemption of redeemable
   noncontrolling interest

 

 

26,506

 

 

 

-

 

 

 

-

 

 

 

(2,696

)

 

 

(27,350

)

 

 

-

 

 

 

-

 

 

 

(1,552

)

 

 

(5,092

)

Settlement of unsecured
   senior notes

 

 

265,265

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(29,507

)

 

 

-

 

 

 

-

 

 

 

235,758

 

Comprehensive income (loss)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

57,541

 

 

 

(2,566,537

)

 

 

(19,652

)

 

 

(2,528,648

)

Balance at December 31, 2022

 

$

7,867,310

 

 

$

505,424

 

 

$

2,581,788

 

 

$

(512,419

)

 

$

(64,707

)

 

$

(14,248

)

 

$

(8,937,603

)

 

$

2,796

 

 

$

1,428,341

 

 

 

Three months ended December 31, 2023

 

 

 

 

 

 

Additional paid-in capital

 

 

Accumulated

 

 

 

 

 

 

 

 

 

 

 

 

Common shares

 

 

Share-based reserve

 

 

Warrants

 

 

Ownership changes

 

 

Redeemable noncontrolling interest

 

 

other comprehensive income (loss)

 

 

Deficit

 

 

Noncontrolling interests

 

 

Total

 

Balance at September 30, 2023

 

$

8,219,846

 

 

$

507,358

 

 

$

2,590,765

 

 

$

(522,949

)

 

$

-

 

 

$

(24,799

)

 

$

(10,020,896

)

 

$

139

 

 

$

749,464

 

Other issuances of common
   shares and warrants

 

 

(447

)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(447

)

Share-based compensation

 

 

-

 

 

 

3,693

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

3,693

 

Issuance and vesting of
   restricted share units and
   performance share units

 

 

348

 

 

 

(348

)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Comprehensive loss

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

8,750

 

 

 

(216,797

)

 

 

-

 

 

 

(208,047

)

Balance at December 31, 2023

 

$

8,219,747

 

 

$

510,703

 

 

$

2,590,765

 

 

$

(522,949

)

 

$

-

 

 

$

(16,049

)

 

$

(10,237,693

)

 

$

139

 

 

$

544,663

 

 

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

 

3


 

CANOPY GROWTH CORPORATION

CONDENSED INTERIM CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY

(in thousands of Canadian dollars, unaudited)

 

 

 

 

 

 

Additional paid-in capital

 

 

Accumulated

 

 

 

 

 

 

 

 

 

 

 

 

Common shares

 

 

Share-based reserve

 

 

Warrants

 

 

Ownership changes

 

 

Redeemable noncontrolling interest

 

 

other comprehensive income (loss)

 

 

Deficit

 

 

Noncontrolling interests

 

 

Total

 

Balance at March 31, 2021

 

$

7,168,557

 

 

$

480,786

 

 

$

2,568,438

 

 

$

(512,340

)

 

$

(121,234

)

 

$

(34,240

)

 

$

(6,068,156

)

 

$

4,709

 

 

$

3,486,520

 

Other issuances of common
   shares and warrants

 

 

296,574

 

 

 

(30,126

)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

266,448

 

Replacement equity instruments
   from the acquisition of Supreme
   Cannabis

 

 

-

 

 

 

5,566

 

 

 

13,350

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

18,916

 

Exercise of Omnibus Plan stock
   options

 

 

8,690

 

 

 

(3,235

)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

5,455

 

Share-based compensation

 

 

-

 

 

 

35,172

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

35,172

 

Issuance and vesting of restricted
   share units

 

 

5,013

 

 

 

(5,013

)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Changes in redeemable
   noncontrolling interest

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

53,500

 

 

 

-

 

 

 

-

 

 

 

13,100

 

 

 

66,600

 

Ownership changes relating to
   noncontrolling interests

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

684

 

 

 

684

 

Redemption of redeemable
   noncontrolling interest

 

 

-

 

 

 

-

 

 

 

-

 

 

 

2,617

 

 

 

(5,109

)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(2,492

)

Comprehensive income (loss)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

7,513

 

 

 

272,435

 

 

 

(14,307

)

 

 

265,641

 

Balance at December 31, 2021

 

$

7,478,834

 

 

$

483,150

 

 

$

2,581,788

 

 

$

(509,723

)

 

$

(72,843

)

 

$

(26,727

)

 

$

(5,795,721

)

 

$

4,186

 

 

$

4,142,944

 

 

 

Nine months ended December 31, 2023

 

 

 

 

 

 

Additional paid-in capital

 

 

Accumulated

 

 

 

 

 

 

 

 

 

 

 

 

Common shares

 

 

Share-based reserve

 

 

Warrants

 

 

Ownership changes

 

 

Redeemable noncontrolling interest

 

 

other comprehensive income (loss)

 

 

Deficit

 

 

Noncontrolling interests

 

 

Total

 

Balance at March 31, 2023

 

$

7,938,571

 

 

$

498,150

 

 

$

2,581,788

 

 

$

(521,961

)

 

$

(51,492

)

 

$

(13,860

)

 

$

(9,672,761

)

 

$

1,587

 

 

$

760,022

 

Private Placement, net of
   issuance costs

 

 

12,836

 

 

 

9,820

 

 

 

8,977

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

31,633

 

Other issuances of common
   shares and warrants

 

 

252,576

 

 

 

(80

)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

11,060

 

 

 

-

 

 

 

-

 

 

 

263,556

 

Exercise of Previous Equity
   Incentive Plan stock options

 

 

165

 

 

 

(165

)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Share-based compensation

 

 

-

 

 

 

10,127

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

10,127

 

Issuance and vesting of
   restricted share units and
   performance share units

 

 

7,149

 

 

 

(7,149

)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Changes in redeemable
   noncontrolling interest

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(18,526

)

 

 

-

 

 

 

-

 

 

 

18,526

 

 

 

-

 

Ownership changes relating to
   noncontrolling interests, net

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

70,018

 

 

 

-

 

 

 

-

 

 

 

(1,436

)

 

 

68,582

 

Redemption of redeemable
   noncontrolling interest

 

 

8,450

 

 

 

-

 

 

 

-

 

 

 

(988

)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(12

)

 

 

7,450

 

Comprehensive loss

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(13,249

)

 

 

(564,932

)

 

 

(18,526

)

 

 

(596,707

)

Balance at December 31, 2023

 

$

8,219,747

 

 

$

510,703

 

 

$

2,590,765

 

 

$

(522,949

)

 

$

-

 

 

$

(16,049

)

 

$

(10,237,693

)

 

$

139

 

 

$

544,663

 

 

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

4


CANOPY GROWTH CORPORATION

CONDENSED INTERIM CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY

(in thousands of Canadian dollars, unaudited)

 

 

Three months ended December 31, 2022

 

 

 

 

 

 

Additional paid-in capital

 

 

Accumulated

 

 

 

 

 

 

 

 

 

 

 

 

Common shares

 

 

Share-based reserve

 

 

Warrants

 

 

Ownership changes

 

 

Redeemable noncontrolling interest

 

 

other comprehensive income (loss)

 

 

Deficit

 

 

Noncontrolling interests

 

 

Total

 

Balance at September 30, 2022
   (As Restated)

 

$

7,818,089

 

 

$

501,455

 

 

$

2,581,788

 

 

$

(505,000

)

 

$

(40,140

)

 

$

(33,707

)

 

$

(8,773,216

)

 

$

2,956

 

 

$

1,552,225

 

Other issuances of common
   shares and warrants

 

 

22,009

 

 

 

(1,379

)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

20,630

 

Share-based compensation

 

 

-

 

 

 

6,054

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

6,054

 

Issuance and vesting of
   restricted share units and
   performance share units

 

 

706

 

 

 

(706

)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Changes in redeemable
   noncontrolling interest

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

22,439

 

 

 

-

 

 

 

-

 

 

 

4,911

 

 

 

27,350

 

Ownership changes relating to
   noncontrolling interests, net

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

1,392

 

 

 

1,392

 

Redemption of redeemable
   noncontrolling interest

 

 

26,506

 

 

 

-

 

 

 

-

 

 

 

(2,696

)

 

 

(27,350

)

 

 

-

 

 

 

-

 

 

 

(1,552

)

 

 

(5,092

)

Comprehensive loss

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

19,459

 

 

 

(259,465

)

 

 

(4,911

)

 

 

(244,917

)

Balance at December 31, 2022
   (As Restated)

 

$

7,867,310

 

 

$

505,424

 

 

$

2,581,788

 

 

$

(507,696

)

 

$

(45,051

)

 

$

(14,248

)

 

$

(9,032,681

)

 

$

2,796

 

 

$

1,357,642

 

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

5


CANOPY GROWTH CORPORATION

CONDENSED INTERIM CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY

(in thousands of Canadian dollars, unaudited)

 

 

Nine months ended December 31, 2022

 

 

 

 

 

 

Additional paid-in capital

 

 

Accumulated

 

 

 

 

 

 

 

 

 

 

 

Common shares

 

 

Share-based reserve

 

 

Warrants

 

 

Ownership changes

 

 

Redeemable noncontrolling interest

 

 

other comprehensive income (loss)

 

 

Deficit

 

 

Noncontrolling interests

 

 

Total

 

Balance at March 31, 2022
   (As Restated)

 

$

7,482,809

 

 

$

492,041

 

 

$

2,581,788

 

 

$

(509,723

)

 

$

(42,860

)

 

$

(42,282

)

 

$

(6,378,199

)

 

$

4,341

 

 

$

3,587,915

 

Cumulative effect from adoption
   of ASU 2020-06

 

 

-

 

 

 

4,452

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(729

)

 

 

-

 

 

 

3,723

 

Other issuances of common
   shares and warrants

 

 

82,231

 

 

 

(1,732

)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

80,499

 

Exercise of Previous Equity
   Incentive Plan stock options

 

 

1,506

 

 

 

(1,236

)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

270

 

Share-based compensation

 

 

-

 

 

 

20,892

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

20,892

 

Issuance and vesting of restricted
   share units

 

 

8,993

 

 

 

(8,993

)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Changes in redeemable
   noncontrolling interest

 

 

-

 

 

 

-

 

 

 

-

 

 

 

4,723

 

 

 

25,159

 

 

 

-

 

 

 

-

 

 

 

22,015

 

 

 

51,897

 

Ownership changes relating to
   noncontrolling interests, net

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

1,851

 

 

 

1,851

 

Redemption of redeemable
   noncontrolling interest

 

 

26,506

 

 

 

-

 

 

 

-

 

 

 

(2,696

)

 

 

(27,350

)

 

 

-

 

 

 

(15,675

)

 

 

(1,552

)

 

 

(20,767

)

Settlement of unsecured
   senior notes

 

 

265,265

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(29,507

)

 

 

-

 

 

 

-

 

 

 

235,758

 

Comprehensive income (loss)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

57,541

 

 

 

(2,638,078

)

 

 

(23,859

)

 

 

(2,604,396

)

Balance at December 31, 2022
   (As Restated)

 

$

7,867,310

 

 

$

505,424

 

 

$

2,581,788

 

 

$

(507,696

)

 

$

(45,051

)

 

$

(14,248

)

 

$

(9,032,681

)

 

$

2,796

 

 

$

1,357,642

 

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

6


 

CANOPY GROWTH CORPORATION

CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands of Canadian dollars, unaudited)

 

Nine months ended December 31,

 

 

Nine months ended December 31,

 

 

2023

 

 

2022

 

 

2022

 

 

2021

 

 

 

 

 

(As Restated)

 

Cash flows from operating activities:

 

 

 

 

 

 

 

 

 

 

Net (loss) income

 

$

(2,586,189

)

 

$

258,128

 

Net loss

 

$

(583,458

)

 

$

(2,661,937

)

Loss from discontinued operations, net of income tax

 

 

(194,451

)

 

 

(169,492

)

Net loss from continuing operations

 

 

(389,007

)

 

 

(2,492,445

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

 

 

 

 

Depreciation of property, plant and equipment

 

 

43,185

 

 

 

56,467

 

 

 

22,485

 

 

 

42,674

 

Amortization of intangible assets

 

 

20,561

 

 

 

27,462

 

 

 

19,396

 

 

 

18,058

 

Share of loss on equity method investments

 

 

-

 

 

 

100

 

Share-based compensation

 

 

21,725

 

 

 

35,856

 

 

 

10,127

 

 

 

20,893

 

Asset impairment and restructuring costs

 

 

1,797,854

 

 

 

113,250

 

Income tax expense (recovery)

 

 

11,587

 

 

 

(490

)

(Gain) loss on asset impairment and restructuring

 

 

(816

)

 

 

1,797,854

 

Income tax expense

 

 

13,762

 

 

 

10,633

 

Non-cash fair value adjustments and charges related to
settlement of unsecured senior notes

 

 

325,742

 

 

 

(893,024

)

 

 

188,452

 

 

 

325,742

 

Change in operating assets and liabilities, net of effects from
purchases of businesses:

 

 

 

 

 

 

 

 

 

 

Amounts receivable

 

 

(8,197

)

 

 

4,083

 

 

 

(14,460

)

 

 

13,143

 

Inventory

 

 

(9,550

)

 

 

6,702

 

 

 

(8,047

)

 

 

(92

)

Prepaid expenses and other assets

 

 

(6,866

)

 

 

28,818

 

 

 

(843

)

 

 

(2,665

)

Accounts payable and accrued liabilities

 

 

(3,202

)

 

 

(30,764

)

 

 

891

 

 

 

(19,084

)

Other, including non-cash foreign currency

 

 

(24,459

)

 

 

(25,713

)

 

 

(47,901

)

 

 

(13,501

)

Net cash used in operating activities - continuing operations

 

 

(205,961

)

 

 

(298,790

)

Net cash used in operating activities - discontinued operations

 

 

(53,930

)

 

 

(119,019

)

Net cash used in operating activities

 

 

(417,809

)

 

 

(419,125

)

 

 

(259,891

)

 

 

(417,809

)

Cash flows from investing activities:

 

 

 

 

 

 

 

 

 

 

Purchases of and deposits on property, plant and equipment

 

 

(6,176

)

 

 

(36,620

)

 

 

(3,200

)

 

 

(6,176

)

Purchases of intangible assets

 

 

(1,265

)

 

 

(4,564

)

 

 

(716

)

 

 

(1,265

)

Proceeds on sale of property, plant and equipment

 

 

10,894

 

 

 

25,660

 

 

 

153,753

 

 

 

10,894

 

Redemption of short-term investments

 

 

415,322

 

 

 

340,218

 

 

 

68,294

 

 

 

415,322

 

Net cash proceeds on sale of subsidiaries

 

 

12,432

 

 

 

10,324

 

Net cash (outflow) proceeds on sale of subsidiaries

 

 

(3,719

)

 

 

12,432

 

Investment in other financial assets

 

 

(67,186

)

 

 

(374,414

)

 

 

(472

)

 

 

(67,186

)

Net cash outflow on acquisition of subsidiaries

 

 

(24,223

)

 

 

(14,947

)

Other investing activities

 

 

2,327

 

 

 

(16,759

)

 

 

(9,234

)

 

 

2,051

 

Net cash provided by (used in) investing activities

 

 

342,125

 

 

 

(71,102

)

Net cash provided by investing activities - operating activities

 

 

204,706

 

 

 

366,072

 

Net cash used in investing activities - discontinued operations

 

 

(2,600

)

 

 

(23,947

)

Net cash provided by investing activities

 

 

202,106

 

 

 

342,125

 

Cash flows from financing activities:

 

 

 

 

 

 

 

 

 

 

Proceeds from issuance of common shares and warrants

 

 

856

 

 

 

1,460

 

 

 

33,795

 

 

 

856

 

Proceeds from exercise of stock options

 

 

270

 

 

 

5,455

 

 

 

-

 

 

 

270

 

Repayment of long-term debt

 

 

(117,951

)

 

 

(50,217

)

 

 

(480,080

)

 

 

(117,951

)

Other financing activities

 

 

(29,096

)

 

 

(3,036

)

 

 

(27,239

)

 

 

(29,096

)

Net cash used in financing activities

 

 

(145,921

)

 

 

(46,338

)

 

 

(473,524

)

 

 

(145,921

)

Effect of exchange rate changes on cash and cash equivalents

 

 

43,731

 

 

 

(2,942

)

 

 

(2,953

)

 

 

43,731

 

Net decrease in cash and cash equivalents

 

 

(177,874

)

 

 

(539,507

)

 

 

(534,262

)

 

 

(177,874

)

Cash and cash equivalents, beginning of period

 

 

776,005

 

 

 

1,154,653

 

Cash and cash equivalents, end of period

 

$

598,131

 

 

$

615,146

 

Cash and cash equivalents, beginning of period1

 

 

677,007

 

 

 

776,005

 

Cash and cash equivalents, end of period2

 

$

142,745

 

 

$

598,131

 

1 Includes cash of our discontinued operations of $9,314 and $13,610 for March 31, 2023 and 2022, respectively.

2 Includes cash of our discontinued operations of $nil and $13,261 for December 31, 2023 and 2022, respectively.

 

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

57


 

CANOPY GROWTH CORPORATION

CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands of Canadian dollars, unaudited)

 

 

Nine months ended December 31,

 

 

Nine months ended December 31,

 

 

2022

 

 

2021

 

 

2023

 

 

2022

 

Supplemental disclosure of cash flow information

 

 

 

 

 

 

 

 

 

 

Cash received during the period:

 

 

 

 

 

 

 

 

 

 

Income taxes

 

$

4,709

 

 

$

993

 

 

$

4,002

 

 

$

4,709

 

Interest

 

$

20,140

 

 

$

10,844

 

 

$

14,230

 

 

$

20,140

 

Cash paid during the period:

 

 

 

 

 

 

 

 

 

 

Income taxes

 

$

1,099

 

 

$

2,641

 

 

$

1,551

 

 

$

1,099

 

Interest

 

$

95,267

 

 

$

83,968

 

 

$

80,108

 

 

$

95,267

 

Noncash investing and financing activities

 

 

 

 

 

 

 

 

 

 

Additions to property, plant and equipment

 

$

425

 

 

$

(5,145

)

 

$

199

 

 

$

425

 

 

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

68


 

CANOPY GROWTH CORPORATION

NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

(in thousands of Canadian dollars, unaudited, unless otherwise indicated)

1. DESCRIPTION OF BUSINESS

Canopy Growth Corporation is a publicly traded corporation, incorporated in Canada, with its head office located at 1 Hershey Drive, Smiths Falls, Ontario. References herein to “Canopy Growth” or “the Company” refer to Canopy Growth Corporation and its subsidiaries.

The principal activities of the Company are the production, distribution and sale of a diverse range of cannabis and cannabinoid-based products for both adult-use and medical purposes under a portfolio of distinct brands in Canada pursuant to the Cannabis Act, SC 2018, c 16 (the "Cannabis Act"), which came into effect on October 17, 2018 and regulates both the medical and adult-use cannabis markets in Canada. The Company has also expanded to jurisdictions outside of Canada where cannabis and/or hemp is federally lawful, permissible and regulated, and the Company, through its subsidiaries, operates in the United States, Australia, Germany, and certain other global markets. Additionally, the Company produces, distributes and sells a range of other consumer products globally, including vaporizers; beauty, skincare, wellnessvaporizers and sleep products; and sports nutrition beverages.similar cannabis accessories.

2. BASIS OF PRESENTATION

These condensed interim consolidated financial statements have been presented in Canadian dollars and are prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). Canopy Growth has determined that the Canadian dollar is the most relevant and appropriate reporting currency as, despite continuing shifts in the relative size of ourthe Company's operations across multiple geographies, the majority of ourits operations are conducted in Canadian dollars and ourits financial results are prepared and reviewed internally by management in Canadian dollars. OurThe Company's condensed interim consolidated financial statements, and the financial information contained herein, are reported in thousands of Canadian dollars, except share and per share amounts or as otherwise stated.

Certain information and footnote disclosures normally included in the audited annual consolidated financial statements prepared in accordance with U.S. GAAP have been omitted or condensed. These condensed interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 20222023 (the “Annual Report”) and have been prepared on a basis consistent with the accounting policies as described in the Annual Report.

These condensed interim consolidated financial statements are unaudited and reflect adjustments (consisting of normal recurring adjustments) that are, in the opinion of management, necessary to provide a fair statement of results for the interim periods in accordance with U.S. GAAP.

The results reported in these condensed interim consolidated financial statements should not be regarded as necessarily indicative of results that may be expected for an entire fiscal year. The policies set out below are consistently applied to all periods presented, unless otherwise noted.

Going Concern

The condensed interim consolidated financial statements have been prepared in accordance with generally accepted accounting principles on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.

As reflected in the condensed interim consolidated financial statements, the Company has certain material debt obligations coming due in the short-term, has suffered recurring losses from operations and requires additional financing to fund its business and operations. If the Company is unable to raise additional capital, it is possible that it will be unable to meet certain of its financial obligations.

These matters, when considered in the aggregate, raise substantial doubt about the Company’s ability to continue as a going concern for at least twelve months from the issuance of these condensed interim consolidated financial statements.

In view of these matters, continuation as a going concern is dependent upon continued operations of the Company, which in turn is dependent upon the Company’s ability to meet its financial requirements and to raise additional capital, and the success of its future operations. The condensed interim consolidated financial statements do not include any adjustments to the amount and classification of assets and liabilities that may be necessary should the Company not continue as a going concern.

Management plans to fund the operations and debt obligations of the Company through existing cash positions. The Company is also currently evaluating several different strategies and intends to pursue actions that are expected to increase its liquidity position, including, but not limited to, pursuing additional actions under the Company's cost-savings plan, seeking additional financing from both the public and private markets through the issuance of equity and/or debt securities, and monetizing additional assets.

9


The Company's management cannot provide assurances that the Company will be successful in accomplishing any of its proposed financing plans. Management also cannot provide any assurance as to unforeseen circumstances that could occur within the next twelve months or, if the Company raises capital, thereafter, which could increase the Company’s need to raise additional capital on an immediate basis, which capital may not be available to the Company.

Principles of consolidation

The accompanyingThese condensed interim consolidated financial statements include the accounts of the Company and all entities in which the Company either has a controlling voting interest or is the primary beneficiary of a variable interest entity. All intercompany accounts and transactions have been eliminated on consolidation. Information on the Company’s subsidiaries with noncontrolling interests is included in Note 21.22.

Use of estimates

The preparation of these condensed interim consolidated financial statements and accompanying notes in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported. Actual results could differ from those estimates.

Share Consolidation

On December 13, 2023, the Company announced that the Company’s board of directors (the “Board”) had approved the consolidation of the Company’s issued and outstanding common shares on the basis of one post-consolidation common share for every 10 pre-consolidation common shares (the “Share Consolidation”). The Share Consolidation was implemented to ensure that the Company continues to comply with the listing requirements of the Nasdaq Global Select Market.

The Share Consolidation was approved by the Company’s shareholders at the annual general and special meeting of shareholders held on September 25, 2023. The Share Consolidation became effective on December 15, 2023. No fractional common shares were issued in connection with the Share Consolidation. Any fractional common shares arising from the Share Consolidation were deemed to have been tendered by its registered owner to the Company for cancellation for no consideration. In addition, the exercise or conversion price and/or the number of common shares issuable under any of the Company’s outstanding convertible securities, were proportionately adjusted in connection with the Share Consolidation.

All issued and outstanding common shares, per share amounts, and outstanding equity instruments and awards exercisable into common shares, as well as the exchange ratios for the Fixed Shares (as defined below) and the Floating Shares (as defined below) in connection with the Acreage Amending Arrangement and the Floating Share Arrangement (as defined below), respectively, contained in the condensed interim consolidated financial statements of the Company and notes thereto have been retroactively adjusted to reflect the Share Consolidation for all prior periods presented.

New accounting policies

Recently Adopted Accounting Pronouncements

Convertible Instruments and Contracts in an Entity’s Own Equity

In August 2020, the FASBFinancial Accounting Standards Board (the "FASB") issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40):Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which simplifies the accounting for convertible instruments by removing the separation

7


models for convertible debt instruments and convertible preferred stock with (1) cash conversion features, and (2) beneficial conversion features. In addition, ASU 2020-06 enhances information transparency by making targeted improvements to the disclosures for convertible instruments and earnings-per-share guidance and amends the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions.

The Company adopted the guidance on April 1, 2022, using the modified retrospective approach with the cumulative effect recognized as an adjustment to the opening deficit balance, and, accordingly, prior period balances and disclosures have not been restated. Upon adoption of ASU 2020-06, the Supreme Debentures (as defined below) will be accounted for under the separation model for a substantial premium instead of a beneficial conversion feature resulting in an increased debt discount to be amortized over the life of the instrument. The adoption of this guidance resulted in increased additional paid-in capital by $4,452, decreased long-term debt by $3,723, and decreased accumulated deficit by $729 for non-cash accretion expense prior to April 1, 2022.

10


Accounting Guidance Not Yet Adopted

Segment Reporting

In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”), which expands reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The Company is evaluating the impact on the consolidated financial statements and expects to implement the provisions of ASU 2023-07 for our fiscal year ending March 31, 2025.

Income Taxes

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”), which enhances income tax disclosures, primarily through changes to the rate reconciliation and disaggregation of income taxes paid. ASU 2023-09 is effective for annual periods beginning after December 15, 2024, with early adoption permitted. The Company is evaluating the impact on the consolidated financial statements and expects to implement the provisions of ASU 2023-09 for our fiscal year ending March 31, 2026.

3. CANOPY USA

 

Reorganization - Creation of Canopy USA

 

On October 24, 2022, Canopy Growth completed a number of strategic transactions in connection with the creation of a new U.S.-domiciled holding company, Canopy USA, LLC ("Canopy USA"), a new U.S.-domiciled holding company (the "Reorganization"“Reorganization”). Following the implementation of the Reorganization, Canopy USA, as of October 24, 2022, holds certain U.S. cannabis investments previously held by Canopy Growth, which is expected to enable Canopy USA, following, among other things, the Meeting (as defined below) and the exercise of the Acreage Option (as defined below), including the issuance of the Fixed Shares (as defined below) to Canopy USA, to consummate the acquisitions of Acreage Holdings, Inc. ("Acreage"), Mountain High Products, LLC, Wana Wellness, LLC and The Cima Group, LLC (collectively, "Wana" and each, a "Wana Entity"), and Lemurian, Inc. ("Jetty").

There were no changes recorded in the estimated fair values of the U.S. cannabis investments described below upon implementation of the Reorganization, and their transfer from Canopy Growth to Canopy USA.

Following the implementation of the Reorganization, as of October 24, 2022, Canopy USA hasholds an ownership interest in the following assets, among others:

Wana - The optionoptions to acquire 100% of the membership interests of Wana (the "Wana Option"Options"), a leading cannabis edibles brand in North America.
Jetty - The optionoptions to acquire 100% of the shares of Jetty (the "Jetty Option"Options"), a California-based producer of high-quality cannabis extracts and pioneer of clean vape technology.

Canopy Growth currently retains the option to acquire the issued and outstanding Class E subordinate voting shares (the “Fixed Shares”) of Acreage (the "Acreage Option"“Acreage Option”), representing approximately 70% of the total shares of Acreage, at a fixed share exchange ratio of 0.30480.03048 of a common share of Canopy Growth per Fixed Share. Concurrently with the closing of the acquisition of the Fixed Shares pursuant to the exercise of the Acreage Option, the Fixed Shares will be issued to Canopy USA. In addition, Canopy USA has agreed to acquire all of the issued and outstanding Class D subordinate voting shares of Acreage (the “Floating Shares”) by way of a court-approved plan of arrangement (the “Floating Share Arrangement”) in exchange for 0.450.045 of a common share of Canopy Growth for each Floating Share held. Acreage is a leading vertically-integrated multi-state cannabis operator, with its main operations in densely populated states across the Northeast U.S. including New Jersey and New York.

In addition, as of October 24, 2022, Canopy USA holdsheld direct and indirect interests in the capital of TerrAscend Corp. ("TerrAscend"(“TerrAscend”), a leading North American cannabis operator with vertically integrated operations and a presence in Pennsylvania, New Jersey, Michigan and California as well as licensed cultivation and processing operations in Maryland. Canopy USA'sUSA’s direct and indirect interests in TerrAscend includes:included: (i) 38,890,570 exchangeable shares in the capital of TerrAscend (the "TerrAscend“TerrAscend Exchangeable Shares"Shares”), an option to purchase 1,072,450 TerrAscend common shares (the "TerrAscend“TerrAscend Common Shares"Shares”) for an aggregate purchase price of $1.00 (the "TerrAscend Option"“TerrAscend Option”) and 22,474,130 TerrAscend Common Share purchase warrants previously held by Canopy Growth (the "TerrAscend Warrants"“TerrAscend Warrants”); and (ii) the debentures and loan agreement between Canopy Growth and certain TerrAscend subsidiaries.

On December 9, 2022, Canopy USA and certain limited partnerships that are controlled by Canopy USA entered into a debt settlement agreement with TerrAscend, TerrAscend Canada Inc. and Arise BioScience, Inc., whereby $125,467 in aggregate loans, including accrued interest thereon, payable by certain subsidiaries of its subsidiaries whereby all of the debt obligations, including all principal and interest,TerrAscend were extinguished and22,474,130 TerrAscend Warrants, being all of the previously issued TerrAscend Warrants controlled by Canopy USA (the “Prior Warrants”) were cancelled in

11


exchange for the issuance offor: (i) 24,601,467 TerrAscend Exchangeable Shares at a notional price of $5.10 per TerrAscend Exchangeable Share; and (ii) 22,474,130 new TerrAscend Warrants (the "New Warrants" and, together with the TerrAscend Exchangeable Shares, the "New TerrAscend Securities") with a weighted average exercise price of $6.07 per TerrAscend Common Share and expiring on December 31, 2032. See Note 10 for further details.Following the issuance of the New TerrAscend Securities, Canopy USA beneficially owns: (i) 63,492,037 TerrAscend Exchangeable Shares; (ii) 22,474,130 New Warrants; and (iii) the TerrAscend Option. The TerrAscend Exchangeable Shares can be converted into TerrAscend Common Shares at Canopy USA's option, subject to the terms of the A&R Protection Agreement (as defined below).

Following the implementation of the Reorganization, Canopy USA was determined to be a variable interest entity ("VIE") pursuant to Accounting Standards Codification ("ASC")ASC 810 - Consolidations ("ASC 810") and prior to the completion of the Reorganization Amendments (as defined below), Canopy Growth was determined to be the primary beneficiary of Canopy USA. As a result of such determination and in accordance with ASC 810, Canopy Growth has consolidated the financial results of Canopy USA.

Amendments to Canopy USA Structure

8Following the creation of Canopy USA, the Nasdaq Stock Market LLC ("Nasdaq") communicated its position to the Company stating that companies that consolidate “the assets and revenues generated from activities in violation under federal law cannot continue to list on Nasdaq”. Since the Company is committed to compliance with the listing requirements of the Nasdaq, the Company and Canopy USA effectuated certain changes to the initial structure of the Company’s interest in Canopy USA that were intended to facilitate the deconsolidation of the financial results of Canopy USA within the Company’s financial statements. These changes included, among other things, modifying the terms of the Protection Agreement between the Company, its wholly-owned subsidiary and Canopy USA as well as the terms of Canopy USA’s limited liability company agreement and amending the terms of certain agreements with third-party investors in Canopy USA to eliminate any rights to guaranteed returns (collectively, the “Reorganization Amendments”).

On May 19, 2023, the Company and Canopy USA implemented the Reorganization Amendments, which included, entering into the First A&R Protection Agreement (as defined below) and amending and restating Canopy USA’s limited liability company agreement (the “A&R LLC Agreement”) in order to: (i) eliminate certain negative covenants that were previously granted by Canopy USA in favor of the Company as well as delegating to the managers of the Canopy USA Board (as defined below) not appointed by Canopy Growth the authority to approve the following key decisions (collectively, the “Key Decisions”): (a) the annual business plan of Canopy USA; (b) decisions regarding the executive officers of Canopy USA and any of its subsidiaries; (c) increasing the compensation, bonus levels or other benefits payable to any current, former or future employees or managers of Canopy USA or any of its subsidiaries; (d) any other executive compensation plan matters of Canopy USA or any of its subsidiaries; and (e) the exercise of the Wana Options or the Jetty Options, which for greater certainty means that the Company’s nominee on the Canopy USA Board will not be permitted to vote on any Key Decisions while the Company owns Non-Voting Shares (as defined below); (ii) reduce the number of managers on the Canopy USA Board from four to three, including, reducing the Company’s nomination right to a single manager; (iii) amend the share capital of Canopy USA to, among other things, (a) create a new class of Canopy USA Class B Shares (as defined below), which may not be issued prior to the conversion of the Non-Voting Shares or the Canopy USA Common Shares (as defined below) into Canopy USA Class B Shares; (b) amend the terms of the Non-Voting Shares such that the Non-Voting Shares will be convertible into Canopy USA Class B Shares (as opposed to Canopy USA Common Shares); and (c) amend the terms of the Canopy USA Common Shares such that upon conversion of all of the Non-Voting Shares into Canopy USA Class B Shares, the Canopy USA Common Shares will, subject to their terms, automatically convert into Canopy USA Class B Shares, provided that the number of Canopy USA Class B Shares to be issued to the former holders of the Canopy USA Common Shares will be equal to no less than 10% of the total issued and outstanding Canopy USA Class B Shares following such issuance. Accordingly, as a result of the Reorganization Amendments, in no circumstances will the Company, at the time of such conversions, own more than 90% of the Canopy USA Class B Shares.

In connection with the Reorganization Amendments, on May 19, 2023, Canopy USA and Huneeus 2017 Irrevocable Trust (the “Trust”) entered into a share purchase agreement (the “Trust SPA”), which sets out the terms of the Trust’s investment in Canopy USA in the aggregate amount of up to US$20 million (the "Trust Transaction"). Agustin Huneeus, Jr. is the trustee of the Trust and is an affiliate of a shareholder of Jetty. Pursuant to the terms of the Trust SPA, the Trust will, subject to certain terms and conditions contained in the Trust SPA be issued Canopy USA Common Shares in two tranches with an aggregate value of up to US$10 million along with warrants of Canopy USA to acquire additional Canopy USA Common Shares. In addition, subject to the terms of the Trust SPA, the Trust has also been granted options to acquire additional Voting Shares (as defined in the A&R LLC Agreement) with a value of up to an additional US$10 million and one such additional option includes the issuance of additional warrants of Canopy USA.

In addition, subject to the terms and conditions of the A&R Protection Agreement and the terms of the option agreements to acquire Wana and Jetty, as applicable, Canopy Growth may be required to issue additional common shares in satisfaction of certain deferred and/or option exercise payments to the shareholders of Wana and Jetty. Canopy Growth will receive additional Non-Voting Shares from Canopy USA as consideration for any Company common shares issued in the future to the shareholders of Wana and Jetty.

12


 

On November 3, 2023, the Company received a letter from the staff of the SEC (the “Staff”) in which the Staff indicated that, despite the Reorganization Amendments, it would object to the deconsolidation of the financial results of Canopy USA from the Company's financial statements in accordance with U.S. GAAP once Canopy USA acquires Wana, Jetty or the Fixed Shares of Acreage. The Company subsequently had discussions with the Office of Chief Accountant of the SEC (the "OCA") and determined to make certain additional amendments to the structure of Canopy USA (the “Additional Reorganization Amendments”) to facilitate the deconsolidation of Canopy USA from the financial results of Canopy Growth in accordance with U.S. GAAP upon Canopy USA’s acquisition of Wana, Jetty or Acreage. In that regard, the Company filed a revised preliminary proxy statement with the SEC on each of January 25, 2024 and February 5, 2024 in connection with the Amendment Proposal (as defined below) that discloses these Additional Reorganization Amendments. In connection with the Additional Reorganization Amendments, Canopy USA and its members expect to enter into a second amended and restated limited liability company agreement (the “Second A&R LLC Agreement”) immediately prior to the completion of the first tranche closing of the Trust Transaction. Upon the effective date of the Second A&R LLC Agreement, the terms of the Non-Voting Shares will be amended such that the Non-Voting Shares will only be convertible into Canopy USA Class B Shares following the date that the NASDAQ Stock Market or The New York Stock Exchange permit the listing of companies that consolidate the financial statements of companies that cultivate, distribute or possess marijuana (as defined in 21 U.S.C 802) in the United States (the “Triggering Event Date”). Based on the Company’s discussions with the OCA, upon effectuating the Additional Reorganization Amendments, the Company believes that the Staff would not object to the deconsolidation of the financial results of Canopy USA from the Company’s financial statements in accordance with U.S. GAAP once Canopy USA acquires Wana, Jetty or the Fixed Shares of Acreage.

Ownership of U.S. Cannabis Investments

Following the implementation of the Reorganization, the shares and interests in Acreage, Wana, Jetty and TerrAscend are held, directly or indirectly, by Canopy USA, and Canopy Growth no longer holds a direct interest in any shares or interests in such entities, other than the Acreage Option. Canopy Growth holds non-voting and non-participating shares (the "Non-Voting Shares"“Non-Voting Shares”) in the capital of Canopy USA. The Non-Voting Shares do not carry voting rights, rights to receive dividends or other rights upon dissolution of Canopy USA, butUSA. Following the Reorganization Amendments, the Non-Voting Shares are convertible into Class A commonB shares of Canopy USA (the “Canopy USA CommonClass B Shares”)., provided that following the execution of the Second A&R LLC Agreement, such conversion shall only be permitted following the Triggering Event Date. The Company also has the right (regardless of the fact that its Non-Voting Shares are non-voting and non-participating) to appoint two membersone member to the Canopy USA board of managers.managers (the "Canopy USA Board").

On October 24, 2022,As of December 31, 2023, a third party investor owned all of the issued and outstanding Class A shares of Canopy USA issued 1,000,000 Canopy(the “Canopy USA Common Shares to VCo Ventures LLC (“VCo Ventures”Shares”), a former shareholder of Jetty, in exchange for US$1,000. Agustin Huneeus Jr. is the manager of VCo Ventures. Following the closing of the investment, and a wholly-owned subsidiary of the Company holds Non-Voting Shares in the capital of Canopy USA, representing approximately more than 99.399% of the issued and outstanding shares in Canopy USA on an as-converted basis. Canopy USA retains a call right (the “Repurchase Right”) to repurchase all shares of Canopy USA that have been issued to VCo Ventures at a price per Canopy USA Common Share equal to the greater of fair market value as determined by an appraiser appointed by Canopy USA and US$2,000 in the aggregate; provided that if the repurchase occurs prior to March 31, 2023, the Repurchase Right can be exercised at the initial subscription price. VCo Ventures has also been granted the right to appoint one member to the Canopy USA board of managers and a put right following the conversion of the Non-Voting Shares into Canopy USA Common Shares on the same terms and conditions as the Repurchase Right.

On October 24, 2022, Canopy USA and the Company also entered into an agreement with, among others, Nancy Whiteman, the controlling shareholder of Wana, which was amended and restated on May 19, 2023, whereby subsidiaries of Canopy USA agreed to pay additional consideration in order to acquire the Wana OptionOptions and the future payments owed in connection with the exercise of the Wana OptionOptions (as described in Note 11) will be reduced to US$3.00 in exchange for the issuance of Canopy USA Common Shares and Canopy Growth common shares (the “Wana Amending Agreement”). In accordance with the terms of the Wana Amending Agreement, Canopy USA Common Shares and Canopy Growth common shares will be issued to the shareholders of Wana, each with a value equal to 7.5% of the fair market value of Wana as of January 1, 2023.the later of: (i) the date that the Wana Options are exercised; and (ii) the closing date of the first tranche of the Trust Transaction (the “Wana Valuation Date”) less any net debt of Wana as of the Wana Valuation Date plus any net cash of Wana as of Wana Valuation Date. The value of Wana and the number of Canopy USA Common Shares will be determined based on the fair market value of Wana and the Canopy USA Common Shares, respectively, as determined by an appraiser appointed by the Company and an appraiser appointed by the shareholders of Wana (and, if required, a third appraiser to be appointed by the initial two appraisers). The Canopy USA Common Shares and Canopy Growth common shares will only be issued to Ms. Whiteman, or entities controlled by Ms. Whiteman, after January 1, 2023on the later of: (i) the date of exercise of the Wana Options and only if(ii) the date that CBG Holdings LLC (“CBG”) and Greenstar Canada Investment Limited Partnership (“Greenstar”), indirect, wholly-owned subsidiaries of Constellation Brands, Inc. (“CBI”), have converted their Canopy Growth common shares into Exchangeable Shares (as defined below).Shares. The Wana Amending Agreement may be terminated and no Canopy USA Common Shares or Canopy Growth common shares will be issued to Ms. Whiteman, or entities controlled by Ms. Whiteman in the event that CBG and Greenstar have not converted their Canopy Growth common shares into Exchangeable Shares by the later of: (i) sixty days after the Meeting; or (ii) MarchDecember 31, 2023. The Canopy USA Common Shares issuable to Ms. Whiteman, or entities controlled by Ms. Whiteman, will also be subject to a repurchase right exercisable at any time after the 36 month anniversary of the closing of the transaction contemplated by the Wana Amending Agreement (the “Wana Repurchase Right”) to repurchase all Canopy USA Common Shares that have been issued at a price per Canopy USA Common Share equal to the greater of fair market value as determined by an appraiser and the initial subscription price multiplied by an accrued annual interest rate of 10%.appraiser. As part of this agreement, Canopy USA has granted Ms. Whiteman the right to appoint one member to the Canopy USA board of managersBoard and a put right on the same terms and conditions as the Wana Repurchase Right.

Canopy Growth and Canopy USA have also entered into a protection agreement (the "Protection Agreement") to provide for certain covenants in order to preserve the value of the Non-Voting Shares held by Canopy Growth until such time as the Non-Voting

13


Shares are converted into Canopy USA Common Sharesin accordance with their terms, provided that following the execution of the Second A&R LLC Agreement, such conversion shall only be permitted following the Triggering Event Date, but does not provide Canopy Growth with the ability to direct the business, operations or activities of Canopy USAUSA. The Protection Agreement was amended and restated in connection with: (a) the Reorganization Amendments (the “First A&R Protection Agreement”); and (b) the Additional Reorganization Amendments (the “Second A&R Protection Agreement” and together with the First A&R Protection Agreement, the “A&R Protection Agreement”)..

Upon closing of Canopy USA'sUSA’s acquisition of Acreage, Canopy Growth will receive additional Non-Voting Shares from Canopy USA in consideration for the issuance of common shares of the Company that shareholders of Acreage will receive in accordance with the terms of the Existing Acreage Arrangement Agreement (as defined below) and the Floating Share Arrangement Agreement.

In addition, subject to the terms and conditions of the Protection Agreement and the terms of the option agreements to acquire Wana and Jetty, as applicable, Canopy Growth may be required to issue additional common shares in satisfaction of certain deferred and/or option exercise payments to the shareholders of Wana and Jetty. Canopy Growth will receive additional Non-Voting Shares from Canopy USA as consideration for any Company common shares issued in the future to the shareholders of Wana and Jetty.(as defined below).

9


Until such time as Canopy Growth converts the Non-Voting Shares into Canopy USA CommonClass B Shares following the Triggering Event Date, Canopy Growth will have no economic or voting interest in Canopy USA, Wana, Jetty, TerrAscend, or Acreage. Canopy USA, Wana, Jetty, TerrAscend, and Acreage will continue to operate independently of Canopy Growth.

Acreage Agreements

On October 24, 2022, Canopy Growth entered into an arrangement agreement with Canopy USA and Acreage, as amended (the "Floating“Floating Share Arrangement Agreement"Agreement”), pursuant to which, subject to approval of the holders of the Floating Shares and the terms and conditions of the Floating Share Arrangement Agreement, Canopy USA will acquire all of the issued and outstanding Floating Shares by way of a court-approved plan on arrangement under the Business Corporations Act (British Columbia) (the "Floating“Floating Share Arrangement"Arrangement”) in exchange for 0.450.045 of a Company common share for each Floating Share held. In connection with the Floating Share Arrangement Agreement, the CompanyCanopy Growth has irrevocably waived the Acreage Floating Option (as defined below) existing under the Existing Acreage Arrangement Agreement.

ItOn October 24, 2022, the Company and Canopy USA entered into a third amendment to tax receivable agreement (the “Amended TRA”) with, among others, certain current or former unitholders (the “Holders”) of High Street Capital Partners, LLC, a subsidiary of Acreage (“HSCP”), pursuant to HSCP’s amended tax receivable agreement (the “TRA”) and related tax receivable bonus plans with Acreage. Pursuant to the Amended TRA, the Company, on behalf of Canopy USA, agreed to issue common shares of the Company with a value of US$30.4 million to certain Holders as consideration for the assignment of such Holder’s rights under the TRA to Canopy USA. As a result of the Amended TRA, Canopy USA is expected thatthe sole member and beneficiary under the TRA. In connection with the foregoing, the Company issued: (i) 564,893 common shares with a value of $20.6 million (US$15.2 million) to certain Holders on November 4, 2022 as the first installment under the Amended TRA; and (ii) 710,208 common shares with a value of $20.6 million (US$15.2 million) to certain Holders on March 17, 2023, as the second installment under the Amended TRA. The Company, on behalf of Canopy USA, also agreed to issue common shares of the Company with a value of approximately US$19.6 million to certain eligible participants pursuant to HSCP’s existing tax receivable bonus plans to be issued immediately prior to completion of the Floating Share Arrangement will be effected by way of a court-approved plan of arrangement under the Arrangement.Business Corporations Act (British Columbia). The Floating Share Arrangement requires the approval of: (i) at least two-thirds of the votes cast by the holders of the Floating Shares; and (ii) at least a majority of the votes cast by the holders of the Floating Shares, excluding the votes cast by "interested parties" and "related parties" (as such terms are defined in Multilateral Instrument 61-101 - Protection Of Minority Security Holders In Special Transactions), at a special meeting of Acreage shareholders.

On October 24, 2022, Canopy Growth and Canopy USA entered into voting support agreements with certain of Acreage'sAcreage’s directors, officers and consultants pursuant to which such persons have agreed, among other things, to vote their Floating Shares in favor of the Floating Share Arrangement, representing approximately 7.3% of the issued and outstanding Floating Shares.

In addition to shareholder and court approvals, the Floating Share Arrangement is subject to approval of the Amendment Proposal (as defined below) and applicable regulatory approvals including, but not limited to, Toronto Stock Exchange (“TSX”) approval and the satisfaction of certain other closing conditions customary in transactions of this nature. Assuming timely receiptThe Floating Share Arrangement received the requisite approval from the holders of all necessary court, shareholder, regulatoryFloating Shares at the special meeting of Acreage shareholders held on March 15, 2023 and other third-party approvals andon March 20, 2023 Acreage obtained a final order from the satisfactionSupreme Court of all other conditions, closingBritish Columbia approving the Floating Share Arrangement. The Floating Share Arrangement Agreement has been amended several times to extend the Exercise Outside Date (as defined in the Floating Share Arrangement Agreement), which was initially March 31, 2023. The most recent amendment to the Floating Share Arrangement Agreement extended the Exercise Outside Date to March 31, 2024. The completion of the acquisitionFloating Share Arrangement is subject to satisfaction or, if permitted, waiver of Acreage is expectedcertain closing conditions, including, among others, approval of the Amendment Proposal on or prior to occur in late 2023.the Exercise Outside Date.

It is intended that Canopy Growth'sGrowth’s existing option to acquire the Fixed Shares on the basis of 0.30480.03048 of a Company common share per Fixed Share will be exercised after the Meeting in accordance with the terms of the arrangement agreement dated April 18, 2019, as amended on May 15, 2019, September 23, 2020 and November 17, 2020 (the "Existing“Existing Acreage Arrangement Agreement"Agreement”). Canopy Growth will not hold any Fixed Shares or Floating Shares. Completion of the acquisition of the Fixed Shares following exercise of the optionAcreage Option is subject to the satisfaction of certain conditions set forth in the Existing Acreage Arrangement Agreement. The acquisition of the Floating Shares pursuant to the Floating Share Arrangement is anticipated to occur immediately prior to the acquisition of the Fixed Shares pursuant to the Existing Acreage Arrangement Agreement in late 2023 such that 100% of the issued and outstanding shares of Acreage will be owned by Canopy USA on closing of the acquisition of both the Fixed Shares and the Floating Shares.

In addition, the Company entered into additional agreements related to Acreage that are described in Note 10.

Special Shareholder Meeting

In connection with the Reorganization, Canopy Growth expects to hold a special meeting of shareholders (the "Meeting") at which Canopy Growth shareholders will be asked to consider and, if deemed appropriate, to pass a special resolution authorizing an amendment to its articles of incorporation, as amended (the "Amendment Proposal"), in order to: (i) create and authorize the issuance of an unlimited number of a new class of non-voting and non-participating exchangeable shares in the capital of Canopy Growth (the “Exchangeable Shares”); and (ii) restate the rights of the Company's common shares to provide for a conversion feature whereby each common share may at any time, at the option of the holder, be converted into one Exchangeable Share. The Exchangeable Shares will not carry voting rights, rights to receive dividends or other rights upon dissolution of Canopy Growth but will be convertible into common shares.

The Amendment Proposal must be approved by at least 66⅔% of the votes cast on a special resolution by Canopy Growth's shareholders present in person or represented by proxy at the Meeting.

On October 24, 2022, CBG and Greenstar entered into a voting and support agreement with Canopy Growth (the “Voting and Support Agreement”). Pursuant to the terms of the Voting and Support Agreement, CBG and Greenstar agreed, subject to the terms and conditions thereof, among other things, to vote all of the Canopy Growth common shares beneficially owned, directed or controlled, directly or indirectly, by them for the Amendment Proposal.

10


In the event the Amendment Proposal is approved, and subject to the conversion by CBI of their Canopy Growth common shares into Exchangeable Shares, Canopy USA is expected to exercise the Wana Option and the Jetty Option. In the event the Amendment Proposal is not approved, Canopy USA will not be permitted to exercise its rights to acquire shares of Acreage, Wana or Jetty and the Floating Share Arrangement Agreement will be terminated. In such circumstances, Canopy will retain its option to acquire the Fixed Shares under the Existing Acreage Arrangement Agreement and Canopy USA will continue to hold the Wana Option and the Jetty Option, as well as the TerrAscend Exchangeable Shares and other securities in the capital of TerrAscend. In addition, the Company is contractually required to cause Canopy USA to exercise its Repurchase Right to acquire the Canopy USA Common Shares held by the third party investors, being the Canopy USA Common Shares held by VCo Ventures.

Balance Sheet Actions

On October 24, 2022, Canopy Growth entered into agreements with certain of its lenders under its term loan credit agreement dated March 18, 2021 (the "Credit Agreement") pursuant to which Canopy Growth will tender US$187,500 of the principal amount outstanding thereunder at a discounted price of US$930 per US$1,000 or US$174,375 in the aggregate (the "Paydown"). The first payment of $117,528 (US $87,852) was made on November 10, 2022 to reduce the principal indebtedness by $126,324 (US $94,427). The second payment pursuant to the Paydown is required to be made by no later than April 17, 2023. See Note 15 for further details.

Canopy Growth also agreed with its lenders to amend certain terms of the Credit Agreement (collectively, the "Credit Agreement Amendments"). The Credit Agreement Amendments include, among other things: (i) reductions to the minimum Liquidity (as defined in the Credit Agreement) covenant to US$100,000, which is to be further reduced as payments are made in accordance with the Paydown; (ii) certain changes to the application of net proceeds from asset sales; (iii) the establishment of a new committed delayed draw term credit facility in an aggregate principal amount of US$100,000; and (iv) the elimination of the additional US$500,000 incremental term loan facility.

Relationship with CBI

In connection with the Reorganization, CBI has indicated its current intention to convert all of its common shares of the Company into Exchangeable Shares, conditional upon the approval of the Amendment Proposal. However, any decision to convert will be made by CBI in its sole discretion, and CBI is not obligated to effect any such conversion.

In connection with the foregoing, on October 24, 2022, Canopy Growth entered into a consent agreement with CBG and Greenstar (the “Consent Agreement”), pursuant to which the parties agreed, among other things, that following the conversion by CBG and Greenstar of their respective Canopy Growth common shares into Exchangeable Shares, other than the Consent Agreement and the termination rights contained therein and the 4.25% unsecured senior Canopy Growth notes due in 2023 (the "Notes") held by Greenstar, all agreements between Canopy Growth and CBI, including the Second Amended and Restated Investor Rights Agreement, dated as of April 18, 2019, by and among certain wholly-owned subsidiaries of CBI and Canopy Growth (the "Second Amended and Restated Investor Rights Agreement"), will be terminated. Pursuant to the terms of the Consent Agreement, CBG and Greenstar also agreed, among other things, that at the time of the conversion by CBG and Greenstar of their Canopy Growth common shares into Exchangeable Shares, (i) CBG will surrender the warrants held by CBG to purchase 139,745,453 common shares for cancellation for no consideration; and (ii) all nominees of CBI that are currently sitting on the board of directors of Canopy Growth (the "Board") will resign from the Board. In addition, pursuant to the Consent Agreement, Canopy Growth is contractually required to convert its Non-Voting Shares into Canopy USA Common Shares and cause Canopy USA to repurchase the Canopy USA Common Shares held by certain third-party investors in Canopy USA in the event CBG and Greenstar have not converted their respective common shares into Exchangeable Shares by the later of: (i) sixty days after the Meeting; or (ii) February 28, 2023 (the “Termination Date”). The Consent Agreement will automatically terminate on the Termination Date.

In the event that CBI does not convert its Canopy Growth common shares into Exchangeable Shares, Canopy USA will not be permitted to exercise its rights to acquire the Fixed Shares, Wana or Jetty, and the Floating Share Arrangement Agreement will be terminated. In such circumstances, Canopy Growth will retain its option to acquire the Fixed Shares under the Existing Acreage Arrangement Agreement and Canopy USA will continue to hold the Wana Option and the Jetty Option, as well as the TerrAscend Exchangeable Shares and other securities in the capital of TerrAscend. In addition, the Company is contractually required to cause Canopy USA to exercise its Repurchase Right to acquire the Canopy USA Common Shares held by the third party investors, being the Canopy USA Common Shares held by VCo Ventures.

Potential Changes to Canopy USA Structure

The Company is committed to both optimizing the value of Canopy USA and remaining in compliance with the Nasdaq Stock Market (the "Nasdaq") listing requirements. Accordingly, while Canopy Growth remains in discussions with the Nasdaq and another

11


exchange with respect to its ongoing listing despite the consolidation of the financial results of Canopy USA with the Company’s financial results, the Company is prepared to make changes to the structure of its interest in Canopy USA such that Canopy Growth would not be required to consolidate the financial results of Canopy USA into Canopy Growth’s financial statements, which may include: (1) reducing Canopy Growth’s economic interest in Canopy USA on an as-converted basis to no greater than 90%; (2) reducing the number of managers on Canopy USA’s board of managers from four to three, including, reducing Canopy Growth’s nomination right to a single manager; (3) modifying the terms of the Protection Agreement and Canopy USA’s Limited Liability Company Agreement in order to eliminate certain negative covenants; and (4) modifying the terms of the agreements with third-party investors in Canopy USA to, among other things, eliminate their right to guaranteed returns.

4. ASSET IMPAIRMENT AND RESTRUCTURING COSTS

Three months ended June 30, 2022

In the three months ended June 30, 2022, the Company performed a quantitative goodwill impairment assessment for the cannabis operations reporting unit in the global cannabis segment, and recognized impairment losses totaling $1,725,368. Refer to Note 13 for further details. Additionally, in the three months ended June 30, 2022, the Company recognized incremental costs primarily associated with the restructuring actions completed in the year ended March 31, 2022, including the closure of certain of its Canadian production facilities, and other operational changes initiated in the three months ended March 31, 2022 to: (i) implement cultivation-related efficiencies and improvements in the Canadian adult-use cannabis business, and (ii) implement a flexible manufacturing platform, including contract manufacturing for certain product formats.

Three months ended September 30, 2022

In the three months ended September 30, 2022, the Company recorded asset impairment and restructuring costs primarily related to:

Impairment losses associated with the divestiture of the Company's Canadian retail operations pursuant to the OEGRC Transaction and the FOUR20 Transaction (as each term is defined below), as described in Note 28 below. In connection with this divestiture, the Company recorded write-downs of property, plant and equipment, operating licenses and brand intangible assets, right-of-use assets, and certain other assets due to the excess of their carrying values over their estimated fair values.

Incremental costs primarily associated with the restructuring actions completed in the year ended March 31, 2022, including the closure of certain of the Company's Canadian production facilities.
Goodwill impairment losses of $2,311 associated with one of the Company's reporting units (refer to Note 13 for further details) and asset impairment charges relating to certain acquired brand intangible assets.

Three months ended December 31, 2022

In the three months ended December 31, 2022, the Company recorded asset impairment and restructuring costs primarily related to:

Asset impairment charges totaling $10,600 relating to certain acquired brand intangible assets within our Canada cannabis segment.
Employee-related restructuring charges associated with actions completed in the three months ended December 31, 2022 as part of the Company's ongoing program to align general and administrative costs with business objectives, and further streamline the Company's operations.
Incremental impairment losses associated with the divestiture of the Company's Canadian retail operations, as described above and in Note 28, as the Company recorded write-downs of certain other assets due to the excess of their carrying values over their estimated fair values, and recognized contractual and other settlement obligations.
Incremental costs primarily associated with the restructuring actions completed in the year ended March 31, 2022, including the closure of certain of the Company's Canadian production facilities.

As a result, in the three and nine months ended December 31, 2022, the Company recognized asset impairment and restructuring costs of $22,259 and $1,794,212, respectively (three and nine months ended December 31, 2021 – $36,439 and $128,198, respectively).

12


5. CASH AND CASH EQUIVALENTS

The components of cash and cash equivalents are as follows:

 

 

December 31,

 

 

March 31,

 

 

 

2022

 

 

2022

 

Cash

 

$

524,979

 

 

$

470,682

 

Cash equivalents

 

 

73,152

 

 

 

305,323

 

 

 

$

598,131

 

 

$

776,005

 

6. SHORT-TERM INVESTMENTS

The components of short-term investments are as follows:

 

 

December 31,

 

 

March 31,

 

 

 

2022

 

 

2022

 

Term deposits

 

$

98,286

 

 

$

319,092

 

Asset-backed securities

 

 

80,924

 

 

 

21,905

 

Government securities

 

 

-

 

 

 

22,253

 

Commercial paper and other

 

 

11,909

 

 

 

232,401

 

 

 

$

191,119

 

 

$

595,651

 

The amortized cost of short-term investments at December 31, 2022 is $193,537 (March 31, 2022 – $599,862).

7. AMOUNTS RECEIVABLE, NET

The components of amounts receivable, net are as follows:

 

 

December 31,

 

 

March 31,

 

 

 

2022

 

 

2022

 

Accounts receivable, net

 

$

85,297

 

 

$

78,059

 

Indirect taxes receivable

 

 

7,835

 

 

 

7,524

 

Interest receivable

 

 

2,585

 

 

 

4,406

 

Other receivables

 

 

8,923

 

 

 

6,454

 

 

 

$

104,640

 

 

$

96,443

 

Included in the accounts receivable, net balance at December 31, 2022 is an allowance for doubtful accounts of $6,477 (March 31, 2022 – $4,764).

8. INVENTORY

The components of inventory are as follows:

 

 

December 31,

 

 

March 31,

 

 

 

2022

 

 

2022

 

Raw materials, packaging supplies and consumables

 

$

34,940

 

 

$

26,821

 

Work in progress

 

 

64,483

 

 

 

65,245

 

Finished goods

 

 

114,514

 

 

 

112,321

 

 

 

$

213,937

 

 

$

204,387

 

In the three and nine months ended December 31, 2022, the Company recorded write-downs related to inventory in cost of goods sold of $9,820 and $32,978, respectively (three and nine months ended December 31, 2021 – $11,811 and $104,662, respectively).

13


9. PREPAID EXPENSES AND OTHER ASSETS

The components of prepaid expenses and other assets are as follows:

 

 

December 31,

 

 

March 31,

 

 

 

2022

 

 

2022

 

Prepaid expenses

 

$

28,736

 

 

$

23,041

 

Deposits

 

 

7,740

 

 

 

10,145

 

Prepaid inventory

 

 

786

 

 

 

449

 

Other assets

 

 

14,889

 

 

 

19,065

 

 

 

$

52,151

 

 

$

52,700

 

14


10. OTHER FINANCIAL ASSETS

The following table outlines changes in other financial assets. Additional details on how the fair value of significant investments is calculated are included in Note 22.

 

 

 

 

 

 

 

 

 

 

 

 

 

Foreign

 

 

 

 

 

 

 

 

 

 

 

Balance at

 

 

 

 

 

 

 

 

currency

 

 

 

 

 

Balance at

 

 

 

 

 

March 31,

 

 

 

 

 

Fair value

 

 

translation

 

 

 

 

 

December 31,

 

Entity

 

Instrument

 

2022

 

 

Additions

 

 

changes

 

 

adjustments

 

 

Other

 

 

2022

 

Acreage1

 

Option

 

$

-

 

 

$

-

 

 

$

37,000

 

 

$

-

 

 

$

-

 

 

$

37,000

 

TerrAscend Exchangeable Shares

 

Exchangeable shares

 

 

229,000

 

 

 

51,000

 

 

 

(207,000

)

 

 

-

 

 

 

-

 

 

 

73,000

 

TerrAscend Canada - October 2019

 

Term loan / debenture

 

 

10,280

 

 

 

-

 

 

 

(146

)

 

 

-

 

 

 

(10,134

)

 

 

-

 

TerrAscend Canada - March 2020

 

Term loan / debenture

 

 

49,890

 

 

 

-

 

 

 

(4,804

)

 

 

-

 

 

 

(45,086

)

 

 

-

 

Arise Bioscience

 

Term loan / debenture

 

 

13,343

 

 

 

-

 

 

 

(1,767

)

 

 

1,268

 

 

 

(12,844

)

 

 

-

 

TerrAscend - October 2019

 

Warrants

 

 

3,730

 

 

 

-

 

 

 

(3,372

)

 

 

-

 

 

 

(358

)

 

 

-

 

TerrAscend - March 2020

 

Warrants

 

 

60,740

 

 

 

-

 

 

 

(46,376

)

 

 

-

 

 

 

(14,364

)

 

 

-

 

TerrAscend - December 2020

 

Warrants

 

 

3,460

 

 

 

-

 

 

 

(2,246

)

 

 

-

 

 

 

(1,214

)

 

 

-

 

TerrAscend - December 2022

 

Warrants

 

 

-

 

 

 

33,000

 

 

 

(17,500

)

 

 

-

 

 

 

-

 

 

 

15,500

 

TerrAscend

 

Option

 

 

6,300

 

 

 

-

 

 

 

(5,050

)

 

 

-

 

 

 

-

 

 

 

1,250

 

Wana

 

Option

 

 

372,343

 

 

 

-

 

 

 

(135,405

)

 

 

22,398

 

 

 

-

 

 

 

259,336

 

Jetty

 

Options

 

 

-

 

 

 

90,120

 

 

 

(9,778

)

 

 

5,048

 

 

 

-

 

 

 

85,390

 

Acreage Hempco1

 

Debenture

 

 

28,824

 

 

 

-

 

 

 

874

 

 

 

2,373

 

 

 

(4,218

)

 

 

27,853

 

Acreage Debt Option Premium

 

Option

 

 

-

 

 

 

38,048

 

 

 

-

 

 

 

581

 

 

 

-

 

 

 

38,629

 

Acreage Tax Receivable Agreement

 

Other

 

 

-

 

 

 

41,491

 

 

 

-

 

 

 

(231

)

 

 

-

 

 

 

41,260

 

Other - at fair value through net income (loss)

 

Various

 

 

10,396

 

 

 

-

 

 

 

(1,185

)

 

 

524

 

 

 

-

 

 

 

9,735

 

Other - classified as held for investment

 

Loan receivable

 

 

12,022

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(2,588

)

 

 

9,434

 

 

 

 

 

$

800,328

 

 

$

253,659

 

 

$

(396,755

)

 

$

31,961

 

 

$

(90,806

)

 

$

598,387

 

1 See Note 29 for information regarding the Acreage Arrangement and Acreage Hempco.

For information regarding the Reorganization, see Note 3. Following the implementation of the Reorganization, Canopy USA, as of October 24, 2022, holds an ownership interest in certain U.S. cannabis investments previously held by the Company, including, among others, interests in the Floating Shares of Acreage, Wana, Jetty, and TerrAscend.

15


TerrAscend Arrangement

On December 9, 2022, Canopy USA and certain limited partnerships that are controlled by Canopy USA entered into a debt settlement agreement (the “TerrAscend Settlement Agreement”) with TerrAscend, TerrAscend Canada Inc. ("TerrAscend Canada") and Arise BioScience, Inc. ("Arise BioScience", together with TerrAscend and TerrAscend Canada, the "TerrAscend Entities") whereby $125,467 in aggregate loans, including accrued interest thereon, payable by certain subsidiaries of TerrAscend were extinguished and 22,474,130 TerrAscend Warrants, being all of the previously issued TerrAscend Warrants controlled by Canopy USA (the “Prior Warrants”) were cancelled in exchange for the issuance of: (i) 24,601,467 TerrAscend Exchangeable Shares at a notional price of $5.10 per TerrAscend Exchangeable Share; and (ii) 22,474,130 new TerrAscend Warrants (the "New Warrants" and, together with the TerrAscend Exchangeable Shares, the "New TerrAscend Securities") with a weighted average exercise price of $6.07 per TerrAscend Common Share and expiring on December 31, 2032 (collectively, the "TerrAscend Arrangement").

Following the issuance of the New TerrAscend Securities, Canopy USA beneficially owns: (i) 63,492,037 TerrAscend Exchangeable Shares; (ii) 22,474,130 New Warrants; and (iii) the TerrAscend Option. The TerrAscend Exchangeable Shares can be converted into TerrAscend Common Shares at Canopy USA's option, subject to the terms of the Protection Agreement.

On December 9, 2022, the estimated fair value of the financial instruments that were derecognized from these consolidated financial statements was $89,094, consisting of: (i) the aggregate term loans or debentures that were extinguished, including accrued interest, with an estimated fair value of $72,191; and (ii) the Prior Warrants that were cancelled, with an estimated fair value of $16,903. Changes in the estimated fair value of these financial instruments up to December 9, 2022 were recorded in other income (expense), net. On December 9, 2022, the estimated fair value of the financial instruments that were received from the TerrAscend Entities was $84,000, consisting of: (i) 24,601,467 TerrAscend Exchangeable Shares with an estimated fair value of $51,000; and (ii) the New Warrants, with an estimated fair value of $33,000. Changes in estimated fair value of these financial instruments from initial recognition to December 31, 2022 were recorded in other income (expense), net. See Note 22 for additional details on how the fair value of all TerrAscend financial instruments are calculated on a recurring basis. The loss of $5,094 resulting from the difference, on December 9, 2022, between the carrying amounts of the derecognized financial instruments and the fair value of the financial assets received, was also recorded in other income (expense), net.

See Note 3 for information regarding the Reorganization. Following the implementation of the Reorganization, as of October 24, 2022, Canopy USA holds certain U.S. cannabis investments previously held by the Company, including the aforementioned direct and indirect interests in the capital of TerrAscend.

Jetty

On May 17, 2022, the Company and Jetty entered into definitive agreements (the “Jetty Agreements”) providing the Company with the right to acquire up to 100% of the outstanding equity interests in Jetty (i) upon the occurrence of changes in U.S. federal law to permit the general cultivation, distribution, and possession of marijuana, or to remove the regulation of such activities from the federal laws of the United States; or (ii) an earlier date at the Company’s sole discretion (the “Jetty Triggering Event”).

The Jetty Agreements are structured as two separate option agreements whereby the Company has the right to acquire up to 100% of the equity interests in Jetty. As consideration for entering into the Jetty Agreements, the Company (i) made an upfront cash payment in the amount of $29,226 (US$22,911), and (ii) issued 8,426,539 common shares with a fair value on closing of $59,123 (US$45,928), for total consideration of $88,349 (collectively, the “Upfront Payment”).

The first option agreement is exercisable in two tranches, with the first tranche providing the Company with the option to acquire 52.78% of Jetty’s equity interests, exercisable following the occurrence of the Jetty Triggering Event. The second tranche provides the Company with the option to acquire 25% of Jetty’s equity interests for their fair market value, subject to certain adjustments. Additionally, the Company expects to make deferred payments (the “Deferred Payments”) computed based on a pre-determined contractual formula. The second option agreement provides the Company with the option to acquire 22.22% of Jetty’s equity interests, exercisable following the occurrence of the Jetty Triggering Event.

Upon initial recognition, the Company estimated the fair value of the Jetty financial instrument to be $90,120, consisting of (i) the Upfront Payment as noted above; and (ii) the present value of the estimated Deferred Payments.

At December 31, 2022, the estimated fair value of the Jetty financial instruments was $85,390, with the change in estimated fair value from initial recognition recorded in other income (expense), net. See Note 22 for additional details on how the fair value of the Jetty financial instruments is calculated on a recurring basis.

16


See Note 3 for information regarding the Reorganization. Following the implementation of the Reorganization, Canopy USA, as of October 24, 2022, holds certain U.S. cannabis investments previously held by the Company, which is expected to enable Canopy USA, following, among other things, the Meeting and the exercise of the Acreage Option, including the issuance of the Fixed Shares to Canopy USA, to consummate the acquisitions of Acreage, Wana, and Jetty.

Until such time as the Company or Canopy USA (as applicable) elects to exercise its rights to acquire Jetty and the Company converts the Non-Voting Shares into Canopy USA Common Shares, the Company will have no direct or indirect economic or voting interests in Jetty, the Company will not directly or indirectly control Jetty, and the Company and Jetty will continue to operate independently of one another.

Acreage-Related Agreements

Tax Receivable Agreement

On October 24, 2022, the Company and Canopy USA entered into a third amendment to the tax receivable agreement (the "Amended TRA") with, among others, certain current or former unitholders (the "Holders") of High Street Capital Partners, LLC, a subsidiary of Acreage ("HSCP"), pursuant to HSCP's amended tax receivable agreement (the "TRA") and related tax receivable bonus plans with Acreage. Pursuant to the Amended TRA, the Company, on behalf of Canopy USA, agreed to issue common shares of the Company with a fair value of US$30,441 to certain Holders as consideration for the assignment of such Holder's rights under the TRA to Canopy USA. As a result of the Amended TRA, Canopy USA is the sole member and beneficiary under the TRA.

In connection with the foregoing, the Company issued 5,648,927 common shares with a value of $20,630 (US$15,220) to certain Holders on November 4, 2022 as the first installment under the Amended TRA with the second payment of approximately US$15,220 in common shares of the Company to occur on the earlier of: (a) the second business day following the date on which the shareholders of Acreage approve the Floating Share Arrangement; or (b) April 24, 2023. Accordingly, as the second payment pursuant to the Amended TRA is not contingent upon any condition, a liability has been recorded in the amount of $20,630 (see Note 16).

The aggregate amount of $41,491 paid, or to be paid, by the Company in common shares in relation to the assignment of rights in favor of Canopy USA in accordance with the Amended TRA represents a financial instrument that has been recorded at cost upon initial recognition.

The Company, on behalf of Canopy USA, also agreed to issue common shares of the Company with a value of approximately US$19,559 to certain eligible participants pursuant to HSCP’s existing tax receivable bonus plans to be issued immediately prior to completion of the Floating Share Arrangement. No accounting recognition was given to this payment in the three months ended December 31, 2022 as such payment is contingent upon the completion of the Floating Share Arrangement or, if the Floating Share Arrangement is not completed, upon the closing of the acquisition of the Fixed Shares under the Existing Acreage Arrangement Agreement.

Acreage Debt Option Premium

 

On November 15, 2022, a wholly-owned subsidiary of Canopy Growth (the "Acreage“Acreage Debt Optionholder"Optionholder”) and Acreage'sAcreage’s existing lenders (the "Lenders"“Lenders”) entered into an option agreement, which superseded the letter agreement dated October 24, 2022 between the parties, pursuant to which the Acreage Debt Optionholder was granted the right to purchase the outstanding principal, including all accrued and unpaid interest thereon, of Acreage’s debt, being an amount up to US$150,000150.0 million (the "Acreage Debt"“Acreage Debt”) from the Lenders in exchange for an option premium payment of $38,04838.0 million (US$28,50028.5) million) (the "Option Premium"“Option Premium”), which was deposited into an escrow account on November 17, 2022. The Acreage Debt Optionholder has the right to exercise the option at its discretion, and if the option is exercised, the Option Premium will be used to reduce the purchase price to be paid for the outstanding Acreage Debt. In the event that Acreage repays the Acreage Debt on or prior to maturity, the Option Premium will be returned to the Acreage Debt Optionholder. In the event that Acreage defaults on the Acreage Debt and the Acreage Debt Optionholder does not exercise its option to acquire the Acreage Debt, the Option Premium will be released to the Lenders.

Special Shareholder Meeting

In connection with the Reorganization, Canopy Growth expects to hold a special meeting of shareholders (the “Meeting”) at which Canopy Growth shareholders will be asked to consider and, if deemed appropriate, to pass a special resolution authorizing an amendment to its articles of incorporation, as amended (the “Amendment Proposal”), in order to: (i) create and authorize the issuance of an unlimited number of a new class of non-voting and non-participating exchangeable shares in the capital of Canopy Growth (the “Exchangeable Shares”); and (ii) restate the rights of the Company’s common shares to provide for a conversion feature whereby each common share may at any time, at the option of the holder, be converted into one Exchangeable Share. The Exchangeable Shares will not carry voting rights, rights to receive dividends or other rights upon dissolution of Canopy Growth but will be convertible into common shares.

The Amendment Proposal must be approved by at least 66⅔% of the votes cast on a special resolution by Canopy Growth’s shareholders present in person or represented by proxy at the Meeting.

On October 24, 2022, CBG and Greenstar entered into a voting and support agreement with Canopy Growth (the “Voting and Support Agreement”). Pursuant to the terms of the Voting and Support Agreement, CBG and Greenstar agreed, subject to the terms and conditions thereof, among other things, to vote all of the Canopy Growth common shares beneficially owned, directed or controlled, directly or indirectly, by them for the Amendment Proposal.

In the event the Amendment Proposal is approved, and subject to the conversion by CBI of their Canopy Growth common shares into Exchangeable Shares, Canopy USA is expected to exercise the Wana Options and the Jetty Options. In the event the Amendment Proposal is not approved, Canopy USA will not be permitted to exercise its rights to acquire shares of Wana or Jetty and the Floating Share Arrangement Agreement will be terminated. In such circumstances, Canopy will retain the Acreage Option under the Existing Acreage Arrangement Agreement and Canopy USA will continue to hold the Wana Options and the Jetty Options, as well as the TerrAscend Exchangeable Shares and other securities in the capital of TerrAscend. In addition, the Company is contractually required to cause Canopy USA to exercise its repurchase right to acquire the Canopy USA Common Shares held by the third party investors.

Relationship with CBI

In connection with the Reorganization, CBI has indicated its current intention to convert all of its common shares of the Company into Exchangeable Shares, conditional upon the approval of the Amendment Proposal. However, any decision to convert will be made by CBI in its sole discretion, and CBI is not obligated to effect any such conversion.

In connection with the foregoing, on October 24, 2022, Canopy Growth entered into a consent agreement with CBG and Greenstar (the “Third Consent Agreement”), pursuant to which the parties agreed, among other things, that following the conversion by CBG and Greenstar of their respective Canopy Growth common shares into Exchangeable Shares, other than the Third Consent Agreement and the termination rights contained therein and the 4.25% unsecured senior notes due in 2023 (the "Canopy Notes") held by Greenstar, all agreements between Canopy Growth and CBI, including the Second Amended and Restated Investor Rights Agreement, dated as of April 18, 2019, by and among certain wholly-owned subsidiaries of CBI and Canopy Growth (the “Second Amended and Restated Investor Rights Agreement”), will be terminated. Pursuant to the terms of the Third Consent Agreement, CBG and Greenstar also agreed, among other things, that at the time of the conversion by CBG and Greenstar of their Canopy Growth common shares into Exchangeable Shares, (i) CBG will surrender the warrants held by CBG to purchase 13,974,545 common shares for cancellation for no consideration; and (ii) all nominees of CBI that are currently sitting on the Board will resign from the Board. In addition, pursuant to the Third Consent Agreement and following the Reorganization Amendments, Canopy Growth is contractually required to convert its Non-Voting Shares into Canopy USA Class B Shares, provided that following the execution of the Second A&R LLC Agreement, such conversion shall only be permitted following the Triggering Event Date, and cause Canopy USA to repurchase the Canopy USA Common Shares held by certain third-party investors in Canopy USA in the event CBG and Greenstar have not converted their respective common shares into Exchangeable Shares by sixty days after the Meeting (the “Termination Date”). The Third Consent Agreement will automatically terminate on the Termination Date.

In the event that CBI does not convert its Canopy Growth common shares into Exchangeable Shares, Canopy USA will not be permitted to exercise its rights to acquire the Fixed Shares from the Company or exercise its rights under the Wana Options or Jetty

15


Options, and the Floating Share Arrangement Agreement will be terminated. In such circumstances, Canopy Growth will retain the Acreage Option under the Existing Acreage Arrangement Agreement and Canopy USA will continue to hold the Wana Options and the Jetty Options, as well as the TerrAscend Exchangeable Shares and other securities in the capital of TerrAscend. If CBI does not convert its Canopy Growth common shares into Exchangeable Shares, the Company is also contractually required to cause Canopy USA to exercise its repurchase right to acquire the Canopy USA Common Shares held by the third party investors.

4. BIOSTEEL

On September 14, 2023, following a review of the strategic options for the BioSteel business unit, Canopy Growth ceased funding the operations of BioSteel Sports Nutrition Inc. ("BioSteel Canada") and commenced proceedings (the "CCAA Proceedings") under the Companies' Creditors Arrangement Act (the "CCAA") in the Ontario Superior Court of Justice (Commercial List) (the "CCAA Court") and sought and obtained recognition of that proceeding under Chapter 15 of the United States Bankruptcy Code. To assist with the sale process, the Court approved the appointment of a monitor.

As a result of the CCAA Proceedings, the most relevant activity of BioSteel Canada became the liquidation and sale of assets. Management concluded that Canopy Growth ceased to have the power to direct the relevant activity of BioSteel Canada because the liquidation and sale transactions required approval from the CCAA Court. Thus, Canopy Growth no longer has a controlling interest in BioSteel Canada and has deconsolidated the entity effective September 14, 2023. The deconsolidation of BioSteel Canada and related impairment charges are classified under losses from discontinued operations.

The strategic decisions made encompassed all operations of the BioSteel business unit, including those of BioSteel Canada. For this reason, the BioSteel segment results for all periods prior to the September 14, 2023 deconsolidation of BioSteel Canada, including costs to exit, are classified as discontinued operations.

On November 16, 2023, BioSteel Sports Nutrition USA LLC ("BioSteel US") and BioSteel Manufacturing LLC ("BioSteel Manufacturing" and collectively with BioSteel Canada and BioSteel US, the “BioSteel Entities”) were added as additional applicants in the CCAA Proceedings. As a result, the most relevant activity of both entities became the liquidation and sale of assets and distribution of cash and proceeds to their respective stakeholders and management concluded that Canopy Growth ceased to have the power to direct the relevant activities of BioSteel US and BioSteel Manufacturing because those activities required approval from the CCAA Court. Thus, Canopy Growth no longer has a controlling interest in either entity and has deconsolidated both entities effective November 16, 2023. The deconsolidation of BioSteel US and BioSteel Manufacturing and related impairment charges are classified under losses from discontinued operations.

 

 

Three months ended

 

 

Nine months ended

 

 

 

December 31,

 

 

December 31,

 

 

December 31,

 

 

December 31,

 

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

 

 

 

 

 

(As Restated)

 

 

 

 

 

(As Restated)

 

Net revenue

 

$

172

 

 

$

19,181

 

 

$

56,610

 

 

$

50,351

 

Cost of goods sold

 

 

1,900

 

 

 

24,504

 

 

 

145,625

 

 

 

64,779

 

Operating expenses

 

 

(726

)

 

 

33,405

 

 

 

97,851

 

 

 

143,423

 

Operating loss

 

 

(1,002

)

 

 

(38,728

)

 

 

(186,866

)

 

 

(157,851

)

Other income (expense), net1

 

 

14,481

 

 

 

2,150

 

 

 

(8,521

)

 

 

(10,687

)

Income tax (expense) recovery

 

 

-

 

 

 

(954

)

 

 

936

 

 

 

(954

)

Net income (loss) on discontinued operations, net of tax

 

$

13,479

 

 

$

(37,532

)

 

$

(194,451

)

 

$

(169,492

)

1 Included in Other income (expense), net for the three and nine months ended December 31, 2023 is a gain on deconsolidation of $12,417 and loss on deconsolidation of $9,820, respectively.

Investment in BioSteel Entities

Canopy Growth continues to have a 90.4% ownership interest in BioSteel Canada and 100% ownership interests in each of BioSteel US and BioSteel Manufacturing, but has deconsolidated the BioSteel Entities because it no longer has a controlling interest in them. Since the estimated amount of the liabilities of the BioSteel Entities exceeds the estimated fair value of the assets available for distribution to its creditors, the fair value of Canopy Growth's equity investment in the BioSteel Entities approximates zero.

Canopy Growth's Amounts Receivable from BioSteel Entities

Prior to Canopy Growth's deconsolidation of BioSteel Canada, Canopy Growth made significant secured loans to BioSteel Canada for purposes of funding its operations. The secured loans and corresponding interest were considered intercompany transactions and eliminated in Canopy Growth's consolidated financial statements prior to September 14, 2023, being the deconsolidation date. As of the deconsolidation date, the secured loans and corresponding interest are now considered related party transactions and have been recognized in Canopy Growth's consolidated financial statements at their estimated fair value of $29,000.

16


As of the deconsolidation date for BioSteel US and BioSteel Manufacturing, Canopy Growth has recorded remaining amounts legally receivable from BioSteel US and BioSteel Manufacturing at their estimated fair value.

The remaining amounts legally receivable from the BioSteel Entities are measured at their expected recoverable amounts. The assets and liabilities related to the BioSteel Entities business units are classified as discontinued operations and the major categories are as follows:

 

 

December 31,

 

 

March 31,

 

 

 

2023

 

 

2023

 

Cash

 

$

-

 

 

$

9,314

 

Short-term investments

 

 

-

 

 

 

69

 

Amounts receivable, net

 

 

-

 

 

 

25,528

 

Receivable from BioSteel Entities

 

 

29,401

 

 

 

-

 

Inventory

 

 

-

 

 

 

65,671

 

Prepaid expenses and other assets

 

 

-

 

 

 

15,709

 

Property, plant and equipment

 

 

-

 

 

 

28,195

 

Intangible assets

 

 

-

 

 

 

27,969

 

Other assets

 

 

-

 

 

 

405

 

Total assets of discontinued operations

 

$

29,401

 

 

$

172,860

 

 

 

 

 

 

 

 

Accounts payable

 

 

-

 

 

 

44,399

 

Other accrued expenses and liabilities

 

 

-

 

 

 

22,248

 

Other current liabilities

 

 

-

 

 

 

977

 

Deferred income tax liabilities

 

 

-

 

 

 

954

 

Other liabilities

 

 

-

 

 

 

2,463

 

Total liabilities of discontinued operations

 

$

-

 

 

$

71,041

 

5. LOSS ON ASSET IMPAIRMENT AND RESTRUCTURING

In the three months ended December 31, 2023, the Company recorded a loss on asset impairment and restructuring. The loss for the three months ended December 31, 2023 primarily relates to the This Works Divestiture (as defined below) as This Works was classified as held for sale and measured at its fair value less costs to sell which was lower than its carrying amount (refer to Note 27).

For the nine months ended December 31, 2023, the loss on asset impairment and restructuring was primarily related to: (i) the Company's divestiture of This Works; and (ii) various incremental impairment losses and other costs associated with the restructuring of the Company's Canadian cannabis operations that were initiated in the three months ended March 31, 2023. The loss on asset impairment and restructuring was partially offset by a gain on the sale of the Company's production facility at 1 Hershey Drive in Smiths Falls, Ontario. Such gain was due to the sale proceeds exceeding the carrying value that was previously impaired at March 31, 2023.

As a result, in the three and nine months ended December 31, 2023, the Company recognized a loss on asset impairment and restructuring of $30,413 and $2,452, respectively (three and nine months ended December 31, 2022 – loss of $22,259 and $1,794,212, respectively).

6. CASH AND CASH EQUIVALENTS

The components of cash and cash equivalents are as follows:

 

 

December 31,

 

 

March 31,

 

 

 

2023

 

 

2023

 

Cash

 

$

87,621

 

 

$

453,146

 

Cash equivalents

 

 

55,124

 

 

 

214,547

 

 

 

$

142,745

 

 

$

667,693

 

17


7. SHORT-TERM INVESTMENTS

The components of short-term investments are as follows:

 

 

December 31,

 

 

March 31,

 

 

 

2023

 

 

2023

 

Government securities

 

$

-

 

 

$

60,157

 

Term deposits

 

 

43,436

 

 

 

30,000

 

Commercial paper and other

 

 

-

 

 

 

15,369

 

 

 

$

43,436

 

 

$

105,526

 

 

The Option Premium represents aamortized cost of short-term investments at December 31, 2023 is $43,436 (March 31, 2023 – $107,661).

8. AMOUNTS RECEIVABLE, NET

The components of amounts receivable, net are as follows:

 

 

December 31,

 

 

March 31,

 

 

 

2023

 

 

2023

 

Accounts receivable, net

 

$

50,957

 

 

$

41,292

 

Indirect taxes receivable

 

 

6,798

 

 

 

11,544

 

Interest receivable

 

 

360

 

 

 

3,966

 

Other receivables

 

 

5,809

 

 

 

11,657

 

 

 

$

63,924

 

 

$

68,459

 

Included in the accounts receivable, net balance at December 31, 2023 is an allowance for doubtful accounts of $10,694 (March 31, 2023 – $8,554).

9. INVENTORY

The components of inventory are as follows:

 

 

December 31,

 

 

March 31,

 

 

 

2023

 

 

2023

 

Raw materials, packaging supplies and consumables

 

$

21,218

 

 

$

18,927

 

Work in progress

 

 

38,495

 

 

 

34,104

 

Finished goods

 

 

27,204

 

 

 

30,199

 

 

 

$

86,917

 

 

$

83,230

 

In the three and nine months ended December 31, 2023, the Company recorded write-downs related to inventory in cost of goods sold of $859 and $8,362, respectively (three and nine months ended December 31, 2022 – $6,454 and $29,274, respectively).

10. PREPAID EXPENSES AND OTHER ASSETS

The components of prepaid expenses and other assets are as follows:

 

 

December 31,

 

 

March 31,

 

 

 

2023

 

 

2023

 

Prepaid expenses

 

$

11,740

 

 

$

11,963

 

Deposits

 

 

2,202

 

 

 

1,522

 

Prepaid inventory

 

 

881

 

 

 

690

 

Other assets

 

 

8,759

 

 

 

10,115

 

 

 

$

23,582

 

 

$

24,290

 

18


11. OTHER FINANCIAL ASSETS

The following table outlines changes in other financial instrument that has been recorded at cost upon initial recognition.assets. Additional details on how the fair value of significant investments is calculated are included in Note 23.

 

 

 

 

 

 

 

 

 

 

 

 

 

Foreign

 

 

 

 

 

 

 

 

 

 

 

Balance at

 

 

 

 

 

 

 

 

currency

 

 

 

 

 

Balance at

 

 

 

 

 

March 31,

 

 

 

 

 

Fair value

 

 

translation

 

 

 

 

 

December 31,

 

Entity

 

Instrument

 

2023

 

 

Additions

 

 

changes

 

 

adjustments

 

 

Other

 

 

2023

 

Acreage1

 

Fixed Shares option and Floating Shares agreement

 

$

55,382

 

 

$

-

 

 

$

(22,296

)

 

$

(86

)

 

$

-

 

 

$

33,000

 

TerrAscend Exchangeable Shares

 

Exchangeable shares

 

 

93,000

 

 

 

-

 

 

 

10,201

 

 

 

(2,201

)

 

 

-

 

 

 

101,000

 

TerrAscend - December 2022

 

Warrants

 

 

26,000

 

 

 

 

 

 

2,702

 

 

 

(702

)

 

 

-

 

 

 

28,000

 

TerrAscend

 

Option

 

 

1,600

 

 

 

-

 

 

 

138

 

 

 

(38

)

 

 

-

 

 

 

1,700

 

Wana

 

Option

 

 

239,078

 

 

 

-

 

 

 

(111,783

)

 

 

(3,755

)

 

 

(4,968

)

 

 

118,572

 

Jetty

 

Options

 

 

75,014

 

 

 

-

 

 

 

(27,243

)

 

 

(1,089

)

 

 

-

 

 

 

46,682

 

Acreage Hempco1

 

Debenture

 

 

29,262

 

 

 

-

 

 

 

(15,775

)

 

 

(112

)

 

 

(397

)

 

 

12,978

 

Acreage Debt Option Premium

 

Option

 

 

35,479

 

 

 

-

 

 

 

1,470

 

 

 

(730

)

 

 

-

 

 

 

36,219

 

Acreage Tax Receivable Agreement

 

Other

 

 

3,109

 

 

 

-

 

 

 

(2,399

)

 

 

(61

)

 

 

-

 

 

 

649

 

Other - at fair value through net income (loss)

 

Various

 

 

1,870

 

 

 

2,156

 

 

 

1,125

 

 

 

(27

)

 

 

-

 

 

 

5,124

 

Other - classified as held for investment

 

Loan receivable

 

 

8,498

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(98

)

 

 

8,400

 

 

 

 

 

$

568,292

 

 

$

2,156

 

 

$

(163,860

)

 

$

(8,801

)

 

$

(5,463

)

 

$

392,324

 

1 See Note 28 for information regarding the Acreage Amended Arrangement and Acreage Hempco.

17

For information regarding the Reorganization, Reorganization Amendments and Additional Reorganization Amendments, see Note 3. Following the implementation of the Reorganization, Canopy USA, as of October 24, 2022, holds an ownership interest in certain U.S. cannabis investments previously held by the Company, including, among others, interests in the Floating Shares of Acreage, Wana, Jetty, and TerrAscend.

19


 

11.12. PROPERTY, PLANT AND EQUIPMENT

The components of property, plant and equipment are as follows:

 

December 31,

 

March 31,

 

 

December 31,

 

March 31,

 

 

2022

 

 

2022

 

 

2023

 

 

2023

 

Buildings and greenhouses

 

$

752,177

 

 

$

766,931

 

 

$

306,611

 

 

$

413,832

 

Production and warehouse equipment

 

 

140,975

 

 

 

159,314

 

 

 

70,990

 

 

 

76,760

 

Leasehold improvements

 

 

24,323

 

 

 

69,304

 

 

 

9,170

 

 

 

13,655

 

Office and lab equipment

 

 

24,263

 

 

 

29,879

 

 

 

10,976

 

 

 

13,636

 

Computer equipment

 

 

18,060

 

 

 

22,293

 

 

 

8,331

 

 

 

8,521

 

Land

 

 

17,395

 

 

 

18,917

 

 

 

5,325

 

 

 

16,781

 

Right-of-use-assets

 

 

 

 

 

 

 

 

 

 

Buildings and greenhouses

 

 

74,153

 

 

 

89,228

 

 

 

33,126

 

 

 

35,167

 

Production and warehouse equipment

 

 

27

 

 

 

55

 

Assets in process

 

 

12,712

 

 

 

19,771

 

 

 

591

 

 

 

3,229

 

 

 

1,064,085

 

 

 

1,175,692

 

 

 

445,120

 

 

 

581,581

 

Less: Accumulated depreciation

 

 

(190,056

)

 

 

(232,912

)

 

 

(104,641

)

 

 

(110,310

)

 

$

874,029

 

 

$

942,780

 

 

$

340,479

 

 

$

471,271

 

 

Depreciation expense included in cost of goods sold for the three and nine months ended December 31, 20222023 is $12,0335,091 and $34,42319,589, respectively (three and nine months ended December 31, 20212022 – $13,81311,611 and $38,66334,001, respectively). Depreciation expense included in selling, general and administrative expenses for the three and nine months ended December 31, 20222023 is $1,544826 and $8,7622,896, respectively (three and nine months ended December 31, 20212022 – $5,5461,509 and $17,8048,673, respectively).

12.13. INTANGIBLE ASSETS

The components of intangible assets are as follows:

 

December 31, 2022

 

 

March 31, 2022

 

 

December 31, 2023

 

 

March 31, 2023

 

 

Gross

 

 

Net

 

 

Gross

 

 

Net

 

 

Gross

 

 

Net

 

 

Gross

 

 

Net

 

 

Carrying

 

Carrying

 

Carrying

 

Carrying

 

 

Carrying

 

Carrying

 

Carrying

 

Carrying

 

 

Amount

 

 

Amount

 

 

Amount

 

 

Amount

 

 

Amount

 

 

Amount

 

 

Amount

 

 

Amount

 

Finite lived intangible assets

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Intellectual property

 

$

141,488

 

 

$

89,758

 

 

$

138,170

 

 

$

97,638

 

 

$

82,378

 

 

$

40,603

 

 

$

98,383

 

 

$

56,333

 

Distribution channel

 

 

72,799

 

 

 

22,045

 

 

 

72,642

 

 

 

24,834

 

 

 

45,948

 

 

 

3,264

 

 

 

58,324

 

 

 

11,231

 

Operating licenses

 

 

24,400

 

 

 

19,762

 

 

 

24,400

 

 

 

22,052

 

 

 

24,472

 

 

 

16,793

 

 

 

24,400

 

 

 

19,012

 

Software and domain names

 

 

36,464

 

 

 

15,221

 

 

 

29,822

 

 

 

14,206

 

 

 

32,199

 

 

 

8,355

 

 

 

34,177

 

 

 

14,579

 

Brands

 

 

5,620

 

 

 

3,128

 

 

 

5,547

 

 

 

3,680

 

 

 

15,490

 

 

 

12,324

 

 

 

16,253

 

 

 

13,249

 

Amortizable intangibles in process

 

 

842

 

 

 

842

 

 

 

5,476

 

 

 

5,476

 

 

 

195

 

 

 

195

 

 

 

508

 

 

 

508

 

Total

 

$

281,613

 

 

$

150,756

 

 

$

276,057

 

 

$

167,886

 

 

$

200,682

 

 

$

81,534

 

 

$

232,045

 

 

$

114,912

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Indefinite lived intangible assets

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Acquired brands

 

 

 

 

$

62,774

 

 

 

 

 

$

74,809

 

 

 

 

 

$

37,538

 

 

 

 

 

$

45,838

 

Operating licenses

 

 

 

 

-

 

 

 

 

 

10,000

 

Total intangible assets

 

 

 

 

$

213,530

 

 

 

 

 

$

252,695

 

 

 

 

 

$

119,072

 

 

 

 

 

$

160,750

 

Amortization expense included in cost of goods sold for the three and nine months ended December 31, 20222023 is $1613 and $4541, respectively (three and nine months ended December 31, 20212022 – $1916 and $6245, respectively). Amortization expense included in selling, general and administrative expenses for the three and nine months ended December 31, 20222023 is $7,0096,310 and $20,51619,355, respectively (three and nine months ended December 31, 20212022 – $10,6396,172, and $27,40018,013, respectively).

1820


 

13.14. GOODWILL

The changes in the carrying amount of goodwill are as follows:

Balance, March 31, 2021

 

$

1,889,354

 

Purchase accounting allocations

 

 

105,323

 

Disposal of consolidated entities

 

 

(58,786

)

Impairment losses

 

 

(40,748

)

Foreign currency translation adjustments

 

 

(28,640

)

Balance, March 31, 2022

 

$

1,866,503

 

 

$

1,866,503

 

Disposal of consolidated entities

 

 

(227

)

 

 

(227

)

Impairment losses

 

 

(1,727,679

)

 

 

(1,785,080

)

Foreign currency translation adjustments

 

 

3,479

 

 

 

4,367

 

Balance, December 31, 2022

 

$

142,076

 

Balance, March 31, 2023

 

$

85,563

 

Foreign currency translation adjustments

 

 

(326

)

Balance, December 31, 2023

 

$

85,237

 

As a result of the continued decline in the price of the Company’s common shares in the three months ended June 30, 2022, the Company determined there to be an indicator of impairment for the cannabis operations reporting unit in the global cannabis segment, which was a reportable segment in the three months ended June 30, 2022. As a result, the Company performed a quantitative interim goodwill impairment assessment for the cannabis operations reporting unit as of June 30, 2022. The Company concluded that the carrying value of the cannabis operations reporting unit was higher than its estimated fair value, and a goodwill impairment loss totaling $1,725,368 was recognized in the three months ended June 30, 2022, representing the entirety of the goodwill assigned to the cannabis operations reporting unit.

The estimated fair value of the cannabis operations reporting unit was determined using the market valuation method, which is consistent with the methodology used by the Company for its annual impairment test conducted at March 31, 2022. The most significant assumptions used in applying this method were (i) the price of the Company’s common shares; and (ii) the estimated control premium associated with ownership of the Company’s common shares.

While the Company changed its reportable segments in the three months ended September 30, 2022 (refer to Note 30), there were no changes to the composition of the Company's reporting units to which goodwill remains assigned at September 30, 2022. In the three months ended September 30, 2022, the Company determined there to be indicators of impairment for one of its other reporting units as slower growth rates resulted in updated long-term financial forecasts indicating lower forecasted revenue and cash flow generation. As a result, the Company performed a quantitative interim goodwill impairment test for the reporting unit as of September 30, 2022 and concluded that the carrying value of the reporting unit was higher than its estimated fair value, as determined using the income valuation method. The Company recognized a goodwill impairment loss totaling $2,311 in the three months ended September 30, 2022, representing the entirety of the goodwill assigned to the reporting unit.

For the remaining reporting units, the Company does not believe that an event occurred or circumstances changed during the threenine months ended September 30, 2022December 31, 2023 that would, more likely than not, reduce the fair value of thesethe Storz & Bickel reporting unitsunit below theirits carrying value. Therefore, the Company concluded that the quantitative goodwill impairment assessment was not required for the remainingStorz & Bickel reporting units at September 30, 2022.

The Company does not believe that an event occurred or circumstances changed during the three months ended December 31, 2022 that would, more likely than not, reduce the fair values of the remaining reporting units below their carrying values. Therefore, the Company concluded that the quantitative goodwill impairment assessment was not required for the remaining reporting unitsunit at December 31, 2022.2023. The carrying value of goodwill associated with all otherthe Storz & Bickel reporting unitsunit was $142,07685,237 at December 31, 2022.

2023.

The Company is required to perform its next annual goodwill impairment analysis on March 31, 2023,2024, or earlier should there be an event that occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount.

19


14.15. OTHER ACCRUED EXPENSES AND LIABILITIES

The components of other accrued expenses and liabilities are as follows:

 

December 31,

 

March 31,

 

 

December 31,

 

March 31,

 

 

2022

 

 

2022

 

 

2023

 

 

2023

 

Employee compensation

 

$

29,213

 

 

$

24,873

 

 

$

17,147

 

 

$

27,322

 

Inventory

 

 

951

 

 

 

10,096

 

Taxes and government fees

 

 

12,148

 

 

 

5,734

 

Professional fees

 

 

6,891

 

 

 

7,640

 

 

 

10,837

 

 

 

5,967

 

Taxes and government fees

 

 

8,541

 

 

 

7,144

 

Other

 

 

30,389

 

 

 

25,525

 

 

 

9,643

 

 

 

14,720

 

 

$

75,985

 

 

$

75,278

 

 

$

49,775

 

 

$

53,743

 

 

15.16. DEBT

The components of debt are as follows:

 

 

December 31,

 

March 31,

 

 

 

December 31,

 

March 31,

 

 

Maturity Date

 

2022

 

 

2022

 

 

Maturity Date

 

2023

 

 

2023

 

Unsecured senior notes at 4.25% interest with
semi-annual interest payments

 

July 15, 2023

 

 

 

 

 

 

 

July 15, 2023

 

 

 

 

 

 

Principal amount

 

 

 

$

337,380

 

 

$

600,000

 

 

 

 

$

-

 

 

$

337,380

 

Accrued interest

 

 

 

 

6,731

 

 

 

5,958

 

 

 

 

 

-

 

 

 

3,148

 

Non-credit risk fair value adjustment

 

 

 

 

19,062

 

 

 

7,140

 

 

 

 

 

-

 

 

 

26,214

 

Credit risk fair value adjustment

 

 

 

 

(37,618

)

 

 

(49,140

)

 

 

 

 

-

 

 

 

(35,492

)

 

 

 

 

325,555

 

 

 

563,958

 

 

 

 

 

-

 

 

 

331,250

 

Convertible debentures

 

September 10, 2025

 

 

30,867

 

 

 

32,858

 

Supreme convertible debentures

 

September 10, 2025

 

 

30,461

 

 

 

31,503

 

Accretion debentures

 

September 10, 2025

 

 

8,506

 

 

 

7,720

 

 

September 10, 2025

 

 

7,650

 

 

 

8,780

 

Credit facility

 

March 18, 2026

 

 

838,407

 

 

 

893,647

 

 

March 18, 2026

 

 

487,108

 

 

 

840,058

 

Equity-settled convertible debentures

 

February 28, 2028

 

 

-

 

 

 

93,228

 

Promissory note

 

December 31, 2024

 

 

85,486

 

 

 

-

 

Other revolving debt facility, loan, and financings

 

 

 

 

2,266

 

 

 

2,808

 

 

 

 

 

1,369

 

 

 

2,062

 

 

 

 

 

1,205,601

 

 

 

1,500,991

 

 

 

 

 

612,074

 

 

 

1,306,881

 

Less: current portion

 

 

 

 

(455,483

)

 

 

(9,296

)

 

 

 

 

(91,336

)

 

 

(556,890

)

Long-term portion

 

 

 

$

750,118

 

 

$

1,491,695

 

 

 

 

$

520,738

 

 

$

749,991

 

 

Credit Facility

On March 18, 2021, the Company entered into the Credit Agreementa term loan credit agreement (the "Credit Agreement") providing for a five-year, first lien senior secured term loan facility in an aggregate principal amount of US$750,000 (the “Credit Facility”). The Company had the ability to obtain up to an additional US$500,000 of incremental senior secured debt pursuant to the Credit Agreement. As described in Note 3, in connection with the balance sheet actions completed as part of the creation of Canopy USA,On October

21


24, 2022, the Company entered into agreements with certain of its lenders under the Credit Agreement pursuant to completewhich the Paydown, which will resultCompany agreed to purchase in the Company tenderingaggregate US$187,500 of principal amountindebtedness outstanding thereunderunder the Credit Facility at a discounted price of US$930 per US$1,000 or US$174,375 in the aggregate. The first payment, which was oversubscribed, in the amount of $117,528 (US$87,852), representing an aggregate was made on November 10, 2022 to reduce the principal payment amount ofindebtedness under the Credit Facility by $126,324 (US$94,427). The second payment of $116,847 (US$87,213) was made on November 10, 2022, and the second payment pursuant to the Paydown is to be made no later than April 17, 2023. The2023 to reduce principal indebtedness under the Credit Agreement by $125,606 (US$93,750). Additionally, on October 24, 2022, the Company alsoand certain of its lenders agreed to make certain amendments to the Credit Agreement Amendments which, among other things, resulted in: (i) reductionsa reduction to the minimum Liquidity (as defined in the Credit Agreement)liquidity covenant to no less than US$100,000, which is to be further reduced as payments are made in accordance with following completion of the Paydown;second principal repurchase on April 17, 2023; (ii) certain changes to the application of net proceeds from asset sales; (iii) the establishment of a new committed delayed draw term credit facility in an aggregate principal amount of US$100,000; and (iv) the elimination of the additional US$500,000 incremental term loan facility.

On July 13, 2023, as part of the Company's balance sheet deleveraging initiatives, the Company entered into agreements with certain of its lenders under the Credit Agreement pursuant to which certain additional amendments were made to the Credit Agreement (the Credit Agreement, as amended as of July 13, 2023, is referred to herein as the "Amended Credit Agreement"). The Amended Credit Agreement required the Company to prepay or repurchase principal indebtedness under the Credit Facility has in an amount equal to the US dollar equivalent of $no93,000 at a discounted price of US$930 per US$1,000 (the "July 2023 Paydown"). In addition, the Amended Credit Agreement requires the Company to apply certain net proceeds from asset sales to prepay or repurchase principal payments, maturesindebtedness under the Credit Facility and receive principal reductions at, in certain circumstances, a discounted price of US$950 per US$1,000. The Amended Credit Agreement also includes, among other things, amendments to the minimum liquidity covenant such that the US$100,000 minimum liquidity covenant ceased to apply concurrently with the July 2023 Paydown. The Company made the July 2023 Paydown on July 21, 2023.

On each of August 11, 2023 and September 14, 2023, pursuant to the terms of the Amended Credit Agreement, the Company repurchased additional outstanding principal amounts under the Credit Facility using certain net proceeds from completed asset sales (the "Second Quarter 2024 Paydowns"). The Second Quarter 2024 Paydowns resulted in an aggregate principal reduction of $73,313 (US$54,491) for a cash payment of $69,647 (US$51,766).

On each of November 28, 2023 and December 27, 2023, pursuant to the terms of the Amended Credit Agreement, the Company repurchased and repaid, as applicable, additional outstanding principal amounts under the Credit Facility using certain net proceeds from completed asset sales (the "Third Quarter 2024 Paydowns"). The Third Quarter 2024 Paydowns resulted in an aggregate principal reduction of $65,379 (US$48,532) for a cash payment of $63,167 (US$46,902).

The Amended Credit Facility continues to mature on March 18, 2026, has a coupon and through December 26, 2023, had an interest rate of LIBOR + 8.50%. After December 26, 2023, interest on amounts outstanding under the Amended Credit Facility is calculated at either the applicable prime rate plus 7.50% per annum, subject to a prime rate floor of 2.00%, or adjusted term SOFR plus 8.50% and isper annum, subject to a LIBORan adjusted term SOFR floor of 1.00%. In the event that LIBOR can no longer be adequately ascertained or is no longer available, an alternative rate as permitted under the Credit Agreement will be used. The Company’s obligations under the Credit Facility are guaranteed by material wholly-owned Canadian and U.S. subsidiaries of the Company. The Credit Facility is secured by substantially all of thesethe assets of the Company and its material wholly-owned Canadian and U.S. subsidiaries, including material real property, of the borrowers and each of the guarantors.property. The Credit Agreement contains representations and warranties, and affirmative and negative covenants, including a financial covenant requiring minimum liquidity of US$200,000 at the end of each fiscal quarter; however, as noted above, as a result of the Credit Agreement Amendments, such minimum liquidity covenant has been reduced to US$100,000, which is to be reduced as payments are made in accordance with the Paydown.

The proceeds from the Credit Facility were $893,160, and the carrying amount is reflected net of financing costs.

20


covenants.

Unsecured Senior Notes

On June 20, 2018, the Company issued the Canopy Notes with an aggregate principal amount of $600,000. The Canopy Notes bearbore interest at a rate of 4.25% per annum, payable semi-annually on January 15th and July 15th of each year commencing from January 15, 2019. The Canopy Notes will maturematured on July 15, 2023. The Canopy Notes arewere subordinated in right of payment to any existing and future senior indebtedness. The Canopy Notes will rankranked senior in right of payment to any future subordinated borrowings. The Canopy Notes arewere effectively junior to any secured indebtedness and the Canopy Notes arewere structurally subordinated to all indebtedness and other liabilities of the Company’s subsidiaries.

 

On June 29, 2022 and June 30, 2022, the Company entered into privately negotiated exchange agreements (the “Exchange Agreements”) with a limited number of holders of the Notes including Greenstar (collectively, the “Noteholders”). Pursuant to the Exchange Agreements, the Company agreed to acquire and cancel approximately $262,620 of aggregate principal amount of the Notes from the Noteholders (the “Exchange Transaction”) for an aggregate purchase price (excluding $5,383 paid to the Noteholders in cash for accrued and unpaid interest) of $259,994 (the “Purchase Price”), which was payable in the Company’s common shares.

On the initial closings, 35,662,420 common shares were to be issued to the Noteholders, other than Greenstar, based on a price equal to US$3.50 per common share, which was the closing price of the common shares on the Nasdaq Global Select Market on June 29, 2022. The Company satisfied the Purchase Price as follows:

On June 30, 2022, 14,069,353 common shares were issued to Noteholders, representing the Company’s acquisition and cancellation of an aggregate principal amount of Notes of $63,098, which were recorded at a fair value of $50,866.
In July 2022, 21,593,067 common shares were issued to Noteholders, representing an aggregate principal amount of Notes of $99,522, which were recorded at a fair value of $76,424 upon acquisition and cancellation.
On the final closing on July 18, 2022 (the “Final Closing”), 11,896,536 common shares were issued to Noteholders other than Greenstar, based on the volume-weighted average trading price of the common shares on the Nasdaq Global Select Market for the 10 consecutive trading days beginning on, and including, June 30, 2022, being US$2.6245 (the “Averaging Price”).
In addition, on the Final Closing on July 18, 2022, 29,245,456 common shares were issued to Greenstar based on a price per common share equal to the Averaging Price. Pursuant to the Exchange Transaction, the Company agreed to acquire and cancel $100,000 in aggregate principal amount, which was recorded at a fair value of $98,078 upon acquisition and cancellation. Prior to the completion of the Exchange Transaction, Greenstar held $200,000 in aggregate principal amount of the Notes.

In total, 62,735,059 common shares were issued in July 2022, representing the Company's acquisition and cancellation of an aggregate principal amount of Notes of $199,522, and a total of 76,804,412 common shares were issued in June and July 2022, representing the Company's acquisition and cancellation of an aggregate principal amount of Notes of $262,620.

TheCanopy Notes were issued pursuant to an indenture dated June 20, 2018, as supplemented on April 30, 2019 and June 29, 2022 (collectively, the “Indenture”“Canopy Notes Indenture”). As a result of athe supplement to the Canopy Notes Indenture dated June 29, 2022 (the “Second Supplemental Indenture”), the Company irrevocably surrendered its right to settle the conversion of any Canopy Note with its common shares. As a result, allhad there been any conversions of Canopy Notes following the execution of the Second Supplemental Indenture will bethese would have been settled entirely in cash.cash, unless otherwise negotiated.

The Noteholders may redeem the Notes at their option at any time from January 15, 2023 to the maturity date for cash. In addition, the holder has the right to redeem the Notes from September 30, 2018 to January 15, 2023, if (i) the market price of the Company’s common shares for at least 20 trading days during a period of 30 consecutive trading days ending on the last trading day of the preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day, (ii) during the 5 business day period after any consecutive 5 trading day period (the “Measurement Period”) in which the trading price per $1 principal amount of the Notes for each trading day in the Measurement Period was less than 98% of the product of the last reported sales price of the Company’s common shares and the conversion rate on each such trading day, (iii) the Notes are called for redemption or (iv) upon occurrence of certain corporate events (a “Fundamental Change”). A Fundamental Change occurred upon completion of the investment by the CBI and its affiliates (together, the “CBI Group”) in the Company in November 2018, and no holders of Notes surrendered any portion of their Notes in connection therewith.22

Under the terms of the Indenture, if a Fundamental Change occurs and a holder elects to redeem its Notes from and including on the date of the Fundamental Change up to, and including, the business day immediately prior to the Fundamental Change repurchase date, the Company, upon conversion by the holder, will settle in cash, subject to certain circumstances.

Prior to July 20, 2021, the Company could not redeem the Notes except in the event of certain changes in Canadian tax law. On or after July 20, 2021, the Company can redeem for cash, subject to certain conditions, any or all of the Notes, at its option, if the last

21


 

reported sales price of the Company’s common shares for at least 20 trading days during any 30 consecutive trading day period ending within 5 trading days immediately preceding the date on which the Company provides notice of redemption exceeds 130% of the initial conversion price on each applicable trading day. The Company may also redeem the Notes, if certain tax laws related to Canadian withholding tax change subject to certain further conditions. The redemption of Notes in either case shall be at a redemption price equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.

TheCanopy Notes were initially recognized at fair value on the balance sheet and continuecontinued to be recorded at fair value.value until their repayment. All subsequent changes in fair value following initial recognition, excluding the impact of the change in fair value related to the Company’s own credit risk, arewere recorded in other income (expense), net. The changes in fair value related to the Company’s own credit risk arewere recorded through other comprehensive income (loss). During the three and nine months ended December 31, 2022,June 30, 2023, the Company entered into privately negotiated exchange agreements (the "June 2023 Exchange Agreements") with certain holders of the Canopy Notes (the "Noteholders"), pursuant to which the Company acquired and cancelled an aggregate principal amount of Canopy Notes of $nil12,500 in exchange for cash, including accrued and unpaid interest owing under such Canopy Notes, and the issuance of an aggregate 2,434,274 Canopy Growth common shares.

On July 13, 2023, the Company entered into privately negotiated redemption agreements (collectively, the "Redemption Agreements") with certain Noteholders of the Canopy Notes pursuant to which approximately $262,620193,000 aggregate principal amount of the outstanding Canopy Notes held by such Noteholders were redeemed by the Company (the "Redemption") for: (i) a cash payment in the aggregate amount of approximately $101,000; (ii) the issuance of an aggregate of 9,043,092 Canopy Growth common shares; and (iii) the issuance of $40,380 aggregate principal amount of unsecured non-interest bearing convertible debentures (the "Debentures"). Following the Redemption, the Company settled the remaining aggregate principal amount owing under the outstanding Canopy Notes in cash and, as of the maturity date, there were no Canopy Notes outstanding.

The Debentures were issued pursuant to a debenture indenture dated July 14, 2023 between the Company and Odyssey Trust Company, in its capacity as trustee. The Debentures were convertible into Canopy Growth common shares (the “Debenture Shares”) at the option of the holder at any time or times following approval from the Company’s shareholders for the issuance of all of the Debenture Shares in excess of the Nasdaq threshold of 19.99% and the TSX requirements of 25%, of the issued and outstanding Canopy Growth common shares in accordance with the applicable rules and regulations of the Nasdaq and the TSX (the “Shareholder Approval”) until the maturity date of January 15, 2024, at a conversion price equal to $5.50, respectively, whichsubject to adjustment in certain events.

The Company obtained Shareholder Approval at its Annual General and Special Meeting of shareholders held on September 25, 2023. As of September 30, 2023, all conversions pursuant to the Debentures had been completed and the amount outstanding under the Debentures was $nil.

The acquisition and cancellation of the Canopy Notes pursuant to the June 2023 Exchange Agreements, Redemption of the Canopy Notes and conversions of the Debentures each resulted in a release of accumulated other comprehensive income into other income (expense), net for the three and nine months ended December 31, 20222023 of $nil$nil and $44,3702,373, respectively. The related tax impact of $nil and $14,86213,433, respectively, for the three and nine months ended December 31, 2022, respectively,2023, associated with the aggregate principal amount acquired and cancelled was also released from accumulated other comprehensive income into income tax expense. Refer to Note 20.21.

In connectionOn April 13, 2023, the Company entered into an exchange agreement (the “April 2023 Exchange Agreement”) with Greenstar in order to acquire and cancel $100,000 aggregate principal amount of the Canopy Notes. Pursuant to the April 2023 Exchange Transaction,Agreement, the Company agreed to acquire and cancel $100,000 aggregate principal amount of the Canopy Notes held by Greenstar in exchange for: (i) a cash payment to Greenstar in the three months ended June 30, 2022,amount of the Company recognizedunpaid and accrued interest owing under the Canopy Notes held by Greenstar; and (ii) a derivative liabilitypromissory note (the “CBI Note”) issuable to Greenstar in the aggregate amount of $26,594100,000 in connection with the incremental common shares that were potentially issuable to Noteholders, other than Greenstar, as at June 30, 2022 at the Averaging Pricepayable on the Final Closing. The derivative liability, and associated fair value changes in the three and nine months ended December 31, 2022, were recorded through other income (expense), net.2024. The derivative liability withCBI Note bears interest at a rate of 4.25% per year, payable on maturity of the CBI Note. As a result, Greenstar no longer holds any Canopy Notes. At December 31, 2023, the estimated fair value of the CBI Note was $39,89685,486 was derecognized upon Final Closing, measured using a discounted cash flow model. See Note 23 for additional details on July 18, 2022.how the fair value of the CBI Note is calculated on a recurring basis.

The overall change in fair value of the Canopy Notes during the three and nine months ended December 31, 2023 was a decrease of $nil and $331,250, respectively (three and nine months ended December 31, 2022 was an increase of $4,427 and a decrease of $238,403, respectively (three and nine months ended December 31, 2021, a decrease of $16,806 and a decrease of $120,372, respectively), which included contractual interest of $3,583nil and $13,3702,925, respectively (three and nine months ended December 31, 20212022 – $6,4443,583 and $19,12813,370, respectively) and principal redemption of $nil and $337,380, respectively (three and nine months ended December 31, 2022 – $nil and $262,620, respectively.respectively). Upon redemption, the principal redeemed during the three and nine months ended December 31, 20222023 had a fair value of $nil and $334,005, respectively (three and nine months ended December 31, 2022 – $nil and $225,369, respectively.respectively). Refer to Note 2223 for additional details on how the fair value of the Canopy Notes iswere calculated.

Supreme Cannabis Convertible Debentures and Accretion Debentures

On October 19, 2018, The Supreme Cannabis Company, Inc. (“Supreme Cannabis”) entered into an indenture with Computershare Trust Company of Canada (the “Trustee”) pursuant to which Supreme Cannabis issued 6.0% senior unsecured convertible debentures (the “Supreme Debentures”) for gross proceeds of $100,000. On September 9, 2020, Supreme Cannabis and the Trustee entered into a supplemental indenture to effect certain amendments to the Supreme Debentures, which included among

23


other things: (i) the cancellation of $63,500 of principal amount of the Supreme Debentures; (ii) an increase in the interest rate to 8% per annum; (iii) the extension of the maturity date to September 10, 2025; and (iv) a reduction in the conversion price to $0.2852.85.

In addition, on September 9, 2020, Supreme Cannabis issued new senior unsecured non-convertible debentures (the “Accretion Debentures”). The principal amount began at $nil and accretesaccreted at a rate of 11.06% per annum based on the remaining principal amount of the Supreme Debentures of $36,500 to a maximum of $13,500, compounding on a semi-annual basis commencing on September 9, 2020, and ending on September 9, 2023. As of September 9, 2023, the principal amount of the Accretion Debentures was finalized as $10,434. The Accretion Debentures are payable in cash, but do not bear cash interest and are not convertible into the common shares of Supreme Cannabis (the “Supreme Shares”). The principal amount of the Accretion Debentures will amortize, or be paid, at 1.0% per month over the 24 months prior to maturity. During the three and nine months ended December 31, 2023 principal payments on Accretion Debentures totaled $1,500 and $2,000, respectively.

As a result of the completion of an arrangement on June 22, 2021 by the Company and Supreme Cannabis, pursuant to which the Company acquired 100% of the issued and outstanding Supreme Shares (the “Supreme Arrangement”), the Supreme Debentures remain outstanding as securities of Supreme Cannabis, which, upon conversion will entitle the holder thereof to receive, in lieu of the number of Supreme Shares to which such holder was theretofore entitled, the consideration payable under the Supreme Arrangement that such holder would have been entitled to be issued and receive if, immediately prior to the effective time of the Supreme Arrangement, such holder had been the registered holder of the number of Supreme Shares to which such holder was theretofore entitled.

In connection with the Supreme Arrangement, the Company, Supreme Cannabis and the Trustee entered into a supplemental indenture whereby the Company agreed to issue common shares upon conversion of any Supreme Debenture. In addition, the Company may force conversion of the Supreme Debentures outstanding with 30 days’ notice if the daily volume weighted average trading price of the Company’s common shares is greater than $38.59$385.90 for any 10 consecutive trading days. The Company, Supreme Cannabis and the Trustee entered into a further supplemental indenture whereby the Company agreed to guarantee the obligations of Supreme Cannabis pursuant to the Supreme Debentures and the Accretion Debentures.

22


Prior to September 9, 2023, the Supreme Debentures arewere not redeemable. Beginning on and after September 9, 2023, Supreme Cannabis may from time to time, upon providing 60 days prior written notice to the Trustee, redeem the Convertible Debentures outstanding, provided that the Accretion Debentures have already been redeemed in full.

Convertible Debentures

On February 21, 2023, the Company entered into a subscription agreement (the “Convertible Debenture Agreement”) with an institutional investor (the “Institutional Investor”) pursuant to which the Institutional Investor agreed to purchase up to US$150,000 aggregate principal amount of senior unsecured convertible debentures (“Convertible Debentures”) in a registered direct offering. The Convertible Debentures were issued pursuant to the indenture dated February 21, 2023 (the “Indenture”) between the Company and Computershare Trust Company of Canada, as trustee. Pursuant to the Convertible Debenture Agreement, an initial $135,160 (US$100,000) aggregate principal amount of the Convertible Debentures was sold to the Institutional Investor on February 21, 2023. The conditions with respect to the remaining US$50,000 aggregate principal amount of the Convertible Debentures were neither satisfied nor waived.

In the three months ended June 30, 2023, $93,228 (US$72,800) in aggregate principal amount of the Convertible Debentures were converted for 8,445,894 Canopy Growth common shares. As of June 30, 2023, all conversions pursuant to the Convertible Debentures were completed and the amount outstanding under the Convertible Debentures was $nil.

24


 

16.17. OTHER LIABILITIES

The components of other liabilities are as follows:

 

As at December 31, 2022

 

 

As at March 31, 2022

 

 

As at December 31, 2023

 

 

As at March 31, 2023

 

 

Current

 

 

Long-term

 

 

Total

 

 

Current

 

 

Long-term

 

 

Total

 

 

Current

 

 

Long-term

 

 

Total

 

 

Current

 

 

Long-term

 

 

Total

 

Lease liabilities

 

$

35,537

 

 

$

83,167

 

 

$

118,704

 

 

$

38,035

 

 

$

101,125

 

 

$

139,160

 

 

$

14,020

 

 

$

67,176

 

 

$

81,196

 

 

$

28,421

 

 

$

78,367

 

 

$

106,788

 

Acquisition consideration
and other investment
related liabilities

 

 

7,908

 

 

 

47,169

 

 

 

55,077

 

 

 

4,020

 

 

 

77,834

 

 

 

81,854

 

 

 

19,473

 

 

 

94

 

 

 

19,567

 

 

 

25,945

 

 

 

30,323

 

 

 

56,268

 

Refund liability

 

 

2,937

 

 

 

-

 

 

 

2,937

 

 

 

3,437

 

 

 

-

 

 

 

3,437

 

 

 

5,618

 

 

 

-

 

 

 

5,618

 

 

 

6,434

 

 

 

-

 

 

 

6,434

 

Settlement liabilities and
other

 

 

37,752

 

 

 

11,555

 

 

 

49,307

 

 

 

18,562

 

 

 

11,090

 

 

 

29,652

 

 

 

15,286

 

 

 

5,735

 

 

 

21,021

 

 

 

32,950

 

 

 

13,733

 

 

 

46,683

 

 

$

84,134

 

 

$

141,891

 

 

$

226,025

 

 

$

64,054

 

 

$

190,049

 

 

$

254,103

 

 

$

54,397

 

 

$

73,005

 

 

$

127,402

 

 

$

93,750

 

 

$

122,423

 

 

$

216,173

 

The estimated deferred payments associated with the Wana financial instrument (the "Wana Deferred Payments") within acquisition consideration and other investment related liabilities at December 31, 20222023 is $39,30711,139 (March 31, 20222023 – $70,06626,370).

In connection with See Note 23 for additional details on how the second installment payable byfair value of the Company,Wana Deferred Payments is calculated on behalf of Canopy USA, pursuant to the Amended TRA, as described in Note 10, a liability has been recorded at December 31, 2022 in the amount of $20,630 in settlement liabilities and other.recurring basis.

 

17.18. REDEEMABLE NONCONTROLLING INTEREST

The net changes in the redeemable noncontrolling interests are as follows:

 

 

BioSteel

 

 

Total

 

As at March 31, 2023

 

$

-

 

 

$

-

 

Net income (loss) attributable to redeemable noncontrolling interest

 

 

(18,526

)

 

 

(18,526

)

Adjustments to redemption amount

 

 

18,526

 

 

 

18,526

 

As at December 31, 2023

 

$

-

 

 

$

-

 

 

 

Vert
Mirabel

 

 

BioSteel

 

 

Total

 

 

Vert
Mirabel

 

 

BioSteel

 

 

Total

 

 

 

 

(As Restated)

 

 

 

 

As at March 31, 2022

 

$

1,000

 

 

$

35,200

 

 

$

36,200

 

 

$

1,000

 

 

$

31,500

 

 

$

32,500

 

Net income (loss) attributable to redeemable noncontrolling interest

 

 

508

 

 

 

(18,316

)

 

 

(17,808

)

 

 

508

 

 

 

(22,523

)

 

 

(22,015

)

Adjustments to redemption amount

 

 

(508

)

 

 

20,874

 

 

 

20,366

 

 

 

(508

)

 

 

2,699

 

 

 

2,191

 

Redemption of redeemable noncontrolling interest

 

 

-

 

 

 

(27,350

)

 

 

(27,350

)

 

 

-

 

 

 

(11,676

)

 

 

(11,676

)

As at December 31, 2022

 

$

1,000

 

 

$

10,408

 

 

$

11,408

 

 

$

1,000

 

 

$

-

 

 

$

1,000

 

In August 2023, the Company issued 1,520,605 common shares relating to its acquisition of the Vert Mirabel redeemable noncontrolling interest which had closed in March 2023.

 

 

Vert
Mirabel

 

 

BioSteel

 

 

Total

 

As at March 31, 2021

 

$

11,500

 

 

$

123,800

 

 

$

135,300

 

Net income (loss) attributable to redeemable noncontrolling interest

 

 

(2,401

)

 

 

(10,699

)

 

 

(13,100

)

Adjustments to redemption amount

 

 

2,401

 

 

 

(50,792

)

 

 

(48,391

)

Redemption of redeemable noncontrolling interest

 

 

 

 

 

(5,109

)

 

 

(5,109

)

As at December 31, 2021

 

$

11,500

 

 

$

57,200

 

 

$

68,700

 

 

18.19. SHARE CAPITAL

CANOPY GROWTH

Authorized

An unlimited number of common shares.

(i) Equity financings

There wereOn September 18, 2023, the Company entered into subscription agreements (the "Subscription Agreements") with certain institutional investors (the "Investors"). Pursuant to the terms of the Subscription Agreements, the Company issued no2,292,947 equity financings duringunits of the nine months ended December 31, 2022 (nine months ended December 31, 2021 - Company (the "Units") to the Investors at a price per Unit of US$no10.90ne) for aggregate gross proceeds of $33,745 (US$25,000) (the "Unit Offering").Each Unit is comprised of one Canopy Growth common share and one common share purchase warrant (a "Warrant"). Each Warrant entitles the holder to acquire one Canopy Growth common share at a price per share equal to US$13.50 for a period of five years from the date of issuance. The Unit Offering closed on September 19, 2023. The Investors also held an over-allotment option to acquire up to an additional 2,292,947 Units at a price per Unit of US$10.90 for aggregate gross proceeds of approximately US$25,000 at the discretion of the Investors at any time on or before November 2, 2023 (the "Over-Allotment Option"). The Over-Allotment Option was not exercised by the Investors and expired on November 2, 2023.

23The gross proceeds from the Unit Offering were allocated to the Canopy Growth common shares, Warrants, and Over-Allotment Option based on their relative fair values.

25


 

(ii) Other issuances of common shares

During the nine months ended December 31, 2023, the Company issued the following common shares, net of share issuance costs, as a result of business combinations, milestones being met, and other equity-settled transactions:

 

 

Number of common shares1

 

 

Share
capital

 

 

Share
based
reserve

 

Settlement of Convertible Debentures

 

 

8,445,894

 

 

$

108,055

 

 

$

-

 

Settlement of Canopy Notes

 

 

11,477,366

 

 

 

57,084

 

 

 

-

 

Settlement of Debentures

 

 

7,341,818

 

 

 

87,754

 

 

 

-

 

Other issuances and share issue costs

 

 

6,165

 

 

 

(317

)

 

 

(80

)

Total

 

 

27,271,243

 

 

$

252,576

 

 

$

(80

)

1 Prior period share amounts have been retrospectively adjusted to reflect the Share Consolidation, which became effective on December 15, 2023. See Note 2 for details.

During the nine months ended December 31, 2022, the Company issued the following common shares, net of share issuance costs, as a result of business combinations, milestones being met, and other equity-settled transactions:

 

 

Number of common shares1

 

 

Share
capital

 

 

Share
based
reserve

 

Jetty Agreements

 

 

842,654

 

 

$

59,013

 

 

$

-

 

HSCP Holders pursuant to Amended TRA

 

 

564,893

 

 

 

20,630

 

 

 

-

 

Completion of acquisition milestones

 

 

22,242

 

 

 

1,379

 

 

 

(1,379

)

Other issuances

 

 

23,780

 

 

 

1,209

 

 

 

(353

)

Total

 

 

1,453,569

 

 

$

82,231

 

 

$

(1,732

)

 

 

Number of common shares

 

 

Share
capital

 

 

Share
based
reserve

 

Jetty Agreements

 

 

8,426,539

 

 

$

59,013

 

 

$

-

 

HSCP Holders pursuant to Amended TRA

 

 

5,648,927

 

 

 

20,630

 

 

 

-

 

Completion of acquisition milestones

 

 

222,421

 

 

 

1,379

 

 

 

(1,379

)

Other issuances

 

 

237,802

 

 

 

1,209

 

 

 

(353

)

Total

 

 

14,535,689

 

 

$

82,231

 

 

$

(1,732

)

For the three and nine months ended December 31, 2022, the Company also issued 8,692,1281 common shares with a value of $Prior year share amounts have been retrospectively adjusted to reflect the Share Consolidation, which became effective on December 15, 2023. See Note 2 for details.26,506 relating to its redemption of the redeemable noncontrolling interest in BioSteel. The redemption increases the Company's interest in BioSteel from 78.6% to 90.3%.

During the nine months ended December 31, 2021, the Company issued the following common shares, net of share issuance costs, as a result of business combinations, milestones being met, and other equity-settled transactions:

 

 

Number of common shares

 

 

Share
capital

 

 

Share
based
reserve

 

Acquisition of Supreme Cannabis

 

 

9,013,400

 

 

$

260,668

 

 

$

-

 

Completion of acquisition milestones

 

 

1,295,285

 

 

 

29,276

 

 

 

(29,721

)

Other issuances

 

 

351,252

 

 

 

6,630

 

 

 

(405

)

Total

 

 

10,659,937

 

 

$

296,574

 

 

$

(30,126

)

 

(iii) Warrants

 

 

Number of
whole
warrants

 

 

Average
exercise
price

 

 

Warrant
value

 

Balance outstanding at March 31, 20221

 

 

128,193,047

 

 

$

58.04

 

 

$

2,581,788

 

Expiry of warrants

 

 

-

 

 

 

-

 

 

 

-

 

Balance outstanding at December 31, 20221

 

 

128,193,047

 

 

$

58.04

 

 

$

2,581,788

 

 

 

Number of
whole
warrants
2

 

 

Average
exercise
price

 

 

Warrant
value

 

Balance outstanding at March 31, 20231

 

 

12,819,305

 

 

$

580.40

 

 

$

2,581,788

 

Issuance of warrants from private placement

 

 

2,292,947

 

 

 

18.33

 

 

 

8,977

 

Expiry of warrants

 

 

(12,692,731

)

 

 

583.62

 

 

 

-

 

Balance outstanding at December 31, 2023

 

 

2,419,521

 

 

$

30.34

 

 

$

2,590,765

 

1 This balance excludes the Tranche C Warrants (as defined below), which represent a derivative liability and have nominal value. See Note 29.28.

2 Prior period warrant amounts have been retrospectively adjusted to reflect the Share Consolidation, which became effective on December 15, 2023. See Note 2 for details.

 

 

Number of
whole
warrants

 

 

Average
exercise
price

 

 

Warrant
value

 

Balance outstanding at March 31, 20211

 

 

127,073,136

 

 

$

58.33

 

 

$

2,568,438

 

Supreme Cannabis warrants

 

 

1,265,742

 

 

 

25.61

 

 

 

13,350

 

Expiry of warrants

 

 

(145,831

)

 

 

32.61

 

 

 

-

 

Balance outstanding at December 31, 20211

 

 

128,193,047

 

 

$

58.04

 

 

$

2,581,788

 

On November 1, 2023, the Tranche A Warrants (as defined below) expired in accordance with their terms without having been exercised. In accordance with the terms of the Tranche B Warrants (as defined below) and Tranche C Warrants, the vesting of the remaining Tranche B Warrants and Tranche C Warrants, as applicable, is conditioned on the exercise, in full, of the Tranche A Warrants. Accordingly, the Tranche B Warrants and Tranche C Warrants are not, and will not become, exercisable and are considered expired as of November 1, 2023.

 

 

Number of
whole
warrants
2

 

 

Average
exercise
price

 

 

Warrant
value

 

Balance outstanding at March 31, 20221

 

 

12,819,305

 

 

$

580.40

 

 

$

2,581,788

 

Expiry of warrants

 

 

-

 

 

 

-

 

 

 

-

 

Balance outstanding at December 31, 20221

 

 

12,819,305

 

 

$

580.40

 

 

$

2,581,788

 

1 This balance excludes the Tranche C Warrants, which represent a derivative liability and have nominal value. See Note 29.28.

2 Prior year warrant amounts have been retrospectively adjusted to reflect the Share Consolidation, which became effective on December 15, 2023. See Note 2 for details.

19.20. SHARE-BASED COMPENSATION

 

CANOPY GROWTH CORPORATION SHARE-BASED COMPENSATION PLAN

Canopy Growth's eligible employees participate in a share-based compensation plan as noted below.

On September 21, 2020,25, 2023, the Company’sCompany's shareholders approved amendments to the Company’s Amended and Restateda new Omnibus Equity Incentive Plan (as amended and restated, the “Omnibus Plan”(the "Omnibus Equity Incentive Plan") pursuant to which the Company can issue share-based long-term incentives. The Omnibus Equity Incentive Plan replaces the Company’s previous equity incentive plan, which was originally approved by the Company’s shareholders extended the maximum term of each Option (as defined below) to be granted by the Company to ten years from the date of grant rather than six years from the date of grant. On May 27, 2021, the Board of Directorson July 30, 2018 (the “Previous Equity Incentive Plan”). The approval of the Company (the "Board") approved certain amendments toOmnibus Equity Incentive Plan and replacement of the Omnibus Plan in order to reduce the maximumPrevious

2426


 

number of shares available for issuance underEquity Incentive Plan are detailed in the Omnibus Plan from 15% ofCompany’s annual definitive proxy statement filed with the issuedSecurities and outstanding shares to Exchange Commission on August 9, 2023.

10% of the issued and outstanding shares from time to time less the number of shares issuable pursuant to other security-based compensation arrangements of the Company. All directors, officers, employees and independent contractorsconsultants of the Company are eligible to receive awards of common share purchase options (“Options”), restricted share units (“RSUs”), performance share units (“PSUs”), deferred share units stock appreciation rights, performance awards, or other shares-based awards (collectively, the “Awards”) under the Omnibus Equity Incentive Plan, subject to certain limitations. The Omnibus Equity Incentive Plan allows for a maximum term of each Option to be ten years from the date of grant and the maximum number of common shares available for issuance under the Omnibus Equity Incentive Plan remains at 10% of the issued and outstanding common shares from time to time, less the number of common shares issuable pursuant to other security-based compensation arrangements of the Company (including common shares reserved for issuance under the Previous Equity Incentive Plan).

The Omnibus Equity Incentive Plan was adopted on September 25, 2023. No further awards will be granted under the Previous Equity Incentive Plan and any new Awards will be issued by the Company pursuant to the terms of the Omnibus Equity Incentive Plan. However, outstanding and unvested awards granted under the Previous Equity Incentive Plan will continue to be governed in accordance with the terms of such plan.

The maximum number of common shares reserved for Awards is 49,489,1398,293,196 at December 31, 2022.2023. As of December 31, 2022,2023, the only Awards issued have been Options, RSUs and PSUsperformance share units ("PSUs") under the Previous Equity Incentive Plan, and Options and RSUs under the Omnibus Equity Incentive Plan.

The Omnibus Equity Incentive Plan is administered by the Corporate Governance, Compensation and Nominating Committee of the Board (the “CGC&N Committee”) which establishes in its discretion, among other things, exercise prices, at not less than the market priceFair Market Value (as defined in the Omnibus Equity Incentive Plan) at the date of grant, vesting terms and expiry dates. Awards under the Omnibus Plan generally vest in increments with 1/3 vesting on each of the first, second and third anniversaries from the date of grant, with expiry dates set(set at up to ten years from issuance,issuance) for Awards, subject to the discretion of the CGC&N Committee pursuant to the Omnibus Plan to provide for an alternative expiry date or vesting period in an award agreement for the grant of Awards, subject to limits contained in the Omnibus Equity Incentive Plan.

Under the Company’s Employee Share Purchase Plan (the “Purchase Plan”) the aggregate number of common shares that may be issued is 600,00060,000, and the maximum number of common shares which may be issued in any one fiscal year shall not exceed 300,00030,000. For the three and nine months ended December 31, 2022,2023, nil and 237,8026,426 common shares were issued under the Purchase Plan (three and nine months ended December 31, 20212022nil and 61,10323,780). The Purchase Plan concluded in August 2023 as all of the common shares available have been purchased and the Company does not currently intend to reinstate the Purchase Plan at this time.

The following is a summary of the changes in the Options outstanding during the nine months ended December 31, 2022:2023:

 

 

Options
issued
1

 

 

Weighted
average
exercise price
1

 

Balance outstanding at March 31, 2023

 

 

1,375,089

 

 

$

271.20

 

Options granted

 

 

2,438,257

 

 

 

6.22

 

Options exercised

 

 

(643

)

 

 

0.60

 

Options forfeited

 

 

(782,151

)

 

 

188.33

 

Balance outstanding at December 31, 2023

 

 

3,030,552

 

 

$

80.00

 

1 Prior period options and exercise price amounts have been retrospectively adjusted to reflect the Share Consolidation, which became effective on December 15, 2023. See Note 2 for details.

 

 

Options
issued

 

 

Weighted
average
exercise price

 

Balance outstanding at March 31, 2022

 

 

16,782,962

 

 

$

33.89

 

Options granted

 

 

4,651,176

 

 

 

4.94

 

Options exercised

 

 

(76,929

)

 

 

3.41

 

Options forfeited

 

 

(6,058,172

)

 

 

29.37

 

Balance outstanding at December 31, 2022

 

 

15,299,037

 

 

$

27.07

 

The following is a summary of the Options outstanding as at December 31, 2022:2023:

 

 

Options Outstanding

 

 

Options Exercisable

 

 

 

 

 

 

Weighted Average

 

 

 

 

 

Weighted Average

 

 

 

 

 

 

Remaining

 

 

 

 

 

Remaining

 

 

 

Outstanding at

 

 

Contractual Life

 

 

Exercisable at

 

 

Contractual Life

 

Range of Exercise Prices1

 

December 31, 20231

 

 

(years)

 

 

December 31, 20231

 

 

(years)

 

$0.60 - $7.50

 

 

2,126,514

 

 

 

5.49

 

 

 

1,971

 

 

 

0.58

 

$7.51 - $56.10

 

 

284,535

 

 

 

4.61

 

 

 

98,291

 

 

 

4.55

 

$56.11 - $676.40

 

 

619,503

 

 

 

1.48

 

 

 

495,814

 

 

 

1.30

 

 

 

 

3,030,552

 

 

 

4.58

 

 

 

596,076

 

 

 

1.83

 

1 Prior period Options and exercise price amounts have been retrospectively adjusted to reflect the Share Consolidation, which became effective on December 15, 2023. See Note 2 for details.

 

 

Options Outstanding

 

 

Options Exercisable

 

 

 

 

 

 

Weighted Average

 

 

 

 

 

Weighted Average

 

 

 

 

 

 

Remaining

 

 

 

 

 

Remaining

 

 

 

Outstanding at

 

 

Contractual Life

 

 

Exercisable at

 

 

Contractual Life

 

Range of Exercise Prices

 

December 31, 2022

 

 

(years)

 

 

December 31, 2022

 

 

(years)

 

$0.06 - $24.62

 

 

6,083,908

 

 

 

4.83

 

 

 

1,369,076

 

 

 

2.77

 

$24.63 - $33.53

 

 

3,281,232

 

 

 

2.58

 

 

 

2,033,996

 

 

 

2.24

 

$33.54 - $36.80

 

 

1,569,568

 

 

 

1.94

 

 

 

1,569,568

 

 

 

1.94

 

$36.81 - $42.84

 

 

1,800,926

 

 

 

2.05

 

 

 

1,794,649

 

 

 

2.02

 

$42.85 - $67.64

 

 

2,563,403

 

 

 

2.10

 

 

 

2,563,403

 

 

 

2.10

 

 

 

 

15,299,037

 

 

 

3.27

 

 

 

9,330,692

 

 

 

2.19

 

 

At December 31, 2022,2023, the weighted average exercise price of the Options outstanding and Options exercisable was $27.0780.00 and $37.46321.19, respectively (March 31, 20222023 – $33.89271.20 and $38.33372.80, respectively).

27


The Company recorded $1,7902,671 and $5,1757,637 in share-based compensation expense related to Options and Purchase Plan shares issued to employees and contractors for the three and nine months ended December 31, 2022,2023, respectively (three and nine months ended December 31, 20212022 – $3,6961,790 and $22,0385,175, respectively). The share-based compensation expense for the nine months ended December 31, 2022,2023, includes an amount related to 1,078,748107,874 Options being provided in exchange for services which are subject to performance conditions (for the nine months ended December 31, 202120221,559,413107,874).

During the three months ended June 30, 2021, the Company issued replacement options to employees in relation to the acquisition of Supreme Cannabis and recorded share-based compensation expense of $823.

25


The Company uses the Black-Scholes option pricing model to establish the fair value of Options granted during the three months ended December 31, 20222023 and 2021,2022, on their measurement date by applying the following assumptions:

 

 

December 31,

 

December 31,

 

 

2023

 

2022

Risk-free interest rate

 

3.95%

 

3.47%

Expected life of options (years)

 

3 - 5

 

3 - 5

Expected volatility

 

101.08%

 

82%

Expected forfeiture rate

 

21.45%

 

20%

Expected dividend yield

 

nil

 

nil

Black-Scholes value of each option1

 

$5.33

 

$33.40

1 Prior year Option value has been retrospectively adjusted to reflect the Share Consolidation, which became effective on December 15, 2023. See Note 2 for details.

 

 

December 31,

 

December 31,

 

 

2022

 

2021

Risk-free interest rate

 

3.47%

 

1.21%

Expected life of options (years)

 

3 - 5

 

3 - 5

Expected volatility

 

82%

 

75%

Expected forfeiture rate

 

20%

 

18%

Expected dividend yield

 

nil

 

nil

Black-Scholes value of each option

 

$3.34

 

$7.55

 

Volatility was estimated by using the historical volatility of the Company. The expected life in years represents the period of time that Options granted are expected to be outstanding. The risk-free rate was based on zero coupon Canada government bonds with a remaining term equal to the expected life of the Options.

During the nine months ended December 31, 2022, 76,929 Options were exercised ranging in price from $0.06 to $8.18 for gross proceeds of $271 (for the nine months ended December 31, 2021 – 421,476 Options were exercised ranging in price from $0.06 to $36.34 for gross proceeds of $5,455).

For the three and nine months ended December 31, 2022,2023, the Company recorded $4,2651,022 and $15,7182,490, respectively in share-based compensation expense related to RSUs and PSUs (for the three and nine months ended December 31, 20212022 – $1,9504,265 and $7,93515,718, respectively).

The following is a summary of the changes in the Company’s RSUs and PSUs during the nine months ended December 31, 2022:

2023:

 

 

Number of RSUs
and PSUs
1

 

Balance outstanding at March 31, 20222023

 

 

3,477,292258,322

 

RSUs and PSUs granted

 

 

3,128,1981,539,859

 

RSUs and PSUs released

 

 

(359,628115,968

)

RSUs and PSUs cancelled and forfeited

 

 

(1,925,026281,023

)

Balance outstanding at December 31, 20222023

 

 

4,320,8361,401,190

 

1 Prior period amounts for RSUs and PSUs (granted pursuant to the Previous Equity Incentive Plan) have been retrospectively adjusted to reflect the Share Consolidation, which became effective on December 15, 2023. See Note 2 for details.

 

During the three and nine months ended December 31, 2022, the Company recorded $nil in share-based compensation expense related to acquisition milestones (for the three and nine months ended December 31, 2021 – $971 and $4,376, respectively).

During the three and nine months ended December 31, 2022, 222,421 common shares were released on completion of acquisition milestones (during the three and nine months ended December 31, 2021 – 419,884 and 1,295,285, respectively). At December 31, 2022, there were up to 125,489 common shares to be issued on the completion of acquisition and asset purchase milestones. In certain cases, the number of common shares to be issued is based on the volume weighted average share price at the time the milestones are met. The number of common shares has been estimated assuming the milestones were met at December 31, 2022.

BioSteel share-based payments

On October 1, 2019, the Company purchased 72% of the outstanding shares of BioSteel Sports Nutrition Inc. (“BioSteel”). BioSteel has a stock option plan under which non-transferable options to purchase common shares of BioSteel may be granted to directors, officers, employees, or independent contractors of the BioSteel. As at December 31, 2022, BioSteel had 924,719 (March 31, 2022 – 1,565,300) options outstanding which vest in equal tranches over a 5-year period. In determining the amount of share-based compensation related to these options, BioSteel used the Black-Scholes option pricing model to establish the fair value of options on their measurement date. The Company recorded $373 and $832 of share-based compensation expense related to the BioSteel options

26


during the three and nine months ended December 31, 2022, respectively, (three and nine months ended December 31, 2021 – $160 and $684, respectively).

20.21. ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)

Accumulated other comprehensive income includes the following components:

 

 

Foreign currency translation adjustments

 

 

Changes of own credit risk of financial liabilities

 

 

Accumulated other comprehensive income (loss)

 

As at March 31, 2023

 

 

(30,261

)

 

 

16,401

 

 

 

(13,860

)

Settlement of unsecured senior notes, net of deferred income tax

 

 

-

 

 

 

11,060

 

 

 

11,060

 

Other comprehensive (loss) income

 

 

575

 

 

 

(13,824

)

 

 

(13,249

)

As at December 31, 2023

 

$

(29,686

)

 

$

13,637

 

 

$

(16,049

)

 

 

Foreign currency translation adjustments

 

 

Changes of own credit risk of financial liabilities

 

 

Accumulated other comprehensive income (loss)

 

 

Foreign currency translation adjustments

 

 

Changes of own credit risk of financial liabilities

 

 

Accumulated other comprehensive income (loss)

 

As at March 31, 2022

 

$

(57,468

)

 

$

15,186

 

 

$

(42,282

)

 

$

(57,468

)

 

$

15,186

 

 

$

(42,282

)

Settlement of unsecured senior notes, net of tax

 

 

-

 

 

 

(29,507

)

 

 

(29,507

)

Settlement of unsecured senior notes, net of deferred income tax

 

 

-

 

 

 

(29,507

)

 

 

(29,507

)

Other comprehensive income

 

 

24,694

 

 

 

32,847

 

 

 

57,541

 

 

 

24,694

 

 

 

32,847

 

 

 

57,541

 

As at December 31, 2022

 

$

(32,774

)

 

$

18,526

 

 

$

(14,248

)

 

$

(32,774

)

 

$

18,526

 

 

$

(14,248

)

 

 

 

Foreign currency translation adjustments

 

 

Changes of own credit risk of financial liabilities

 

 

Accumulated other comprehensive income (loss)

 

As at March 31, 2021

 

$

(28,246

)

 

$

(5,994

)

 

$

(34,240

)

Other comprehensive (loss) income

 

 

(18,767

)

 

 

26,280

 

 

 

7,513

 

As at December 31, 2021

 

$

(47,013

)

 

$

20,286

 

 

$

(26,727

)

28


 

21.22. NONCONTROLLING INTERESTS

The net change in the noncontrolling interests is as follows:

 

 

BioSteel

 

 

Other

 

 

Total

 

As at March 31, 2023

 

 

1,447

 

 

 

140

 

 

 

1,587

 

Comprehensive loss

 

 

(18,526

)

 

 

-

 

 

 

(18,526

)

Net loss attributable to redeemable noncontrolling interest

 

 

18,526

 

 

 

-

 

 

 

18,526

 

Share-based compensation

 

 

148

 

 

 

-

 

 

 

148

 

Ownership changes

 

 

(1,595

)

 

 

(1

)

 

 

(1,596

)

As at December 31, 2023

 

$

-

 

 

$

139

 

 

$

139

 

 

 

 

Vert
Mirabel

 

 

BioSteel

 

 

Other

 

 

Total

 

As at March 31, 2022

 

$

-

 

 

$

2,497

 

 

$

1,844

 

 

$

4,341

 

Comprehensive income (loss)

 

 

508

 

 

 

(18,316

)

 

 

(1,844

)

 

 

(19,652

)

Net (income) loss attributable to redeemable noncontrolling
   interest

 

 

(508

)

 

 

18,316

 

 

 

-

 

 

 

17,808

 

Share-based compensation

 

 

-

 

 

 

495

 

 

 

-

 

 

 

495

 

Ownership changes

 

 

-

 

 

 

(1,552

)

 

 

1,356

 

 

 

(196

)

As at December 31, 2022

 

$

-

 

 

$

1,440

 

 

$

1,356

 

 

$

2,796

 

 

 

Vert
Mirabel

 

 

BioSteel

 

 

Other non-
material
interests

 

 

Total

 

As at March 31, 2021

 

$

-

 

 

$

1,658

 

 

$

3,051

 

 

$

4,709

 

Comprehensive loss

 

 

(2,401

)

 

 

(10,699

)

 

 

(1,207

)

 

 

(14,307

)

Net loss attributable to redeemable noncontrolling interest

 

 

2,401

 

 

 

10,699

 

 

 

-

 

 

 

13,100

 

Share-based compensation

 

 

-

 

 

 

684

 

 

 

-

 

 

 

684

 

As at December 31, 2021

 

$

-

 

 

$

2,342

 

 

$

1,844

 

 

$

4,186

 

 

 

Vert
Mirabel

 

 

BioSteel

 

 

Other non-
material
interests

 

 

Total

 

 

 

 

 

 

(As Restated)

 

 

 

 

 

 

 

As at March 31, 2022

 

$

-

 

 

$

2,497

 

 

$

1,844

 

 

$

4,341

 

Comprehensive income (loss)

 

 

508

 

 

 

(22,523

)

 

 

(1,844

)

 

 

(23,859

)

Net (income) loss attributable to redeemable noncontrolling
   interest

 

 

(508

)

 

 

22,523

 

 

 

-

 

 

 

22,015

 

Share-based compensation

 

 

-

 

 

 

495

 

 

 

-

 

 

 

495

 

Ownership changes

 

 

-

 

 

 

-

 

 

 

1,356

 

 

 

1,356

 

Redemption of redeemable noncontrolling interests, net

 

 

-

 

 

 

(1,552

)

 

 

-

 

 

 

(1,552

)

As at December 31, 2022

 

$

-

 

 

$

1,440

 

 

$

1,356

 

 

$

2,796

 

 

22.23. FAIR VALUE OF FINANCIAL INSTRUMENTS

Fair value measurements are made using a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value:

Level 1 – defined as observable inputs such as quoted prices in active markets;
Level 2 – defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and
Level 3 – defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.

The fair value measurement is categorized in its entirety by reference to its lowest level of significant input.

The Company records cash, accounts receivable, interest receivable and accounts payable, and other accrued expenses and liabilities at cost. The carrying values of these instruments approximate their fair value due to their short-term maturities. Unless

27


otherwise noted, it is management's opinion that the Company is not exposed to significant interest or credit risks arising from these financial instruments.

Assets and liabilities recognized or disclosed at fair value on a nonrecurring basis may include items such as property, plant and equipment, goodwill and other intangible assets, equity and other investments and other assets. The Company determines the fair value of these items using Level 3 inputs, as described in the related sections below.

29


The following table represents ourthe Company's financial assets and liabilities measured at estimated fair value on a recurring basis:

 

Fair value measurement using

 

 

 

 

 

Fair value measurement using

 

 

 

 

 

Quoted

 

 

Significant

 

 

 

 

 

 

 

 

Quoted

 

 

Significant

 

 

 

 

 

 

 

 

prices in

 

other

 

Significant

 

 

 

 

prices in

 

other

 

Significant

 

 

 

 

active

 

observable

 

unobservable

 

 

 

 

active

 

observable

 

unobservable

 

 

 

 

markets

 

inputs

 

inputs

 

 

 

 

markets

 

inputs

 

inputs

 

 

 

 

(Level 1)

 

 

(Level 2)

 

 

(Level 3)

 

 

Total

 

 

(Level 1)

 

 

(Level 2)

 

 

(Level 3)

 

 

Total

 

December 31, 2022

 

 

 

 

 

 

 

 

 

 

 

 

December 31, 2023

 

 

 

 

 

 

 

 

 

 

 

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

Short-term investments

 

$

43,436

 

 

$

-

 

 

$

-

 

 

$

43,436

 

Restricted short-term investments

 

 

7,275

 

 

 

-

 

 

 

-

 

 

 

7,275

 

Other financial assets

 

 

3,613

 

 

 

-

 

 

 

380,311

 

 

 

383,924

 

Liabilities:

 

 

 

 

 

 

 

 

 

Long-term debt

 

 

-

 

 

 

-

 

 

 

85,486

 

 

 

85,486

 

Other liabilities

 

 

-

 

 

 

-

 

 

 

11,139

 

 

 

11,139

 

 

 

 

 

 

 

 

 

 

March 31, 2023

 

 

 

 

 

 

 

 

 

 

 

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Short-term investments

 

$

191,119

 

 

$

-

 

 

$

-

 

 

$

191,119

 

 

$

105,526

 

 

$

-

 

 

$

-

 

 

$

105,526

 

Restricted short-term investments

 

 

12,932

 

 

 

-

 

 

 

-

 

 

 

12,932

 

 

 

11,765

 

 

 

-

 

 

 

-

 

 

 

11,765

 

Other financial assets

 

 

251

 

 

 

-

 

 

 

508,813

 

 

 

509,064

 

 

 

269

 

 

 

-

 

 

 

559,525

 

 

 

559,794

 

Liabilities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Unsecured senior notes

 

 

-

 

 

 

325,555

 

 

 

-

 

 

 

325,555

 

 

 

-

 

 

 

331,250

 

 

 

-

 

 

 

331,250

 

Warrant derivative liability

 

 

-

 

 

 

-

 

 

 

668

 

 

 

668

 

Other liabilities

 

 

-

 

 

 

-

 

 

 

43,102

 

 

 

43,102

 

 

 

-

 

 

 

-

 

 

 

29,952

 

 

 

29,952

 

 

 

 

 

 

 

 

 

 

March 31, 2022

 

 

 

 

 

 

 

 

 

 

 

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

Short-term investments

 

$

595,651

 

 

$

-

 

 

$

-

 

 

$

595,651

 

Restricted short-term investments

 

 

12,216

 

 

 

-

 

 

 

-

 

 

 

12,216

 

Other financial assets

 

 

490

 

 

 

-

 

 

 

787,816

 

 

 

788,306

 

Liabilities:

 

 

 

 

 

 

 

 

 

Unsecured senior notes

 

 

-

 

 

 

563,958

 

 

 

-

 

 

 

563,958

 

Liability arising from Acreage Arrangement

 

 

-

 

 

 

-

 

 

 

47,000

 

 

 

47,000

 

Warrant derivative liability

 

 

-

 

 

 

-

 

 

 

26,920

 

 

 

26,920

 

Other liabilities

 

 

-

 

 

 

-

 

 

 

70,066

 

 

 

70,066

 

 

The following table summarizes the valuation techniques and significant unobservable inputs in the fair value measurement of significant level 2 financial instruments:

 

Financial asset / financial liability

 

Valuation techniques

 

Key inputs

 

Unsecured senior notes

 

Senior note pricing model

 

Quoted prices in over-the-counter broker market

 

28


The following table summarizes the valuation techniques and significant unobservable inputs in the fair value measurement of significant level 3 financial instruments:

29


 

Financial asset / financial liability

 

Valuation techniques

 

Significant unobservable inputs

 

Relationship of unobservable inputs to fair value

 

Acreage financial instrument

 

Probability weighted expected return model

 

Probability of each scenario

 

Change in probability of occurrence in each scenario will result in a change in fair value

 

 

 

model

 

Number of common shares to be issued

 

Increase or decrease in value and number of common shares will result in a decrease or increase in fair value

Intrinsic value of Acreage

Increase or decrease in intrinsic value will result in an increase or decrease in fair value

 

 

 

 

 

Probability and timing of US legalization

 

Increase or decrease in probability of US legalization will result in an increase or decrease in fair value

 

 

 

 

 

Estimated premium on US legalization

 

Increase or decrease in estimated premium on US legalization will result in an increase or decrease in fair value

 

 

 

 

 

Control premium

 

Increase or decrease in estimated control premium will result in an increase or decrease in fair value

 

 

 

 

 

Market access premium

 

Increase or decrease in estimated market access premium will result in an increase or decrease in fair value

30


 

TerrAscend Exchangeable Shares, TerrAscend Option

 

Put option pricing model

 

Probability and timing of US legalization

 

Increase or decrease in probability of US legalization will result in an increase or decrease in fair value

 

Hempco Debenture

 

Discounted cash flow

 

Discount rate

 

Increase or decrease in discount rate will result in a decrease or increase in fair value

 

TerrAscend warrants - December 2022

 

Black-Sholes option pricing model

 

Probability and timing of US legalization

 

Increase or decrease in probability of US legalization will result in an increase or decrease in fair value

 

Wana financial instrument - Call

 

Discounted cash flow

 

Expected future Wana cash flows

 

Increase or decrease in expected future Wana cash flows will result in an increase or decrease in fair value

 

OptionOptions

 

 

 

Discount rate

 

Increase or decrease in discount rate will result in a decrease or increase in fair value

 

Wana financial instrument - Deferred Payments

 

Monte Carlo simulation model

 

Probability and timing of US legalization

 

Increase or decrease in probability of US legalization will result in an increase or decrease in fair value

 

 

 

 

 

Volatility of Wana equity

 

Increase or decrease in volatility will result in an increase or decrease in fair value

 

Jetty financial instrument -

 

Discounted cash flow

 

Expected future Jetty cash flows

 

Increase or decrease in expected future Jetty cash flows will result in an increase or decrease in fair value

 

Call OptionOptions

 

 

 

Discount rate

 

Increase or decrease in discount rate will result in a decrease or increase in fair value

30


 

Jetty financial instrument - Deferred Payments

 

Monte Carlo simulation model

 

Probability and timing of US legalization

 

Increase or decrease in probability of US legalization will result in an increase or decrease in fair value

 

Payments

 

 

 

Volatility of Jetty equity and revenue

 

Increase or decrease in volatility will result in an increase or decrease in fair value

 

Warrant derivative liability

Monte Carlo simulation model

Volatility of Canopy Growth share price

Increase or decrease in volatility will result in an increase or decrease in fair value

BioSteel redeemable noncontrolling interestCBI promissory note

 

Discounted cash flow

 

Discount rate

 

Increase or decrease in discount rate will result in a decrease or increase in fair value

 

BioSteel redeemable noncontrolling

Discounted cash flow

Discount rate

Increase or decrease in discount rate will result in a decrease or increase in fair value

interest

 

 

 

Expected future BioSteel cash flows

 

Increase or decrease in expected future BioSteel cash flows will result in an increase or decrease in fair value

 

Vert Mirabel redeemableAcreage Debt Option Premium

Monte Carlo simulation model

Volatility of Acreage share price

Increase or decrease in volatility will result in a decrease or increase in fair value

Acreage Tax Receivable

 

Discounted cash flow

 

Discount rate

 

Increase or decrease in discount rate will result in a decrease or increase in fair value

 

noncontrolling interestAgreement

Probability-weighted expected return

Probability of each scenario

Change in probability of occurrence in each scenario will result in a change in fair value

 

 

 

model

Future wholesale price

Probability and production levelstiming of US legalization

 

Increase or decrease in future wholesale price and production levelsprobability of US legalization will result in an increase or decrease in fair value

 

31


23.24. REVENUE

Revenue is disaggregated as follows:

 

Three months ended

 

 

Nine months ended

 

 

Three months ended

 

 

Nine months ended

 

 

December 31,

 

December 31,

 

December 31,

 

December 31,

 

 

December 31,

 

December 31,

 

December 31,

 

December 31,

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

Canada cannabis

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Canadian adult-use cannabis

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Business-to-business1

 

$

21,522

 

 

$

33,282

 

 

$

73,379

 

 

$

117,902

 

 

$

23,386

 

 

$

21,522

 

 

$

71,591

 

 

$

73,379

 

Business-to-consumer

 

 

11,036

 

 

 

14,477

 

 

 

36,243

 

 

 

48,473

 

 

 

-

 

 

 

11,036

 

 

 

-

 

 

 

36,243

 

 

 

32,558

 

 

 

47,759

 

 

 

109,622

 

 

 

166,375

 

 

 

23,386

 

 

 

32,558

 

 

 

71,591

 

 

 

109,622

 

Canadian medical cannabis2

 

 

14,059

 

 

 

12,919

 

 

 

41,714

 

 

 

39,504

 

 

 

15,642

 

 

 

14,059

 

 

 

45,043

 

 

 

41,714

 

 

$

46,617

 

 

$

60,678

 

 

$

151,336

 

 

$

205,879

 

 

$

39,028

 

 

$

46,617

 

 

$

116,634

 

 

$

151,336

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Rest-of-world cannabis

 

 

 

 

 

 

 

 

 

 

 

 

$

10,527

 

 

$

5,846

 

 

$

29,666

 

 

$

30,179

 

C3

 

 

-

 

 

 

9,675

 

 

 

-

 

 

 

33,005

 

Other rest-of-world cannabis

 

 

5,846

 

 

 

12,624

 

 

 

30,179

 

 

 

32,357

 

 

$

5,846

 

 

$

22,299

 

 

$

30,179

 

 

$

65,362

 

 

 

 

 

 

 

 

 

 

 

 

Storz & Bickel

 

$

20,214

 

 

$

25,205

 

 

$

49,351

 

 

$

63,786

 

 

$

18,453

 

 

$

20,214

 

 

$

48,517

 

 

$

49,351

 

BioSteel

 

$

16,363

 

 

$

16,974

 

 

$

64,173

 

 

$

31,147

 

This Works

 

$

8,289

 

 

$

10,730

 

 

$

20,677

 

 

$

26,308

 

 

$

8,165

 

 

$

8,289

 

 

$

21,256

 

 

$

20,677

 

Other

 

 

3,884

 

 

 

5,086

 

 

 

13,475

 

 

 

16,073

 

 

 

2,332

 

 

 

3,884

 

 

 

8,285

 

 

 

13,475

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net revenue

 

$

101,213

 

 

$

140,972

 

 

$

329,191

 

 

$

408,555

 

 

$

78,505

 

 

$

84,850

 

 

$

224,358

 

 

$

265,018

 

 

1Canadian adult-use business-to-business net revenue during the three and nine months ended December 31, 20222023 reflects excise taxes of $10,7979,741 and $33,75431,596, respectively (three and nine months ended December 31, 20212022 – $12,75410,797 and $43,50133,754, respectively).

2Canadian medical cannabis net revenue for the three and nine months ended December 31, 20222023 reflects excise taxes of $1,3391,815 and $3,6254,827, respectively (three and nine months ended December 31, 20212022 – $1,2981,339 and $4,0393,625, respectively).

31


 

The Company recognizes variable consideration related to estimated future product returns and price adjustments as a reduction of the transaction price at the time revenue for the corresponding product sale is recognized. Net revenue reflects actual returns and variable consideration related to estimated returns and price adjustments in the amount of $8,8691,430 and $15,3452,937 for the three and nine months ended December 31, 2022,2023, respectively (three and nine months ended December 31, 20212022 – $3,7265,684 and $12,3757,788, respectively). As of December 31, 2022,2023, the liability for estimated returns and price adjustments was $2,9375,618 (March 31, 20222023 – $3,4376,434).

24.25. OTHER INCOME (EXPENSE), NET

Other income (expense), net is disaggregated as follows:

 

 

Three months ended

 

 

Nine months ended

 

 

 

December 31,

 

 

December 31,

 

 

December 31,

 

 

December 31,

 

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

Fair value changes on other financial assets

 

$

(146,672

)

 

$

(95,815

)

 

$

(163,860

)

 

$

(396,755

)

Fair value changes on liability arising from Acreage
   Arrangement

 

 

-

 

 

 

-

 

 

 

-

 

 

 

47,000

 

Fair value changes on debt

 

 

(5,400

)

 

 

(8,964

)

 

 

(30,614

)

 

 

(32,365

)

Fair value changes on warrant derivative liability

 

 

-

 

 

 

23

 

 

 

-

 

 

 

26,252

 

Fair value changes on acquisition related contingent
   consideration and other

 

 

8,629

 

 

 

1,762

 

 

 

19,146

 

 

 

25,902

 

(Charges) and gain related to settlement of debt

 

 

(571

)

 

 

8,912

 

 

 

(13,124

)

 

 

4,224

 

Interest income

 

 

2,548

 

 

 

7,048

 

 

 

13,833

 

 

 

15,922

 

Interest expense

 

 

(24,623

)

 

 

(33,286

)

 

 

(84,223

)

 

 

(90,658

)

Foreign currency gain (loss)

 

 

(4,069

)

 

 

814

 

 

 

529

 

 

 

1,857

 

Other income (expense), net

 

 

(879

)

 

 

4,016

 

 

 

5,043

 

 

 

2,547

 

 

 

$

(171,037

)

 

$

(115,490

)

 

$

(253,270

)

 

$

(396,074

)

 

 

 

Three months ended

 

 

Nine months ended

 

 

 

December 31,

 

 

December 31,

 

 

December 31,

 

 

December 31,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

Fair value changes on other financial assets

 

$

(95,815

)

 

$

(68,666

)

 

$

(396,755

)

 

$

(263,946

)

Fair value changes on liability arising from Acreage
   Arrangement

 

 

-

 

 

 

59,000

 

 

 

47,000

 

 

 

497,000

 

Fair value changes on unsecured senior notes

 

 

(8,964

)

 

 

606

 

 

 

(32,365

)

 

 

81,342

 

Fair value changes on warrant derivative liability

 

 

23

 

 

 

67,282

 

 

 

26,252

 

 

 

578,084

 

Fair value changes on acquisition related contingent
   consideration and other

 

 

1,762

 

 

 

712

 

 

 

25,902

 

 

 

544

 

Gain (loss) and charges related to settlement of debt

 

 

8,912

 

 

 

-

 

 

 

4,224

 

 

 

-

 

Interest income

 

 

7,048

 

 

 

1,575

 

 

 

15,922

 

 

 

6,977

 

Interest expense

 

 

(33,288

)

 

 

(26,408

)

 

 

(90,660

)

 

 

(77,618

)

Foreign currency gain (loss)

 

 

2,966

 

 

 

990

 

 

 

(8,828

)

 

 

2,902

 

Gain (loss) on disposal/acquisition of consolidated entity

 

 

4,142

 

 

 

-

 

 

 

6,223

 

 

 

(1,653

)

Other income (expense), net

 

 

(126

)

 

 

(809

)

 

 

(3,677

)

 

 

(12,863

)

 

 

$

(113,340

)

 

$

34,282

 

 

$

(406,762

)

 

$

810,769

 

32


 

25.26. INCOME TAXES

There have been no material changes to income tax matters in connection with normal course operations during the nine months ended December 31, 2022.2023.

The Company is subject to income tax in numerous jurisdictions with varying income tax rates. During the most recent period ended and the fiscal year to date, there were no material changes to the statutory income tax rates in the taxing jurisdictions where the majority of the Company’s income for tax purposes was earned, or where its temporary differences or losses are expected to be realized or settled. Although statutory income tax rates remain stable, the Company’s effective income tax rate may fluctuate, arising as a result of the Company’s evolving footprint, discrete transactions and other factors that, to the extent material, are disclosed in these financial statements.

The Company continues to believe that the amount of unrealized tax benefits appropriately reflects the uncertainty of items that are or may in the future be under discussion, audit, dispute or appeal with a tax authority or which otherwise result in uncertainty in the determination of income for tax purposes. If appropriate, an unrealized tax benefit will be realized in the reporting period in which the Company determines that realization is not in doubt. Where the final determined outcome is different from the Company’s estimate, such difference will impact the Company’s income taxes in the reporting period during which such determination is made.

27. THIS WORKS DIVESTITURE

 

32


26. EARNINGS (LOSS) PER SHARE

Basic and diluted earnings (loss) per share are calculated usingOn December 18, 2023, the following numerators and denominators:

 

 

Three months ended

 

 

Nine months ended

 

 

 

December 31,

 

 

December 31,

 

 

December 31,

 

 

December 31,

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

Basic (loss) earnings per share computation

 

 

 

 

 

 

 

 

 

 

 

 

Net (loss) income attributable to common shareholders of
   Canopy Growth

 

$

(261,583

)

 

$

(108,925

)

 

$

(2,566,537

)

 

$

272,435

 

Weighted average number of common shares outstanding

 

 

486,112,598

 

 

 

393,818,282

 

 

 

453,237,882

 

 

 

390,423,083

 

Basic (loss) earnings per share

 

$

(0.54

)

 

$

(0.28

)

 

$

(5.66

)

 

$

0.70

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Diluted (loss) earnings per share computation

 

 

 

 

 

 

 

 

 

 

 

 

Net (loss) income used in the computation of basic (loss)
   earnings per share

 

$

(261,583

)

 

$

(108,925

)

 

$

(2,566,537

)

 

$

272,435

 

Numerator adjustments for diluted (loss) earnings per share:

 

 

 

 

 

 

 

 

 

 

 

 

Adjustment to net loss attributable to noncontrolling
   interests and redeemable noncontrolling interest

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(13,100

)

Removal of fair value changes on unsecured senior notes

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(81,342

)

Net (loss) income used in the computation of diluted (loss)
   earnings per share

 

$

(261,583

)

 

$

(108,925

)

 

$

(2,566,537

)

 

$

177,993

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average number of common shares outstanding
   used in the computation of basic (loss) earnings per share

 

 

486,112,598

 

 

 

393,818,282

 

 

 

453,237,882

 

 

 

390,423,083

 

Denominator adjustments for diluted (loss) earnings per
   share:

 

 

 

 

 

 

 

 

 

 

 

 

Dilutive impact of assumed exercise or conversion of:

 

 

 

 

 

 

 

 

 

 

 

 

Unsecured senior notes

 

 

-

 

 

 

-

 

 

 

-

 

 

 

12,454,620

 

Redeemable noncontrolling interest

 

 

-

 

 

 

-

 

 

 

-

 

 

 

4,528,898

 

Stock options

 

 

-

 

 

 

-

 

 

 

-

 

 

 

745,700

 

Other securities

 

 

-

 

 

 

-

 

 

 

-

 

 

 

2,834,501

 

Weighted average number of common shares for
   computation of diluted (loss) earnings per share

 

 

486,112,598

 

 

 

393,818,282

 

 

 

453,237,882

 

 

 

410,986,802

 

Diluted (loss) earnings per share1

 

$

(0.54

)

 

$

(0.28

)

 

$

(5.66

)

 

$

0.43

 

1 In computing diluted earnings per share, incremental common shares are not considered in periods in which a net loss is reported, as the inclusion of the common share equivalents would be anti-dilutive.

27. ACQUISITION

The following table summarizes the consolidated balance sheet impact at acquisition of the Company's business combination that occurred in the nine months ended December 31, 2022:

 

 

Verona

 

 

 

Manufacturing

 

 

 

Facility

 

Property, plant and equipment

 

$

28,771

 

Debt and other liabilities

 

 

(2,373

)

Net assets acquired

 

$

26,398

 

 

 

 

 

Consideration paid in cash

 

$

24,223

 

Other consideration

 

 

2,175

 

Total consideration

 

$

26,398

 

 

 

 

 

Consideration paid in cash

 

$

24,223

 

Less: Cash and cash equivalents acquired

 

 

-

 

Net cash outflow

 

$

24,223

 

The table above summarizes the fair value of the consideration given and the fair values assigned to the assets acquired and liabilities assumed for the acquisition completed in the nine months ended December 31, 2022.

33


Acquisition of Verona Manufacturing Facility

On November 8, 2022, the Company, through its affiliate BioSteel, completed the acquisition (the "Verona Acquisition") of a manufacturing facility located in Verona, Virginia (the "Verona Facility") from Flow Beverage Corp. ("Flow"), one of BioSteel's contract manufacturers. Consideration was $26,398 (US$19,477), consisting of cash paid of $15,685 (US$11,573) and $8,538 (US$6,299) related to the repayment of debt and the retirement of certain lease obligations, and $2,175 (US$1,605) in remediation and indemnity holdbacks to be retained by the Company and paid within one year of the closing of the Verona Acquisition. BioSteel and Flow have also entered into a co-manufacturing agreement whereby, in addition to the production of BioSteel-branded sports hydration beverages, BioSteel will produce Flow's portfolio of branded water at the Verona Facility.

Due to the timing of the Verona Acquisition, the purchase price allocation for the Verona Acquisition is provisional. The fair value assigned to the consideration paid and net assets acquired is based on management's best estimate using the information currently available and may be revised by the Company as additional information is received.

28. RETAIL DIVESTITURE

The Company entered into the following two agreementsan agreement to divest all of its retail businessinterest in Canada, which includesThis Works to a London-based investment firm (the “This Works Divestiture”). The Company completed the retail stores operating under the Tweed and Tokyo Smoke banners:

An agreement with OEG Retail Cannabis (“OEGRC”), a prior Canopy Growth licensee partner,This Works Divestiture on December 18, 2023, pursuant to which OEGRC acquired ownership of 23 of the Company's corporate-owned retail stores in Manitoba, Saskatchewan and Newfoundland and Labrador, as well as all Tokyo Smoke-related intellectual property (the “OEGRC Transaction”). In connection with the OEGRC Transaction, the Tokyo Smoke brand has been transferred to OEGRC and all acquired retail stores branded as Tweed will be rebranded by OEGRC. In addition, the master franchise agreement between the Company and OEGRC, pursuant to which OEGRC licenses the Tokyo Smoke brand in Ontario, was terminated effective on the closing of the OEGRC Transaction. The OEGRC Transaction closed on December 30, 2022.
An agreement (the "FOUR20 Agreement") with 420 Investments Ltd. (“FOUR20”), a licensed cannabis retailer, pursuant to which FOUR20 acquired ownership of five of the Company's corporate-owned retail stores in Alberta (the “FOUR20 Transaction”). Pursuant to the FOUR20 Agreement, the stores will be rebranded under FOUR20's retail banner upon closing of the FOUR20 Transaction. The FOUR20 Transaction closed on October 26, 2022.

In the three months ended December 31, 2022, upon closing of the OEGRC Transaction and the FOUR20 Transaction, the Company received a cash payment of $882,2491,333) and a loan note of $5,2403,106) with a maturity date of December 18, 2027. The Company will also be entitledmay receive an earnout payment of up to deferred consideration$5,9053,500), subject to certain financial targets.

Prior to closing of the This Works Divestiture, the net assets of This Works were recorded as held for sale and the Company recorded asset impairment and restructuring charges of $5,50028,144, and an earn-out payment of $. 6,099, subject toUpon the achievement of certain revenue targets by the divested retail stores.

Following the divestiturecompletion of the retail stores pursuant toThis Works Divestiture, the OEGRC TransactionCompany no longer controls This Works and the FOUR20 Transaction, the Company derecognized the assets and liabilities on the closing date:

Current assets1

 

$

13,793

 

Intangible assets

 

 

16,828

 

Less: valuation allowance

 

 

(20,154

)

Current liabilities

 

 

(6,661

)

Cumulative translation adjustment

 

 

2,322

 

Net assets disposed

 

$

6,128

 

 

 

 

 

Consideration received in cash

 

$

2,249

 

Future cash consideration

 

 

7,286

 

Costs to sell

 

 

(3,407

)

Total consideration

 

$

6,128

 

 

 

 

 

Gain on disposal of consolidated entity

 

$

-

 

1 Included in current assets is $5,968of the associated retail stores from these consolidated financial statements at their carrying amounts on their respective closing dates, as follows:cash.

Current assets

 

$

6,461

 

Property, plant and equipment

 

 

7,990

 

Other long-term assets

 

 

144

 

Current liabilities

 

 

(9,492

)

Net assets disposed

 

$

5,103

 

 

 

 

 

Consideration received in cash

 

$

88

 

Future cash consideration

 

 

11,599

 

Costs to sell

 

 

(2,442

)

Total consideration

 

$

9,245

 

 

 

 

 

Gain on disposal of consolidated entity

 

$

4,142

 

The gain calculated on the derecognition of the assets and liabilities of the retail storesThis Works is the difference between the carrying amounts of the derecognized assets and liabilities, and the fair value of consideration received, net of costs to sell.

29.28. ACREAGE ARRANGEMENT AND AMENDMENTS TO CBI INVESTOR RIGHTS AGREEMENT AND WARRANTS

Acreage Arrangement

34


On September 23, 2020, the Company and Acreage entered into a second amendment (the “Acreage Amending Agreement”) to the arrangement agreement (the “Original Acreage Arrangement Agreement”) and plan of arrangement (the “Original Acreage Arrangement”) between the Company and Acreage dated April 18, 2019, as amended on May 15, 2019. In connection with the Acreage Amending Agreement, the Company and Acreage implemented an amended and restated plan of arrangement (the “Acreage Amended Arrangement”) on September 23, 2020. Pursuant to the terms of the Original Acreage Arrangement, shareholders of Acreage and holders of certain securities convertible into the existing Acreage subordinated voting shares as of June 26, 2019, received an immediate aggregate total payment of US$300,000 ($395,190) in exchange for granting Canopy Growth both the right and the obligation to acquire all of the issued and outstanding shares of Acreage following the occurrence or waiver (at the Company's discretion) of changes in U.S. federal law to permit the general cultivation, distribution, and possession of marijuana or to remove the

33


regulation of such activities from the federal laws of the United States (the “Triggering Event”) and subject to the satisfaction or waiver of the conditions set out in the Original Acreage Arrangement Agreement.

The Acreage Amended Arrangement provides for, among other things, the following:

Following the occurrence or waiver (at the discretion of Canopy Growth) of the Triggering Event and subject to the satisfaction or waiver of the conditions set out in the Original Acreage Arrangement Agreement (as modified in connection with the Acreage Amending Agreement), Canopy Growth will acquire all of the issued and outstanding Fixed Shares based on an amended exchange ratio equal to 0.30480.03048 of a common share to be received for each Fixed Share held. The foregoing exchange ratio for the Fixed Shares is subject to adjustment in accordance with the Acreage Amended Arrangement if, among other things, Acreage issues greater than the permitted number of Fixed Shares;
Upon the occurrence or waiver (at the discretion of Canopy Growth) of the Triggering Event, Canopy Growth will have the right (the "Acreage Floating Option") exercisable for a period of 30 days, to acquire all of the issued and outstanding Floating Shares for cash or common shares or a combination thereof, in Canopy Growth’s sole discretion at a price equal to the 30-day volume weighted average trading price of the Floating Shares on the Canadian Securities Exchange, subject to a minimum call price of US$6.41 per Floating Share. The foregoing exchange ratio for the Floating Shares is subject to adjustment in accordance with the Acreage Amended Arrangement if Acreage issues greater than the permitted number of Floating Shares. The acquisition of the Floating Shares, if acquired, will take place concurrently with the closing of the acquisition of the Fixed Shares;
Immediately prior to the acquisition of the Fixed Shares, each issued and outstanding Class F multiple voting share will automatically be exchanged for one Fixed Share and thereafter be acquired by Canopy Growth upon the same terms and conditions as the acquisition of the Fixed Shares;
If the occurrence or waiver of the Triggering Event does not occur by September 23, 2030, Canopy Growth’s rights to acquire both the Fixed Shares and the Floating Shares will terminate;
Upon implementation of the Acreage Amended Arrangement, Canopy Growth made a cash payment to the shareholders of Acreage and holders of certain convertible securities in the aggregate amount of US$37,500 ($49,849); and
Acreage is only permitted to issue an aggregate of up to 32,700,000 Fixed Shares and Floating Shares.

See Note 3 for information regarding the Reorganization. In connection with the Reorganization and the Floating Share Arrangement Agreement, Canopy Growth irrevocably waived the Acreage Floating Option and subject to, among other things, the terms of the Floating Share Arrangement Agreement, Canopy USA will acquire all of the issued and outstanding Floating Shares. Following the implementation of the Reorganization, Canopy USA, as of October 24, 2022, holds certain U.S. cannabis investments previously held by the Company, which is expected to enable Canopy USA, following, among other things, the Meeting and the exercise of the Acreage Option, including the issuance of the Fixed Shares to Canopy USA, to consummate the acquisitions of Acreage, Wana and Jetty.

At December 31, 2022,2023, the right and the obligation (the “Acreage financial instrument”) toto: (i) acquire the Fixed Shares pursuant to the Existing Acreage Arrangement Agreement; and (ii) acquire the Floating Shares pursuant to the Floating Share Arrangement Agreement (together, the “Acreage financial instrument”), represents a financial asset of $37,00033,000 (March 31, 20222023 – $47,00055,382 liability), asasset). At December 31, 2023, the estimated fair value of the Acreage business is more than the estimated fair value of the consideration to be provided upon the exercise of the Acreage financial instrument. Fair value changes on the Acreage financial instrument are recognized in other income (expense), net; see Note 24.25. The fair value determination includes a high degree of subjectivity and judgment, which results in significant estimation uncertainty. See Note 2223 for additional details on how the fair value of the Acreage financial instrument is calculated on a recurring basis. From a measurement perspective, the Company has elected the fair value option under ASC 825 - Financial Instruments ("ASC 825").

In connection with the Acreage Amended Arrangement, on September 23, 2020, an affiliate of the Company advanced US$50,000 ($66,995) to Universal Hemp, LLC, a wholly owned subsidiary of Acreage (“Acreage Hempco”) pursuant to a secured debenture (“Hempco Debenture”). In accordance with the terms of the Hempco Debenture, the funds advanced to Acreage Hempco cannot be used, directly or indirectly, in connection with or for any cannabis or cannabis-related operations in the United States, unless and until such operations comply with all applicable laws of the United States. The Hempco Debenture bears interest at a rate of 6.1% per annum and matures on September 23, 2030, or such earlier date in accordance with the terms of the Hempco Debenture. All interest payments made pursuant to the Hempco Debenture are payable in cash by Acreage Hempco. The Hempco Debenture is not convertible and is not guaranteed by Acreage. In connection with the Reorganization, as described in Note 3, on October 24, 2022, the Company transferred the Hempco Debenture to Canopy USA.

35


The amount advanced on September 23, 2020 pursuant to the Hempco Debenture has been recorded in other financial assets (see Note 10)11), and the Company has elected the fair value option under ASC 825 (see Note 22)23). At December 31, 2022,2023, the estimated fair value of the Hempco Debenture issued to an affiliate of the Company by Acreage Hempco was $27,85312,978 (March 31, 20222023

34


$28,82429,262), measured using a discounted cash flow model (see Note 22)23). Refer to Note 1011 for details on fair value changes, foreign currency translation adjustment, and anticipated interest to be received. An additional US$50,000 may be advanced pursuant to the Hempco Debenture subject to the satisfaction of certain conditions by Acreage Hempco.

 

Amendment to the CBI Investor Rights Agreement and warrants

On April 18, 2019, certain wholly-ownedwholly owned subsidiaries of CBI and Canopy Growth entered into the Second Amended and Restated Investor Rights Agreement (the "Amended Investor Rights Agreement") and a consent agreement. In connection with these agreements, on June 27, 2019, Canopy Growth (i) extended the term of the first tranche of warrants, which allow CBI to acquire 88.58.85 million additional shares of Canopy Growth for a fixed price of $50.40504.00 per share (the “Tranche A Warrants”), to November 1, 2023; and (ii) replaced the second tranche of warrants with two new tranches of warrants (the “Tranche B Warrants” and the “Tranche C Warrants”) as follows:

the Tranche B Warrants arewere exercisable to acquire 38.53.85 million common shares at a price of C$76.68766.80 per common share; and
the Tranche C Warrants arewere exercisable to acquire 12.81.28 million common shares at a price equal to the 5-day volume-weighted average price of the common shares immediately prior to exercise.

In connection with the Tranche B Warrants and the Tranche C Warrants, Canopy Growth willagreed to provide CBI with a share repurchase credit of up to $1.583 billion on the aggregate exercise price of the Tranche B Warrants and Tranche C Warrants in the event that Canopy Growth does not purchase for cancellation the lesser of (i) 27,378,8662,737,886 common shares; and (ii) common shares with a value of $1.583 billion, during the period commencing on April 18, 2019 and ending on the date that is 24 months after the date that CBI exercises all of the Tranche A Warrants. The share repurchase credit feature is accounted for as a derivative liability, with the fair value continuing to be $nil at December 31, 2022.

The modifications to the Tranche A Warrants resulted in them meeting the definition of a derivative instrument under ASC 815 - Derivatives and Hedging (“ASC 815”). They continue to bewere classified in equity as the number of shares and exercise price were both fixed at inception.

The Tranche B Warrants arewere accounted for as derivative instruments (the “warrant derivative liability”) measured at fair value in accordance with ASC 815. At December 31, 2022,

On November 1, 2023, the fair valueTranche A Warrants expired in accordance with their terms without having been exercised. In accordance with the terms of the warrant derivative liability was $668 (March 31, 2022 – $26,920),Tranche B Warrants and fair value changes are recognized in other income (expense), net; see Note 24. See Note 22 for additional details on howTranche C Warrants, the fair valuevesting of the warrant derivative liabilityremaining Tranche B Warrants and Tranche C Warrants, as applicable, is calculatedconditioned on a recurring basis.

Thethe exercise, in full, of the Tranche A Warrants. Accordingly, the Tranche B Warrants and Tranche C Warrants are accounted fornot, and will not become, exercisable and are considered expired as derivative instruments, with the fair value continuing to be $nil at December 31, 2022.of November 1, 2023.

As described in Note 3, in connection with the Reorganization, the Company entered into the Third Consent Agreement, pursuant to which CBG and Greenstar agreed, among other things, that in the event that CBG and Greenstar convert their ownership in the Company's common shares into Exchangeable Shares, CBG will surrender the warrants held by CBG to purchase 139,745,45313,974,545 common shares of the Company for cancellation for no consideration. In addition, following such conversion by CBG and Greenstar of their common shares into Exchangeable Shares, other than the Third Consent Agreement and the termination rights contained therein and the CBI Note (as defined below), all agreements between the Company and CBI will terminate, including the Amended Investor Rights Agreement. In such circumstances it is expected that the CBI nominees that are currently sitting on the Board will resign as directors of the Company following the termination of the Amended Investor Rights Agreement.

29. COMMITMENTS AND CONTINGENCIES

Legal proceedings

In the ordinary course of business, the Company is at times subject to various legal proceedings and disputes, including the proceedings specifically discussed below. The Company assesses the liabilities and contingencies in connection with outstanding legal proceedings utilizing the latest information available. Where it is probable that the Company will incur a loss and the amount of the loss can be reasonably estimated, a liability is recorded in the consolidated financial statements. Where a loss is only reasonably possible or the amount of the loss cannot be reasonably estimated, no liability is recorded in the consolidated financial statements, but disclosures, as necessary, are provided.

For the purposes of these condensed interim consolidated financial statements, there have been no material changes with respect to legal proceedings that the Company is subject to since our Annual Report on Form 10-K for the fiscal year ended March 31, 2023, except with respect to certain aspects of the legal proceedings disclosed below:

Request for arbitration

On December 29, 2023, a request for arbitration was made to the Company. Damages are being sought in the amount of US$no32,667 consideration.against the Company based on alleged breaches of a Share Purchase Agreement (“SPA”), including breaches of the duty of good faith and honest performance in relation to certain milestone payments in the SPA. The Company denies the allegations,

35


believes that the respondents have meritorious defenses, and expects to vigorously defend the claims, although the Company cannot predict when or how the arbitration will be resolved or estimate what the potential loss or range of loss would be, if any.

30. SEGMENT INFORMATION

Reportable segments

Prior to the three months ended September 30, 2022, the Company had the following two reportable segments: (i) global cannabis; and (ii) other consumer products. Following the completion of certain restructuring actions which were initiated in the three months ended March 31, 2022, and which were aligned with the Company's strategic review of its business, the Company has changed the structure of its internal management financial reporting. Accordingly, in the three months ended September 30, 2022, the Company began reporting its financial results for the following fivefour reportable segments:

 

Canada cannabis - includes the production, distribution and sale of a diverse range of cannabis, hemp and cannabiscannabis-related products in Canada pursuant to the Cannabis Act;
Rest-of-world cannabis - includes the production, distribution and sale of a diverse range of cannabis hemp and cannabishemp products internationally pursuant to applicable international legislation, regulations and permits;permits. Priority markets include medical cannabis markets in Australia, Germany, Poland and Czech Republic where the Company offers branded high-quality flower, oil and softgel extracts products under our recognized Spectrum Therapeutics brand (in Australia, Poland and Czech Republic) and more recently the Canopy Medical brand in Germany;
Storz & Bickel - includes the production, distribution and sale of vaporizers;
BioSteel - includes the production, distributionvaporizers and sale of consumer packaged goods ("CPG") including sports nutrition beverages, mixes, protein, gum and mints, some of which have been blended with hemp-derived CBD isolate;accessories; and
This Works - includes the production, distribution and sale of beauty, skincare, wellness and sleep products, some of which have been blended with hemp-derived CBD isolate. On December 18, 2023, the Company completed the sale of This Works and as of such date, the results of This Works are no longer included in the Company's financial results.

36


 

These segments reflect how the Company's operations are managed, how the Company's Chief Executive Officer, who is the Chief Operating Decision Maker (“CODM”), allocates resources and evaluates performance, and how the Company's internal management financial reporting is structured. The Company's CODM evaluates the performance of these segments, with a focus on (i) segment net revenue, and (ii) segment gross margin as the measure of segment profit or loss. Accordingly, information regarding segment net revenue and segment gross margin for the comparative periods has been restated to reflect the aforementioned change in reportable segments. The remainder of the Company's operations include revenue derived from, and cost of sales associated with, the Company's non-cannabis extraction activities and other ancillary activities; these are included within "other".

 

Three months ended

 

 

Nine months ended

 

 

Three months ended

 

 

Nine months ended

 

 

December 31,

 

December 31,

 

December 31,

 

December 31,

 

 

December 31,

 

December 31,

 

December 31,

 

December 31,

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

Segmented net revenue

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Canada cannabis

 

$

46,617

 

 

$

60,678

 

 

$

151,336

 

 

$

205,879

 

 

$

39,028

 

 

$

46,617

 

 

$

116,634

 

 

$

151,336

 

Rest-of-world cannabis

 

 

5,846

 

 

 

22,299

 

 

 

30,179

 

 

 

65,362

 

 

 

10,527

 

 

 

5,846

 

 

 

29,666

 

 

 

30,179

 

Storz & Bickel

 

 

20,214

 

 

 

25,205

 

 

 

49,351

 

 

 

63,786

 

 

 

18,453

 

 

 

20,214

 

 

 

48,517

 

 

 

49,351

 

BioSteel

 

 

16,363

 

 

 

16,974

 

 

 

64,173

 

 

 

31,147

 

This Works

 

 

8,289

 

 

 

10,730

 

 

 

20,677

 

 

 

26,308

 

 

 

8,165

 

 

 

8,289

 

 

 

21,256

 

 

 

20,677

 

Other

 

 

3,884

 

 

 

5,086

 

 

 

13,475

 

 

 

16,073

 

 

 

2,332

 

 

 

3,884

 

 

 

8,285

 

 

 

13,475

 

 

$

101,213

 

 

$

140,972

 

 

$

329,191

 

 

$

408,555

 

 

$

78,505

 

 

$

84,850

 

 

$

224,358

 

 

$

265,018

 

Segmented gross margin:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Canada cannabis

 

$

(5,281

)

 

$

(13,121

)

 

 

(25,466

)

 

$

(97,925

)

 

$

11,113

 

 

$

(5,281

)

 

$

24,739

 

 

$

(25,467

)

Rest-of-world cannabis

 

 

(2,184

)

 

 

4,660

 

 

 

(3,676

)

 

 

24,245

 

 

 

4,192

 

 

 

(2,184

)

 

 

10,364

 

 

 

(3,676

)

Storz & Bickel

 

 

9,186

 

 

 

11,172

 

 

 

20,809

 

 

 

27,623

 

 

 

9,449

 

 

 

9,186

 

 

 

21,074

 

 

 

20,809

 

BioSteel

 

 

(7,669

)

 

 

1,352

 

 

 

(804

)

 

 

(2,361

)

This Works

 

 

4,032

 

 

 

5,469

 

 

 

8,982

 

 

 

12,423

 

 

 

4,253

 

 

 

4,032

 

 

 

10,534

 

 

 

8,982

 

Other

 

 

(525

)

 

 

558

 

 

 

143

 

 

 

2,183

 

 

 

(781

)

 

 

(525

)

 

 

(1,297

)

 

 

144

 

 

 

(2,441

)

 

 

10,090

 

 

 

(12

)

 

 

(33,812

)

 

 

28,226

 

 

 

5,228

 

 

 

65,414

 

 

 

792

 

Selling, general and administrative expenses

 

 

122,636

 

 

 

116,835

 

 

 

351,891

 

 

 

355,165

 

 

 

54,436

 

 

 

89,604

 

 

 

174,810

 

 

 

271,425

 

Share-based compensation

 

 

6,428

 

 

 

6,777

 

 

 

21,725

 

 

 

35,856

 

 

 

3,693

 

 

 

6,055

 

 

 

10,127

 

 

 

20,893

 

Asset impairment and restructuring costs

 

 

22,259

 

 

 

36,439

 

 

 

1,794,212

 

 

 

128,198

 

Loss on asset impairment and restructuring

 

 

30,413

 

 

 

22,259

 

 

 

2,452

 

 

 

1,794,212

 

Operating loss

 

 

(153,764

)

 

 

(149,961

)

 

 

(2,167,840

)

 

 

(553,031

)

 

 

(60,316

)

 

 

(112,690

)

 

 

(121,975

)

 

 

(2,085,738

)

Loss from equity method investments

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(100

)

Other income (expense), net

 

 

(113,340

)

 

 

34,282

 

 

 

(406,762

)

 

 

810,769

 

 

 

(171,037

)

 

 

(115,490

)

 

 

(253,270

)

 

 

(396,074

)

(Loss) income before incomes taxes

 

$

(267,104

)

 

$

(115,679

)

 

$

(2,574,602

)

 

$

257,638

 

Loss before incomes taxes

 

$

(231,353

)

 

$

(228,180

)

 

$

(375,245

)

 

$

(2,481,812

)

 

Asset information by segment is not provided to, or reviewed by, the Company’s CODM as it is not used to make strategic decisions, allocate resources, or assess performance.

 

36


Entity-wide disclosures

Disaggregation of net revenue by geographic area:

 

Three months ended

 

 

Nine months ended

 

 

Three months ended

 

 

Nine months ended

 

 

December 31,

 

December 31,

 

December 31,

 

December 31,

 

 

December 31,

 

December 31,

 

December 31,

 

December 31,

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

Canada

 

$

65,851

 

 

$

78,644

 

 

$

226,312

 

 

$

241,440

 

 

$

41,024

 

 

$

50,333

 

 

$

123,724

 

 

$

163,002

 

Germany

 

 

12,772

 

 

 

23,143

 

 

 

36,383

 

 

 

71,619

 

 

 

13,460

 

 

 

12,772

 

 

 

35,287

 

 

 

36,383

 

United States

 

 

10,292

 

 

 

22,764

 

 

 

30,688

 

 

 

60,856

 

 

 

10,334

 

 

 

9,447

 

 

 

28,102

 

 

 

29,825

 

Other

 

 

12,298

 

 

 

16,421

 

 

 

35,808

 

 

 

34,640

 

 

 

13,687

 

 

 

12,298

 

 

 

37,245

 

 

 

35,808

 

 

$

101,213

 

 

$

140,972

 

 

$

329,191

 

 

$

408,555

 

 

$

78,505

 

 

$

84,850

 

 

$

224,358

 

 

$

265,018

 

 

Disaggregation of property, plant and equipment by geographic area:

 

 

December 31,

 

 

March 31,

 

 

 

2022

 

 

2022

 

Canada

 

$

726,613

 

 

$

827,591

 

United States

 

 

96,159

 

 

 

63,247

 

Other

 

 

51,257

 

 

 

51,942

 

 

 

$

874,029

 

 

$

942,780

 

37


 

 

December 31,

 

 

March 31,

 

 

 

2023

 

 

2023

 

Canada

 

$

285,941

 

 

$

361,129

 

United States

 

 

3,561

 

 

 

58,226

 

Germany

 

 

50,951

 

 

 

51,341

 

Other

 

 

26

 

 

 

575

 

 

 

$

340,479

 

 

$

471,271

 

 

For the three months ended December 31, 2022,2023, noone customer represented more than 10% of the Company’s net revenue (three months ended December 31, 20212022noneone).

 

For the nine months ended December 31, 2022,2023, noone customer represented more than 10% of the Company's net revenue (nine months ended December 31, 20212022onenone).

31.31. SUBSEQUENT EVENTS

January 2024 Private Placement

Canadian Cannabis Operations RestructuringOn January 18, 2024, the Company entered into subscription agreements (the "January 2024 Subscription Agreements") with certain institutional investors (the "January 2024 Investors"). Pursuant to the terms of the January 2024 Subscription Agreements, the Company issued 8,158,510 units of the Company (the "January 2024 Units") to the January 2024 Investors at a price per January 2024 Unit of US$4.29 for aggregate gross proceeds of approximately $47,117 (US$35,000) (the "January 2024 Unit Offering"). Each January 2024 Unit is comprised of (a) one Canopy Growth common share and (b)(i) one Series A common share purchase warrant (a "Series A Warrant") or (ii) one Series B common share purchase warrant (a "Series B Warrant" and, together with the Series A Warrants, the "January 2024 Warrants"). Each January 2024 Warrant entitles the holder to acquire one Canopy Growth common share from the Company at a price per share equal to US$4.83. The Series A Warrants are currently exercisable and will remain exercisable until January 19, 2029, and the Series B Warrants will be exercisable for a period commencing on July 19, 2024 until July 19, 2029. The January 2024 Unit Offering closed on January 19, 2024.

 

Expiration of Supreme January 2021 Warrants

On February 9, 2023,January 29, 2024, the warrants governed by the warrant indenture dated January 29, 2021 between Supreme Cannabis and Computershare Trust Company of Canada, in its capacity as warrant agent (the “Warrant Agent”), as supplemented by the supplemental indenture dated June 22, 2021 between Supreme Cannabis, the Company announced a series of comprehensive steps to align its Canadian cannabis operations and resources in response to unfavorable market realities, which include:

Transitioning to an asset-light model by: (i) exiting cannabis flower cultivation in the Company's Smiths Falls, Ontario facility; (ii) ceasing the sourcing of cannabis flower from the Company's Mirabel, Quebec facility; and (iii) consolidating cultivation at the Company's existing facilities in Kincardine, Ontario and Kelowna, British Columbia;
Moving to an adaptive third-party sourcing model for all cannabis beverages, edibles, vapes, and extracts which will enable the Company to select and bring to market new product formats without the required investment in research and development and production footprint;
As a result of the aforementioned changes, the Company intends to consolidate flower, pre-rolled joints, softgel, and oil manufacturing in the Company’s current beverage production facility in Smiths Falls, Ontario and reduce headcount across the business; and
The Company intends to close the 1 Hershey Drive facility in Smiths Falls, Ontarioand the Company isWarrant Agent expired in active discussionsaccordance with respect to restructuring the joint-venture entity which holds the cultivation facility in Mirabel, Quebec.

their terms without having been exercised.

37

38


 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

Introduction

 

This Management’s Discussion and Analysis (“MD&A”) should be read together with other information, including our unaudited condensed interim consolidated financial statements and the related notes to those statements included in Part I, Item 1 of this Quarterly Report (the “Interim Financial Statements”), our consolidated financial statements appearing in our Annual Report on Form 10-K for the year ended March 31, 20222023 (the “Annual Report”), Part I, Item 1A, Risk Factors, of the Annual Report and Part II, Item 1A, Risk Factors, of this Quarterly Report. This MD&A provides additional information on our business, recent developments, financial condition, cash flows and results of operations, and is organized as follows:

 

Part 1 - Business Overview. This section provides a general description of our business, which we believe is important in understanding the results of our operations, financial condition, and potential future trends.

 

Part 2 - Results of Operations. This section provides an analysis of our results of operations for the third quarter of fiscal 20232024 in comparison to the third quarter of fiscal 2022,2023, and for the nine months ended December 31, 20222023 in comparison to the nine months ended December 31, 2021.2022.

 

Part 3 - Financial Liquidity and Capital Resources.This section provides an analysis of our cash flows and outstanding debt and commitments. Included in this analysis is a discussion of the amount of financial capacity available to fund our ongoing operations and future commitments.

 

We prepare and report our Interim Financial Statements in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP"). Our Interim Financial Statements, and the financial information contained herein, are reported in thousands of Canadian dollars, except share and per share amounts or as otherwise stated. We have determined that the Canadian dollar is the most relevant and appropriate reporting currency as, despite continuing shifts in the relative size of our operations across multiple geographies, the majority of our operations are conducted in Canadian dollars and our financial results are prepared and reviewed internally by management in Canadian dollars.

 

Special Note Regarding Forward-Looking Statements

 

This Quarterly Report contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and other applicable securities laws, which involve certain known and unknown risks and uncertainties. Forward-looking statements predict or describe our future operations, business plans, business and investment strategies and the performance of our investments. These forward-looking statements are generally identified by their use of such terms and phrases as “intend,” “goal,” “strategy,” “estimate,” “expect,” “project,” “projections,” “forecasts,” “plans,” “seeks,” “anticipates,” “potential,” “proposed,” “will,” “should,” “could,” “would,” “may,” “likely,” “designed to,” “foreseeable future,” “believe,” “scheduled” and other similar expressions. Our actual results or outcomes may differ materially from those anticipated. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date the statement was made.

 

Forward-looking statements include, but are not limited to, statements with respect to:

 

laws and regulations and any amendments thereto applicable to our business and the impact thereof, including uncertainty regarding the application of U.S. state and federal law to U.S. hemp (including CBD)cannabidiol "CBD") products and the scope of any regulations by the U.S. Food and Drug Administration, the U.S. Drug Enforcement Administration, the U.S. Federal Trade Commission, the U.S. Patent and Trademark Office, the U.S. Department of Agriculture (the “USDA”) and any state equivalent regulatory agencies over U.S. hemp (including CBD) products;
expectations regarding the amount or frequency of impairment losses, including as a result of the write-down of intangible assets, including goodwill;
our ability to refinance debt as and when required on terms favorable to us and comply with covenants contained in our debt facilities and debt instruments;
the Company’s ability to execute on its strategy to accelerate the Company’s entry into the U.S. cannabis market through the creation of Canopy USA, LLC ("Canopy USA");
expectations regarding the Company’s ability to deconsolidate the financial results of Canopy USA from the financial results of Canopy Growth upon Canopy USA’s acquisition of Wana (as defined below), Jetty (as defined below) and the Fixed Shares (as defined below) of Acreage;
the timing and execution of the Second A&R LLC Agreement (as defined below);

38


expectations regarding the potential success of, and the costs and benefits associated with the Reorganization Amendments (as defined below);
expectations regardingrelated to our announcement of certain restructuring actions and the potential success of, and the costs and benefits associated with the comprehensive steps and actions being undertaken by the Company with respect to its Canadian operations (the “Canadian Transformative Plan”); including any progress, challenges and effects related thereto as well as changes in strategy, metrics, investments, operating expenses, employee turnover and other changes with respect thereto;
expectations to capitalize on the opportunity for growth in the United States cannabis sector and the anticipated benefits of such strategy;

39


the timing and outcome of the Floating Share Arrangement (as defined below), the anticipated benefits of the Floating Share Arrangement, the anticipated timing of the Acreage (as defined below) special meeting of shareholders and the acquisition of the Fixed Shares (as defined below) and the Floating Shares (as defined below) by Canopy USA, the satisfaction or waiver of the closing conditions set out in the Floating Share Arrangement Agreement (as defined below) and the Existing Acreage Amended Arrangement Agreement (as defined below), including receipt of all regulatory approvals, and the anticipated timing and occurrence of the Company’s exercise of the option to acquire the Fixed Shares (the "Acreage Option") and closing of such transaction;
the Acreage Amended Arrangement and the Floating Share Arrangement, including the occurrence or waiver (at our discretion) of the Triggering Event (as defined below), the anticipated timing and occurrence of the Company’s exercise of the Acreage Option and the satisfaction or waiver of the conditions to closing the acquisition of Acreage;
expectations regarding the Option Premium (as defined below), including the ability to, and timing of, the exercise of such option;
the Wana Amendments (as defined below), including the occurrence or waiver (at Canopy USA’s discretion) of the Triggering Event;
the issuance of additional common shares of the Company to satisfy the payments to certain Holders (as defined below) under the Amended TRA (as defined below), to eligible participants to the existing tax receivable bonus plans of HSCP (as defined below), to satisfy any deferred and/or option exercise payments to the shareholders of Wana (as defined below) and Jetty (as defined below) and the issuance of additional Non-Voting Shares (as defined below) issuable to Canopy Growth from Canopy USA in consideration thereof;
the satisfaction or waiver of the closing conditions set out in the Trust SPA (as defined below), the acquisition of the Canopy USA Common Shares (as defined below) and warrants of Canopy USA by the Trust (as defined below) in connection with the first tranche and second tranche closings in accordance with the Trust SPA, the anticipated timing and occurrence of the exercise of the options held by the Trust to acquire the Voting Shares (as defined in the Trust SPA) and the additional warrants of Canopy USA, as applicable, and closing of such transactions;
the potential conversion of common shares of the Company held by the CBI Group (as defined below) to Exchangeable Shares (as defined below), including the termination of the Second Amended and Restated Investor Rights Agreement (as defined below);
the anticipated timing and occurrence of the Meeting (as defined below) to approve the Amendment Proposal (as defined below);
the timing of the Paydown (as defined below) and the reduction in interest rates;
expectations related to our announcement of certain restructuring actions (the “Restructuring Actions”), the Reorganization, the Canadian Transformative Plan and any progress, challenges and effects related thereto as well as changes in strategy, metrics, investments, costs, operating expenses, employee turnover and other changes with respect thereto;
our ability to refinance debt as and when required on terms favorable to us and comply with covenants contained in our debt facilities and debt instruments;
expectations regarding the laws and regulations and any amendments thereto relating to the U.S. hemp industry in the U.S., including the promulgation of regulations for the U.S. hemp industry by the USDA and relevant state regulatory authorities;
expectations regarding the potential success of, and the costs and benefits associated with, our acquisitions, joint ventures, strategic alliances, equity investments and dispositions;
the Acreage Amended Arrangement (as defined below) and the Floating Share Arrangement, including the occurrence or waiver (at our discretion) of the Triggering Event (as defined below), the anticipated timing and occurrence of the Company's exercise of the option to acquire the Fixed Shares and the satisfaction or waiver of the conditions to closing the acquisition of Acreage;
the Wana Agreements (as defined below), including the occurrence or waiver (at Canopy USA's discretion) of the Triggering Event;
the grant, renewal and impact of any license or supplemental license to conduct activities with cannabis or any amendments thereof;
our international activities and joint venture interests, including required regulatory approvals and licensing, anticipated costs and timing, and expected impact;
our ability to successfully create and launch brands and further create, launch and scale cannabis-based products and U.S. hemp-derived consumer products in jurisdictions where such products are legal and that we currently operate in;
the benefits, viability, safety, efficacy, dosing and social acceptance of cannabis, including CBD and other cannabinoids;
our remediation plan and our ability to remediate the material weaknesses in our internal control over financial reporting;
our ability to continue as a going concern;
the anticipated benefits and impact of the investments in us (the “CBI"CBI Group Investments”Investments") from Constellation Brands, Inc. (“CBI”) and its affiliates (together,(collectively, the “CBI Group”);
the potential exercise of the warrants held by the CBI Group, pre-emptive rights and/or top-up rights held by the CBI Group;
expectations regarding the use of proceeds of equity financings, including the proceeds from the CBI Group Investments;financings;
the legalization of the use of cannabis for medical or adult-use in jurisdictions outside of Canada, the related timing and impact thereof and our intentions to participate in such markets, if and when such use is legalized;
our ability to execute on our strategy and the anticipated benefits of such strategy;
the ongoing impact of the legalization of additional cannabis product types and forms for adult-use in Canada, including federal, provincial, territorial and municipal regulations pertaining thereto, the related timing and impact thereof and our intentions to participate in such markets;

39


the ongoing impact of developing provincial, territorial and municipal regulations pertaining to the sale and distribution of cannabis, the related timing and impact thereof, as well as the restrictions on federally regulated cannabis producers participating in certain retail markets and our intentions to participate in such markets to the extent permissible;
the timing and nature of legislative changes in the U.S. regarding the regulation of cannabis including tetrahydrocannabinol (“THC”);
the future performance of our business and operations;
our competitive advantages and business strategies;
the competitive conditions of the industry;
the expected growth in the number of customers using our products;

40


our ability or plans to identify, develop, commercialize or expand our technology and research and development initiatives in cannabinoids, or the success thereof;
expectations regarding revenues, expenses and anticipated cash needs;
expectations regarding cash flow, liquidity and sources of funding;
expectations regarding capital expenditures;
the expansion of our production and manufacturing, the costs and timing associated therewith and the receipt of applicable production and sale licenses;
the expected growth inexpectations with respect to our growing, production and supply chain capacities;
expectations regarding the resolution of litigation and other legal and regulatory proceedings, reviews and investigations;
expectations with respect to future production costs;
expectations with respect to future sales and distribution channels and networks;
the expected methods to be used to distribute and sell our products;
our future product offerings;
the anticipated future gross margins of our operations;
accounting standards and estimates;
expectations regarding our distribution network;
expectations regarding the costs and benefits associated with our contracts and agreements with third parties, including under our third-party supply and manufacturing agreements;
our ability to comply with the listing requirements of the Nasdaq Stock Market LLC (“Nasdaq”) and the Toronto Stock Exchange (“TSX”); and
expectations on price changes in cannabis markets.

 

Certain of the forward-looking statements contained herein concerning the industries in which we conduct our business are based on estimates prepared by us using data from publicly available governmental sources, market research, industry analysis and on assumptions based on data and knowledge of these industries, which we believe to be reasonable. However, although generally indicative of relative market positions, market shares and performance characteristics, such data is inherently imprecise. The industries in which we conduct our business involve risks and uncertainties that are subject to change based on various factors, which are described further below.

 

The forward-looking statements contained herein are based upon certain material assumptions that were applied in drawing a conclusion or making a forecast or projection, including: (i) management’s perceptions of historical trends, current conditions and expected future developments; (ii) our ability to generate cash flow from operations; (iii) general economic, financial market, regulatory and political conditions in which we operate; (iv) the production and manufacturing capabilities and output from our facilities and our joint ventures, strategic alliances and equity investments; (v) consumer interest in our products; (vi) competition; (vii) anticipated and unanticipated costs; (viii) government regulation of our activities and products including but not limited to the areas of taxation and environmental protection; (ix) the timely receipt of any required regulatory authorizations, approvals, consents, permits and/or licenses; (x) our ability to obtain qualified staff, equipment and services in a timely and cost-efficient manner; (xi) our ability to conduct operations in a safe, efficient and effective manner; (xii) our ability to realize anticipated benefits, synergies or generate revenue, profits or value from our recent acquisitions into our existing operations; and (xiii) other considerations that management believes to be appropriate in the circumstances. While our management considers these assumptions to be reasonable based on information currently available to management, there is no assurance that such expectations will prove to be correct.

 

By their nature, forward-looking statements are subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking statements in this Quarterly Report and other reports we file with, or furnish to, the Securities and Exchange Commission (the “SEC”) and other regulatory agencies and made by our directors, officers, other employees and other persons authorized to speak on our behalf. Such factors include, without limitation, risks related to our ability to remediate the material weaknesses in our internal

40


control over financial reporting, or inability to otherwise maintain an effective system of internal control; the risk that our recent restatement could negatively affect investor confidence and raise reputation risks; our ability to continue as a going concern; our limited operating history; the risks that if Canopy USA acquires Wana, Jetty or the Fixed Shares of Acreage without structural amendments to our interest in Canopy USA, the listing of our common shares on the Nasdaq Stock Market (the "Nasdaq")we may be jeopardized; our abilityrequired to implement structural changeswrite down intangible assets, including goodwill, due to our interest in Canopy USA, if necessary; inherent uncertainty associated with projections;impairment; the diversion of management time on issues related to Canopy USA; the ability of parties to certain transactions to receive, in a timely manner and on satisfactory terms, the necessary regulatory, court and shareholder approvals; the risks that our Restructuring Actions willthe Trust’s ownership interest in Canopy USA is currently not result inquantifiable and the expected cost-savings, efficienciesTrust may have significant ownership and other benefits or will result in greater than anticipated turnover in personnel;influence over Canopy USA upon completion of the Trust Transaction (as defined below); the risks that we may be required to write down intangible assets, including goodwill, due to impairment; changes in laws, regulations and guidelines and our compliance with such laws, regulations and guidelines; risk relating to the long term macroeconomics effectsconditions in the Floating Share Arrangement and the Acreage Amending Agreement (as defined below) not being satisfied or waived; the risks related to Acreage’s financial statements expressing doubt about its ability to continue as a going concern; the risks related to the Company losing the Option Premium in the event Acreage cannot satisfy its debt obligations as they become due; the risks related to the fact that the Company has not received audited financial statements with respect to Jetty; the adequacy of our capital resources and liquidity, including but not limited to, availability of sufficient cash flow to execute our business plan (either within the COVID-19 pandemicexpected timeframe or at all); volatility in and/or degradation of general economic, market, industry or business conditions; risks relating to our current and any future pandemic or epidemic; consumer demand foroperations in emerging markets; compliance with applicable environmental, economic, health and safety, energy and other policies and regulations and in particular health concerns with respect to vaping and the use of cannabis and U.S. hemp products; inflation risks; theproducts in vaping devices; risks and uncertainty regarding future product development; changes in regulatory requirements in relation to our business and products; our reliance on licenses issued by and contractual arrangements with various federal, state and provincial governmental authorities; the risk that cost savings and any other synergies from the CBI Group Investments may not be fully realized or may take

41


longer to realize than expected; the implementation and effectiveness of key personnel changes; risksinherent uncertainty associated with jointly owned investments; risks relating to our current and future operations in emerging markets; risks relating to inventory write downs;projections; future levels of revenues and the impact of increasing levels of competition; third-party manufacturing risks; third-party transportation risks; inflation risks; our exposure to risks related to the protectionan agricultural business, including wholesale price volatility and enforcement ofvariable product quality; changes in laws, regulations and guidelines and our intellectual property rights;compliance with such laws, regulations and guidelines; risks relating to inventory write downs; risks relating to our ability to refinance debt as and when required on terms favorable to us and to comply with covenants contained in our debt facilities and debt instruments; risks associated with jointly owned investments; our ability to manage disruptions in credit markets or changes to our credit ratings; future levels of capital, environmental or maintenance expenditures, general and administrative and other expenses; the success or timing of completion of ongoing or anticipated capital or maintenance projects; risks related to the integration of acquired businesses; the timing and manner of the legalization of cannabis in the United States; business strategies, growth opportunities and expected investment; the adequacy of our capital resources and liquidity, including but not limited to, availability of sufficient cash flow to execute our business plan (either within the expected timeframe or at all); counterparty risks and liquidity risks that may impact our ability to obtain loans and other credit facilities on favorable terms; the potential effects of judicial, regulatory or other proceedings, litigation or threatened litigation or proceedings, or reviews or investigations, on our business, financial condition, results of operations and cash flows; risks related to stock exchange restrictions; risks associated with divestment and restructuring; volatility in and/or degradation of general economic, market, industry or business conditions; our exposure to risks related to an agricultural business, including wholesale price volatility and variable product quality; third-party manufacturing risks; third-party transportation risks; compliance with applicable environmental, economic, health and safety, energy and other policies and regulations and in particular health concerns with respect to vaping and the use of cannabis and U.S. hemp products in vaping devices; the anticipated effects of actions of third parties such as competitors, activist investors or federal, state, provincial, territorial or local regulatory authorities, self-regulatory organizations, plaintiffs in litigation or persons threatening litigation; changesconsumer demand for cannabis and U.S. hemp products; the risks that the Canadian Transformative Plan will not result in regulatory requirementsthe expected cost-savings, efficiencies and other benefits or will result in relationgreater than anticipated turnover in personnel; the implementation and effectiveness of key personnel changes; risks related to stock exchange restrictions; risks related to the protection and enforcement of our businessintellectual property rights; the risks related to the Exchangeable Shares having different rights from our common shares and products;there may never be a trading market for the Exchangeable Shares; future levels of capital, environmental or maintenance expenditures, general and administrative and other expenses; risks relating to the long term macroeconomic effects of the COVID-19 pandemic and any future pandemic or epidemic; and the factors discussed under the heading “Risk Factors” in the Annual Report and in Item 1A of Part II of this Quarterly Report. Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking statements.

 

Forward-looking statements are provided for the purposes of assisting the reader in understanding our financial performance, financial position and cash flows as of and for periods ended on certain dates and to present information about management’s current expectations and plans relating to the future, and the reader is cautioned that the forward-looking statements may not be appropriate for any other purpose. While we believe that the assumptions and expectations reflected in the forward-looking statements are reasonable based on information currently available to management, there is no assurance that such assumptions and expectations will prove to have been correct. Forward-looking statements are made as of the date they are made and are based on the beliefs, estimates, expectations and opinions of management on that date. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking statements, except as required by law. The forward-looking statements contained in this Quarterly Report and other reports we file with, or furnish to, the SEC and other regulatory agencies and made by our directors, officers, other employees and other persons authorized to speak on our behalf are expressly qualified in their entirety by these cautionary statements.

 

Part 1 - Business Overview

 

We are a world-leading cannabis and consumer packaged goods (“CPG”) company which produces, distributes, and sells a diverse range of cannabis, hemp, and CPG products. Cannabis products are principally sold for adult-use and medical purposes under a portfolio of distinct brands in Canada pursuant to the Cannabis Act, SC 2018, c 16 (the “Cannabis Act”), and globally pursuant to applicable international and Canadian legislation, regulations, and permits. Our core operations are in Canada, the United States, and

41


priority growth markets internationally, including Australia, Germany, Poland and Czech Republic. Our other product offerings, which are sold by our subsidiaries in jurisdictions where it is permissible to do so, include (i) Storz & Bickel vaporizers; (ii) BioSteel Sports Nutrition Inc. ("BioSteel"GmbH (“Storz & Bickel”) sports nutrition beverages, mixes, protein, gumvaporizers and mints, some of which have been infused with hemp-derived CBD isolate; and (iii) This Works beauty, skincare, wellness and sleep products, some of which have been blended with hemp-derived CBD isolate. Our core operations are in Canada, the United States, and Germany.accessories.

 

On October 17, 2018, the Cannabis Act came into effect in Canada, regulating both the medical and adult-use cannabis markets in Canada and providing provincial, territorial and municipal governments the authority to prescribe regulations regarding the distribution and sale of adult-use cannabis. On October 17, 2019, the second phase of adult-use cannabis products was legalized pursuant to certain amendments to the regulations under the Cannabis Act. We currently offer product varieties in dried cannabis flower, oil, softgels, vape pen power sources, pod-based vape devices, vape cartridges, cannabis-infusedcannabis extracts and concentrates, cannabis beverages, cannabis gummies and cannabis-infused edibles,cannabis vapes with product availability varying based on provincial and territorial regulations. OurIn Canada, our adult-use cannabis products are predominantly sold to provincial and territorial agencies under a “business-to-business” wholesale model, with those provincial and territorial agencies then being responsible for the distribution of our products to brick-and-mortar stores and for online retail sales. As described under "Recent Developments" below, in the second quarter ofIn fiscal 2023, we entered into agreements to divestcompleted the divestiture of our retail business across Canada, which included the retail stores operating under the Tweed and Tokyo Smoke banners under a “business-to-consumer” model. The divestiture was completed in the third quarter of fiscal 2023.

42


Our Spectrum Therapeutics medical divisionbrand is a global leader in medical cannabis. Spectrum Therapeutics produces and distributes a diverse portfolio of medical cannabis products to healthcare practitioners and medical customerspatients in Canada, and in several other countries where it is federally permissible to do so.

Subsequent to the passage of the 2018 Farm Bill in December 2018, we began building our hemp supply chain in the United States through our investment in processing, extraction and finished goods manufacturing facilities. In the United States, we currently offer (i) a line of premium quality, hemp-derived wellness gummies, oils, softgels and topicals under the Martha Stewart CBD brand; (ii) a line of premium, ready-to-drink CBD-infused sparkling waters; and (iii) whisl, a CBD vape.brand.

In June 2019, we implemented a plan of arrangement pursuant to an arrangement agreement (the “Original Acreage Arrangement Agreement”) with Acreage Holdings, Inc. (“Acreage”), a U.S. multi-state cannabis operator. In September 2020, we entered into a second amendment to the Original Acreage Arrangement Agreement (the “Acreage Amending Agreement”) and implemented an amended and restated plan of arrangement (the “Acreage Amended Arrangement”). Pursuant to the Acreage Amended Arrangement, following the occurrence or waiver (at our discretion) of changes in U.S. federal law to permit the general cultivation, distribution, and possession of marijuana or to remove the regulation of such activities from the federal laws of the United States (the “Triggering Event”) and subject to the satisfaction or waiver of the conditions set out in the Original Acreage Arrangement Agreement (as modified by the Acreage Amending Agreement), wewe: (i) agreed to acquire approximately 70% of the issued and outstanding shares of Acreage, and (ii) obtained the right (the "Acreage“Acreage Floating Option"Option”) to acquire the other approximately 30% of the issued and outstanding shares of Acreage. In connection with the Floating Share Arrangement Agreement (as defined below), Canopy Growth has irrevocably waived the Acreage Floating Option existing under the Existing Acreage Arrangement Agreement.Agreement (as defined below). The acquisition of Acreage, if completed through Canopy USA, will provide a pathway into cannabis markets in the United States; however, we and Acreage will continue to operate as independent companies until the acquisition of Acreage is completed.

On October 14, 2021, we entered into definitive option agreements (the “Wana Agreements”) with Mountain High Products, LLC, Wana Wellness, LLC and The Cima Group, LLC (collectively, “Wana”) providing us with the right, upon the occurrence or waiver (at our discretion) of the Triggering Event, to acquire 100% of the outstanding membership interests of Wana. Wana manufactures and sells gummies in the state of Colorado and licenses its intellectual property to partners, who manufacture, distribute, and sell Wana-branded gummies across the United States, including in California, Arizona, Illinois, Michigan and Florida, and across Canada. Additionally, on May 17, 2022, we and Lemurian, Inc. (“Jetty”) entered into definitive agreements (the “Jetty Agreements”) providing us with the right to acquire up to 100% of the outstanding equity interests in Jetty upon the Triggering Event. Jetty is a California-based producer of high-quality cannabis extracts and pioneer of clean vape technology.

As described below under "Recent Developments"“Recent Developments”, on October 25, 2022, we announced the implementation of our internal reorganization pursuant to which, among other things, we formed Canopy USA, a new Delaware holding company Canopy USA (the "Reorganization"“Reorganization”). Following the implementation of the Reorganization, as of October 24, 2022, Canopy USA holds certain U.S. cannabis investments that were previously held by Canopy Growth, which is expected to enable Canopy USA, following, among other things, the Meeting (as defined below) and the exercise of the Acreage Option (as defined below), including the issuance of the Fixed Shares (as defined below) to Canopy USA, to consummate the acquisitions of Acreage, Wana, and Jetty.

Our cannabis products contain THC, CBD, or a combination of these two cannabinoids which are found in the cannabis sativa plant species. THC is the primary psychoactive or intoxicating cannabinoid found in cannabis. We also refer throughout this MD&A to “hemp”,“hemp,” which is a term used to classify varieties of the cannabis sativa plant that contain CBD and 0.3% or less THC content (by dry weight). Conversely, references to the term “marijuana” refers to varieties of the cannabis sativa plant with more than 0.3% THC content and moderate levels of CBD.THC.

Our licensed operational capacity in Canada includes indoor and greenhouse cultivation space; post-harvest processing and cannabinoid extraction capability; advanced manufacturing capability for oil and softgel encapsulation and pre-rolled joints; a beverage production facility;joints which is primarily completed at our Smiths Falls facility. Our Canadian cannabis cultivation facilities are now concentrated at our existing licensed facilities in Kincardine, Ontario and confectionary manufacturing. These capabilities allow us to supply the adult-useKelowna, British Columbia. Our remaining products are manufactured through third-party sourcing and medical markets with a complimentary balance of flower productsmanufacturing for certain cannabis beverages, edibles, vapes and extracted cannabinoid input for our oil, CBD, ingestible cannabis, cannabis extracts and cannabis topical products.extracts.

42


 

Segment Reporting

 

Prior to the second quarter of fiscal 2023, we had the following two reportable segments: (i) global cannabis; and (ii) other consumer products. Following the completion of certain restructuring actions which were initiated in the fourth quarter of fiscal 2022, and which were aligned with our strategic review of our business, we have changed the structure of our internal management financial reporting. Accordingly,In addition, the commencement of the CCAA Proceedings resulted in the second quarterremoval of fiscal 2023 we began reportingone of our segments. We now report our financial results for the following fivefour reportable segments:

43


Canada cannabis

segments: (i)- includes the production, distribution and sale of a diverse range of cannabis, hemp and cannabis-related products in Canada cannabis; (ii) rest-of-world cannabis; (iii) pursuant to the Cannabis Act;

Rest-of-world cannabis - includes the production, distribution and sale of a diverse range of cannabis and hemp products internationally pursuant to applicable international legislation, regulations and permits. Priority markets include medical cannabis markets in Australia, Germany, Poland and Czech Republic where we offer branded high-quality flower, oil and softgel extracts products under our recognized Spectrum Therapeutics brand (in Australia, Poland and Czech Republic) and more recently the Canopy Medical brand in Germany;
Storz & Bickel; (iv) BioSteel;Bickel - includes the production, distribution and (v)sale of vaporizers and accessories; and
This Works - includes the production, distribution and sale of beauty, skincare, wellness and sleep products, some of which have been blended with hemp-derived CBD isolate. On December 18, 2023, the Company completed the sale of This Works withand as of such date, the principal activitiesresults of each of these reportable segments described above under "Business Overview".This Works are no longer included in the Company's financial results.

 

These segments reflect how our operations are managed, how our Chief Executive Officer, who is the Chief Operating Decision Maker (“CODM”), allocates resources and evaluates performance, and how our internal management financial reporting is structured. Our CODM evaluates the performance of these segments, with a focus on (i) segment net revenue, and (ii) segment gross margin as the measure of segment profit or loss. Accordingly,The information regarding segment net revenue and segment gross margin for the comparative periods has been restated to reflect the aforementioned change in reportable segments. The remainder of our operations include revenue derived from, and cost of sales associated with, our non-cannabis extraction activities and other ancillary activities; these are included within "other"."other."

 

Recent Developments

 

Reorganization - Creation of Canopy USA

 

On October 24, 2022, Canopy Growth completed a number of strategic transactions in connection with the creation of a new U.S.-domiciled holding company, Canopy USA (the “Reorganization”). Following the implementation of the Reorganization, Canopy USA, as of October 24, 2022, holds certain U.S. cannabis investments previously held by Canopy Growth, which is expected to enable Canopy USA, following, among other things, the Meeting (as defined below) and the exercise of the Acreage Option, including the issuance of the Fixed Shares to Canopy USA, to consummate the acquisitions of Acreage, Wana, and Jetty.

Following the implementation of the Reorganization, as of October 24, 2022, Canopy USA hasholds an ownership interest in the following assets, among others:

Wana - The optionoptions to acquire 100% of the membership interests of Wana (the "Wana Option"Options"), a leading cannabis edibles brand in North America.

Jetty - The optionoptions to acquire 100% of the shares of Jetty (the "Jetty Option"Options"), a California-based producer of high-quality cannabis extracts and pioneer of clean vape technology.

 

Canopy Growth currently retains the option to acquire the issued and outstanding Class E subordinate voting shares (the "Fixed Shares"“Fixed Shares”) of Acreage (the “Acreage Option”), representing approximately 70% of the total shares of Acreage, at a fixed share exchange ratio of 0.30480.03048 of a Canopy Growth common share of Canopy Growth per Fixed Share. Concurrently with the closing of the acquisition of the Fixed Shares pursuant to the exercise of the Acreage Option, the Fixed Shares will be issued to Canopy USA. In addition, Canopy USA has agreed to acquire all of the issued and outstanding Class D subordinate voting shares of Acreage (the “Floating Shares”) by way of a court-approved plan of arrangement (the “Floating Share Arrangement”) in exchange for 0.450.045 of a common share of Canopy Growth for each Floating Share held. Acreage is a leading vertically-integrated multi-state cannabis operator, with its main operations in densely populated states across the Northeast U.S. including New Jersey and New York.

In addition, as of October 24, 2022, Canopy USA holdsheld direct and indirect interests in the capital of TerrAscend Corp. ("TerrAscend"(“TerrAscend”), a leading North American cannabis operator with vertically integrated operations and a presence in Pennsylvania, New Jersey, Michigan and California as well as licensed cultivation and processing operations in Maryland. Canopy USA'sUSA’s direct and

43


indirect interests in TerrAscend includes:included: (i) 38,890,570 exchangeable shares in the capital of TerrAscend (the "TerrAscend“TerrAscend Exchangeable Shares"Shares”), an option to purchase 1,072,450 TerrAscend common shares (the "TerrAscend“TerrAscend Common Shares"Shares”) for an aggregate purchase price of $1.00 (the "TerrAscend Option"“TerrAscend Option”), and 22,474,130 TerrAscend Common Share purchase warrants previously held by Canopy Growth (the “TerrAscend Warrants”); and (ii) the debentures and loan agreement between Canopy Growth and certain TerrAscend subsidiaries.

On December 9, 2022, Canopy USA and certain limited partnerships that are controlled by Canopy USA entered into a debt settlement agreement (the "Debt Settlement Agreement") with TerrAscend, TerrAscend Canada Inc. (“TerrAscend Canada”) and Arise Bioscience, Inc. (“Arise Bioscience”) whereby $125,467 in aggregate loans, including accrued interest thereon, payable by certain subsidiaries of its subsidiaries whereby all of the debt obligations, including all principal and interest,TerrAscend, were extinguished and 22,474,130 TerrAscend Warrants, being all of the previously issued TerrAscend Warrants controlled by Canopy USA (the “Prior Warrants”) were cancelled in exchange for the issuance offor: (i) 24,601,467 TerrAscend Exchangeable Shares at a notional price of $5.10 per TerrAscend Exchangeable Share; and (ii) 22,474,130 new TerrAscend Warrants (the “New Warrants” and, together with the TerrAscend Exchangeable Shares, the “New TerrAscend Securities”) with a weighted average exercise price of $6.07 per TerrAscend Common Share and expiring on December 31, 2032; see "TerrAscend Arrangement" below.2032. Following the issuance of the New TerrAscend Securities, Canopy USA beneficially owns: (i) 63,492,037 TerrAscend Exchangeable Shares; (ii) 22,474,130 New Warrants; and (iii) the TerrAscend Option. The TerrAscend Exchangeable Shares can be converted into TerrAscend Common Shares at Canopy USA’s option, subject to the terms of the A&R Protection Agreement (as defined below).

Following the implementation of the Reorganization Canopy USA was determined to be a variable interest entity ("VIE") pursuant to Accounting Standards Codification ("ASC")ASC 810 - Consolidations ("ASC 810") and prior to the completion of the Reorganization Amendments (as defined below), Canopy Growth was determined to be the primary beneficiary of Canopy USA. As a result of such determination and in accordance with ASC 810, Canopy Growth has consolidated the financial results of Canopy USA.

Amendments to Canopy USA Structure

Following the creation of Canopy USA, Nasdaq communicated its position to us stating that companies that consolidate “the assets and revenues generated from activities in violation under federal law cannot continue to list on Nasdaq”. Since we are committed to compliance with the listing requirements of the Nasdaq, we and Canopy USA effectuated certain changes to the initial structure of the Company’s interest in Canopy USA that were intended to facilitate the deconsolidation of the financial results of Canopy USA within our financial statements. These changes included, among other things, modifying the terms of the Protection Agreement between us, our wholly-owned subsidiary and Canopy USA as well as the terms of Canopy USA’s limited liability company agreement and amending the terms of certain agreements with third-party investors in Canopy USA to eliminate any rights to guaranteed returns (collectively, the “Reorganization Amendments”).

On May 19, 2023, Canopy Growth and Canopy USA implemented the Reorganization Amendments, which included, entering into the First A&R Protection Agreement (as defined below) and amending and restating Canopy USA’s limited liability company agreement (the “A&R LLC Agreement”) in order to: (i) eliminate certain negative covenants that were previously granted by Canopy USA in favor of Canopy Growth as well as delegating to the managers of the Canopy USA Board not appointed by Canopy Growth the authority to approve the following key decisions (collectively, the “Key Decisions”): (a) the annual business plan of Canopy USA; (b) decisions regarding the executive officers of Canopy USA and any of its subsidiaries; (c) increasing the compensation, bonus levels or other benefits payable to any current, former or future employees or managers of Canopy USA or any of its subsidiaries; (d) any other executive compensation plan matters of Canopy USA or any of its subsidiaries; and (e) the exercise of the Wana Options or the Jetty Options, which for greater certainty means that Canopy Growth’s nominee on the Canopy USA Board will not be permitted to vote on any Key Decisions while Canopy Growth owns Non-Voting Shares; (ii) reduce the number of managers on the Canopy USA Board from four to three, including, reducing Canopy Growth’s nomination right to a single manager; (iii) amend the share capital of Canopy USA to, among other things, (a) create a new class of Canopy USA Class B Shares, which may not be issued prior to the conversion of the Non-Voting Shares or the Canopy USA Common Shares into Canopy USA Class B Shares; (b) amend the terms of the Non-Voting Shares such that the Non-Voting Shares will be convertible into Canopy USA Class B Shares (as opposed to Canopy USA Common Shares); and (c) amend the terms of the Canopy USA Common Shares such that upon conversion of all of the Non-Voting Shares into Canopy USA Class B Shares, the Canopy USA Common Shares will, subject to their terms, automatically convert into Canopy USA Class B Shares, provided that the number of Canopy USA Class B Shares to be issued to the former holders of the Canopy USA Common Shares will be equal to no less than 10% of the total issued and outstanding Canopy USA Class B Shares following such issuance. Accordingly, as a result of the Reorganization Amendments, in no circumstances will Canopy Growth, at the time of such conversions, own more than 90% of the Canopy USA Class B Shares.

In connection with the Reorganization Amendments, on May 19, 2023, Canopy USA and Huneeus 2017 Irrevocable Trust (the “Trust”) entered into a share purchase agreement (the “Trust SPA”), which sets out the terms of the Trust’s investment in Canopy USA in the aggregate amount of up to US$20 million (the "Trust Transaction"). Agustin Huneeus, Jr. is the trustee of the Trust and is an affiliate of a shareholder of Jetty. Pursuant to the terms of the Trust SPA, the Trust will, subject to certain terms and conditions

44


contained in the Trust SPA be issued Canopy USA Common Shares in two tranches with an aggregate value of up to US$10 million along with warrants of Canopy USA to acquire additional Canopy USA Common Shares. In addition, subject to the terms of the Trust SPA, the Trust has also been granted options to acquire additional Voting Shares (as defined in the A&R LLC Agreement) with a value of up to an additional US$10 million and one such additional option includes the issuance of additional warrants of Canopy USA.

In addition, subject to the terms and conditions of the A&R Protection Agreement and the terms of the option agreements to acquire Wana and Jetty, as applicable, Canopy Growth may be required to issue additional common shares in satisfaction of certain deferred and/or option exercise payments to the shareholders of Wana and Jetty. Canopy Growth will receive additional Non-Voting Shares from Canopy USA as consideration for any Canopy Growth common shares issued in the future to the shareholders of Wana and Jetty.

On November 3, 2023, we received a letter from the staff of the SEC (the “Staff”) in which the Staff indicated that, despite the Reorganization Amendments, it would object to the deconsolidation of the financial results of Canopy USA from the Company's financial statements in accordance with U.S. GAAP once Canopy USA acquires Wana, Jetty or the Fixed Shares of Acreage. We subsequently had discussions with the Office of Chief Accountant of the SEC (the "OCA") and determined to make certain additional amendments to the structure of Canopy USA (the “Additional Reorganization Amendments”) to facilitate the deconsolidation of Canopy USA from the financial results of Canopy Growth in accordance with U.S. GAAP upon Canopy USA’s acquisition of Wana, Jetty or Acreage. In that regard, we filed a revised preliminary proxy statement with the SEC on each of January 25, 2024 and February 5, 2024 in connection with the Amendment Proposal (as defined below) that discloses these Additional Reorganization Amendments. In connection with the Additional Reorganization Amendments, Canopy USA and its members expect to enter into a second amended and restated limited liability company agreement (the “Second A&R LLC Agreement”) immediately prior to the completion of the first tranche closing of the Trust Transaction. Upon the effective date of the Second A&R LLC Agreement, the terms of the Non-Voting Shares will be amended such that the Non-Voting Shares will only be convertible into Canopy USA Class B Shares following the date that the NASDAQ Stock Market or The New York Stock Exchange permit the listing of companies that consolidate the financial statements of companies that cultivate, distribute or possess marijuana (as defined in 21 U.S.C 802) in the United States (the “Triggering Event Date”). Based on our discussions with the OCA, upon effectuating the Additional Reorganization Amendments, we believe that the Staff would not object to the deconsolidation of the financial results of Canopy USA from the Company’s financial statements in accordance with U.S. GAAP once Canopy USA acquires Wana, Jetty or the Fixed Shares of Acreage.

 

Ownership of U.S. Cannabis Investments

 

Following the implementation of the Reorganization, the shares and interests in Acreage, Wana, Jetty and TerrAscend are held, directly or indirectly, by Canopy USA, and Canopy Growth no longer holds a direct interest in any shares or interests in such entities, other than the Acreage Option. Canopy Growth holds non-voting and non-participating shares (the "Non-Voting Shares") in the

44


capital of Canopy USA. The Non-Voting Shares do not carry voting rights, rights to receive dividends or other rights upon dissolution of Canopy USA, butUSA. Following the Reorganization Amendments, the Non-Voting Shares are convertible into Class A commonB shares of Canopy USA (the “Canopy USA CommonClass B Shares”). The Company, provided that following the execution of the Second A&R LLC Agreement, such conversion shall only be permitted following the Triggering Event Date. Canopy Growth also has the right (regardless of the fact that its Non-Voting Shares are non-voting and non-participating) to appoint two membersone member to the Canopy USA board of managers.managers (the “Canopy USA Board”).

On October 24, 2022,As of December 31, 2023, a third party investor owned all of the issued and outstanding Class A shares of Canopy USA issued 1,000,000 Canopy(the “Canopy USA Common Shares to VCo Ventures LLC (“VCo Ventures”Shares”), a former shareholder of Jetty, in exchange for US$1 million. Agustin Huneeus Jr. is the manager of VCo Ventures. Following the closing of the investment, and a wholly-owned subsidiary of the CompanyCanopy Growth holds Non-Voting Shares in the capital of Canopy USA, representing approximately 99.3%more than 99% of the issued and outstanding shares in Canopy USA on an as-converted basis. Canopy USA retains a call right (the “Repurchase Right”) to repurchase all shares of Canopy USA that have been issued to VCo Ventures at a price per Canopy USA Common Share equal to the greater of fair market value as determined by an appraiser appointed by Canopy USA and US$2 million in the aggregate; provided that if the repurchase occurs prior to March 31, 2023, the Repurchase Right can be exercised at the initial subscription price. VCo Ventures has also been granted the right to appoint one member to the Canopy USA board of managers and a put right following the conversion of the Non-Voting Shares into Canopy USA Common Shares on the same terms and conditions as the Repurchase Right.

On October 24, 2022, Canopy USA and the CompanyCanopy Growth also entered into an agreement with, among others, Nancy Whiteman, the controlling shareholder of Wana, which was amended and restated on May 19, 2023, whereby subsidiaries of Canopy USA agreed to pay additional consideration in order to acquire the Wana OptionOptions and the future payments owed in connection with the exercise of the Wana OptionOptions will be reduced to US$3.00 in exchange for the issuance of Canopy USA Common Shares and Canopy Growth common shares (the “Wana Amending Agreement”). In accordance with the terms of the Wana Amending Agreement, Canopy USA Common Shares and Canopy Growth common shares will be issued to the shareholders of Wana, each with a value equal to 7.5% of the fair market value of Wana as of January 1, 2023.the later of: (i) the date that the Wana Options are exercised; and (ii) the closing date of the first tranche of the Trust Transaction (the “Wana Valuation Date”) less any net debt of Wana as of the Wana Valuation Date plus any net cash of Wana as of Wana Valuation Date. The value of Wana and the number of Canopy USA Common Shares will be determined based on the fair market value of Wana and the Canopy USA Common Shares, respectively, as determined by an appraiser appointed by the CompanyCanopy Growth and an appraiser appointed by the shareholders of Wana (and, if required, a third appraiser to be appointed by the

45


initial two appraisers). The Canopy USA Common Shares and Canopy Growth common shares will only be issued to Ms. Whiteman, or entities controlled by Ms. Whiteman, after January 1, 2023on the later of: (i) the date of exercise of the Wana Options and only if(ii) the date that CBG Holdings LLC (“CBG”) and Greenstar, Canada Investment Limited Partnership ("Greenstar")indirect, wholly-owned subsidiaries of CBI, have converted their Canopy Growth common shares into Exchangeable Shares. The Wana Amending Agreement may be terminated and no Canopy USA Common Shares or Canopy Growth common shares will be issued to Ms. Whiteman, or entities controlled by Ms. Whiteman in the event that CBG and Greenstar have not converted their Canopy Growth common shares into Exchangeable Shares by the later of: (i) sixty days after the Meeting; or (ii) MarchDecember 31, 2023. The Canopy USA Common Shares issuable to Ms. Whiteman, or entities controlled by Ms. Whiteman, will also be subject to a repurchase right exercisable at any time after the 36 month anniversary of the closing of the transaction contemplated by the Wana Amending Agreement (the “Wana Repurchase Right”) to repurchase all Canopy USA Common Shares that have been issued at a price per Canopy USA Common Share equal to the greater of fair market value as determined by an appraiser and the initial subscription price multiplied by an accrued annual interest rate of 10%.appraiser. As part of this agreement, Canopy USA has granted Ms. Whiteman the right to appoint one member to the Canopy USA board of managersBoard and a put right on the same terms and conditions as the Wana Repurchase Right.

Canopy Growth and Canopy USA have also entered into a protection agreement (the "Protection Agreement") to provide for certain covenants in order to preserve the value of the Non-Voting Shares held by Canopy Growth until such time as the Non-Voting Shares are converted into Canopy USA Common Sharesin accordance with their terms, provided that following the execution of the Second A&R LLC Agreement, such conversion shall only be permitted following the Triggering Event Date, but does not provide Canopy Growth with the ability to direct the business, operations or activities of Canopy USAUSA. The Protection Agreement was amended and restated in connection with: (a) the Reorganization Amendments (the "First A&R Protection Agreement"); and (b) the Additional Reorganization Amendments (the “Second A&R Protection Agreement” and together with the First A&R Protection Agreement, the “A&R Protection Agreement”).

Upon closing of Canopy USA'sUSA’s acquisition of Acreage, Canopy Growth will receive additional Non-Voting Shares from Canopy USA in consideration for the issuance of common shares of the CompanyCanopy Growth that shareholders of Acreage will receive in accordance with the terms of the Existing Acreage Arrangement Agreement and the Floating Share Arrangement Agreement.

In addition, subject to the terms and conditions of the Protection Agreement and the terms of the option agreements to acquire Wana and Jetty, as applicable, Canopy Growth may be required to issue additional common shares in satisfaction of certain deferred and/or option exercise payments to the shareholders of Wana and Jetty. Canopy Growth will receive additional Non-Voting Shares from Canopy USA as consideration for any Company common shares issued in the future to the shareholders of Wana and Jetty.

Until such time as Canopy Growth converts the Non-Voting Shares into Canopy USA CommonClass B Shares following the Triggering Event Date, Canopy Growth will have no economic or voting interest in Canopy USA, Wana, Jetty, TerrAscend, or Acreage. Canopy USA, Wana, Jetty, TerrAscend, and Acreage will continue to operate independently of Canopy Growth.

Acreage Agreements

 

On October 24, 2022, Canopy Growth entered into an arrangement agreement with Canopy USA and Acreage, as amended (the "Floating“Floating Share Arrangement Agreement"Agreement”), pursuant to which, subject to approval of the holders of the Floating Shares and the terms and

45


conditions of the Floating Share Arrangement Agreement, Canopy USA will acquire all of the issued and outstanding Floating Shares by way of a court-approved plan on arrangement under the Business Corporations Act (British Columbia) (the "Floating“Floating Share Arrangement"Arrangement”) in exchange for 0.450.045 of a Company common share for each Floating Share held. In connection with the Floating Share Arrangement Agreement, Canopy Growth has irrevocably waived the Acreage Floating Option existing under the Existing Acreage Arrangement Agreement.

It is expected that the Floating Share Arrangement will be effected by way of a court-approved plan of arrangement under the Business Corporations Act (British Columbia). The Floating Share Arrangement requires the approval of: (i) at least two-thirds of the votes cast by the holders of the Floating Shares; and (ii) at least a majority of the votes cast by the holders of the Floating Shares, excluding the votes cast by "interested parties" and "related parties" (as such terms are defined in Multilateral Instrument 61-101 - Protection Of Minority Security Holders In Special Transactions), at a special meeting of Acreage shareholders.

On October 24, 2022, the CompanyCanopy Growth and Canopy USA entered into a third amendment to tax receivable agreement (the "Amended TRA"“Amended TRA”) with, among others, certain current or former unitholders (the "Holders"“Holders”) of High Street Capital Partners, LLC, a subsidiary of Acreage ("HSCP"(“HSCP”), pursuant to HSCP'sHSCP’s amended tax receivable agreement (the "TRA"“TRA”) and related tax receivable bonus plans with Acreage. Pursuant to the Amended TRA, the Company,Canopy Growth, on behalf of Canopy USA, agreed to issue Canopy Growth common shares of the Company with a value of US$30.4 million to certain Holders as consideration for the assignment of such Holder’s rights under the TRA to Canopy USA. As a result of the Amended TRA, Canopy USA is the sole member and beneficiary under the TRA. In connection with the foregoing, the Company issued 5,648,927Canopy Growth issued: (i) 564,893 common shares with a value of $20.6 million (US$15.2 million) to certain Holders on November 4, 2022 as the first installment under the Amended TRATRA; and (ii) 710,208 common shares with a value of $20.6 million (US$15.2 million) to certain Holders on March 17, 2023, as the second payment of approximately US$15.2 million in common shares ofinstallment under the Company to occur on the earlier of: (a) the second business day following the date on which the shareholders of Acreage approve the Floating Share Arrangement; or (b) April 24, 2023. The Company,Amended TRA. Canopy Growth, on behalf of Canopy USA, also agreed to issue Canopy Growth common shares of the Company with a value of approximately US$19.6 million to certain eligible participants pursuant to HSCP’s existing tax receivable bonus plans to be issued immediately prior to completion of the Floating Share Arrangement.

On October 24, 2022, Canopy Growth and Canopy USA entered into voting support agreements with certain of Acreage'sAcreage’s directors, officers and consultants pursuant to which such persons have agreed, among other things, to vote their Floating Shares in favor of the Floating Share Arrangement, representing approximately 7.3% of the issued and outstanding Floating Shares.

In addition to shareholder and court approvals, the Floating Share Arrangement is subject to approval of the Amendment Proposal and applicable regulatory approvals including, but not limited to, Toronto Stock Exchange ("TSX")TSX approval and the satisfaction of certain other closing conditions customary in transactions of this nature. Assuming timely receipt The Floating Share Arrangement received the requisite approval from the holders

46


of all necessary court, shareholder, regulatoryFloating Shares at the special meeting of Acreage shareholders held on March 15, 2023 and other third-party approvals andon March 20, 2023 Acreage obtained a final order from the satisfactionSupreme Court of all other conditions, closingBritish Columbia approving the Floating Share Arrangement. The Floating Share Arrangement Agreement has been amended several times to extend the Exercise Outside Date (as defined in the Floating Share Arrangement Agreement), which was initially March 31, 2023. The most recent amendment to the Floating Share Arrangement Agreement extended the Exercise Outside Date to March 31, 2024. The completion of the acquisitionFloating Share Arrangement is subject to satisfaction or, if permitted, waiver of Acreage is expectedcertain closing conditions, including, among others, approval of the Amendment Proposal on or prior to occur in late 2023.the Exercise Outside Date.

It is intended that Canopy Growth'sGrowth’s existing option to acquire the Fixed Shares on the basis of 0.30480.03048 of a CompanyCanopy Growth common share per Fixed Share will be exercised after the Meeting in accordance with the terms of the arrangement agreement dated April 18, 2019, as amended on May 15, 2019, September 23, 2020 and November 17, 2020 (the "Existing“Existing Acreage Arrangement Agreement"Agreement”). Canopy Growth will not hold any Fixed Shares or Floating Shares. Completion of the acquisition of the Fixed Shares following exercise of the optionAcreage Option is subject to the satisfaction of certain conditions set forth in the Existing Acreage Arrangement Agreement. The acquisition of the Floating Shares pursuant to the Floating Share Arrangement is anticipated to occur immediately prior to the acquisition of the Fixed Shares pursuant to the Existing Acreage Arrangement Agreement in late 2023 such that 100% of the issued and outstanding shares of Acreage will be owned by Canopy USA on closing of the acquisition of both the Fixed Shares and the Floating Shares.

On November 15, 2022, a wholly-owned subsidiary of Canopy Growth (the "Acreage“Acreage Debt Optionholder"Optionholder”) and Acreage'sAcreage’s existing lenders (the "Lenders"“Lenders”) entered into an option agreement, which superseded the letter agreement dated October 24, 2022 between the parties, pursuant to which the Acreage Debt Optionholder was granted the right to purchase the outstanding principal, including all accrued and unpaid interest thereon, of Acreage'sAcreage’s debt, being an amount up to US$150.0 million (the "Acreage Debt"“Acreage Debt”) from the Lenders in exchange for an option premium payment of $38.0 million (US$28.5 million) (the "Option Premium"“Option Premium”), which was deposited into an escrow account on November 17, 2022. The Acreage Debt Optionholder has the right to exercise the option at its discretion, and if the option is exercised, the Option Premium will be used to reduce the purchase price to be paid for the outstanding Acreage Debt. In the event that Acreage repays the Acreage Debt on or prior to maturity, the Option Premium will be returned to the Acreage Debt Optionholder. In the event that Acreage defaults on the Acreage Debt and the Acreage Debt Optionholder does not exercise its option to acquire the Acreage Debt, the Option Premium will be released to the Lenders.

 

46


Special Shareholder Meeting

 

In connection with the Reorganization, Canopy Growth expects to hold a special meeting of shareholders (the "Meeting"“Meeting”) at which Canopy Growth shareholders will be asked to consider and, if deemed appropriate, to pass a special resolution authorizing an amendment to its articles of incorporation, as amended (the "Amendment Proposal"“Amendment Proposal”), in order to: (i) create and authorize the issuance of an unlimited number of a new class of non-voting and non-participating exchangeable shares in the capital of Canopy Growth (the “Exchangeable Shares”); and (ii) restate the rights of the Company'sCanopy Growth’s common shares to provide for a conversion feature whereby each common share may at any time, at the option of the holder, be converted into one Exchangeable Share. The Exchangeable Shares will not carry voting rights, rights to receive dividends or other rights upon dissolution of Canopy Growth but will be convertible into common shares.

The Amendment Proposal must be approved by at least 66⅔% of the votes cast on a special resolution by Canopy Growth'sGrowth’s shareholders present in person or represented by proxy at the Meeting. On October 24, 2022, CBG and Greenstar, indirect, wholly-owned subsidiaries of CBI, entered into a voting and support agreement (the "Voting and Support Agreement") with Canopy Growth (the “Voting and Support Agreement”).Growth. Pursuant to the terms of the Voting and Support Agreement, CBG and Greenstar agreed, subject to the terms and conditions thereof, among other things, to vote all of the Canopy Growth common shares beneficially owned, directed or controlled, directly or indirectly, by them for the Amendment Proposal.

In the event the Amendment Proposal is approved, and subject to the conversion by CBI of their Canopy Growth common shares into Exchangeable Shares, Canopy USA is expected to exercise the Wana OptionOptions and the Jetty Option.Options. In the event the Amendment Proposal is not approved, Canopy USA will not be permitted to exercise its rights to acquire shares of Acreage, Wana or Jetty, and the Floating Share Arrangement Agreement will be terminated. In such circumstances, Canopy Growth will retain its option to acquire the Fixed SharesAcreage Option under the Existing Acreage Arrangement Agreement and Canopy USA will continue to hold the Wana OptionOptions and the Jetty Option,Options, as well as the TerrAscend Exchangeable Shares and other securities in the capital of TerrAscend. In addition, the CompanyCanopy Growth is contractually required to cause Canopy USA to exercise its Repurchase Rightrepurchase right to acquire the Canopy USA Common Shares held by the third party investors, being the Canopy USA Common Shares held by VCo Ventures.investors.

 

Balance Sheet Actions47

On October 24, 2022, Canopy Growth entered into agreements with certain of its lenders under its term loan credit agreement dated March 18, 2021 (the "Credit Agreement") pursuant to which Canopy Growth will tender US$187.5 million of the principal amount outstanding thereunder at a discounted price of US$930 per US$1,000 or US$174.4 million in the aggregate (the "Paydown"). The first payment of approximately $117.5 million (US$87.9 million) was made on November 10, 2022 to reduce the principal indebtedness by approximately $126.3 million (US$94.4 million). The second payment pursuant to the Paydown is required to be made by no later than April 17, 2023.

Canopy Growth also agreed with its lenders to amend certain terms of the Credit Agreement (collectively, the "Credit Agreement Amendments"). The Credit Agreement Amendments include, among other things: (i) reductions to the minimum Liquidity (as defined in the Credit Agreement) covenant to US$100.0 million, which is to be further reduced as payments are made in accordance with the Paydown; (ii) certain changes to the application of net proceeds from asset sales; (iii) the establishment of a new committed delayed draw term credit facility in an aggregate principal amount of US$100.0 million; and (iv) the elimination of the additional US$500.0 million incremental term loan facility.


 

Relationship with CBI

 

In connection with the Reorganization, CBI has indicated its current intention to convert all of its Canopy Growth common shares of the Company into Exchangeable Shares, conditional upon the approval of the Amendment Proposal. However, any decision to convert will be made by CBI in its sole discretion, and CBI is not obligated to effect any such conversion.

In connection with the foregoing, on October 24, 2022, Canopy Growth entered into a consent agreement with CBG and Greenstar (the “Consent“Third Consent Agreement”), pursuant to which the parties agreed, among other things, that following the conversion by CBG and Greenstar of their respective Canopy Growth common shares into Exchangeable Shares, other than the Third Consent Agreement and the termination rights contained therein and the 4.25% unsecured senior notes due in 2023 (the "Notes"“Canopy Notes”) held by Greenstar, all agreements between Canopy Growth and CBI, including the Second Amended and Restated Investor Rights Agreement, dated as of April 18, 2019, by and among certain wholly-owned subsidiaries of CBI and Canopy Growth (the “Second Amended and Restated Investor Rights Agreement”), will be terminated. Pursuant to the terms of the Third Consent Agreement, CBG and Greenstar also agreed, among other things, that at the time of the conversion by CBG and Greenstar of their Canopy Growth common shares into Exchangeable Shares, (i) CBG will surrender the warrants held by CBG to purchase 139,745,45313,974,545 common shares for cancellation for no consideration; and (ii) all nominees of CBI that are currently sitting on the board of directors of Canopy Growth (the "Board"“Board”) will

47


resign from the Board. In addition, pursuant to the Third Consent Agreement and following the Reorganization Amendments, Canopy Growth is contractually required to convert its Non-Voting Shares into Canopy USA CommonClass B Shares, provided that following the execution of the Second A&R LLC Agreement, such conversion shall only be permitted following the Triggering Event Date, and cause Canopy USA to repurchase the Canopy USA Common Shares held by certain third-party investors in Canopy USA in the event CBG and Greenstar have not converted their respective common shares into Exchangeable Shares by the later of: (i) sixty days after the Meeting; or (ii) February 28, 2023Meeting (the “Termination Date”). The Third Consent Agreement will automatically terminate on the Termination Date.

 

In the event that CBI does not convert its Canopy Growth common shares into Exchangeable Shares, Canopy USA will not be permitted to exercise its rights to acquire the Fixed Shares from Canopy Growth or exercise its rights under the Wana Options or Jetty Options and the Floating Share Arrangement Agreement will be terminated. In such circumstances, Canopy Growth will retain its option to acquire the Fixed SharesAcreage Option under the Existing Acreage Arrangement Agreement and Canopy USA will continue to hold the Wana OptionOptions and the Jetty Option,Options, as well as the TerrAscend Exchangeable Shares and other securities in the capital of TerrAscend. In addition, the CompanyIf CBI does not convert its Canopy Growth common shares into Exchangeable Shares, Canopy Growth is also contractually required to cause Canopy USA to exercise its Repurchase Rightrepurchase right to acquire the Canopy USA Common Shares held by the third party investors, being the Canopy USA Common Shares held by VCo Ventures.investors.

 

Potential ChangesRefinancing of $100.0 Million of Canopy Notes Due in July 2023

On April 13, 2023, we entered into an exchange agreement (the “April 2023 Exchange Agreement”) with Greenstar in order to acquire and cancel $100.0 million aggregate principal amount of our outstanding Canopy USA StructureNotes. Pursuant to the April 2023 Exchange Agreement, we agreed to acquire and cancel $100.0 million aggregate principal amount of the Canopy Notes held by Greenstar in exchange for: (i) a cash payment to Greenstar in the amount of the unpaid and accrued interest owing under the Canopy Notes held by Greenstar; and (ii) a promissory note of $100.0 million maturing December 31, 2024 bearing interest at a rate of 4.25% per annum, payable in cash on maturity (the “CBI Note”). As a result, Greenstar no longer holds any Canopy Notes.

Agreements with Indiva

On May 30, 2023, we entered into a license assignment and assumption agreement with Indiva Limited ("Indiva") and its subsidiary, Indiva Inc. (the "Indiva License Agreement"), allowing us to assume the exclusive rights and interests to manufacture, distribute, and sell Wana branded products in Canada. Simultaneously, we and Indiva also entered into a contract manufacturing agreement, under which we will grant Indiva the exclusive right to manufacture and supply Wana branded products in Canada for five years, with the ability to renew for an additional five-year term upon mutual agreement of the parties.

 

We remain committedalso subscribed for 37.2 million common shares of Indiva for an aggregate purchase price of $2.2 million. In addition, we paid Indiva $0.5 million in cash on May 30, 2023, and agreed to both optimizingpay Indiva an additional $1.3 million on May 30, 2024 provided that the value of Canopy USA and remaining in complianceparties are complying with the Nasdaq listing requirements. Accordingly, while we remain in discussions with the Nasdaq and another exchange with respect to our ongoing listing despite the consolidation of the financial results of Canopy USA with our financial results, we are prepared to make changes to the structure of our interest in Canopy USA such that we would not be required to consolidate the financial results of Canopy USA into Canopy Growth’s financial statements, which may include: (1) reducing Canopy Growth’s economic interest in Canopy USA on an as-converted basis to no greater than 90%, (2) reducing the number of managers on Canopy USA’s board of managers from four to three, including, reducing Canopy Growth’s nomination right to a single manager, (3) modifying the terms of the ProtectionIndiva License Agreement and Canopy USA’s Limited Liability Company Agreement in order to eliminate certain negative covenants, and (4) modifying(collectively, the terms of the agreements with third-party investors in Canopy USA to, among other things, eliminate their right to guaranteed returns."Indiva Investment").

 

Canadian Cannabis Operations RestructuringEquitization of $12.5 Million of Canopy Notes Due in July 2023

On June 29, 2023, we entered into privately negotiated exchange agreements (the "June 2023 Exchange Agreements") with certain holders (the "Noteholders") of the Canopy Notes to acquire and cancel $12.5 million aggregate principal amount of the Canopy Notes from the Noteholders in exchange for cash, including accrued and unpaid interest owing under the Canopy Notes, and the issuance of approximately 2.43 million Canopy Growth common shares (the "June 2023 Exchange Transaction").

48


Conversion of US$100.0 Million Convertible Debentures

 

On February 9,21, 2023, we announcedentered into a seriessubscription agreement (the “Convertible Debenture Agreement”) with an institutional investor (the “Institutional Investor”) pursuant to which the Institutional Investoragreed to purchase up to US$150.0 million aggregate principal amount of comprehensive stepssenior unsecured convertible debentures (“Convertible Debentures”) in a registered direct offering. The Convertible Debentures were issued under the indenture dated February 21, 2023 between us and Computershare Trust Company of Canada, in its capacity as trustee. Pursuant to alignthe Convertible Debenture Agreement, an initial $135.2 million (US$100.0 million) aggregate principal amount of the Convertible Debentures were sold to the Institutional Investor on February 21, 2023. The conditions with respect to the remaining US$50 million aggregate principal amount of the Convertible Debentures were neither satisfied nor waived. The Convertible Debentures were convertible into our Canadian cannabis operations and resources in responsecommon shares at the option of the Institutional Investor at any time or times prior to unfavorable market realities, which include:

Transitioningthe maturity date of February 28, 2028, at a conversion price equal to an asset-light model by: (i) exiting cannabis flower cultivation in92.5% of the volume-weighted average price of our Smiths Falls, Ontario facility; (ii) ceasingcommon shares during the sourcingthree consecutive trading days ending on the business day immediately prior to the date of cannabis flower from our Mirabel, Quebec facility; and (iii) consolidating cultivation at our existing facilities in Kincardine, Ontario and Kelowna, British Columbia;
Moving to an adaptive third-party sourcing model for all cannabis beverages, edibles, vapes, and extracts which will enableconversion. No cash payment or any other property of Canopy Growth was made by us to select and bring to market exciting and exclusive formats without the required investmentInstitutional Investor in research and development and production footprint;
Asconnection with, or as a result of, the aforementionedissuance, conversion or repayment of the Convertible Debentures.

As of June 30, 2023, all conversions pursuant to the Convertible Debentures were completed and the amount outstanding under the Convertible Debentures was $nil.

Maturity of Canopy Notes Due in July 2023

On July 13, 2023, we entered into privately negotiated redemption agreements (collectively, the “Redemption Agreements”) with certain Noteholders of our Canopy Notes, pursuant to which approximately $193 million aggregate principal amount of the outstanding Canopy Notes held by such Noteholders were redeemed (the "Redemption") on the applicable closing date for: (i) an aggregate cash payment of approximately $101 million; (ii) the issuance of 9.04 million Canopy Growth common shares; and (iii) the issuance of approximately $40.4 million aggregate principal amount of newly issued unsecured non-interest bearing convertible debentures (the "Debentures"). Following the Redemption, we settled the remaining aggregate principal amount owing under the outstanding Canopy Notes and, as of the maturity date, there were no Canopy Notes outstanding.

The Debentures were issued pursuant to a debenture indenture dated July 14, 2023 between us and Odyssey Trust Company, in its capacity as trustee. The Debentures were convertible into Canopy Growth common shares (the “Debenture Shares”) at the option of the holder at any time or times following approval from our shareholders for the issuance of all the Debenture Shares in excess of the Nasdaq threshold of 19.99% and the TSX requirements of 25% of the issued and outstanding Canopy Growth common shares in accordance with the applicable rules and regulations of Nasdaq and the TSX (the "Shareholder Approval") until the maturity date of January 15, 2024, at a conversion price equal to $5.50, subject to adjustment in certain events.

We obtained Shareholder Approval, at our Annual General and Special Meeting of shareholders held on September 25, 2023. As of September 30, 2023, all conversions pursuant to the Debentures have been completed and the amount outstanding under the Debentures was $nil.

Balance Sheet Deleveraging Initiatives

On October 24, 2022, we entered into agreements with certain of our lenders under the term loan credit agreement dated March 18, 2021 (the “Credit Agreement”) pursuant to which we agreed to purchase in the aggregate US$187.5 million of the principal indebtedness outstanding under the Credit Facility at a discounted price of US$930 per US$1,000 or US$174.4 million in the aggregate. The first payment, which was oversubscribed, in the amount of $117.5 million (US$87.9 million) was made on November 10, 2022 to reduce the principal indebtedness under the Credit Facility by approximately $126.3 million (US$94.4 million). The second payment of $116.8 million (US$87.2 million) was made on April 17, 2023 to reduce principal indebtedness under the Credit Facility by $125.6 million (US$93.8 million). Additionally, on October 24, 2022 we and certain of our lenders agreed to make certain amendments to the Credit Agreement which, among other things, resulted in: (i) a reduction to the minimum liquidity covenant to no less than US$100.0 million following completion of the second principal repurchase on April 17, 2023; (ii) certain changes we intend to consolidate flower, pre-rolled joints, softgel, and oil manufacturing in our current beverage productionthe application of net proceeds from asset sales; (iii) the establishment of a new committed delayed draw term credit facility in Smiths Falls, Ontarioan aggregate principal amount of US$100.0 million; and reduce headcount across(iv) the business; and

elimination of the additional US$500.0 million incremental term loan facility.

We intend

On July 13, 2023, we entered into agreements with certain of our lenders under the Credit Agreement pursuant to closewhich certain additional amendments were made to the 1 Hershey Drive facilityCredit Agreement (collectively, the Credit Agreement, as amended as of July 13, 2023, is referred to herein as the “Amended Credit Agreement”). The Amended Credit Agreement required us to prepay or repurchase principal indebtedness under the Credit Facility in Smiths Falls, Ontario and we are in active discussions with respectan amount equal to restructuring the joint-venture entity which holdsUS dollar equivalent of $93.0 million at a discounted price of US$930 per US$1,000 (the “July 2023 Paydown”). In addition, the cultivation facility in Mirabel, Quebec.Amended Credit Agreement requires us to apply certain net

49


 

TerrAscend Arrangementproceeds from asset sales to prepay or repurchase principal indebtedness under the Credit Facility and receive principal reductions at, in certain circumstances, a discounted price of US$950 per US$1,000. The Amended Credit Agreement also includes, among other things, amendments to the minimum liquidity covenant such that the US$100.0 million minimum ceased to apply concurrently with the July 2023 Paydown. The July 2023 Paydown was made on July 21, 2023.

On each of August 11, 2023 and September 14, 2023, pursuant to the terms of the Amended Credit Agreement, we repurchased additional outstanding principal amounts under the Credit Facility using certain net proceeds from completed asset sales (the “Second Quarter 2024 Paydowns”). The Second Quarter 2024 Paydowns resulted in an aggregate principal reduction of $73.3 million (US$54.5 million) for a cash payment of $69.6 million (US$51.8 million).

On each of November 28, 2023 and December 27, 2023, pursuant to the terms of the Amended Credit Agreement, we repurchased and repaid, as applicable, additional outstanding principal amounts under the Credit Facility using certain net proceeds from completed asset sales (the "Third Quarter 2024 Paydowns"). The Third Quarter 2024 Paydowns resulted in an aggregate principal reduction of $65.4 million (US$48.5 million) for a cash payment of $63.2 million (US$46.9 million).

September 2023 Private Placement – Unit Offering

On September 18, 2023, we entered into subscription agreements (the “Subscription Agreements”) with certain institutional investors (the “Investors”). Pursuant to the terms of the Subscription Agreements, we issued 2,292,947 units of the Company (the “Units”) to the Investors at a price per Unit of US$10.90 for aggregate gross proceeds of approximately $33.7 million (US$25.0 million) (the “Unit Offering”). Each Unit is comprised of one Canopy Growth common share and one common share purchase warrant (a “Warrant”). Each Warrant entitles the holder to acquire one Canopy Growth common share at a price per share equal to US$13.50 for a period of five years from the date of issuance. The Unit Offering closed on September 19, 2023.The Investors also held an over-allotment option to acquire up to an additional 2,292,947 Units at a price per Unit of US$10.90 for aggregate gross proceeds of approximately US$25.0 million at the discretion of the Investors at any time on or before November 2, 2023 (the “Over-Allotment Option”). The Over-Allotment Option was not exercised by the Investors and expired on November 2, 2023.

January 2024 Private Placement – Unit Offering

On January 18, 2024, we entered into subscription agreements (the "January 2024 Subscription Agreements") with certain institutional investors (the "January 2024 Investors"). Pursuant to the terms of the January 2024 Subscription Agreements, we issued 8,158,510 units of the Company (the "January 2024 Units") to the January 2024 Investors at a price per January 2024 Unit of US$4.29 for aggregate gross proceeds of approximately $47.1 million (US$35.0 million) (the "January 2024 Unit Offering"). Each January 2024 Unit is comprised of (a) one Canopy Growth common share and (b)(i) one Series A common share purchase warrant (a "Series A Warrant") or (ii) one Series B common share purchase warrant (a "Series B Warrant" and, together with the Series A Warrants, the "January 2024 Warrants"). Each January 2024 Warrant entitles the holder to acquire one Canopy Growth common share from the Company at a price per share equal to US$4.83. The Series A Warrants are currently exercisable and will remain exercisable until January 19, 2029, and the Series B Warrants will be exercisable for a period commencing on July 19, 2024 until July 19, 2029. The January 2024 Unit Offering closed on January 19, 2024.

Share Consolidation

 

On December 9, 2022, Canopy USA and certain limited partnerships13, 2023, the Company announced that are controlled by Canopy USA entered into a debt settlement agreement (the “TerrAscend Settlement Agreement”) with TerrAscend, TerrAscend Canada Inc. ("TerrAscend Canada") and Arise BioScience, Inc. ("Arise BioScience", together with TerrAscend and TerrAscend Canada, the "TerrAscend Entities") whereby $125,467 in aggregate loans, including accrued interest thereon, payable by certain subsidiaries of TerrAscend, were extinguished and 22,474,130 TerrAscend Warrants, being allBoard had approved the consolidation of the previouslyCompany’s issued TerrAscend Warrants controlled by Canopy USAand outstanding common shares on the basis of one post-consolidation common share for every 10 pre-consolidation common shares (the “Prior Warrants”“Share Consolidation”) were cancelled in exchange for: (i) 24,601,467 TerrAscend Exchangeable Shares at a notional price of $5.10 per TerrAscend Exchangeable Share; and (ii) 22,474,130 new TerrAscend Warrants (the "New Warrants" and, together. The Share Consolidation was implemented to ensure that the Company continues to comply with the TerrAscend Exchangeable Shares,listing requirements of the "New TerrAscend Securities") with a weighted average exercise price of $6.07 per TerrAscend Common Share and expiring on December 31, 2032 (collectively, the “TerrAscend Arrangement”).Nasdaq Global Select Market.

 

FollowingThe Share Consolidation was approved by the issuanceCompany’s shareholders at the annual general and special meeting of shareholders held on September 25, 2023. The Share Consolidation became effective on December 15, 2023. No fractional common shares were issued in connection with the Share Consolidation. Any fractional common shares arising from the Share Consolidation were deemed to have been tendered by its registered owner to the Company for cancellation for no consideration. In addition, the exercise or conversion price and/or the number of common shares issuable under any of the New TerrAscend Securities, Canopy USA beneficially owns: (i) 63,492,037 TerrAscend Exchangeable Shares; (ii) 22,474,130 New Warrants; and (iii)Company’s outstanding convertible securities, were proportionately adjusted in connection with the TerrAscend Option. The TerrAscend Exchangeable Shares can be converted into TerrAscend Common Shares at Canopy USA's option, subject to the terms of the Protection Agreement.Share Consolidation.

 

48All issued and outstanding common shares, per share amounts, and outstanding equity instruments and awards exercisable into common shares, as well as the exchange ratios for the Fixed Shares and the Floating Shares under the Acreage Amending Agreement and the Floating Share Arrangement Agreement, respectively, contained in the condensed interim consolidated financial statements of the Company and notes thereto have been retroactively adjusted to reflect the Share Consolidation for all prior periods presented.


 

Acquisition50


Divestiture of Verona Manufacturing FacilityThis Works

 

On November 8, 2022,December 18, 2023, the Company throughentered into an agreement to divest all of its affiliate BioSteel,interest in This Works to a London-based investment firm (the “This Works Divestiture”). The Company completed the acquisition (the "Verona Acquisition") of a manufacturing facility located in Verona, Virginia (the "Verona Facility") from Flow Beverage Corp. ("Flow"), one of BioSteel's contract manufacturers. Consideration was $26.4 million (US$19.5 million), consisting of cash paid of $15.7 million (US$11.6 million) and $8.5 million (US$6.3 million) for the repayment of debt and the retirement of certain lease obligations, and $2.2 million (US$1.6 million) in remediation and indemnity holdbacks to be retained by us and paid within one year of the closing of the Verona Acquisition. BioSteel and Flow have also entered into a co-manufacturing agreement whereby, in addition to the production of BioSteel-branded sports hydration beverages, BioSteel will produce Flow's portfolio of branded water at the Verona Facility.

Refer to Note 27 of our Interim Financial Statements for information regarding the fair value of the consideration given and the provisional fair values assigned to the assets acquired and liabilities assumed in connection with the Verona Acquisition.

This Works Divestiture of Canadian Retail Operations

On September 27, 2022, we announced entering into the following two agreements to divest our retail business in Canada, which includes the retail stores operating under the Tweed and Tokyo Smoke banners.

The first agreement (the "OEGRC Agreement") was entered into with OEG Retail Cannabis ("OEGRC"), a prior Canopy Growth licensee partner that previously owned and operated our franchised Tokyo Smoke stores in Ontario. As part of the OEGRC Agreement, OEGRC acquired ownership of 23 of our corporate-owned retail stores in Manitoba, Saskatchewan, and Newfoundland and Labrador, as well as all Tokyo Smoke-related intellectual property (the “OEGRC Transaction”). In connection with the OEGRC Transaction, the Tokyo Smoke brand has been transferred to OEGRC and all acquired retail stores branded as Tweed will be rebranded by OEGRC. In addition, the master franchise agreement between us and OEGRC,on December 18, 2023, pursuant to which OEGRC licenses the Tokyo Smoke brand in Ontario, was terminated effective on the closingCompany received a cash payment of the OEGRC Transaction.$2,249 (£1,333) and a loan note of $5,240 (£3,106) with a maturity date of December 18, 2027. The OEGRC Transaction closed on December 30, 2022.

The second agreement (the "FOUR20 Agreement") was entered into with 420 Investments Ltd. ("FOUR20")Company will also be entitled to an earnout payment of up to $5,905 (£3,500), a licensed cannabis retailer, pursuantsubject to which FOUR20 acquired the ownership of five of our corporate-owned retail stores in Alberta (the “FOUR20 Transaction”). Pursuant to the FOUR20 Agreement, these stores will be rebranded under FOUR20's retail banner following the closing of the FOUR20 Transaction. The FOUR20 Transaction closed on October 26, 2022.

Refer to Note 28 of our Interim Financial Statements for further information regarding the divestiture of our Canadian retail operations.certain financial targets.

 

Part 2 - Results of Operations

 

The results of operations presented below reports the financial performance of the continuing operations of Canopy Growth in the three and nine month periods ending December 31, 2023. Further to Note 4 in the Company’s accompanying financial statements, the BioSteel segment results for all periods prior to the September 14, 2023 and November 16, 2023, being the effective dates of deconsolidation as a result of the CCAA Proceedings, are classified as discontinued operations and therefore are excluded from continuing operations.

Discussion of Third Quarter of Fiscal 20232024 Results of Operations

 

 

 

Three months ended December 31,

 

 

 

 

 

 

 

(in thousands of Canadian dollars, except share amounts and
     where otherwise indicated)

 

2022

 

 

2021

 

 

$ Change

 

 

% Change

 

Selected consolidated financial information:

 

 

 

 

 

 

 

 

 

 

 

 

Net revenue

 

$

101,213

 

 

$

140,972

 

 

$

(39,759

)

 

 

(28

%)

Gross margin percentage

 

 

(2

%)

 

 

7

%

 

 

-

 

 

(900 bps)

 

Net loss

 

$

(266,722

)

 

$

(115,496

)

 

$

(151,226

)

 

 

(131

%)

Net loss attributable to Canopy Growth
   Corporation

 

$

(261,583

)

 

$

(108,925

)

 

$

(152,658

)

 

 

(140

%)

Basic and diluted loss per share1

 

$

(0.54

)

 

$

(0.28

)

 

$

(0.26

)

 

 

(93

%)

 

 

 

 

 

 

 

 

 

 

 

 

 

1For the three months ended December 31, 2022, the weighted average number of outstanding common shares, basic and diluted, totaled 486,112,598 (three months ended December 31, 2021 - 393,818,282).

 

49


 

 

Three months ended December 31,

 

 

 

 

 

 

 

(in thousands of Canadian dollars, except share amounts and
     where otherwise indicated)

 

2023

 

 

2022

 

 

$ Change

 

 

% Change

 

Selected consolidated financial information:

 

 

 

 

 

 

 

 

 

 

 

 

Net revenue

 

$

78,505

 

 

$

84,850

 

 

$

(6,345

)

 

 

(7

%)

Gross margin percentage

 

 

36

%

 

 

6

%

 

 

-

 

 

3,000 bps

 

Net loss from continuing operations

 

$

(230,276

)

 

$

(226,844

)

 

$

(3,432

)

 

 

(2

%)

Net loss from continuing operations
   attributable to Canopy Growth Corporation

 

$

(230,276

)

 

$

(226,302

)

 

$

(3,974

)

 

 

(2

%)

Basic and diluted loss per share from
   continuing operations
1,2

 

$

(2.78

)

 

$

(4.66

)

 

$

1.88

 

 

 

40

%

 

 

 

 

 

 

 

 

 

 

 

 

 

1 For the three months ended December 31, 2023, the weighted average number of outstanding common shares, basic and diluted, totaled 82,919,190 (three months ended December 31, 2022 - 48,611,260).

 

2 Prior year share and per share amounts have been retrospectively adjusted to reflect the Share Consolidation, which became effective on December 15, 2023.

 

 

Revenue

 

We report net revenue in fivefour segments: (i) Canada cannabis; (ii) rest-of-world cannabis; (iii) Storz & Bickel; (iv) BioSteel; and (v)(iv) This Works. Revenue derived from the remainder of our operations are included within "other". The following tables presenttable presents segmented net revenue by channel and by form, for the three months ended December 31, 20222023 and 2021:2022:

 

Revenue by Channel

 

Three months ended December 31,

 

 

 

 

 

 

Net Revenue

 

Three months ended December 31,

 

 

 

 

 

 

(in thousands of Canadian dollars)

 

2022

 

 

2021

 

 

$ Change

 

 

% Change

 

 

2023

 

 

2022

 

 

$ Change

 

 

% Change

 

Canada cannabis

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Canadian adult-use cannabis

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Business-to-business1

 

$

21,522

 

 

$

33,282

 

 

$

(11,760

)

 

 

(35

%)

 

$

23,386

 

 

$

21,522

 

 

$

1,864

 

 

 

9

%

Business-to-consumer

 

 

11,036

 

 

 

14,477

 

 

 

(3,441

)

 

 

(24

%)

 

 

-

 

 

 

11,036

 

 

 

(11,036

)

 

 

(100

%)

 

 

32,558

 

 

 

47,759

 

 

 

(15,201

)

 

 

(32

%)

 

 

23,386

 

 

 

32,558

 

 

 

(9,172

)

 

 

(28

%)

Canadian medical cannabis2

 

 

14,059

 

 

 

12,919

 

 

 

1,140

 

 

 

9

%

 

 

15,642

 

 

 

14,059

 

 

 

1,583

 

 

 

11

%

 

$

46,617

 

 

$

60,678

 

 

$

(14,061

)

 

 

(23

%)

 

$

39,028

 

 

$

46,617

 

 

$

(7,589

)

 

 

(16

%)

Rest-of-world cannabis

 

 

 

 

 

 

 

 

 

 

 

C3

 

 

-

 

 

 

9,675

 

 

 

(9,675

)

 

 

(100

%)

Other rest-of-world cannabis3

 

 

5,846

 

 

 

12,624

 

 

 

(6,778

)

 

 

(54

%)

 

$

5,846

 

 

$

22,299

 

 

$

(16,453

)

 

 

(74

%)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Rest-of-world cannabis3

 

$

10,527

 

 

$

5,846

 

 

$

4,681

 

 

 

80

%

Storz & Bickel

 

$

20,214

 

 

$

25,205

 

 

$

(4,991

)

 

 

(20

%)

 

$

18,453

 

 

$

20,214

 

 

$

(1,761

)

 

 

(9

%)

BioSteel4

 

$

16,363

 

 

$

16,974

 

 

$

(611

)

 

 

(4

%)

This Works

 

$

8,289

 

 

$

10,730

 

 

$

(2,441

)

 

 

(23

%)

 

$

8,165

 

 

$

8,289

 

 

$

(124

)

 

 

(1

%)

Other

 

 

3,884

 

 

 

5,086

 

 

 

(1,202

)

 

 

(24

%)

 

 

2,332

 

 

 

3,884

 

 

 

(1,552

)

 

 

(40

%)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net revenue

 

$

101,213

 

 

$

140,972

 

 

$

(39,759

)

 

 

(28

%)

 

$

78,505

 

 

$

84,850

 

 

$

(6,345

)

 

 

(7

%)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

1 Reflects excise taxes of $10,797 and other revenue adjustments, representing our determination of returns and pricing adjustments, of $2,000 for the three months ended December 31, 2022 (three months ended December 31, 2021 - excise taxes of $12,754 and other revenue adjustments of $1,000).

 

2 Reflects excise taxes of $1,339 for the three months ended December 31, 2022 (three months ended December 31, 2021 - $1,298).

 

3 Reflects other revenue adjustments of $3,684 for the three months ended December 31, 2022 (three months ended December 31, 2021 - $1,421).

 

4 Reflects other revenue adjustments of $3,185 for the three months ended December 31, 2022 (three months ended December 31, 2021 - $1,305).

 

1 Reflects excise taxes of $9,741 and other revenue adjustments, representing our determination of returns and pricing adjustments, of $1,113 for the three months ended December 31, 2023 (three months ended December 31, 2022 - excise taxes of $10,797 and other revenue adjustments of $2,000).

1 Reflects excise taxes of $9,741 and other revenue adjustments, representing our determination of returns and pricing adjustments, of $1,113 for the three months ended December 31, 2023 (three months ended December 31, 2022 - excise taxes of $10,797 and other revenue adjustments of $2,000).

 

2 Reflects excise taxes of $1,815 for the three months ended December 31, 2023 (three months ended December 31, 2022 - $1,339).

2 Reflects excise taxes of $1,815 for the three months ended December 31, 2023 (three months ended December 31, 2022 - $1,339).

 

3 Reflects other revenue adjustments of $317 for the three months ended December 31, 2023 (three months ended December 31, 2022 - $3,684).

3 Reflects other revenue adjustments of $317 for the three months ended December 31, 2023 (three months ended December 31, 2022 - $3,684).

 

51


 

Net revenue was $101.2$78.5 million in the third quarter of fiscal 2023,2024, a decrease of $6.3 million as compared to $141.0$84.9 million in the third quarter of fiscal 2022. The year-over-year decrease is primarily attributable to: (i) the continuing decrease in net revenue from our Canada cannabis segment, as increased competition in the Canadian adult-use market has resulted in lower sales velocities and continued price compression; (ii) the divestiture of our interest in C3 Cannabinoid Compound Company GmbH (“C3”) in the fourth quarter of fiscal 2022; (iii) a decline in our U.S. CBD business, as we focused our product and brand portfolio; and (iv) softer performance in our Storz & Bickel and This Works businesses.2023.

 

Canada cannabis

 

Net revenue from our Canada cannabis segment was $39.0 million in the third quarter of fiscal 2024, as compared to $46.6 million in the third quarter of fiscal 2023, as compared to $60.7 million in the third quarter of fiscal 2022.2023.

 

Canadian adult-use cannabis net revenue was $23.4 million in the third quarter of fiscal 2024, as compared to $32.6 million in the third quarter of fiscal 2023, as compared to $47.8 million in the third quarter of fiscal 2022.2023.

Net revenue from the business-to-business channel was $23.4 million in the third quarter of fiscal 2024, as compared to $21.5 million in the third quarter of fiscal 2023,2023. The year-over-year increase is primarily attributable to the growth in the large format products of Tweed flower as comparedwell as the addition of the Wana brand gummies to $33.3 millionthe portfolio.
Revenue from the adult-use business-to-consumer channel was $nil in the third quarter of fiscal 2022. The year-over-year decrease is primarily attributable to: (i) the continuing impacts of price compression across all categories of the Canadian adult-use market, predominantly resulting from increased competition; and (ii) lower sales volumes across the premium and value-priced categories of the Canadian adult-use cannabis market.
Revenue from the business-to-consumer channel was2024, as compared to $11.0 million in the third quarter of fiscal 2023, as compared2023. The year-over-year decrease is attributable to $14.5 millionthe divestiture of our retail business in Canada in the third quarter of fiscal 2022. The year-over-year decrease is primarily attributable to: (i) the closing of the FOUR20 Transaction on October 26, 2022, as described under "Recent Developments" above; (ii) the continuing rapid increase in the number of third-party owned retail stores across Canada, which has resulted in increased competition for traffic at our corporate-owned stores which we continued to operate in certain provinces; and (iii) price compression resulting from the increased competition, which impacted most of our product categories.2023.

 

Canadian medical cannabis net revenue was $15.6 million in the third quarter of fiscal 2024, as compared to $14.1 million in the third quarter of fiscal 2023, as compared to $12.9 million in the third quarter of fiscal 2022.2023. The year-over-year increase is primarily attributable to an increase in the average size of medical orders

50


placed by our customers due largely to a shift in our customer mix, partially offset byand a year-over-year decrease in the total numberlarger assortment of medical orders which was primarily relatedcannabis product choices offered to the increasing number of adult-use cannabis retail stores across Canada.our customers.

 

Rest-of-world cannabis

 

Rest-of-world cannabis revenue was $10.5 million in the third quarter of fiscal 2024, as compared to $5.8 million in the third quarter of fiscal 2023, as compared to $22.3 million in the third quarter of fiscal 2022.2023. The year-over-year decreaseincrease is attributable to:

the divestitureto growth in Germany, Poland and Czech Republic driven by increased shipments of C3, which was completed on January 31, 2022, and resulted in a decrease in revenue of $9.7 millionhigh quality flower products as compared to the third quarter of fiscal 2022; and
a year-over-year decrease of $6.8 million in other rest-of-world cannabis revenue, primarily attributable to: (i) a decline in our U.S. CBD business following our strategy shift initiated in the fourth quarter of fiscal 2022 to re-focus and refine our portfolio of product and brand offerings, and we recognized additional variable consideration which we expect to incurwell as a result; and (ii) in the third quarter of fiscal 2022, we generated revenue of $4.2 million from opportunistic bulk cannabis sales, predominantly to Israel; these sales did not repeat in the third quarter of fiscal 2023. Additionally, in the third quarter of fiscal 2023, we recognized a downward adjustment of $0.9 million related to a customer in Israel. These declines were partially offset by year-over-yearcontinued strong growth in our globalAustralian medical cannabis business, particularly in Australia and in our European markets.
business.

 

Storz & Bickel

 

Revenue from Storz & Bickel was $18.5 million in the third quarter of fiscal 2024, as compared to $20.2 million in the third quarter of fiscal 2023, as compared to $25.2 million in the third quarter of fiscal 2022. The year-over-year decrease is primarily attributable to: (i) the slowdown in consumer spending in North America and Europe, as consumers are exercising caution in an uncertain and inflationary environment; and (ii) the impact of changes in foreign exchange rates.

BioSteel

Revenue from BioSteel was $16.4 million in the third quarter of fiscal 2023, as compared to $17.0 million in the third quarter of fiscal 2022.2023. The year-over-year decrease is primarily attributable to timing shiftsproduction constraints and ramp-up of newly launched portable vaporizer in the distribution and salessecond quarter of our products into our key markets.fiscal 2024.

 

This Works

 

Revenue from This Works was $8.2 million in the third quarter of fiscal 2024, as compared to $8.3 million in the third quarter of fiscal 2023, as compared to $10.7 million in the third quarter of fiscal 2022.2023. The year-over-year decreaserevenue is primarily attributable to: (i) continuing softer performance in certain of our product lines, particularly our "Sleep" line, relativeslightly lower due to the third quartercompletion of fiscal 2022; (ii) lower sales velocities through e-commerce channels; and (iii) the impact of changes in foreign exchange rates.This Works Divestiture on December 18, 2023.

 

Cost of Goods Sold and Gross Margin

 

The following table presents cost of goods sold, gross margin and gross margin percentage on a consolidated basis for the three months ended December 31, 20222023 and 2021:2022:

 

 

Three months ended December 31,

 

 

 

 

 

 

 

Three months ended December 31,

 

 

 

 

 

 

(in thousands of Canadian dollars except where indicated)

(in thousands of Canadian dollars except where indicated)

2022

 

 

2021

 

 

$ Change

 

 

% Change

 

(in thousands of Canadian dollars except where indicated)

2023

 

 

2022

 

 

$ Change

 

 

% Change

 

Net revenue

 

$

101,213

 

 

$

140,972

 

 

$

(39,759

)

 

 

(28

%)

 

$

78,505

 

 

$

84,850

 

 

$

(6,345

)

 

 

(7

%)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of goods sold

 

$

103,654

 

 

$

130,882

 

 

$

(27,228

)

 

 

(21

%)

 

$

50,279

 

 

$

79,622

 

 

$

(29,343

)

 

 

(37

%)

Gross margin

 

 

(2,441

)

 

 

10,090

 

 

 

(12,531

)

 

 

(124

%)

 

 

28,226

 

 

 

5,228

 

 

 

22,998

 

 

 

440

%

Gross margin percentage

 

 

(2

%)

 

 

7

%

 

 

-

 

 

(900 bps)

 

 

 

36

%

 

 

6

%

 

 

-

 

 

3,000 bps

 

 

Cost of goods sold was $103.7$50.3 million in the third quarter of fiscal 2023,2024, as compared to $130.9$79.6 million in the third quarter of fiscal 2022.2023. Our gross margin was $(2.4)$28.2 million in the third quarter of fiscal 2023,2024, or (2%)36% of net revenue, as compared to a gross margin of $10.1$5.2 million and gross margin percentage of 7%6% of net revenue in the third quarter of fiscal 2022.2023. The year-over-year decreaseincrease in the gross margin percentage wasis primarily attributable to:

52


a shiftImprovement in our Canada cannabis segment, primarily attributable to: (i) the realized benefit of our cost savings program and strategic changes to our business that were initiated in the business mix relative to the thirdfourth quarter of fiscal 2022 resulting fromand the fourth quarter of fiscal 2023; (ii) a year-over-year decrease in the proportionate revenue contribution from the higher-margin C3 business, as a resultwrite-downs of the completionexcess inventory; and (iii) opportunistic utilization of the divestiture of C3 on January 31, 2022;lower cost inputs;
aA year-over-year decrease in the amount of payroll subsidies receivedrestructuring charges, from the Canadian government pursuant to a COVID-19 relief program, from $6.6$2.0 million in the third quarter of fiscal 20222023 to $nil in the third quarter of fiscal 2023;

51


a decline in BioSteel's gross margin, primarily due to: (i) inventory write-downs, primarily related to aging inventory; and (ii) higher third-party shipping, distribution and warehousing costs across North America relative to the third quarter of fiscal 2022; and
additional variable consideration recognized in respect of our U.S. CBD business, which we expect to incur in relation to the re-focusing of our product and brand portfolio.

These factors, resulting in a year-over-year decrease in our gross margin percentage, were partially offset by the following:

improvement in our Canada cannabis segment, attributable to the realized benefit of our cost savings program that we announced in April 2022;
charges totaling $3.1 million in the third quarter of fiscal 2022 relating to the flow-through of inventory step-up associated with the acquisition of Supreme Cannabis in the first quarter of fiscal 2022;
a year-over-year decrease in restructuring charges, from $4.6 million in the third quarter of fiscal 2022, related to inventory write-downs resulting from strategic changes to our business, including the closure of our facility in Langley, British Columbia, to $3.6 million in2024. In the third quarter of fiscal 2023, restructuring charges related primarily to inventory write-downs and other associated charges resulting primarily fromfrom: (i) the strategic changes to our business that were initiated in the fourth quarter of fiscal 2022, and charges associated with certain contract manufacturing agreements that are not expected to occur past fiscal 2023; and
the realized benefit of our cost savings program and the strategic changes to our U.S. CBD business, including the shift to a contract manufacturing model for certain product format; and (ii) amounts deemed excess based on current and projected demand;
Improvement in our Rest-of-world cannabis segment, primarily due to lower excess and obsolete inventory charges in the re-focusingthird quarter of our U.S. CBDfiscal 2024; and
Improvement in the Storz & Bickel segment, primarily due to lower input costs and a positive shift in product and brand portfolio.mix to higher-margin newly launched products.

52


 

We report gross margin and gross margin percentage in fivefour segments: (i) Canada cannabis; (ii) rest-of-world cannabis; (iii) Storz & Bickel; (iv) BioSteel; and (v)(iv) This Works. Cost of sales associated with the remainder of our operations are included within "other". The following table presents segmented gross margin and gross margin percentage for the three months ended December 31, 20222023 and 2021:2022:

 

 

Three months ended December 31,

 

 

 

 

 

 

 

Three months ended December 31,

 

 

 

 

 

 

(in thousands of Canadian dollars except where indicated)

(in thousands of Canadian dollars except where indicated)

2022

 

 

2021

 

 

$ Change

 

 

% Change

 

(in thousands of Canadian dollars except where indicated)

2023

 

 

2022

 

 

$ Change

 

 

% Change

 

Canada cannabis segment

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net revenue

 

$

46,617

 

 

$

60,678

 

 

$

(14,061

)

 

 

(23

%)

 

$

39,028

 

 

$

46,617

 

 

$

(7,589

)

 

 

(16

%)

Cost of goods sold

 

 

51,898

 

 

 

73,799

 

 

 

(21,901

)

 

 

(30

%)

 

 

27,915

 

 

 

51,898

 

 

 

(23,983

)

 

 

(46

%)

Gross margin

 

 

(5,281

)

 

 

(13,121

)

 

 

7,840

 

 

 

60

%

 

 

11,113

 

 

 

(5,281

)

 

 

16,394

 

 

 

310

%

Gross margin percentage

 

 

(11

%)

 

 

(22

%)

 

 

 

1,100 bps

 

 

 

28

%

 

 

(11

%)

 

 

 

3,900 bps

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Rest-of-world cannabis segment

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Revenue

 

$

5,846

 

 

$

22,299

 

 

$

(16,453

)

 

 

(74

%)

 

$

10,527

 

 

$

5,846

 

 

$

4,681

 

 

 

80

%

Cost of goods sold

 

 

8,030

 

 

 

17,639

 

 

 

(9,609

)

 

 

(54

%)

 

 

6,335

 

 

 

8,030

 

 

 

(1,695

)

 

 

(21

%)

Gross margin

 

 

(2,184

)

 

 

4,660

 

 

 

(6,844

)

 

 

(147

%)

 

 

4,192

 

 

 

(2,184

)

 

 

6,376

 

 

 

292

%

Gross margin percentage

 

 

(37

%)

 

 

21

%

 

 

 

(5,800) bps

 

 

 

40

%

 

 

(37

%)

 

 

 

7,700 bps

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Storz & Bickel segment

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Revenue

 

$

20,214

 

 

$

25,205

 

 

$

(4,991

)

 

 

(20

%)

 

$

18,453

 

 

$

20,214

 

 

$

(1,761

)

 

 

(9

%)

Cost of goods sold

 

 

11,028

 

 

 

14,033

 

 

 

(3,005

)

 

 

(21

%)

 

 

9,004

 

 

 

11,028

 

 

 

(2,024

)

 

 

(18

%)

Gross margin

 

 

9,186

 

 

 

11,172

 

 

 

(1,986

)

 

 

(18

%)

 

 

9,449

 

 

 

9,186

 

 

 

263

 

 

 

3

%

Gross margin percentage

 

 

45

%

 

 

44

%

 

 

 

100 bps

 

 

 

51

%

 

 

45

%

 

 

 

600 bps

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

BioSteel segment

 

 

 

 

 

 

 

 

 

Revenue

 

$

16,363

 

 

$

16,974

 

 

$

(611

)

 

 

(4

%)

Cost of goods sold

 

 

24,032

 

 

 

15,622

 

 

 

8,410

 

 

 

54

%

Gross margin

 

 

(7,669

)

 

 

1,352

 

 

 

(9,021

)

 

 

(667

%)

Gross margin percentage

 

 

(47

%)

 

 

8

%

 

 

 

(5,500) bps

 

 

 

 

 

 

 

 

 

 

 

 

 

This Works segment

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Revenue

 

$

8,289

 

 

$

10,730

 

 

$

(2,441

)

 

 

(23

%)

 

$

8,165

 

 

$

8,289

 

 

$

(124

)

 

 

(1

%)

Cost of goods sold

 

 

4,257

 

 

 

5,261

 

 

 

(1,004

)

 

 

(19

%)

 

 

3,912

 

 

 

4,257

 

 

 

(345

)

 

 

(8

%)

Gross margin

 

 

4,032

 

 

 

5,469

 

 

 

(1,437

)

 

 

(26

%)

 

 

4,253

 

 

 

4,032

 

 

 

221

 

 

 

5

%

Gross margin percentage

 

 

49

%

 

 

51

%

 

 

 

(200) bps

 

 

 

52

%

 

 

49

%

 

 

 

300 bps

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Revenue

 

$

2,332

 

 

$

3,884

 

 

$

(1,552

)

 

 

(40

%)

Cost of goods sold

 

$

4,409

 

 

$

4,528

 

 

$

(119

)

 

 

(3

%)

 

 

3,113

 

 

 

4,409

 

 

 

(1,296

)

 

 

(29

%)

Gross margin

 

 

(781

)

 

 

(525

)

 

 

(256

)

 

 

(49

%)

Gross margin percentage

 

 

(33

%)

 

 

(14

%)

 

 

 

(1,900) bps

 

 

Canada cannabis

 

Gross margin for our Canada cannabis segment was $11.1 million in the third quarter of fiscal 2024, or 28% of net revenue, as compared to $(5.3) million in the third quarter of fiscal 2023, or (11%) of net revenue, as compared to $(13.1) million in the third quarter of fiscal 2022, or (22%) of net revenue. The year-over-year increase in the gross margin percentage was primarily attributable to: (i) the realized benefit of our cost savings program that we announced in April 2022; and (ii) charges totaling $3.1 million recognizedstrategic changes to our business that

53


were initiated in the thirdfourth quarter of fiscal 2022 relating toand the flow-through of inventory step-up associated with the acquisition of Supreme Cannabis in the firstfourth quarter of fiscal 2022.

These factors were partially offset by: (i) the impacts on our gross margin percentage from the2023; (ii) a year-over-year decrease in net revenuewrite-downs of excess inventory; and continued price compression; and (ii) a decrease in the amount(iii) opportunistic utilization of payroll subsidies received from the Canadian government pursuant to a COVID-19 relief program, from $6.6 million in the third quarter of fiscal 2022 to $nil in the third quarter of fiscal 2023.lower cost inputs;

53


 

Rest-of-world cannabis

 

Gross margin for our rest-of-world cannabis segment was $4.2 million in the third quarter of fiscal 2024, or 40% of net revenue, as compared to $(2.2) million in the third quarter of fiscal 2023, or (37%) of net revenue, as compared to $4.7 million in the third quarter of fiscal 2022, or 21% of net revenue. The year-over-year decreaseincrease in the gross margin percentage is primarily attributable to:

the decrease in the proportionate revenue contribution from the higher-margin C3 business relative to the third quarter of fiscal 2022, as a result of the completion of the divestiture of C3 on January 31, 2022;
additional variable consideration recognized in respect of our U.S. CBD business which we expect to incur in relation to the re-focusing of our product and brand portfolio; and
a significant reduction in bulk cannabis sales relative to the third quarter of fiscal 2022, and andownward adjustment related to a customer in Israel which further impacted revenue.

These factors were partially offset by: (i) the growth in our Australian medical cannabis business; (ii) the realized benefit of our cost savings program and the strategic changes to our U.S. CBD business that were initiated in the fourth quarter of fiscal 2022, including the shift to a contract manufacturing model for certain product formats and the re-focusing of our U.S. CBD product and brand portfolio; and (iii) the year-over-year decrease in restructuring charges, as we recorded charges of $2.6 millionan exited international market in the third quarter of fiscal 2022 relating to inventory write-downs resulting from strategic changes to our business. These charges decreased to $0.3 million2023. Both items did not recur in the third quarter of fiscal 2023.2024.

 

Storz & Bickel

 

Gross margin for our Storz & Bickel segment was $9.4 million in the third quarter of fiscal 2024, or 51% of net revenue, as compared to $9.2 million in the third quarter of fiscal 2023, as compared to $11.2 million in the third quarter of fiscal 2022. Our gross margin percentage wasor 45% in the third quarter of fiscal 2023, relatively consistent with our gross margin percentage of 44% in the third quarter of fiscal 2022.

BioSteel

Gross margin for our BioSteel segment was $(7.7) million in the third quarter of fiscal 2023, or (47%) of net revenue, as compared to $1.4 million in the third quarter of fiscal 2022, or 8% of net revenue. The year-over-year decreaseincrease in the gross margin percentage is driven primarily attributable to: (i) inventory write-downs, primarily relatedby lower input costs and a positive shift in product mix to aging inventory; (ii) restructuring charges of $1.6 million, relating primarily to charges associated with certain contract manufacturing agreements that are not expected to occur past fiscal 2023; and (iii) higher third-party shipping, distribution and warehousing costs across North America relative to the third quarter of fiscal 2022.higher-margin newly launched products.

 

This Works

 

Gross margin for our This Works segment was $4.3 million in the third quarter of fiscal 2024, or 52% of net revenue, as compared to $4.0 million in the third quarter of fiscal 2023, as comparedor 49% of net revenue. The year-over-year increase in the gross margin percentage is primarily due to $5.5 millionlower excess and obsolete inventory charges in the third quarter of fiscal 2022. Our gross margin percentage was 49% in the third quarter of fiscal 2023, relatively consistent with our gross margin percentage of 51% in the third quarter of fiscal 2022.2024.

54


 

Operating Expenses

 

The following table presents operating expenses for the three months ended December 31, 20222023 and 2021:2022:

 

 

Three months ended December 31,

 

 

 

 

 

 

 

Three months ended December 31,

 

 

 

 

 

 

(in thousands of Canadian dollars)

 

2022

 

 

2021

 

 

$ Change

 

 

% Change

 

 

2023

 

 

2022

 

 

$ Change

 

 

% Change

 

Operating expenses

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

General and administrative

 

$

33,677

 

 

$

27,421

 

 

$

6,256

 

 

 

23

%

 

$

22,735

 

 

$

31,314

 

 

$

(8,579

)

 

 

(27

%)

Sales and marketing

 

 

62,207

 

 

 

64,398

 

 

 

(2,191

)

 

 

(3

%)

 

 

18,326

 

 

 

32,410

 

 

 

(14,084

)

 

 

(43

%)

Research and development

 

 

4,907

 

 

 

6,510

 

 

 

(1,603

)

 

 

(25

%)

 

 

1,311

 

 

 

4,907

 

 

 

(3,596

)

 

 

(73

%)

Acquisition-related costs

 

 

13,347

 

 

 

1,617

 

 

 

11,730

 

 

 

725

%

Acquisition, divestiture, and other costs

 

 

4,981

 

 

 

13,347

 

 

 

(8,366

)

 

 

(63

%)

Depreciation and amortization

 

 

8,498

 

 

 

16,889

 

 

 

(8,391

)

 

 

(50

%)

 

 

7,083

 

 

 

7,626

 

 

 

(543

)

 

 

(7

%)

Selling, general and administrative expenses

 

 

122,636

 

 

 

116,835

 

 

 

5,801

 

 

 

5

%

 

 

54,436

 

 

 

89,604

 

 

 

(35,168

)

 

 

(39

%)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Share-based compensation

 

 

6,428

 

 

 

5,806

 

 

 

622

 

 

 

11

%

Share-based compensation related to
acquisition milestones

 

 

-

 

 

 

971

 

 

 

(971

)

 

 

(100

%)

Share-based compensation expense

 

 

6,428

 

 

 

6,777

 

 

 

(349

)

 

 

(5

%)

 

 

3,693

 

 

 

6,055

 

 

 

(2,362

)

 

 

(39

%)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Asset impairment and restructuring costs

 

 

22,259

 

 

 

36,439

 

 

 

(14,180

)

 

 

(39

%)

Loss on asset impairment and restructuring

 

 

30,413

 

 

 

22,259

 

 

 

8,154

 

 

 

37

%

Total operating expenses

 

$

151,323

 

 

$

160,051

 

 

$

(8,728

)

 

 

(5

%)

 

$

88,542

 

 

$

117,918

 

 

$

(29,376

)

 

 

(25

%)

 

Selling, general and administrative expenses

 

Selling, general and administrative expenses were $122.6$54.4 million in the third quarter of fiscal 2023,2024, as compared to $116.8$89.6 million in the third quarter of fiscal 2022.2023.

 

General and administrative expense was $33.7$22.7 million in the third quarter of fiscal 2023,2024, as compared to $27.4$31.3 million in the third quarter of fiscal 2022.2023. The year-over-year increasedecrease is primarily attributable to:

a year-over-year decrease in the amount of payroll subsidies received from the Canadian government pursuant to a COVID-19 relief program, from $10.6 million received in the third quarter of fiscal 2022 to $nil in the third quarter of fiscal 2023.
the increase noted above was partially offset by the impact of the restructuring actions and cost savings programs initiated in the fourth quarterquarters of both fiscal 2022 which included operational changes designed to align general and administrative costs with business objectives, and further streamline the organization to drive process-related efficiencies.fiscal 2023. We realized reductions relative to the third quarter of fiscal 20222023 primarily in relation to: (i) compensation costs for finance, information technology, legal and other administrative functions; and (ii) third-party costs associated with administrative functions; and (iii)a reduction in facilities and insurance costs.

 

Sales and marketing expense was $62.2$18.3 million in the third quarter of fiscal 2023,2024, as compared to $64.4$32.4 million in the third quarter of fiscal 2022.2023. The year-over-year decrease is primarily attributable to: (i) the divestiture of our retail business in Canada in the third quarter of fiscal 2023; (ii) cost reductions related to the previously-noted restructuring actions that were initiated in the fourth quarter of fiscal 2022,and cost savings programs, which resulted in a reduction in compensation costs and a rationalization of our sales and marketing spending in certain areas of our business. This decrease was partially offset bybusiness, particularly for our Canadian cannabis and U.S. CBD businesses, and a year-over-year increase attributable to higher sponsorship fees associated with BioSteel's partnership deals, including the partnership with the National Hockey League and National Hockey League Players' Association, and increased advertising, trade activity and promotion expenses associated with BioSteel's new product launches.reduction in compensation costs.

54


 

Research and development expense was $1.3 million in the third quarter of fiscal 2024, as compared to $4.9 million in the third quarter of fiscal 2023, as compared to $6.5 million in the third quarter of fiscal 2022.2023. The year-over-year decrease is primarily attributable to cost reductions associated with the previously-noted restructuring actions that were initiated in the fourth quarter of fiscal 2022,and cost savings programs, as wewe: (i) continued to realize reductions in compensation costs and concluded or curtailedcurtail research and development projects; and (ii) shifted to outsourced contract model for certain research and development projects. We also realized a reduction in research

Acquisition, divestiture, and developmentother costs associated with the completion of the divestiture of C3 on January 31, 2022, which resulted in no costs being recorded in relation to C3were $5.0 million in the third quarter of fiscal 2023.

Acquisition-related costs were2024, as compared to $13.3 million in the third quarter of fiscal 2023, as compared to $1.6 million in2023. In the third quarter of fiscal 2022. In2024, costs were incurred primarily in relation to:

Approximately $2.4 million of additional advisory fees relating to the modification of the Credit Agreement that occurred in July 2023.
Approximately $2.0 million of legal and audit costs related to the restatement of our consolidated financial statements for the following previously filed periods: (i) audited consolidated financial statements for the fiscal year ended March 31, 2022, originally included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2022, and (ii) unaudited consolidated financial statements for the quarterly periods ended June 30, 2022, September 30, 2022 and December 31, 2022, originally included in the our Quarterly Reports on Form 10-Q for such quarterly periods, in connection with the correction of material misstatement arising from an internal review of financial reporting matters related to sales in the BioSteel business unit that were accounted for incorrectly, and the filing of our Annual Report on Form 10-K for the fiscal years ended March 31, 2023 and 2022 in June 2023; and
The Reorganization of Canopy USA.

Comparatively, in the third quarter of fiscal 2023, costs were incurred primarily in relation to the Reorganization, and the divestiture of certain of our corporate-owned retail stores in Canada, (both of which are described under "Recent Developments" above), and evaluating other potential acquisition opportunities. Comparatively, in the third quarter of fiscal 2022, costs were incurred primarily in relation to the plan to acquire Wana, the divestiture of C3, and evaluating other potential acquisition opportunities.

 

55


Depreciation and amortization expense was $8.5$7.1 million in the third quarter of fiscal 2023,2024, as compared to $16.9$7.6 million in the third quarter of fiscal 2022.2023. The year-over-year decrease is primarily attributable to:

(i) the previously-noted restructuring actions that were initiated in fiscal 2022,and cost savings programs, including the closure of certain of our Canadian facilities and other operational changes to implement cultivation-related efficiencies and improvements in the Canadian adult-use cannabis business,business; and the shift to a contract manufacturing model for certain product formats;
(ii) the divestiture of certain of our corporate-owned retail storesbusiness in Canada in connection with the OEGRC Transaction and the FOUR20 Transaction (as described under "Recent Developments" above);
the decrease in amortization expense associated with the impairment of certain of our intellectual property intangible assets in the fourth quarter of fiscal 2022; and
the completion of the divestiture of C3 on January 31, 2022, which resulted in no depreciation and amortization expense being recorded in relation to C3 in the third quarter of fiscal 2023.

 

Share-based compensation expense

 

Share-based compensation expense was $6.4$3.7 million in the third quarter of fiscal 2023,2024, as compared to $5.8$6.1 million in the third quarter of fiscal 2022.2023. The year-over-year increasedecrease is primarily attributable to 4.7 million stock option grants, and 3.1 million restricted share unit ("RSU") and performance share unit ("PSU") grants in the nine months ended December 31, 2022. The increase related to these grants was partially offset by the impact of our previously-noted restructuring actions, which resulted in 6.1 millionforfeitures of stock option forfeituresoptions, restricted share units and 1.9 million RSUperformance units and PSU forfeituresresults in the nine months ended December 31, 2022 (includinglower relative expenses in future periods. While 2.4 million stock option forfeitures and 0.8 million RSU and PSU forfeituresoptions were granted in the thirdfirst quarter of fiscal 2023).2024 and 1.5 million restricted share units were granted in the second quarter of fiscal 2024, the associated expense relating to both items partially offset the decrease noted.

 

Share-based compensation expense related to acquisition milestones was $nilLoss on asset impairment and restructuring

Loss on asset impairment and restructuring recorded in the third quarter of fiscal 2023, as compared to $1.0operating expenses were $30.4 million in the third quarter of fiscal 2022. The year-over-year decrease is primarily attributable to: (i) the completion of vesting, in prior quarters, of the share-based compensation associated with certain of our acquisitions; and (ii)2024, as a result of the restructuring actions completed in the fourth quarter of fiscal 2022, the acceleration of share-based compensation expense relatedcompared to unvested milestones associated with acquisitions completed in prior fiscal years.

Asset impairment and restructuring costs

Asset impairment and restructuring costs recorded in operating expenses were $22.3 million in the third quarter of fiscal 2023, as compared to $36.4 million in the third quarter of fiscal 2022.2023.

 

AssetLoss on asset impairment and restructuring costs recorded in the third quarter of fiscal 2024 were primarily related to the charges associated with the completion of the This Works Divestiture, as $28.1 million of write-downs occurred due to the sale. In addition, there were various incremental impairment losses and other costs associated with the restructuring of our Canadian cannabis operations that were initiated in the three months ended March 31, 2023.

Comparatively, in the third quarter of fiscal 2023, the loss on asset impairment and restructuring were primarily related to:

assetAsset impairment charges totaling $10.6 million relating to certain acquired brand intangible assets within our Canada cannabis segment;
employee-relatedEmployee-related restructuring charges associated with actions completed in the third quarter of fiscal 2023 as part of our ongoing program to align general and administrative costs with business objectives, and further streamline the organization;
incrementalIncremental impairment losses associated with the divestiture of our Canadian retail operations in connection withwith: (i) the OEGRC Transactionclosing, on October 26, 2022, of the transaction by which 420 Investments Ltd. acquired the ownership of five of our corporate-owned retail stores in Alberta; and (ii) the FOUR20 Transaction,closing, on December 30, 2022, of the transaction by which OEG Retail Cannabis acquired ownership of 23 of our corporate-owned retail stores in Manitoba, Saskatchewan and Newfoundland and Labrador, as described above under "Recent Developments",well as all Tokyo Smoke-related intellectual property, as we recorded write-downs of certain other assets due to the excess of their carrying values over their estimated fair values, and recognized contractual and other settlement obligations; and

55


incrementalIncremental costs primarily associated with the restructuring actions completed in fiscal 2022, including the closure of certain of our Canadian production facilities.

 

Comparatively, in the third quarter of fiscal 2022, we recorded charges primarily associated with adjustments related to changes in the estimated fair value of certain of our Canadian sites that were closed in December 2020 as part of a strategic review of our operations. The charges recorded in the third quarter of fiscal 2022 primarily represented the difference between the net book value of the associated long-lived assets and their estimated fair value.

Other

 

The following table presents other income (expense), net, and income tax (expense) recoveryexpense for the three months ended December 31, 20222023 and 2021:2022:

 

 

 

Three months ended December 31,

 

 

 

 

 

 

 

(in thousands of Canadian dollars)

 

2022

 

 

2021

 

 

$ Change

 

 

% Change

 

Other income (expense), net

 

 

(113,340

)

 

 

34,282

 

 

 

(147,622

)

 

 

(431

%)

Income tax recovery

 

 

382

 

 

 

183

 

 

 

199

 

 

 

109

%

56


 

 

Three months ended December 31,

 

 

 

 

 

 

 

(in thousands of Canadian dollars)

 

2023

 

 

2022

 

 

$ Change

 

 

% Change

 

Other income (expense), net

 

 

(171,037

)

 

 

(115,490

)

 

 

(55,547

)

 

 

(48

%)

Income tax recovery

 

 

1,077

 

 

 

1,336

 

 

 

(259

)

 

 

(19

%)

 

Other income (expense), net

 

Other income (expense), net was an expense amount of $113.3$171.0 million in the third quarter of fiscal 2023,2024, as compared to an incomeexpense amount of $34.3$115.5 million in the third quarter of fiscal 2022.2023. The year-over-year change of $147.6$55.5 million from an income amount to an expense amount, is primarily attributable to:

 

Decrease in non-cash incomeChange of $67.3$50.9 million related to fair value changes on the warrant derivative liability associated with the Tranche B Warrants held by CBI (as defined in Note 29 of the Interim Financial Statements). The fair value of the warrant derivative liability remained consistent during the third quarter of fiscal 2023, as the impact of the decrease in our share price during the period was completely offset by: (i) the fact that the warrant derivative liability was valued at only $0.7 million at September 30, 2022, meaning the impact of factors such as changes in our share price during the period are having an increasingly insignificant impact on the fair value determination; and (ii) the shorter expected time to maturity of the Tranche B Warrants. Comparatively, the income amount recognized in the third quarter of fiscal 2022 of $67.3 million, associated with a decrease in the fair value of the warrant derivative liability, was primarily attributable to a decrease of approximately 37% in our share price during the third quarter of fiscal 2022, further impacted by a shorter expected time to maturity of the Tranche B Warrants.

Decrease in non-cash income of $59.0 million related to the non-cash fair value changes on the liability arising from the Acreage Arrangement,our other financial assets, from an incomeexpense amount of $59.0$95.8 million in the third quarter of fiscal 2022 to a fair value change of $nil in the third quarter of fiscal 2023. The fair value change of $nil associated with the Acreage Amended Arrangement in the third quarter of fiscal 2023 is a result of the change, in the first quarter of fiscal 2023, from a liability amount to an asset amount recorded in other financial assets; in the third quarterexpense of fiscal 2023, the fair value of the Acreage call option decreased, as explained below, but remained in an asset position. Comparatively, the income amount recognized in the third quarter of fiscal 2022, associated with a decrease in the liability arising from the Acreage Arrangement, was primarily attributable to a decrease of approximately 37% in our share price in the third quarter of fiscal 2022, relative to a decrease of approximately 40% in Acreage’s share price during that same period. As a result, the probability-weighted expected return model used to determine the fair value of the liability arising from the Acreage Arrangement at December 31, 2021 reflected a lower estimated value of the Canopy Growth common shares expected to be issued at the exchange ratio of 0.3048 upon a Triggering Event, relative to the estimated value of the Fixed Shares expected to be acquired at that time (changes in our share price have a more significant impact on the model relative to changes in Acreage's share price); this resulted in a reduction of the liability amount in the third quarter of fiscal 2022.

Change of $9.6 million related to the non-cash fair value changes on the Notes, from an income amount of $0.6$146.7 million in the third quarter of fiscal 2022 to an expense amount of $9.0 million in the third quarter of fiscal 2023.2024. The expense amount recognized in the third quarter of fiscal 2023 was primarily attributable to the accrual of interest on the Notes, and changes in credit spreads during the period. Comparatively, the income amount recognized in the third quarter of fiscal 2022 was primarily attributable to the decrease in our share price of approximately 37% during that period.

Increase in non-cash expense of $27.1 million related to fair value changes on our other financial assets, from $68.7 million in the third quarter of fiscal 2022 to $95.8 million in the third quarter of fiscal 2023. The expense amount in the third quarter of fiscal 20232024 is primarily attributable to fair value decreases relating to our investments in:
o
The TerrAscend Exchangeable Shares, including the additional 24.6 million TerrAscend Exchangeable Shares received on December 9, 2022 as part of the TerrAscend Arrangement (as described under "Recent Developments" above),Wana financial instrument, in the amount of $31.5 million. This decrease is primarily attributable to: (i) a decrease of approximately 12% in TerrAscend's share price during the third quarter of fiscal 2023, impacting the 38.9$62.6 million, TerrAscend Exchangeable Shares that were held by us throughout the entire period; and (ii) a decrease of approximately 43% in TerrAscend's share price from December 9, 2022 to December 31, 2022, impacting the additional TerrAscend Exchangeable Shares received as part of the TerrAscend Arrangement;
o
The Wana and Jetty financial instruments, in the amounts of $16.2 million and $10.2 million, respectively,which was attributable primarily to an increasechanges in expectations of the discount rates used in the valuation of these instruments; this increase was in-line with the increase in interest rates relativefuture cash flows to the prior fiscal period;be generated by Wana;
o
The Acreage call option,financial instrument, in the amount of $35.0$43.6 million. On a quarterly basis, we determine the fair value of the Acreage call optionfinancial instrument using a probability-weighted expected return model, incorporating several potential scenarios and outcomes associated with the Acreage Amended Arrangement. The fair value decrease in the third quarter of fiscal 20232024 is primarily attributable to a decrease of approximately 16%36% in our share price during the third quarter of fiscal 2023,2024, relative to a decrease of approximately 29%54% in Acreage'sAcreage’s share price during that same period. As a result, the model at December 31, 20222023 reflects both a lower estimated value of the Canopy Growth common shares expected to be issued upon a Triggering Event, and a lower estimated value of the Acreage shares expected to be

57


acquired at that time. In the third quarter of fiscal 2023,2024, the relative share price movements resulted in a decrease in the value of the Acreage call option;financial instrument;
o
The New Warrants issued by TerrAscend as part of the TerrAscend Arrangement,Exchangeable Shares, in the amount of $17.5$22.9 million, which was primarily attributable to a decrease of approximately 43%21% in TerrAscend'sTerrAscend’s share price from December 9, 2022during the third quarter of fiscal 2024;
o
The New Warrants, in the amount of $10.5 million, which was primarily attributable to December 31, 2022.a decrease of approximately 21% in TerrAscend’s share price during the third quarter of fiscal 2024; and
o
The Jetty financial instrument, in the amount of $9.9 million, which was attributable primarily to changes in expectations of the future cash flows to be generated by Jetty.

 

These fair value decreases were partially offset by fair value increases related to our investments in:

o
The secured debenture (the "Hempco Debenture") advanced by an affiliate of the Company to Universal Hemp, LLC, a wholly owned subsidiary of Acreage ("Acreage Hempco"), in the amount of $2.1 million, which was attributable primarily to changes in expectations of future cash flows to be received.

Comparatively, the expense amount in the third quarter of fiscal 2023 was primarily attributable to fair value decreases relating to our investments in: (i) the TerrAscend Exchangeable Shares ($31.5 million); (ii) the New Warrants ($17.5 million); (iii) the Acreage call option ($35.0 million); (iv) the Wana financial instrument ($16.2 million); and (v) the Jetty financial instrument ($10.2 million). The fair value decreases were partially offset by fair value increases associated with the secured debentures issued by TerrAscend Canada and Arise Bioscience and the associated Prior Warrants, up to the closing of the TerrAscend Arrangement on December 9, 2022transactions contemplated in connection with the Debt Settlement Agreement (totaling $9.9 million), which were driven largely by an increase of approximately 55% in TerrAscend’s share price from September 30, 2022 to December 9, 2022.

Comparatively, in the third quarter of fiscal 2022 the expense amount was primarily attributable to fair value decreases relating to our investments in the TerrAscend Exchangeable Shares ($53.0 million), and the secured debentures issued by TerrAscend Canada and Arise Bioscience and associated Prior Warrants (totaling $13.0 million), driven largely by: (i) a decrease of approximately 12% in TerrAscend’s share price in the third quarter of fiscal 2022; and (ii) re-assessments of the probability and timing of changes in federal laws in the United States regarding the permissibility of the cultivation, distribution or possession of marijuana in the third quarter of fiscal 2022..

 

Increase in interest expenseChange of $6.9$9.5 million related to charges associated with the settlement of our debt, from $26.4an income amount of $8.9 million in the third quarter of fiscal 20222023 to $33.3an expense amount of $0.6 million in the third quarter of fiscal 2023. The year-over-year increase is2024. In the third quarter of fiscal 2024 we recognized charges of $0.6 million, primarily attributable to: (i) the increase in interest rates relative to the prior period, thus impacting the amount of interest payable associatedconnection with the variable interest rate debt owing underprincipal repayments on the Credit Agreement;Facility. The Third Quarter 2024 Paydowns resulted in a principal reduction of $65,379 (US$48,532) for a cash payment of $63,167 (US$46,902) and (ii) the strengtheningincluded write-offs of the U.S. dollar relative to the Canadian dollar, as compared to the prior year period.

Inrelated deferred financing costs. Comparatively, in the third quarter of fiscal 2023, we recognized incomea gain in the amount of $8.9 million in connection with the Paydown, as described under "Recent Developments" above, pursuant to the balance sheet actions completed as part of the Reorganization. The income amount represents the gain recognized upon the first payment made in connection with the Paydown paydown

56


on November 10, 2022, as we repaid $126.3 million (US$94.4 million) of the principal amount outstanding under the Credit Agreement at a discounted price of US$930 per US$1,000.

 

IncreaseDecrease in interest incomeexpense of $5.5$3.6 million related to non-cash fair value changes on our debt, from $1.6$9.0 million in the third quarter of fiscal 20222023 to $7.0$5.4 million in the third quarter of fiscal 2023.2024. The year-over-year increasechange is primarily attributable to the increase in interest rates relative to the comparative fiscal period, the impact of which was only partially offsetdriven by the year-over-year combined decreasefair value change of the unsecured senior notes in our cash and cash equivalents and short-term investments balances.the third quarter of fiscal 2023 versus the fair value changes on the CBI Note in the third quarter of fiscal 2024.

 

InDecrease in non-cash income of $6.9 million related to fair value changes on acquisition related contingent consideration and other, from $1.8 million in the third quarter of fiscal 2023 we recognized a gainto $8.6 million in the third quarter of $4.1 millionfiscal 2024. These fair value changes relate primarily to the estimated deferred payments associated with the closing of the OEGRC Transaction and the FOUR20 Transaction, and the derecognition of the assets and liabilities of the Canadian retail operations from our consolidated financial statements. The gain represents the difference between the carrying amounts of the derecognized assets and liabilities, andinvestment in Wana, with the fair value changes in both periods primarily associated with changes in expectations of the consideration received. See "Recent Developments" above for further details.future cash flows to be generated by Wana.

 

Income tax recovery

 

Income tax recovery in the third quarter of fiscal 20232024 was $0.4$1.1 million, compared to an income tax recovery of $0.2$1.3 million in the third quarter of fiscal 2022.2023. In the third quarter of fiscal 2023,2024, income tax expenserecovery consisted of deferred income tax recovery of $0.9$0.6 million (compared to an expensea recovery of $2.4$1.8 million in the third quarter of fiscal 2022)2023) and current income tax expenserecovery of $0.5 million (compared to a recoveryan expense of $2.6$0.5 million in the third quarter of fiscal 2022)2023).

 

The changedecrease of $3.2$1.2 million from deferred income tax expense toin the deferred income tax recovery is primarily a result of the change in deferred tax liabilities that arose in connection with the required revaluation of the accounting carrying value, but not the tax basis, of property, plant and equipment, intangible assets, and other financial assets. In connection with certainassets, net of deferred tax assets mainlyrecognized in respect to losses for tax purposes,the quarter where the accounting criteria for recognition of an asset has yet to be satisfied and it is not probable that they will be used, the deferred tax asset has not been recognized.satisfied.

 

The changeincrease of $3.0$1.0 million from ain current income tax recovery to current income tax expense arose primarily as a result of the reduction in connection withthe number of legal entities that generated income for tax purposes that could not be reduced by the group’s tax attributes.purposes.

58


 

Net Loss from Continuing Operations

 

The net loss from continuing operations in the third quarter of fiscal 20232024 was $266.7$230.3 million, as compared to a net loss of $115.5$226.8 million in the third quarter of fiscal 2022.2023. The year-over-year increase in the net loss is primarily attributable to: (i) the year-over-year increase in loss on asset impairment and restructuring; (ii) the year-over-year change in other income (expense), net, of $147.6 million, from an income amount to an expense amount; (ii) the year-over-year decrease in our gross margin;$55.5 million; and (iii) offset by the year-over-year increasedecrease in selling, general and administrative expenses. These factors were only partially offset by the year-over-year decrease in asset impairment and restructuring costs. These variances are described above.

 

Adjusted EBITDA (Non-GAAP Measure)

 

Our “Adjusted EBITDA” is a non-GAAP measure used by management that is not defined by U.S. GAAP and may not be comparable to similar measures presented by other companies. Management calculates Adjusted EBITDA as the reported net income (loss), adjusted to exclude income tax expense;recovery (expense); other income (expense), net; loss on equity method investments; share-based compensation expense; depreciation and amortization expense; (gain)/loss on asset impairmentsimpairment and restructuring costs;restructuring; restructuring costs recorded in cost of goods sold; and charges related to the flow-through of inventory step-up on business combinations, and further adjusted to remove acquisition-relatedacquisition, divestiture, and other costs. Asset impairments related to periodic changes to our supply chain processes are not excluded from Adjusted EBITDA given their occurrence through the normal course of core operational activities. Accordingly, management believes that Adjusted EBITDA provides meaningful and useful financial information, as this measure demonstrates the operating performance of businesses.

57


The following table presents Adjusted EBITDA for the three months ended December 31, 2023 and 2022:

 

 

Three months ended December 31,

 

 

 

 

 

 

 

(in thousands of Canadian dollars)

 

2023

 

 

2022

 

 

$ Change

 

 

% Change

 

Net loss from continuing operations

 

$

(230,276

)

 

$

(226,844

)

 

$

(3,432

)

 

 

(2

%)

Income tax recovery

 

 

(1,077

)

 

 

(1,336

)

 

 

259

 

 

 

19

%

Other (income) expense, net

 

 

171,037

 

 

 

115,490

 

 

 

55,547

 

 

 

48

%

Share-based compensation

 

 

3,693

 

 

 

6,055

 

 

 

(2,362

)

 

 

(39

%)

Acquisition, divestiture, and other costs

 

 

4,981

 

 

 

13,347

 

 

 

(8,366

)

 

 

(63

%)

Depreciation and amortization1

 

 

12,240

 

 

 

19,308

 

 

 

(7,068

)

 

 

(37

%)

Loss on asset impairment and restructuring

 

 

30,413

 

 

 

22,259

 

 

 

8,154

 

 

 

37

%

Restructuring costs recorded in cost of goods sold

 

 

-

 

 

 

2,007

 

 

 

(2,007

)

 

 

(100

%)

Adjusted EBITDA

 

$

(8,989

)

 

$

(49,714

)

 

$

40,725

 

 

 

82

%

1 From Consolidated Statements of Cash Flows.

 

The Adjusted EBITDA loss in the third quarter of fiscal 2024 was $9.0 million, as compared to an Adjusted EBITDA loss of $49.7 million in the third quarter of fiscal 2023. The year-over-year decrease in Adjusted EBITDA loss is primarily attributable to the year-over-year increase in our gross margin and the year-over-year decrease in our selling, general and administrative expenses.

Discussion of Results of Operation for the Nine Months Ended December 31, 2023

 

 

Nine months ended December 31,

 

 

 

 

 

 

 

(in thousands of Canadian dollars, except share amounts and
     where otherwise indicated)

 

2023

 

 

2022

 

 

$ Change

 

 

% Change

 

Selected consolidated financial information:

 

 

 

 

 

 

 

 

 

 

 

 

Net revenue

 

$

224,358

 

 

$

265,018

 

 

$

(40,660

)

 

 

(15

%)

Gross margin percentage

 

 

29

%

 

 

0

%

 

 

-

 

 

2,900 bps

 

Net loss from continuing operations

 

$

(389,007

)

 

$

(2,492,445

)

 

$

2,103,438

 

 

 

84

%

Net loss from continuing operations
   attributable to Canopy Growth Corporation

 

$

(389,007

)

 

$

(2,491,109

)

 

$

2,102,102

 

 

 

84

%

Basic and diluted loss per share from
   continuing operations
1, 2

 

$

(5.56

)

 

$

(54.96

)

 

$

49.40

 

 

 

90

%

 

 

 

 

 

 

 

 

 

 

 

 

 

1 For the nine months ended December 31, 2023, the weighted average number of outstanding common shares, basic and diluted, totaled 69,918,744 (nine months ended December 31, 2022 - 45,323,788).

 

2 Prior year share and per share amounts have been retrospectively adjusted to reflect the Share Consolidation, which became effective on December 15, 2023.

 

58


Revenue

We report net revenue in four segments: (i) Canada cannabis; (ii) rest-of-world cannabis; (iii) Storz & Bickel; and (iv) This Works. Revenue derived from the remainder of our operations are included within "other". The following table presents segmented net revenue for the nine months ended December 31, 2023 and 2022:

Net Revenue

 

Nine months ended December 31,

 

 

 

 

 

 

 

(in thousands of Canadian dollars)

 

2023

 

 

2022

 

 

$ Change

 

 

% Change

 

Canada cannabis

 

 

 

 

 

 

 

 

 

 

 

 

Canadian adult-use cannabis

 

 

 

 

 

 

 

 

 

 

 

 

Business-to-business1

 

$

71,591

 

 

$

73,379

 

 

$

(1,788

)

 

 

(2

%)

Business-to-consumer

 

 

-

 

 

 

36,243

 

 

 

(36,243

)

 

 

(100

%)

 

 

 

71,591

 

 

 

109,622

 

 

 

(38,031

)

 

 

(35

%)

Canadian medical cannabis2

 

 

45,043

 

 

 

41,714

 

 

 

3,329

 

 

 

8

%

 

 

$

116,634

 

 

$

151,336

 

 

$

(34,702

)

 

 

(23

%)

 

 

 

 

 

 

 

 

 

 

 

 

 

Rest-of-world cannabis3

 

$

29,666

 

 

$

30,179

 

 

$

(513

)

 

 

(2

%)

Storz & Bickel

 

$

48,517

 

 

$

49,351

 

 

$

(834

)

 

 

(2

%)

This Works

 

$

21,256

 

 

$

20,677

 

 

$

579

 

 

 

3

%

Other

 

 

8,285

 

 

 

13,475

 

 

 

(5,190

)

 

 

(39

%)

 

 

 

 

 

 

 

 

 

 

 

 

 

Net revenue

 

$

224,358

 

 

$

265,018

 

 

$

(40,660

)

 

 

(15

%)

 

 

 

 

 

 

 

 

 

 

 

 

 

1Reflects excise taxes of $31,596 and other revenue adjustments, representing our determination of returns and pricing adjustments, of $2,483 for the nine months ended December 31, 2023 (nine months ended December 31, 2022 - excise taxes of $33,754 and other revenue adjustments of $2,903).

 

2 Reflects excise taxes of $4,827 for the nine months ended December 31, 2023 (nine months ended December 31, 2022 - $3,625).

 

3 Reflects other revenue adjustments of $454 for the nine months ended December 31, 2023 (nine months ended December 31, 2022 - $4,885).

 

Net revenue was $224.4 million in the nine months ended December 31, 2023, a decrease of $40.7 million as compared to $265.0 million in the nine months ended December 31, 2022.

Canada cannabis

Net revenue from our Canada cannabis segment was $116.6 million in the nine months ended December 31, 2023, as compared to $151.3 million in the nine months ended December 31, 2022.

Canadian adult-use cannabis net revenue was $71.6 million in the nine months ended December 31, 2023, as compared to $109.6 million in the nine months ended December 31, 2022.

Net revenue from the business-to-business channel was $71.6 million in the nine months ended December 31, 2023, as compared to $73.4 million in the nine months ended December 31, 2022. The year-over-year decrease is primarily attributable to lower sales volumes across our premium and value-priced categories which, for the value-priced category, is largely the result of a strategy shift. For the premium category, the decrease is primarily attributable to supply chain constraints and shortages of in-demand flower. This decrease was partially offset by increased sales of our mainstream brands, primarily resulting from improved product attributes and new products introduced under the Tweed brand.
Revenue from the adult-use business-to-consumer channel was $nil in the nine months ended December 31, 2023, as compared to $36.2 million in the nine months ended December 31, 2022. The year-over-year decrease is attributable to the divestiture of our retail business in Canada in the third quarter of fiscal 2023.

Canadian medical cannabis net revenue was $45.0 million in the nine months ended December 31, 2023, as compared to $41.7 million in the nine months ended December 31, 2022. The year-over-year increase is primarily attributable to an increase in the average size of medical orders placed by our customers due largely to a shift in our customer mix, and a larger assortment of cannabis product choices offered to our customers.

59


Rest-of-world cannabis

Rest-of-world cannabis revenue was $29.7 million in the nine months ended December 31, 2023, as compared to $30.2 million in the nine months ended December 31, 2022. The year-over-year decrease is attributable to:

A decline in our U.S. CBD business, primarily due to: (i) the opportunistic sale, in the first quarter of fiscal 2023, of bulk crude CBD resin which did not recur in the first quarter of fiscal 2024; and (ii) the continuing impact of our strategy shift to re-focus and refine our portfolio of product and brand offerings on premium products;
Bulk cannabis sales, predominantly to a customer in an exited international market, in the amount of $4.2 million recognized in the first six months of fiscal 2023, which did not recur in the first six months of fiscal 2024; and
Softness in the German medical cannabis market, offset by increased sales in Australia, Poland and Czech Republic.

Storz & Bickel

Revenue from Storz & Bickel was $48.5 million in the nine months ended December 31, 2023, as compared to $49.4 million in the nine months ended December 31, 2022. The year-over-year decrease is primarily attributable to production constraints and ramp-up of newly launched portable vaporizer in the second quarter of fiscal 2024, offset by the expansion of our distribution and retail channels in the United States, helped by favorable foreign currency translation.

This Works

Revenue from This Works was $21.3 million in the nine months ended December 31, 2023, as compared to $20.7 million in the nine months ended December 31, 2022. The year-over-year increase is primarily attributable to an expanded product portfolio in our "Bodycare" line and continued success and strengthening sales velocity of our "In Transit" skincare product lineup, further supported by favorable foreign currency translations, slightly offset by the completion of the This Works Divestiture on December 18, 2023.

Cost of Goods Sold and Gross Margin

The following table presents cost of goods sold, gross margin and gross margin percentage on a consolidated basis for the nine months ended December 31, 2023 and 2022:

 

 

Nine months ended December 31,

 

 

 

 

 

 

 

(in thousands of Canadian dollars except where indicated)

2023

 

 

2022

 

 

$ Change

 

 

% Change

 

Net revenue

 

$

224,358

 

 

$

265,018

 

 

$

(40,660

)

 

 

(15

%)

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of goods sold

 

$

158,944

 

 

$

264,226

 

 

$

(105,282

)

 

 

(40

%)

Gross margin

 

 

65,414

 

 

 

792

 

 

 

64,622

 

 

 

8,159

%

Gross margin percentage

 

 

29

%

 

 

0

%

 

 

-

 

 

2,900 bps

 

Cost of goods sold was $158.9 million in the nine months ended December 31, 2023, as compared to $264.2 million in the nine months ended December 31, 2022. Our gross margin was $65.4 million in the nine months ended December 31, 2023, or 29% of net revenue, as compared to a gross margin of $0.8 million and gross margin percentage of 0% of net revenue in the nine months ended December 31, 2022. The year-over-year increase in the gross margin percentage is primarily attributable to:

Improvement in our Canada cannabis segment, primarily attributable to: (i) the realized benefit of our cost savings program and strategic changes to our business that were initiated in the fourth quarter of fiscal 2022 and the fourth quarter of fiscal 2023; (ii) a year-over-year decrease in write-downs of excess inventory; and (iii) capturing of value from previously identified excess inventory;
A year-over-year decrease in restructuring charges, from $10.1 million in the first nine months of fiscal 2023 to reversal of $0.7 in the first nine months of fiscal 2024. In the first nine months of fiscal 2023, restructuring charges related primarily to inventory write-downs resulting from: (i) the strategic changes to our business that were initiated in the fourth quarter of fiscal 2022, including the shift to a contract manufacturing model for certain product format; and (ii) amounts deemed excess based on current and projected demand; and
Improvement in our Rest-of-world cannabis and This Works segments, primarily due to lower excess and obsolete inventory charges in the first nine months of fiscal 2024.

The factors above, resulting in a year-over-year increase in our gross margin percentage, were partially offset by a decrease in the amount of payroll subsidies received from the Canadian government pursuant to a COVID-19 relief program, from $1.6 million in the nine months ended December 31, 2022 to $nil in the nine months ended December 31, 2023.

60


We report gross margin and gross margin percentage in four segments: (i) Canada cannabis; (ii) rest-of-world cannabis; (iii) Storz & Bickel; and (iv) This Works. Cost of sales associated with the remainder of our operations are included within "other". The following table presents segmented gross margin and gross margin percentage for the nine months ended December 31, 2023 and 2022:

 

 

Nine months ended December 31,

 

 

 

 

 

 

 

(in thousands of Canadian dollars except where indicated)

2023

 

 

2022

 

 

$ Change

 

 

% Change

 

 Canada cannabis segment

 

 

 

 

 

 

 

 

 

 

 

 

 Net revenue

 

$

116,634

 

 

$

151,336

 

 

$

(34,702

)

 

 

(23

%)

 Cost of goods sold

 

 

91,895

 

 

 

176,803

 

 

 

(84,908

)

 

 

(48

%)

 Gross margin

 

 

24,739

 

 

 

(25,467

)

 

 

50,206

 

 

 

197

%

 Gross margin percentage

 

 

21

%

 

 

(17

%)

 

 

 

 

3,800 bps

 

 

 

 

 

 

 

 

 

 

 

 

 

 Rest-of-world cannabis segment

 

 

 

 

 

 

 

 

 

 

 

 

 Revenue

 

$

29,666

 

 

$

30,179

 

 

$

(513

)

 

 

(2

%)

 Cost of goods sold

 

 

19,302

 

 

 

33,855

 

 

 

(14,553

)

 

 

(43

%)

 Gross margin

 

 

10,364

 

 

 

(3,676

)

 

 

14,040

 

 

 

382

%

 Gross margin percentage

 

 

35

%

 

 

(12

%)

 

 

 

 

4,700 bps

 

 

 

 

 

 

 

 

 

 

 

 

 

 Storz & Bickel segment

 

 

 

 

 

 

 

 

 

 

 

 

 Revenue

 

$

48,517

 

 

$

49,351

 

 

$

(834

)

 

 

(2

%)

 Cost of goods sold

 

 

27,443

 

 

 

28,542

 

 

 

(1,099

)

 

 

(4

%)

 Gross margin

 

 

21,074

 

 

 

20,809

 

 

 

265

 

 

 

1

%

 Gross margin percentage

 

 

43

%

 

 

42

%

 

 

 

 

100 bps

 

 

 

 

 

 

 

 

 

 

 

 

 

 This Works segment

 

 

 

 

 

 

 

 

 

 

 

 

 Revenue

 

$

21,256

 

 

$

20,677

 

 

$

579

 

 

 

3

%

 Cost of goods sold

 

 

10,722

 

 

 

11,695

 

 

 

(973

)

 

 

(8

%)

 Gross margin

 

 

10,534

 

 

 

8,982

 

 

 

1,552

 

 

 

17

%

 Gross margin percentage

 

 

50

%

 

 

43

%

 

 

 

 

700 bps

 

 

 

 

 

 

 

 

 

 

 

 

 

 Other

 

 

 

 

 

 

 

 

 

 

 

 

 Revenue

 

$

8,285

 

 

$

13,475

 

 

$

(5,190

)

 

 

(39

%)

 Cost of goods sold

 

 

9,582

 

 

 

13,331

 

 

 

(3,749

)

 

 

(28

%)

 Gross margin

 

 

(1,297

)

 

 

144

 

 

 

(1,441

)

 

 

(1,001

%)

 Gross margin percentage

 

 

(16

%)

 

 

1

%

 

 

 

 

(1,700) bps

 

Canada cannabis

Gross margin for our Canada cannabis segment was $24.7 million in the nine months ended December 31, 2023, or 21% of net revenue, as compared to $(25.5) million in the nine months ended December 31, 2022, or (17%) of net revenue. The year-over-year increase in the gross margin percentage was primarily attributable to: (i) the realized benefit of our cost savings program and strategic changes to our business that were initiated in the fourth quarter of fiscal 2022 and the fourth quarter of fiscal 2023; (ii) a year-over-year decrease in write-downs of excess inventory; and (iii) capturing of value from previously identified excess inventory. These increases were partially offset by a decrease in the amount of payroll subsidies received from the Canadian government pursuant to a COVID-19 relief program, from $1.6 million in the nine months ended December 31, 2022 to $nil in the nine months ended December 31, 2023.

Rest-of-world cannabis

Gross margin for our rest-of-world cannabis segment was $10.4 million in the nine months ended December 31, 2023, or 35% of net revenue, as compared to $(3.7) million in the nine months ended December 31, 2022, or (12%) of net revenue. The year-over-year increase in the gross margin percentage is primarily attributable to an improvement in our U.S. CBD business, due primarily to the year-over-year decrease in restructuring charges, as we recorded charges of $7.3 million in the nine months ended December 31, 2022 relating to inventory write-downs resulting from strategic changes to our business. These charges decreased to $nil in the nine months ended December 31, 2023 and the realized benefit of our cost savings program and the strategic changes made to our business, including the shift to a contract manufacturing model for certain product formats and the re-focusing of our U.S. CBD product and

61


brand portfolio. Further supporting the improved gross margin was a shift in the business mix to increased sales in Australia, Poland and Czech Republic compared to the nine months ended December 31, 2022.

Storz & Bickel

Gross margin for our Storz & Bickel segment was $21.1 million in the nine months ended December 31, 2023, or 43% of net revenue, as compared to $20.8 million in the nine months ended December 31, 2022, or 42% of net revenue. Gross margins were broadly consistent on a year-over-year basis.

This Works

Gross margin for our This Works segment was $10.5 million in the nine months ended December 31, 2023, or 50% of net revenue, as compared to $9.0 million in the nine months ended December 31, 2022, or 43% of net revenue. The year-over-year increase in the gross margin percentage is primarily due to lower excess and obsolete inventory charges in the nine months ended December 31, 2023.

Operating Expenses

The following table presents operating expenses for the nine months ended December 31, 2023 and 2022:

 

 

Nine months ended December 31,

 

 

 

 

 

 

 

(in thousands of Canadian dollars)

 

2023

 

 

2022

 

 

$ Change

 

 

% Change

 

 Operating expenses

 

 

 

 

 

 

 

 

 

 

 

 

 General and administrative

 

$

65,899

 

 

$

89,869

 

 

$

(23,970

)

 

 

(27

%)

 Sales and marketing

 

 

58,678

 

 

 

106,133

 

 

 

(47,455

)

 

 

(45

%)

 Research and development

 

 

3,768

 

 

 

17,349

 

 

 

(13,581

)

 

 

(78

%)

 Acquisition, divestiture, and other costs

 

 

24,373

 

 

 

31,546

 

 

 

(7,173

)

 

 

(23

%)

 Depreciation and amortization

 

 

22,092

 

 

 

26,528

 

 

 

(4,436

)

 

 

(17

%)

 Selling, general and administrative expenses

 

 

174,810

 

 

 

271,425

 

 

 

(96,615

)

 

 

(36

%)

 

 

 

 

 

 

 

 

 

 

 

 

 Share-based compensation expense

 

 

10,127

 

 

 

20,893

 

 

 

(10,766

)

 

 

(52

%)

 

 

 

 

 

 

 

 

 

 

 

 

 Loss on asset impairment and restructuring

 

 

2,452

 

 

 

1,794,212

 

 

 

(1,791,760

)

 

 

(100

%)

 Total operating expenses

 

$

187,389

 

 

$

2,086,530

 

 

$

(1,899,141

)

 

 

(91

%)

Selling, general and administrative expenses

Selling, general and administrative expenses were $174.8 million in the nine months ended December 31, 2023, as compared to $271.4 million in the nine months ended December 31, 2022.

General and administrative expense was $65.9 million in the nine months ended December 31, 2023, as compared to $89.9 million in the nine months ended December 31, 2022. The year-over-year decrease is primarily attributable to the impact of the restructuring actions and cost savings programs initiated in the fourth quarters of both fiscal 2022 and fiscal 2023. We realized reductions relative to the nine months ended December 31, 2023 primarily in relation to: (i) compensation costs for finance, information technology, legal and other administrative functions; and (ii) a reduction in facilities and insurance costs. The decrease noted above was partially offset by a year-over-year decrease in the amount of payroll subsidies received from the Canadian government pursuant to a COVID-19 relief program, from $2.9 million received in the nine months ended December 31, 2022 to $nil in the nine months ended December 31, 2023.

Sales and marketing expense was $58.7 million in the nine months ended December 31, 2023, as compared to $106.1 million in the nine months ended December 31, 2022. The year-over-year decrease is primarily attributable to: (i) the divestiture of our retail business in Canada in the third quarter of fiscal 2023; (ii) cost reductions related to the previously-noted restructuring actions and cost savings programs, which resulted in a rationalization of our sales and marketing spending in certain areas of our business, particularly for our Canadian cannabis and U.S. CBD businesses, and a reduction in compensation costs.

Research and development expense was $3.8 million in the nine months ended December 31, 2023, as compared to $17.3 million in the nine months ended December 31, 2022. The year-over-year decrease is primarily attributable to cost reductions associated with the previously-noted restructuring actions and cost savings programs, as we: (i) continued to realize reductions in

62


compensation costs and curtail research and development projects; and (ii) shifted to outsourced contract model for certain research and development projects.

Acquisition, divestiture, and other costs were $24.4 million in the nine months ended December 31, 2023, as compared to $31.5 million in the nine months ended December 31, 2022. In the nine months ended December 31, 2023, costs were incurred primarily in relation to:

Approximately $8.9 million of costs relating to the modification of the Credit Agreement that occurred in July 2023.
Approximately $8.8 million of legal and audit costs related to the restatement of our consolidated financial statements for the following previously filed periods: (i) audited consolidated financial statements for the fiscal year ended March 31, 2022, originally included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2022, and (ii) unaudited consolidated financial statements for the quarterly periods ended June 30, 2022, September 30, 2022 and December 31, 2022, originally included in the our Quarterly Reports on Form 10-Q for such quarterly periods, in connection with the correction of material misstatement arising from an internal review of financial reporting matters related to sales in the BioSteel business unit that were accounted for incorrectly, and the filing of our Annual Report on Form 10-K for the fiscal years ended March 31, 2023 and 2022 in June 2023;
The Reorganization of Canopy USA; and
Evaluating other potential acquisition opportunities.

Comparatively, in the nine months ended December 31, 2022, costs were incurred primarily in relation to the Reorganization and the planned divestiture of certain of our corporate-owned retail stores, and evaluating other potential acquisition opportunities.

Depreciation and amortization expense was $22.1 million in the nine months ended December 31, 2023, as compared to $26.5 million in the nine months ended December 31, 2022. The year-over-year decrease is primarily attributable to: (i) the previously-noted restructuring actions and cost savings programs, including the closure of certain of our Canadian facilities and other operational changes to implement cultivation-related efficiencies and improvements in the Canadian adult-use cannabis business; and (ii) the divestiture of our retail business in Canada in the third quarter of fiscal 2023.

Share-based compensation expense

Share-based compensation expense was $10.1 million in the nine months ended December 31, 2023, as compared to $20.9 million in the nine months ended December 31, 2022. The year-over-year decrease is primarily attributable to the impact of our previously-noted restructuring actions, which resulted in forfeitures of stock options, restricted share units and performance units and results in lower relative expenses in future periods. While 2.4 million stock options were granted in the first quarter of fiscal 2024 and 1.5 million restricted share units were granted in the second quarter of fiscal 2024, the associated expense relating to both items partially offset the decrease noted. However, the impact was limited because the stock options and restricted share units were only issued part-way through the period.

Loss on asset impairment and restructuring

Loss on asset impairment and restructuring recorded in operating expenses were $2.5 million in the nine months ended December 31, 2023, as compared to $1.8 billion in the nine months ended December 31, 2022.

Loss on asset impairment and restructuring recorded in the nine months ended December 31, 2023 were primarily related to the charges associated with the completion of the This Works Divestiture, as $28.1 million of write-downs occurred due to the sale. In addition, there were various incremental impairment losses and other costs associated with the restructuring of our Canadian cannabis operations that were initiated in the three months ended March 31, 2023. These charges were offset by a gain on the sale of our production facility at 1 Hershey Drive in Smiths Falls, Ontario. The gain is due to the sale proceeds exceeding the carrying value that was previously impaired at March 31, 2023.

Comparatively, in the nine months ended December 31, 2022, the loss on asset impairment and restructuring were primarily related to:

Goodwill impairment losses of $1.8 billion, substantially of which was associated with our cannabis operations reporting unit in the global cannabis segment. Refer to “Impairment of Goodwill” in “Critical Accounting Policies and Estimates” section below;
Impairment losses associated with the planned divestiture of our Canadian retail operations, as we recorded write-downs of property, plant and equipment, operating license and brand intangible assets, right-of-use assets, and certain other assets due to the excess of their carrying values over their estimated fair value; and
Incremental costs primarily associated with the restructuring actions completed in fiscal 2022, including the closure of certain of our Canadian production facilities, and operational changes initiated in the fourth quarter of fiscal 2022 to: (i) implement

63


cultivation-related efficiencies and improvements in the Canadian recreational cannabis business; and (ii) implement a flexible manufacturing platform, including contract manufacturing for certain product formats.

Other

The following table presents other income (expense), net, and income tax expense for the nine months ended December 31, 2023 and 2022:

 

 

Nine months ended December 31,

 

 

 

 

 

 

 

(in thousands of Canadian dollars)

 

2023

 

 

2022

 

 

$ Change

 

 

% Change

 

Other income (expense), net

 

 

(253,270

)

 

 

(396,074

)

 

 

142,804

 

 

 

36

%

Income tax expense

 

 

(13,762

)

 

 

(10,633

)

 

 

(3,129

)

 

 

(29

%)

Other income (expense), net

Other income (expense), net was an expense amount of $253.3 million in the nine months ended December 31, 2023, as compared to an expense amount of $396.1 million in the nine months ended December 31, 2022. The year-over-year change of $142.8 million is primarily attributable to:

Change of $232.9 million related to non-cash fair value changes on our other financial assets, from an expense amount of $396.8 million in the nine months ended December 31, 2022 to $163.9 million in the nine months ended December 31, 2023. The expense amount recognized in the nine months ended December 31, 2023 is primarily attributable to fair value decreases relating to our investments in:
o
The Wana financial instrument, in the amount of $111.8 million, primarily attributable to changes in expectations of future cash flows to be generated by Wana;
o
The Jetty financial instrument, in the amount of $27.2 million, primarily attributable to changes in expectations of future cash flows to be generated by Jetty;
o
The Acreage financial instrument, in the amount of $22.3 million. On a quarterly basis, we determine the fair value of the Acreage financial instrument using a probability-weighted expected return model, incorporating several potential scenarios and outcomes associated with the Acreage Amended Arrangement. The fair value increase in the nine months ended December 31, 2023 is primarily attributable to a decrease of approximately 71% in our share price during the nine months ended December 31, 2023, relative to a decrease of approximately 67% in Acreage’s share price during that same period. As a result, the model at December 31, 2023 reflects both a lower estimated value of the Canopy Growth common shares expected to be issued upon a Triggering Event, and a lower estimated value of the Acreage shares expected to be acquired at that time. In the nine months ended December 31, 2023, the relative share price movements resulted in an increase in the value of the Acreage financial instrument; and
o
The Hempco Debenture, in the amount of $15.8 million, primarily attributable to changes in expectations of future cash flows to be received.

These fair value decreases were partially offset by fair value increases primarily attributable to our investments in:

o
The TerrAscend Exchangeable Shares, in the amount of $10.2 million, primarily attributable to an increase of approximately 7% in TerrAscend’s share price during the nine months ended December 31, 2023; and
o
The New Warrants, in the amount of $2.7 million, primarily attributable to an increase of approximately 7% in TerrAscend’s share price during the nine months ended December 31, 2023.

Comparatively, the expense amount in the nine months ended December 31, 2022 was primarily attributable to fair value decreases relating to our investments in: (i) the TerrAscend Exchangeable Shares ($207.0 million); (ii) the secured debentures issued by TerrAscend Canada and Arise Bioscience and associated Prior Warrants (totaling $58.7 million); (iii) the New Warrants issued by TerrAscend ($17.5 million) and (iv) the TerrAscend Option ($5.1 million), which were all driven largely by a decrease of approximately 78% in TerrAscend’s share price in the nine months ended December 31, 2022. Additionally, the fair value of our investment in the Wana and Jetty financial instruments decreased $135.4 million and $9.8 million, respectively, due primarily to changes in expectations of the future cash flows to be generated by Wana and an increase in discount rates used in the valuation of both the Wana and Jetty financial instruments. The fair value decreases were partially offset by a fair value increase related to the Acreage financial instrument in the amount of $37.0 million.

Increase of $17.3 million related to charges associated with the settlement of our debt, from $4.2 million income in the nine months ended December 31, 2022 to $13.1 million expense in the nine months ended December 31, 2023. In the nine months ended December 31, 2023 we recognized charges of $13.1 million, primarily in connection with the conversion of the Convertible Debentures (as described above under “Recent Developments”) into Canopy Growth common shares at a

64


conversion price of 92.5% of the volume-weighted average price of our common shares during the three consecutive trading days ending on the business day immediately prior to the date of conversion and the Second Quarter 2024 Paydowns and Third Quarter 2024 Paydowns which resulted in a principal reduction of $73,313 (US$54,491) and $65,379 (US$48,532), respectively, for a cash payment of $69,647 (US$51,766) and $63,167 (US$46,902), respectively, and included write-offs of the related deferred financing costs. These charges were partially offset by a gain recognized upon the second payment made in connection with the Paydown on April 17, 2023 (also as described above under “Recent Developments”), as we repaid $125.6 million (US$93.8 million) of the principal amount outstanding under the Credit Agreement at a discounted price of US$930 per US$1,000.
Comparatively, in the nine months ended December 31, 2022, we recognized income in the amount of $4.2 million primarily relating to: (i) the gain recognized upon the first payment made in connection with the paydown on November 10, 2022, as we repaid $126.3 million (US$94.4 million) of the principal amount outstanding under the Credit Agreement at a discounted price of US$930 per US$1,000; and (ii) the release of amounts recorded in accumulated other comprehensive income in relation to the credit risk fair value adjustment associated with the portion of the Canopy Notes that were acquired and cancelled in June and July 2022. These were offset by charges relating to the Exchange Transaction and primarily include: (i) the recognition of, and fair value changes through to the Final Closing on, a derivative liability in connection with the incremental common shares that were potentially issuable as at June 30, 2022 at the Averaging Price on the Final Closing, pursuant to the Exchange Agreements; and (ii) professional fees associated with the Exchange Transaction.

Change of $1.8 million related to non-cash fair value changes on our debt, from an expense amount of $32.4 million in the nine months ended December 31, 2022 to an expense amount of $30.6 million in the nine months ended December 31, 2023. The year-over-year change, is primarily attributable to the fair value changes on the unsecured non-interest bearing convertible debentures, partially offset by the fair value changes on the CBI Note, and the fair value change of the unsecured senior notes prior to redemption in July 2023; compared to the fair value change of the unsecured senior notes in the nine months ended December 31, 2022.

Decrease in non-cash income of $26.3 million related to fair value changes on the warrant derivative liability associated with the Tranche B Warrants, from an income amount of $26.3 million in the nine months ended December 31, 2022 to a fair value change of $nil in the nine months ended December 31, 2023. The fair value change of $nil in the nine months ended December 31, 2023 is the result of the fair value of the warrant derivative liability decreasing to $nil in the fourth quarter of fiscal 2023, and expiring as of November 1, 2023. Comparatively, the income amount recognized in the nine months ended December 31, 2022 of $26.3 million, associated with a decrease in the fair value of the warrant derivative liability, was primarily attributable to a decrease of approximately 67% in our common share price during the nine months ended December 31, 2022, further impacted by an increase in the risk-free interest rate and a shorter expected time to maturity of the Tranche B Warrants.

Decrease in non-cash income of $6.8 million related to fair value changes on acquisition related contingent consideration and other, from $25.9 million in the nine months ended December 31, 2022 to $19.1 million in the nine months ended December 31, 2023. These fair value changes relate primarily to the estimated deferred payments associated with our investment in Wana, with the fair value changes in both periods primarily associated with changes in expectations of future cash flows to be generated by Wana.

Decrease in non-cash income of $47.0 million related to the fair value changes on the liability arising from the Acreage Amended Arrangement, from an income amount of $47.0 million in the nine months ended December 31, 2022 to a fair value change of $nil in the nine months ended December 31, 2023. The fair value change of $nil associated with the Acreage financial instrument in the nine months ended December 31, 2023 is a result of the change from a liability amount to an asset amount recorded in other financial assets; in the nine months ended December 31, 2023, the fair value of the Acreage financial instrument increased, as explained above, and remained in an asset position. Comparatively, the income amount recognized in the nine months ended December 31, 2022, associated with a decrease in the liability arising from the Acreage Amended Arrangement to $nil, was primarily attributable to a decrease of approximately 61% in our share price during the first quarter of fiscal 2023, relative to a decrease of approximately 27% in Acreage’s share price during that same period. As a result, the probability-weighted expected return model used to determine the fair value of the liability arising from the Acreage Amended Arrangement at June 30, 2022 reflected a lower estimated value of the Canopy Growth common shares expected to be issued at the exchange ratio of 0.03048 upon a Triggering Event, relative to the estimated value of the Fixed Shares expected to be acquired at that time (changes in our share price have a more significant impact on the model relative to changes in Acreage’s share price); in the first quarter of fiscal 2023, this resulted in a change from a liability amount to an asset amount.

Income tax expense

Income tax expense in the nine months ended December 31, 2023 was $13.8 million, compared to income tax expense of $10.6 million in the nine months ended December 31, 2022. In the nine months ended December 31, 2023, income tax expense consisted of

65


deferred income tax expense of $13.4 million (compared to an expense of $7.0 million in the nine months ended December 31, 2022) and current income tax expense of $0.4 million (compared to an expense of $3.6 million in the nine months ended December 31, 2022).

The increase of $6.4 million in the deferred income tax expense is primarily a result of (i) an increase due to the settlements of the Canopy Notes; and (ii) decrease in the change in deferred tax liabilities that arose in connection with the required revaluation of the accounting carrying value, but not the tax basis, of property, plant and equipment, intangible assets, and other financial assets.

The decrease of $3.2 million in current income tax expense arose primarily as a result of the reduction in the number of legal entities that generated income for tax purposes.

Net Loss from Continuing Operations

The net loss in the nine months ended December 31, 2023 was $389.0 million, as compared to a net loss of $2.5 billion in the nine months ended December 31, 2022. The year-over-year decrease in the net loss is primarily attributable to: (i) the year-over-year change from a loss on asset impairment and restructuring with respect to goodwill impairment losses of $1.7 billion recorded in the nine months ended December 31, 2022 to a gain on asset impairment and restructuring; (ii) the year-over-year change in other income (expense), net, of $142.8 million; and (iii) the decrease in selling, general and administrative expenses. These variances are described above.

Adjusted EBITDA (Non-GAAP Measure)

Our “Adjusted EBITDA” is a non-GAAP measure used by management that is not defined by U.S. GAAP and may not be comparable to similar measures presented by other companies. Management calculates Adjusted EBITDA as the reported net income (loss), adjusted to exclude income tax recovery (expense); other income (expense), net; loss on equity method investments; share-based compensation expense; depreciation and amortization expense; (gain)/loss on asset impairment and restructuring; restructuring costs recorded in cost of goods sold; and charges related to the flow-through of inventory step-up on business combinations, and further adjusted to remove acquisition, divestiture, and other costs. Asset impairments related to periodic changes to our supply chain processes are not excluded from Adjusted EBITDA given their occurrence through the normal course of core operational activities. Accordingly, management believes that Adjusted EBITDA provides meaningful and useful financial information, as this measure demonstrates the operating performance of businesses.

 

The following table presents Adjusted EBITDA for the three months ended December 31, 2022 and 2021:

 

 

Three months ended December 31,

 

 

 

 

 

 

 

(in thousands of Canadian dollars)

 

2022

 

 

2021

 

 

$ Change

 

 

% Change

 

Net loss

 

$

(266,722

)

 

$

(115,496

)

 

$

(151,226

)

 

 

(131

%)

Income tax recovery

 

 

(382

)

 

 

(183

)

 

 

(199

)

 

 

(109

%)

Other (income) expense, net

 

 

113,340

 

 

 

(34,282

)

 

 

147,622

 

 

 

431

%

Share-based compensation1

 

 

6,428

 

 

 

6,777

 

 

 

(349

)

 

 

(5

%)

Acquisition-related costs

 

 

13,347

 

 

 

1,617

 

 

 

11,730

 

 

 

725

%

Depreciation and amortization1

 

 

20,602

 

 

 

30,017

 

 

 

(9,415

)

 

 

(31

%)

Asset impairment and restructuring costs

 

 

22,259

 

 

 

36,439

 

 

 

(14,180

)

 

 

(39

%)

Restructuring costs recorded in cost of goods sold

 

 

3,626

 

 

 

4,554

 

 

 

(928

)

 

 

(20

%)

Charges related to the flow-through of inventory
   step-up on business combinations

 

 

-

 

 

 

3,147

 

 

 

(3,147

)

 

 

(100

%)

Adjusted EBITDA

 

$

(87,502

)

 

$

(67,410

)

 

$

(20,092

)

 

 

(30

%)

 

 

 

 

 

 

 

 

 

 

 

 

 

1 From Consolidated Statements of Cash Flows.

 

The Adjusted EBITDA loss in the third quarter of fiscal 2023 was $87.5 million, as compared to an Adjusted EBITDA loss of $67.4 million in the third quarter of fiscal 2022. The year-over-year increase in the Adjusted EBITDA loss is primarily attributable to the year-over-year decrease our gross margin, and the year-over-year increase in our general and administrative expenses. These variances are described above.

Discussion of Results of Operations for the Nine Months Ended December 31, 2022

 

 

Nine months ended December 31,

 

 

 

 

 

 

 

(in thousands of Canadian dollars, except share amounts and
     where otherwise indicated)

 

2022

 

 

2021

 

 

$ Change

 

 

% Change

 

Selected consolidated financial information:

 

 

 

 

 

 

 

 

 

 

 

 

Net revenue

 

$

329,191

 

 

$

408,555

 

 

$

(79,364

)

 

 

(19

%)

Gross margin percentage

 

 

0

%

 

 

(8

%)

 

 

-

 

 

800 bps

 

Net (loss) income

 

$

(2,586,189

)

 

$

258,128

 

 

$

(2,844,317

)

 

 

(1,102

%)

Net (loss) income attributable to Canopy Growth
   Corporation

 

$

(2,566,537

)

 

$

272,435

 

 

$

(2,838,972

)

 

 

(1,042

%)

Basic (loss) earnings per share1

 

$

(5.66

)

 

$

0.70

 

 

$

(6.36

)

 

 

(909

%)

Diluted (loss) earnings per share1

 

$

(5.66

)

 

$

0.43

 

 

$

(6.09

)

 

 

(1,416

%)

 

 

 

 

 

 

 

 

 

 

 

 

 

1For the nine months ended December 31, 2022, the weighted average number of outstanding common shares, basic and diluted, totaled 453,237,882 (nine months ended December 31, 2021 - basic of 390,423,083 and diluted of 410,986,802).

 

59


Revenue

We report net revenue in five segments: (i) Canada cannabis; (ii) rest-of-world cannabis; (iii) Storz & Bickel; (iv) BioSteel; and (v) This Works. Revenue derived from the remainder of our operations are included within "other". The following tables present segmented net revenue, by channel and by form, for the nine months ended December 31, 20222023 and 2021:2022:

 

Revenue by Channel

 

Nine months ended December 31,

 

 

 

 

 

 

 

(in thousands of Canadian dollars)

 

2022

 

 

2021

 

 

$ Change

 

 

% Change

 

Canada cannabis

 

 

 

 

 

 

 

 

 

 

 

 

Canadian adult-use cannabis

 

 

 

 

 

 

 

 

 

 

 

 

Business-to-business1

 

$

73,379

 

 

$

117,902

 

 

$

(44,523

)

 

 

(38

%)

Business-to-consumer

 

 

36,243

 

 

 

48,473

 

 

 

(12,230

)

 

 

(25

%)

 

 

 

109,622

 

 

 

166,375

 

 

 

(56,753

)

 

 

(34

%)

Canadian medical cannabis net revenue2

 

 

41,714

 

 

 

39,504

 

 

 

2,210

 

 

 

6

%

 

 

$

151,336

 

 

$

205,879

 

 

$

(54,543

)

 

 

(26

%)

Rest-of-world cannabis

 

 

 

 

 

 

 

 

 

 

 

 

C3

 

 

-

 

 

 

33,005

 

 

 

(33,005

)

 

 

(100

%)

Other rest-of-world cannabis3

 

 

30,179

 

 

 

32,357

 

 

 

(2,178

)

 

 

(7

%)

 

 

$

30,179

 

 

$

65,362

 

 

$

(35,183

)

 

 

(54

%)

 

 

 

 

 

 

 

 

 

 

 

 

 

Storz & Bickel

 

$

49,351

 

 

$

63,786

 

 

$

(14,435

)

 

 

(23

%)

BioSteel4

 

$

64,173

 

 

$

31,147

 

 

$

33,026

 

 

 

106

%

This Works

 

$

20,677

 

 

$

26,308

 

 

$

(5,631

)

 

 

(21

%)

Other

 

 

13,475

 

 

 

16,073

 

 

 

(2,598

)

 

 

(16

%)

 

 

 

 

 

 

 

 

 

 

 

 

 

Net revenue

 

$

329,191

 

 

$

408,555

 

 

$

(79,364

)

 

 

(19

%)

 

 

 

 

 

 

 

 

 

 

 

 

 

1 Reflects excise taxes of $33,754 and other revenue adjustments, representing our determination of returns and pricing adjustments, of $2,903 for the nine months ended December 31, 2022 (nine months ended December 31, 2021 - excise taxes of $43,501 and other revenue adjustments of $4,000).

 

2 Reflects excise taxes of $3,625 for the nine months ended December 31, 2022 (nine months ended December 31, 2021 - $4,039).

 

3 Reflects other revenue adjustments of $4,885 for the nine months ended December 31, 2022 (nine months ended December 31, 2021 - $2,440).

 

4 Reflects other revenue adjustments of $7,557 for the nine months ended December 31, 2022 (nine months ended December 31, 2021 - $5,935).

 

Net revenue was $329.2 million in the nine months ended December 31, 2022, as compared to $408.6 million in the nine months ended December 31, 2021. The year-over-year decrease is primarily attributable to: (i) the continuing decrease in net revenue from our Canada cannabis segment, as increased competition in the Canadian adult-use market has resulted in lower sales velocities, continued price compression, and reduced traffic at our corporate-owned retail stores; (ii) the divestiture of our interest in C3 in the fourth quarter of fiscal 2022; (iii) a decline in our U.S. CBD business, as we focused our product and brand offerings; and (iv) lower revenues from our Storz & Bickel and This Works businesses. These decreases were partially offset by continued growth in our BioSteel business, resulting from the continued expansion of our distribution and retail channels, and strong international sales growth.

Canada cannabis

Net revenue from our Canada cannabis segment was $151.3 million in the nine months ended December 31, 2022, as compared to $205.9 million in the nine months ended December 31, 2021.

Canadian adult-use cannabis net revenue was $109.6 million in the nine months ended December 31, 2022, as compared to $166.4 million in the nine months ended December 31, 2021.

Net revenue from the business-to-business channel was $73.4 million in the nine months ended December 31, 2022, as compared to $117.9 million in the nine months ended December 31, 2021. The year-over-year decrease is primarily attributable to: (i) the continuing impacts of price compression across all categories of the Canadian adult-use market, predominantly resulting from increased competition; and (ii) lower sales volumes across the premium and value-priced categories of the Canadian adult-use market. These factors were partially offset by a more favorable product mix due primarily to a decrease in the volume of value-priced dried product sold compared to the prior year.
Revenue from the business-to-consumer channel was $36.2 million in the nine months ended December 31, 2022, as compared to $48.5 million in the nine months ended December 31, 2021. The year-over-year decrease is primarily attributable to: (i) the continuing rapid increase in the number of third-party owned retail stores across Canada, which has resulted in increased competition for traffic at our corporate-owned stores which we operate in certain provinces; (ii) price compression resulting

60


from the increased competition; and (iii) the closing of the FOUR20 Transaction on October 26, 2022, as described under "Recent Developments" above.

Canadian medical cannabis net revenue was $41.7 million in the nine months ended December 31, 2022, as compared to $39.5 million in the nine months ended December 31, 2021. The year-over-year increase is primarily attributable to an increase in the average size of medical orders placed by our customers due largely to a shift in our customer mix, partially offset by a year-over-year decrease in the total number of medical orders which was primarily related to the increasing number of adult-use cannabis retail stores across Canada.

Rest-of-world cannabis

Rest-of-world cannabis revenue was $30.2 million in the nine months ended December 31, 2022, as compared to $65.4 million in the nine months ended December 31, 2021. The year-over-year decrease is attributable to:

the divestiture of C3, which resulted in a decrease in revenue of $33.0 million as compared to the nine months ended December 31, 2021; and
a year-over-year decrease of $2.2 million in other rest-of-world cannabis revenue, primarily attributable to: (i) a decline in revenue in our U.S. CBD business following our strategy shift initiated in the fourth quarter of fiscal 2022 to re-focus and refine our portfolio of product and brand offerings, and we recognized additional variable consideration which we expect to incur as a result; and (ii) a decrease in bulk cannabis sales relative to the nine months ended December 31, 2021, and a downward adjustment of $0.9 million related to a customer Israel. These declines were partially offset by the year-over-year growth in our global medical cannabis business, particularly in Australia.

Storz & Bickel

Revenue from Storz & Bickel was $49.4 million in the nine months ended December 31, 2022, as compared to $63.8 million in the nine months ended December 31, 2021. The year-over-year decrease is primarily attributable to: (i) the slowdown in consumer spending in North America and Europe; (ii) temporary disruptions with certain distributors, primarily in the first half of the fiscal year; and (iii) the impact of changes in foreign exchange rates.

BioSteel

Revenue from BioSteel was $64.2 million in the nine months ended December 31, 2022, as compared to $31.1 million in the nine months ended December 31, 2021. The year-over-year increase is primarily attributable to: (i) continued growth in our distribution and retail channels, which resulted in increased sales velocities across North America; and (ii) strong international sales growth of ready-to-drink products and beverage mixes. All of BioSteel's major product lines contributed to the year-over-year revenue growth.

This Works

Revenue from This Works was $20.7 million in the nine months ended December 31, 2022, as compared to $26.3 million in the nine months ended December 31, 2021. The year-over-year decrease is primarily attributable to: (i) softer performance relative to the nine months ended December 31, 2022 in certain of our product lines, particularly our "Sleep" line; (ii) lower sales velocities through e-commerce channels; and (iii) and the impact of changes in foreign exchange rates.

Cost of Goods Sold and Gross Margin

The following table presents cost of goods sold, gross margin and gross margin percentage on a consolidated basis for the nine months ended December 31, 2022 and 2021:

 

 

Nine months ended December 31,

 

 

 

 

 

 

 

(in thousands of Canadian dollars except where indicated)

2022

 

 

2021

 

 

$ Change

 

 

% Change

 

Net revenue

 

$

329,191

 

 

$

408,555

 

 

$

(79,364

)

 

 

(19

%)

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of goods sold

 

$

329,203

 

 

$

442,367

 

 

$

(113,164

)

 

 

(26

%)

Gross margin

 

 

(12

)

 

 

(33,812

)

 

 

33,800

 

 

 

100

%

Gross margin percentage

 

 

0

%

 

 

(8

%)

 

 

-

 

 

800 bps

 

Cost of goods sold was $329.2 million in the nine months ended December 31, 2022, as compared to $442.4 million in the nine months ended December 31, 2021. Our gross margin was $nil in the nine months ended December 31, 2022, or 0% of net revenue, as

61


compared to a gross margin of $(33.8) million and gross margin percentage of (8%) of net revenue in the nine months ended December 31, 2021. The year-over-year increase in the gross margin percentage was primarily attributable to:

the inventory write-downs we recorded in the second quarter of fiscal 2022, primarily related to excess Canadian cannabis inventory resulting from underperformance relative to forecast as well as declines in expected near-term demand;
the realized benefit of our cost savings program and strategic changes to our business that were initiated in the fourth quarter of fiscal 2022;
charges totaling $7.7 million recognized in the nine months ended December 31, 2021 relating to the flow-through of inventory step-up associated with the acquisition of Supreme Cannabis in the first quarter of fiscal 2022; and
the year-over-year increase in revenue at BioSteel, which drove improved operating leverage on our North American cost structure and gross margin improvement relative to the nine months ended December 31, 2021.

These factors were partially offset by the following, which impacted our gross margin percentage in the nine months ended December 31, 2022:

Restructuring charges totaling $15.6 million relating to: (i) inventory write-downs and other associated charges resulting primarily from the strategic changes to our business that were initiated in the fourth quarter of fiscal 2022; and (ii) charges associated with certain contract manufacturing agreements that are not expected to occur past fiscal 2023. Comparatively, in the nine months ended December 31, 2021, we recorded restructuring charges totaling $4.6 million relating to inventory write-downs resulting from strategic changes to our business, including the closure of our facility in Langley, British Columbia;
A decrease in the amount of payroll subsidies received from the Canadian government, pursuant to a COVID-19 relief program, from $20.8 million in the nine months ended December 31, 2021 to $1.6 million in the nine months ended December 31, 2022;
A shift in the business mix relative to the nine months ended December 31, 2021, resulting from a decrease in the proportionate revenue contribution from the higher-margin C3 business relative to the nine months ended December 31, 2021, as a result of the completion of the divestiture of C3 on January 31, 2022;
In our Canadian adult-use cannabis business, the impacts on our gross margin percentage from the year-over-year decrease in net revenue and continued price compression; and
Additional variable consideration recognized in respect of our U.S. CBD business, which we expect to incur in relation to the re-focusing of our product and brand portfolio.

62


We report gross margin and gross margin percentage in five segments: (i) Canada cannabis; (ii) rest-of-world cannabis; (iii) Storz & Bickel; (iv) BioSteel; and (v) This Works. Cost of sales associated with the remainder of our operations are included within "other". The following table presents segmented gross margin and gross margin percentage for the nine months ended December 31, 2022 and 2021:

 

 

Nine months ended December 31,

 

 

 

 

 

 

 

(in thousands of Canadian dollars except where indicated)

2022

 

 

2021

 

 

$ Change

 

 

% Change

 

Canada cannabis segment

 

 

 

 

 

 

 

 

 

 

 

 

Net revenue

 

$

151,336

 

 

$

205,879

 

 

$

(54,543

)

 

 

(26

%)

Cost of goods sold

 

 

176,802

 

 

 

303,804

 

 

 

(127,002

)

 

 

(42

%)

Gross margin

 

 

(25,466

)

 

 

(97,925

)

 

 

72,459

 

 

 

74

%

Gross margin percentage

 

 

(17

%)

 

 

(48

%)

 

 

 

 

3,100 bps

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Rest-of-world cannabis segment

 

 

 

 

 

 

 

 

 

 

 

 

Revenue

 

$

30,179

 

 

$

65,362

 

 

$

(35,183

)

 

 

(54

%)

Cost of goods sold

 

 

33,855

 

 

 

41,117

 

 

 

(7,262

)

 

 

(18

%)

Gross margin

 

 

(3,676

)

 

 

24,245

 

 

 

(27,921

)

 

 

(115

%)

Gross margin percentage

 

 

(12

%)

 

 

37

%

 

 

 

 

(4,900) bps

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Storz & Bickel segment

 

 

 

 

 

 

 

 

 

 

 

 

Revenue

 

$

49,351

 

 

$

63,786

 

 

$

(14,435

)

 

 

(23

%)

Cost of goods sold

 

 

28,542

 

 

 

36,163

 

 

 

(7,621

)

 

 

(21

%)

Gross margin

 

 

20,809

 

 

 

27,623

 

 

 

(6,814

)

 

 

(25

%)

Gross margin percentage

 

 

42

%

 

 

43

%

 

 

 

 

(100) bps

 

 

 

 

 

 

 

 

 

 

 

 

 

 

BioSteel segment

 

 

 

 

 

 

 

 

 

 

 

 

Revenue

 

$

64,173

 

 

$

31,147

 

 

$

33,026

 

 

 

106

%

Cost of goods sold

 

 

64,977

 

 

 

33,508

 

 

 

31,469

 

 

 

94

%

Gross margin

 

 

(804

)

 

 

(2,361

)

 

 

1,557

 

 

 

66

%

Gross margin percentage

 

 

(1

%)

 

 

(8

%)

 

 

 

 

700 bps

 

 

 

 

 

 

 

 

 

 

 

 

 

 

This Works segment

 

 

 

 

 

 

 

 

 

 

 

 

Revenue

 

$

20,677

 

 

$

26,308

 

 

$

(5,631

)

 

 

(21

%)

Cost of goods sold

 

 

11,695

 

 

 

13,885

 

 

 

(2,190

)

 

 

(16

%)

Gross margin

 

 

8,982

 

 

 

12,423

 

 

 

(3,441

)

 

 

(28

%)

Gross margin percentage

 

 

43

%

 

 

47

%

 

 

 

 

(400) bps

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other

 

 

 

 

 

 

 

 

 

 

 

 

Cost of goods sold

 

$

13,332

 

 

$

13,890

 

 

$

(558

)

 

 

(4

%)

Canada cannabis

Gross margin for our Canada cannabis segment was $(25.5) million in the nine months ended December 31, 2022, or (17%) of net revenue, as compared to $(97.9) million in the nine months ended December 31, 2021, or (48%) of net revenue. The year-over-year increase in the gross margin percentage was primarily attributable to: (i) the previously-described inventory write-downs we recorded in the second quarter of fiscal 2022; (ii) the realized benefit of our cost savings program that we announced in April 2022; and (iii) charges totaling $7.7 million recognized in the nine months ended December 31, 2021 relating to the flow-through of inventory step-up associated with the acquisition of Supreme Cannabis in the first quarter of fiscal 2022.

These factors were partially offset by: (i) the year-over-year decrease in net revenue, continued price compression, and the impact of the under-absorption of costs attributable to lower production volumes; and (ii) a decrease in the amount of payroll subsidies received from the Canadian government pursuant to a COVID-19 relief program, from $20.8 million in the nine months ended December 31, 2021 to $1.6 million in the nine months ended December 31, 2022.

63


Rest-of-world cannabis

Gross margin for our rest-of-world cannabis segment was $(3.7) million in the nine months ended December 31, 2022, or (12%) of net revenue, as compared to $24.2 million in the nine months ended December 31, 2021, or 37% of net revenue. The year-over-year decrease in the gross margin percentage is primarily attributable to:

the decrease in the proportionate revenue contribution from the higher-margin C3 business relative to the nine months ended December 31, 2021, as a result of the completion of the divestiture of C3 on January 31, 2022;
additional variable consideration recognized in respect of our U.S. CBD business, which we expect to incur in relation to the re-focusing of our product and brand portfolio; and
restructuring charges of $7.3 million recorded in the nine months ended December 31, 2022 relating to inventory write-downs at our U.S. CBD business associated with: (i) the strategic changes to our business that were initiated in the fourth quarter of fiscal 2022; and (ii) amounts deemed excess based on current and projected demand. Comparatively, in the nine months ended December 31, 2021, we recorded restructuring charges of $2.6 million relating to inventory write-downs resulting from strategic changes to our business.

These factors were partially offset by: (i) the growth in our Australian medical business; and (ii) the realized benefit of our cost savings program and the strategic changes to our business that were initiated in the fourth quarter of fiscal 2022, including the shift to a contract manufacturing model for certain product formats and the re-focusing of our U.S. CBD product and brand portfolio.

Storz & Bickel

Gross margin for our Storz & Bickel segment was $20.8 million in the nine months ended December 31, 2022, as compared to $27.6 million in the nine months ended December 31, 2021. Our gross margin percentage was 42% in the nine months ended December 31, 2022, relatively consistent with our gross margin percentage of 43% in the nine months ended December 31, 2021.

BioSteel

Gross margin for our BioSteel segment was $(0.8) million in the nine months ended December 31, 2022, or (1%) of net revenue, as compared to $(2.4) million in the nine months ended December 31, 2021, or (8%) of net revenue. The year-over-year increase in our gross margin percentage is primarily attributable to the increase in revenue, as described above, which drove improved leverage on our North American cost structure relative to the nine months ended December 31, 2021. These factors were partially offset by: (i) restructuring charges of $5.5 million relating to charges related to certain contract manufacturing agreements that are not expected to occur past fiscal 2023; and (ii) inventory write-downs, primarily related to aging inventory.

This Works

Gross margin for our This Works segment was $9.0 million in the nine months ended December 31, 2022, or 43% of net revenue, as compared to $12.4 million in the nine months ended December 31, 2021, or 47% of net revenue. The year-over-year decrease in our gross margin percentage is primarily attributable to restructuring charges of $1.2 million recorded in the nine months ended December 31, 2021 relating to inventory write-downs associated with the strategic changes to our business that were initiated in the fourth quarter of fiscal 2022.

64


Operating Expenses

The following table presents operating expenses for the nine months ended December 31, 2022 and 2021:

 

 

Nine months ended December 31,

 

 

 

 

 

 

 

(in thousands of Canadian dollars)

 

2022

 

 

2021

 

 

$ Change

 

 

% Change

 

Operating expenses

 

 

 

 

 

 

 

 

 

 

 

 

General and administrative

 

$

92,450

 

 

$

96,643

 

 

$

(4,193

)

 

 

(4

%)

Sales and marketing

 

 

180,825

 

 

 

179,464

 

 

 

1,361

 

 

 

1

%

Research and development

 

 

17,349

 

 

 

23,616

 

 

 

(6,267

)

 

 

(27

%)

Acquisition-related costs

 

 

32,146

 

 

 

9,788

 

 

 

22,358

 

 

 

228

%

Depreciation and amortization

 

 

29,121

 

 

 

45,654

 

 

 

(16,533

)

 

 

(36

%)

Selling, general and administrative expenses

 

 

351,891

 

 

 

355,165

 

 

 

(3,274

)

 

 

(1

%)

 

 

 

 

 

 

 

 

 

 

 

 

 

Share-based compensation

 

 

21,725

 

 

 

31,480

 

 

 

(9,755

)

 

 

(31

%)

Share-based compensation related to
     acquisition milestones

 

 

-

 

 

 

4,376

 

 

 

(4,376

)

 

 

(100

%)

Share-based compensation expense

 

 

21,725

 

 

 

35,856

 

 

 

(14,131

)

 

 

(39

%)

 

 

 

 

 

 

 

 

 

 

 

 

 

Asset impairment and restructuring costs

 

 

1,794,212

 

 

 

128,198

 

 

 

1,666,014

 

 

 

1,300

%

Total operating expenses

 

$

2,167,828

 

 

$

519,219

 

 

$

1,648,609

 

 

 

318

%

Selling, general and administrative expenses

Selling, general and administrative expenses were $351.9 million in the nine months ended December 31, 2022, as compared to $355.2 million in the nine months ended December 31, 2021.

General and administrative expense was $92.5 million in the nine months ended December 31, 2022, as compared to $96.6 million in the nine months ended December 31, 2021. The year-over-year decrease is primarily attributable to:

the restructuring actions initiated in the fourth quarter of fiscal 2022, which included operational changes designed to align general and administrative costs with business objectives, and further streamline the organization to drive process-related efficiencies. We realized reductions relative to the nine months ended December 31, 2021, primarily in relation to: (i) compensation costs for finance, information technology, legal and other administrative functions; (ii) third-party costs associated with administrative functions; (iii) professional consulting fees; and (iv) facilities and insurance costs.
the above cost reductions were partially offset by a year-over-year decrease in the amount of payroll subsidies received from the Canadian government pursuant to a COVID-19 relief program. We received $2.9 million in the nine months ended December 31, 2022, as compared to $33.9 million received in the nine months ended December 31, 2021.

Sales and marketing expense was $180.8 million in the nine months ended December 31, 2022, relatively consistent with $179.5 million in the nine months ended December 31, 2021.

Research and development expense was $17.3 million in the nine months ended December 31, 2022, as compared to $23.6 million in the nine months ended December 31, 2021. The year-over-year decrease is primarily attributable to cost reductions associated with the previously-noted restructuring actions that were initiated in the fourth quarter of fiscal 2022. We continued to realize reductions in compensation costs and concluded or curtailed certain research and development projects in-line with the rationalization of our initiatives to focus on opportunities outside of pharmaceutical drug development. We also realized a reduction in research and development costs associated with the completion of the divestiture of C3 on January 31, 2022, which resulted in no costs being recorded in relation to C3 in the third quarter of fiscal 2023.

Acquisition-related costs were $32.1 million in the nine months ended December 31, 2022, as compared to $9.8 million in the nine months ended December 31, 2021. In the nine months ended December 31, 2022, costs were incurred primarily in relation to the Reorganization and the divestiture of certain of our corporate-owned retail stores in Canada in connection with the OEGRC Transaction and the FOUR20 Transaction (each of which are described under "Recent Developments" above), the plan to acquire Jetty, and evaluating other potential acquisition opportunities. Comparatively, in the nine months ended December 31, 2021, costs were incurred primarily in relation to the plan to acquire Wana, the divestiture of C3, the acquisitions of Supreme Cannabis and AV Cannabis Inc., and evaluating other potential acquisition opportunities.

65


Depreciation and amortization expense was $29.1 million in the nine months ended December 31, 2022, as compared to $45.7 million in the nine months ended December 31, 2021. The year-over-year decrease is primarily attributable to:

the previously-noted restructuring actions that were initiated in fiscal 2022;
the divestiture of certain of our corporate-owned retail stores in Canada in connection with the OEGRC Transaction and the FOUR20 Transaction (as described under "Recent Developments" above);
the decrease in amortization expense associated with the impairment of certain of our intellectual property intangible assets; and
the completion of the divestiture of C3 on January 31, 2022, which resulted in no depreciation and amortization expense being recorded in relation to C3 in the nine months ended December 31, 2022.

Share-based compensation expense

Share-based compensation expense was $21.7 million in the nine months ended December 31, 2022, as compared to $31.5 million in the nine months ended December 31, 2021. The year-over-year decrease is primarily attributable to the impact of our previously-noted restructuring actions, which resulted in 6.1 million stock option forfeitures and 1.9 million RSU and PSU forfeitures in the nine months ended December 31, 2022. The decrease attributable to these forfeitures was partially offset by 4.7 million stock option grants and 3.1 million RSU and PSU grants in the nine months ended December 31, 2022.

Share-based compensation expense related to acquisition milestones was $nil in the nine months ended December 31, 2022, as compared to $4.4 million in the nine months ended December 31, 2021. The year-over-year decrease is primarily attributable to: (i) the completion of vesting, in prior quarters, of the share-based compensation associated with certain of our acquisitions; and (ii) as a result of the restructuring actions completed in the fourth quarter of fiscal 2022, the acceleration of share-based compensation expense related to unvested milestones associated with acquisitions completed in prior fiscal years.

Asset impairment and restructuring costs

Asset impairment and restructuring costs recorded in operating expenses were $1.8 billion in the nine months ended December 31, 2022, as compared to $128.2 million in the nine months ended December 31, 2021.

Asset impairment and restructuring costs recorded in the nine months ended December 31, 2022 were primarily related to:

goodwill impairment losses of $1.7 billion, substantially all of which was associated with our cannabis operations reporting unit in the global cannabis segment. Refer to "Impairment of Goodwill" in "Critical Accounting Policies and Estimates" section below;
asset impairment charges totaling $13.1 million relating to certain acquired brand intangible assets, primarily within our Canada cannabis segment;
impairment losses associated with the divestiture of our Canadian retail operations in connection with the OEGRC Transaction and the FOUR20 Transaction, as described above under "Recent Developments", as we: (i) recorded write-downs of property, plant and equipment, operating license and brand intangible assets, right-of-use assets, and certain other assets due to the excess of their carrying values over their estimated fair value; and (ii) recognized contractual and other settlement obligations;
incremental costs primarily associated with the restructuring actions completed in fiscal 2022, including the closure of certain of our Canadian production facilities, and operational changes initiated in the fourth quarter of fiscal 2022 to: (i) implement cultivation-related efficiencies and improvements in the Canadian adult-use cannabis business; and (ii) implement a flexible manufacturing platform, including contract manufacturing for certain product formats; and
employee-related restructuring charges associated with actions completed in the third quarter of fiscal 2023 as part of our ongoing program to align general and administrative costs with business objectives, and further streamline the organization.

Comparatively, in the nine months ended December 31, 2021, we recorded charges primarily related to:

operational changes resulting from the continuing strategic review of our business as a result of fiscal 2022 acquisition activities, which resulted in the closure of our Niagara-on-the-Lake, Ontario and Langley, British Columbia facilities in November 2021;
adjustments related to changes in the estimated fair value of certain of our Canadian sites that were closed in December 2020, and the Canadian facilities that were closed in November 2021. Adjustments for certain of these facilities were made to reflect either their final or estimated selling prices; and
incremental costs associated with the closure of these facilities.

66


Other

The following table presents loss from equity method investments, other income (expense), net, and income tax (expense) recovery for the nine months ended December 31, 2022 and 2021:

 

 

Nine months ended December 31,

 

 

 

 

 

 

 

(in thousands of Canadian dollars)

 

2022

 

 

2021

 

 

$ Change

 

 

% Change

 

Loss from equity method investments

 

$

-

 

 

$

(100

)

 

$

100

 

 

 

100

%

Other income (expense), net

 

 

(406,762

)

 

 

810,769

 

 

 

(1,217,531

)

 

 

(150

%)

Income tax (expense) recovery

 

 

(11,587

)

 

 

490

 

 

 

(12,077

)

 

 

(2,465

%)

Loss from equity method investments

The loss from equity method investments was $nil in the nine months ended December 31, 2022, as compared to $0.1 million in the nine months ended December 31, 2021. The year-over-year decrease in the loss is primarily attributable to the impairment of our remaining investment in Agripharm Corp. in the first quarter of fiscal 2022. As a result of this impairment, there were no remaining equity method investment balances at December 31, 2022.

Other income (expense), net

Other income (expense), net was an expense amount of $406.8 million in the nine months ended December 31, 2022, as compared to an income amount of $810.8 million in the nine months ended December 31, 2021. The year-over-year change of $1.2 billion, from an income amount to an expense amount, is primarily attributable to:

Decrease in non-cash income of $551.8 million related to fair value changes on the warrant derivative liability associated with the Tranche B Warrants held by CBI. The decrease of $26.3 million in the fair value of the warrant derivative liability (resulting in non-cash income) in the nine months ended December 31, 2022 is primarily attributable to a decrease of approximately 67% in our share price during the nine months ended December 31, 2022, further impacted by an increase in the risk-free interest rate and a shorter expected time to maturity of the Tranche B Warrants. Comparatively, the income amount recognized in the nine months ended December 31, 2021 of $578.1 million, associated with a decrease in the fair value of the warrant derivative liability, was primarily attributable to a decrease of approximately 73% in our share price during that period, further impacted by a shorter expected time to maturity of the Tranche B Warrants.

Decrease in non-cash income of $450.0 million related to the non-cash fair value changes on the liability arising from the Acreage Arrangement, from $497.0 million in the nine months ended December 31, 2021 to $47.0 million in the nine months ended December 31, 2022. The income amount recognized in the nine months ended December 31, 2022, associated with a decrease in the liability arising from the Acreage Arrangement to $nil during the first quarter of fiscal 2023, is primarily attributable to a decrease of approximately 61% in our share price during the first quarter of fiscal 2023, relative to a decrease of approximately 27% in Acreage’s share price during that same period. As a result, the model at June 30, 2022 reflected a lower estimated value of the Canopy Growth common shares expected to be issued at the exchange ratio of 0.3048 upon a Triggering Event, relative to the estimated value of the Fixed Shares expected to be acquired at that time; in the first quarter of fiscal 2023, this resulted in a change from a liability amount to an asset amount of $60.0 million recorded in other financial assets. Fair value changes associated with the Acreage call option asset in the nine months ended December 31, 2022 are described below. Comparatively, the income amount recognized in the nine months ended December 31, 2021, associated with a decrease in the liability arising from the Acreage Arrangement, was primarily attributable to a decrease of approximately 73% in our share price in the nine months ended December 31, 2021, relative to a decrease of approximately 59% in Acreage’s share price during that same period.

Change of $113.7 million related to the non-cash fair value changes on the Notes, from an income amount of $81.3 million in the nine months ended December 31, 2021 to an expense amount of $32.4 million in the nine months ended December 31, 2022. The expense amount recognized in the nine months ended December 31, 2022 was primarily attributable to the impact of the acquisition and cancellation of approximately $262.6 million of aggregate principal amount of the Notes pursuant to privately negotiated exchange agreements (the "Exchange Agreements") entered into on June 29, 2022 and June 30, 2022 (the "Exchange Transaction"), including changes in credit spreads resulting from the Exchange Transaction. These changes were partially offset by the decrease in our share price of approximately 61% up to the date of the Exchange Transaction, at which time we surrendered our right to settle the conversion of any Note with our common shares. Comparatively, the income amount recognized in the nine months ended December 31, 2021 was primarily attributable to the decrease in our share price of approximately 73% during that period.

67


Increase in non-cash expense of $132.8 million related to fair value changes on our other financial assets, from $263.9 million in the nine months ended December 31, 2021 to $396.8 million in the nine months ended December 31, 2022. The expense amount in the nine months ended December 31, 2022 is primarily attributable to fair value decreases relating to our investments in:
o
The TerrAscend Exchangeable Shares, including the additional 24.6 million TerrAscend Exchangeable Shares received on December 9, 2022 as part of the TerrAscend Arrangement (as described under "Recent Developments" above), in the amount of $207.0 million. This decrease is primarily attributable to: (i) a decrease of approximately 78% in TerrAscend's share price during the nine months ended December 31, 2022, impacting the 38.9 million TerrAscend Exchangeable Shares that were held by us throughout the entire period; and (ii) a decrease of approximately 43% in TerrAscend's share price from December 9, 2022 to December 31, 2022, impacting the additional TerrAscend Exchangeable Shares received as part of the TerrAscend Arrangement;
o
The secured debentures issued by TerrAscend Canada and Arise Bioscience and the associated Prior Warrants, up to the closing of the TerrAscend Arrangement on December 9, 2022 (totaling $58.7 million), which were driven largely by a decrease of approximately 62% in TerrAscend's share price from March 31, 2022 to December 9, 2022;
o
The TerrAscend Option, in the amount of $5.1 million, which was driven largely by a decrease of approximately 78% in TerrAscend’s share price in the nine months ended December 31, 2022; and
o
The New Warrants issued by TerrAscend as part of the TerrAscend Arrangement, in the amount of $17.5 million, primarily attributable to a decrease of approximately 43% in TerrAscend's share price from December 9, 2022 to December 31, 2022.
o
The Wana and Jetty financial instruments, in the amounts of $135.4 million and $9.8 million, respectively, attributable primarily to: (i) changes in expectations of the future cash flows to be generated by Wana; and (ii) an increase in discount rates used in the valuation of both the Wana and Jetty financial instruments, in-line with the increase in interest rates relative to the prior fiscal period.

These fair value decreases were partially offset by (i) a fair value increase related to the Acreage call option in the amount of $37.0 million, primarily attributable to: (i) a re-assessment of certain of the assumptions made and scenario outcomes contemplated in the probability-weighted expected return model used to determine the value of the Acreage call option; and (ii) the factors described above in our discussion of fair value changes on the liability arising from the Acreage Arrangement. The factors resulting in a fair value increase related to the Acreage call option were partially offset by the share price changes for both Canopy Growth and Acreage during the third quarter of fiscal 2023, as described above under our analysis of our results for the third quarter of fiscal 2023, which resulted in a fair value decrease related to the Acreage call option during that period.

Comparatively, in the nine months ended December 31, 2021 the expense amount was primarily attributable to fair value decreases relating to our investments in the TerrAscend Exchangeable Shares ($166.0 million), and the secured debentures issued by TerrAscend Canada and Arise Bioscience and associated Prior Warrants (totaling $89.3 million), driven largely by: (i) a decrease of approximately 39% in TerrAscend’s share price in the nine months ended December 31, 2021; and (ii) re-assessments of the probability and timing of changes in federal laws in the United States regarding the permissibility of the cultivation, distribution or possession of marijuana in the second quarter of fiscal 2022.

Increase in interest expense of $13.0 million, from $77.6 million in the nine months ended December 31, 2021 to $90.7 million in the nine months ended December 31, 2022. The year-over-year increase is primarily attributable to: (i) the increase in interest rates relative to the prior year period, thus impacting the amount of interest payable associated with the variable interest rate debt owing under the Credit Agreement; and (ii) the strengthening of the U.S. dollar relative to the Canadian dollar, as compared to the prior year period.

Increase in non-cash income of $25.4 million related to fair value changes on acquisition related contingent consideration and other. In the nine months ended December 31, 2022, we recorded fair value changes related to the estimated deferred payments associated with our investment in Wana. These fair value changes were primarily associated with changes in expectations of future cash flows to be generated by Wana.

Increase in interest income of $8.9 million, from $7.0 million in the nine months ended December 31, 2021 to $15.9 million in the nine months ended December 31, 2022. The year-over-year increase is primarily attributable to the increase in interest rates relative to the comparative fiscal period, the impact of which was only partially offset by the year-over-year combined decrease in our cash and cash equivalents and short-term investments balances.

Change of $7.9 million, from a loss of $1.7 million in the nine months ended December 31, 2021 to a gain of $6.2 million in the nine months ended December 31, 2022, related to the disposal of consolidated entities. The year-over-year change is primarily attributable to the gain recognized in the third quarter of fiscal 2023 associated with the closing of the divestiture of

68


our Canadian retail operations in connection with the OEGRC Transaction and the FOUR20 Transaction, and as described above under "Recent Developments".

Income tax (expense) recovery

Income tax expense in the nine months ended December 31, 2022 was $11.6 million, compared to an income tax recovery of $0.5 million in the nine months ended December 31, 2021. In the nine months ended December 31, 2022, the income tax expense consisted of deferred income tax expense of $8.0 million (compared to an expense of $0.4 million in the nine months ended December 31, 2021) and current income tax expense of $3.6 million (compared to a recovery of $0.9 million in the nine months ended December 31, 2021).

The increase of $7.6 million in the deferred income tax expense is primarily a result of changes in the convertible senior notes, current year changes being less than prior year in respect of deferred tax liabilities that arose in connection with the required revaluation of the accounting carrying value, but not the tax basis, of property, plant and equipment, intangible assets, and other financial assets. In connection with certain deferred tax assets, mainly in respect to losses for tax purposes, where the accounting criteria for recognition of an asset has yet to be satisfied and it is not probable that they will be used, the deferred tax asset has not been recognized.

The change of $4.5 million, from a current income tax recovery to a current income tax expense, arose primarily in connection with legal entities that generated income for tax purposes that could not be reduced by the group’s tax attributes.

Net (Loss) Income

The net loss in the nine months ended December 31, 2022 was $2.6 billion, as compared to net income of $258.1 million in the nine months ended December 31, 2021. The year-over-year change from net income to a net loss is primarily attributable: (i) to the year-over-year increase in asset impairment and restructuring costs, which was largely related to the goodwill impairment losses of $1.7 billion recorded in the first quarter of fiscal 2023; and (ii) the year-over-year change in other income (expense), net, of $1.2 billion, from an income amount to an expense amount. These variances are described above.

Adjusted EBITDA (Non-GAAP Measure)

The following table presents Adjusted EBITDA for the nine months ended December 31, 2022 and 2021:

 

 

Nine months ended December 31,

 

 

 

 

 

 

 

(in thousands of Canadian dollars)

 

2022

 

 

2021

 

 

$ Change

 

 

% Change

 

Net (loss) income

 

$

(2,586,189

)

 

$

258,128

 

 

$

(2,844,317

)

 

 

(1,102

%)

Income tax expense (recovery)

 

 

11,587

 

 

 

(490

)

 

 

12,077

 

 

 

2,465

%

Other (income) expense, net

 

 

406,762

 

 

 

(810,769

)

 

 

1,217,531

 

 

 

150

%

Loss on equity method investments

 

 

-

 

 

 

100

 

 

 

(100

)

 

 

(100

%)

Share-based compensation1

 

 

21,725

 

 

 

35,856

 

 

 

(14,131

)

 

 

(39

%)

Acquisition-related costs

 

 

32,146

 

 

 

9,788

 

 

 

22,358

 

 

 

228

%

Depreciation and amortization1

 

 

63,746

 

 

 

83,929

 

 

 

(20,183

)

 

 

(24

%)

Asset impairment and restructuring costs

 

 

1,794,212

 

 

 

117,567

 

 

 

1,676,645

 

 

 

1,426

%

Restructuring costs recorded in cost of goods sold

 

 

15,610

 

 

 

4,554

 

 

 

11,056

 

 

 

243

%

Charges related to the flow-through of inventory
   step-up on business combinations

 

 

-

 

 

 

7,684

 

 

 

(7,684

)

 

 

(100

%)

Adjusted EBITDA

 

$

(240,401

)

 

$

(293,653

)

 

$

53,252

 

 

 

18

%

 

 

 

 

 

 

 

 

 

 

 

 

 

1 From Statements of Cash Flows.

 

 

 

Nine months ended December 31,

 

 

 

 

 

 

 

(in thousands of Canadian dollars)

 

2023

 

 

2022

 

 

$ Change

 

 

% Change

 

Net loss from continuing operations

 

$

(389,007

)

 

$

(2,492,445

)

 

$

2,103,438

 

 

 

84

%

Income tax expense

 

 

13,762

 

 

 

10,633

 

 

 

3,129

 

 

 

29

%

Other (income) expense, net

 

 

253,270

 

 

 

396,074

 

 

 

(142,804

)

 

 

(36

%)

Share-based compensation

 

 

10,127

 

 

 

20,893

 

 

 

(10,766

)

 

 

(52

%)

Acquisition, divestiture, and other costs

 

 

24,373

 

 

 

31,546

 

 

 

(7,173

)

 

 

(23

%)

Depreciation and amortization1

 

 

41,881

 

 

 

60,732

 

 

 

(18,851

)

 

 

(31

%)

Loss on asset impairment and restructuring

 

 

2,452

 

 

 

1,794,212

 

 

 

(1,791,760

)

 

 

(100

%)

Restructuring costs recorded in cost of goods sold

 

 

(689

)

 

 

10,129

 

 

 

(10,818

)

 

 

(107

%)

Adjusted EBITDA

 

$

(43,831

)

 

$

(168,226

)

 

$

124,395

 

 

 

74

%

 

 

 

 

 

 

 

 

 

 

 

 

 

1 From Statements of Cash Flows.

 

 

The Adjusted EBITDA loss in the nine months ended December 31, 20222023 was $240.4$43.8 million, as compared to an Adjusted EBITDA loss of $293.7$168.2 million in the nine months ended December 31, 2021.2022. The year-over-year decrease in the Adjusted EBITDA loss is primarily attributable to the year-over-year improvementincrease in our gross margin, and the year-over-year reductiondecrease in our total selling, general and administrative expense. These variances are described above.

69


expenses.

 

Part 3 – Financial Liquidity and Capital Resources

The Interim Financial Statements have been prepared in accordance with generally accepted accounting principles on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.

66


As reflected in the Interim Financial Statements, we have suffered recurring losses from operations and require additional financing to fund our business and operations. If we are unable to raise additional capital, it is possible that we will be unable to meet certain of our financial obligations.

These matters, when considered in the aggregate, raise substantial doubt about our ability to continue as a going concern for at least twelve months from the issuance of the Interim Financial Statements.

In view of these matters, continuation as a going concern is dependent upon our continued operations, which in turn is dependent upon our ability to meet our financial requirements and to raise additional capital, and the success of our future operations. The Interim Financial Statements do not include any adjustments to the amount and classification of assets and liabilities that may be necessary should we not continue as a going concern.

Management plans to fund our operations and debt obligations through existing cash positions. We are also currently evaluating several different strategies and intend to pursue actions that are expected to increase our liquidity position, including, but not limited to, pursuing additional actions under our cost-savings plan, seeking additional financing from both the public and private markets through the issuance of equity and/or debt securities, and monetizing additional assets.

Our management cannot provide assurances that we will be successful in accomplishing any of our proposed financing plans. Our management also cannot provide any assurance as to unforeseen circumstances that could occur within the next 12 months or, if after we raise capital, thereafter, which could increase our need to raise additional capital on an immediate basis, which capital may not be available to us.

 

We manage liquidity risk by reviewing, on an ongoing basis, our sources of liquidity and capital requirements. As of December 31, 2022, we had cash and cash equivalents of $598.1 million and short-term investments of $191.1 million, which are predominantly invested in liquid securities issued byhave completed the United States and Canadian governments. In evaluating our capital requirements and our ability to fund the execution of our strategy, we believe we have adequate available liquidity to enable us to meet our working capital and other operating requirements, fund growth initiatives and capital expenditures, settle our liabilities, and repay scheduled principal and interest payments onfollowing debt for at least the next twelve months.financings:

 

Our objective is to generate sufficient cash to fund our operating requirements and expansion plans. While we have incurred net losses on a U.S. GAAP basis and Adjusted EBITDA losses to date, and our cash and cash equivalents have decreased $177.9 million from
On March 31, 2022 (and, together with short-term investments, decreased $582.4 million from March 31, 2022), as discussed in the “Cash Flows” section below, management anticipates the success and eventual profitability of the business. We have also ensured that we have access to public capital markets through our U.S. and Canadian public stock exchange listings. In March18, 2021, we entered into the Credit Agreementa term loan credit agreement with the lenders party thereto and Wilmington Trust, National Association, as administrative agent and collateral agent for the lenders. The Credit Agreement provideslenders (the "Credit Agreement") providing for a creditfive-year, first lien senior secured term loan facility (the “Credit Facility”) in the initialan aggregate principal amount of US$750.0 million.million (the "Credit Facility"). As described under "Recent Developments" above, pursuant to the balance sheet actions completed in connection with the Reorganization, on October 24, 2022, we have entered into agreements with certain of our lenders under the Credit Facility pursuant to completewhich we agreed to purchase in the Paydown, which will result in us tenderingaggregate US$187.5 million of the principal indebtedness outstanding under the Credit Facility at a discounted price of US$930 per $1,000 or US$174,375 in the aggregate. The first payment, which was oversubscribed, in the amount of approximately $117.5 million (US$87.9 million) was made on November 10, 2022 to reduce the principal indebtedness under the Credit Facility by approximately $126.3 million (US$94.4 million). The second payment of approximately $116.8 million (US$87.2 million) was made on April 17, 2023 to reduce principal indebtedness under the Credit Facility by approximately $125.6 million (US$93.8 million). Additionally, on October 24, 2022, we and certain of our lenders agreed to make certain amendments to the Credit Agreement which, among other things, resulted in: (i) a reduction to the minimum liquidity covenant to no less than US$100.0 million following completion of the second principal repurchase on April 17, 2023; (ii) certain changes to the application of net proceeds from asset sales; (iii) the establishment of a new committed delayed draw term credit facility in an aggregate principal amount of US$100.0 million; and (iv) the elimination of the additional US$500.0 million incremental term loan facility.

As described above under “Recent Developments”, on July 13, 2023, we entered into agreements with certain of our lenders under the Credit Agreement pursuant to which certain additional amendments were made to the Credit Agreement (collectively, the Credit Agreement, as amended as of July 13, 2023, is referred to herein as the “Amended Credit Agreement”). The Amended Credit Agreement required us to prepay or repurchase principal indebtedness under the Credit Facility in an amount equal to the US dollar equivalent of $93,000 at a discounted price of US$930 per US$1,000 (the “July 2023 Paydown”). In addition, the Amended Credit Agreement requires us to apply certain net proceeds from asset sales to prepay or repurchase principal indebtedness under the Credit Facility and receive principal reductions at, in certain circumstances, a discounted price of US$950 per US$1,000. The Amended Credit Agreement also includes, among other things, amendments to the minimum liquidity covenant such that the US$100,000 minimum ceased to apply concurrently with the July 2023 Paydown. The July 2023 Paydown was made on July 21, 2023.

As described above under "Recent Developments", on each of August 11, 2023 and September 14, 2023, we repurchased additional outstanding principal amounts under the Credit Facility using certain net proceeds from completed asset sales (the "Second Quarter 2024 Paydowns"). The Second Quarter 2024 Paydowns resulted in an aggregate principal reduction of $73.3 million (US$54.5 million) for a cash payment of $69.6 million (US$51.8 million).

On each of November 28, 2023 and December 27, 2023, pursuant to the terms of the Amended Credit Agreement, we repurchased and repaid, as applicable, additional outstanding principal amounts under the Credit Facility using certain net

67


proceeds from completed asset sales (the "Third Quarter 2024 Paydowns"). The Third Quarter 2024 Paydowns resulted in an aggregate principal reduction of $65.4 million (US$48.5 million) for a cash payment of $63.2 million (US$46.9 million).

On February 21, 2023, we entered into the Convertible Debenture Agreement with an Institutional Investor pursuant to which the Institutional Investor purchased $135.2 million (US$100.0 million) aggregate principal amount of the Convertible Debentures in a registered direct offering. As of June 30, 2023, all conversions pursuant to the Convertible Debentures were completed and the amount outstanding under the Credit Agreement. Convertible Debentures was $nil.

On November 10, 2022, $126.3April 13, 2023, we entered into the April 2023 Exchange Agreement with Greenstar in order to acquire and cancel $100.0 million (US$94.4 million)aggregate principal amount of our outstanding Canopy Notes. Pursuant to the April 2023 Exchange Agreement, we agreed to acquire and cancel $100.0 million aggregate principal was repaidamount of the Canopy Notes held by Greenstar in exchange for: (i) a cash payment to Greenstar in the amount of the unpaid and accrued interest owing under the Canopy Notes held by Greenstar; and (ii) the CBI Note (collectively, the "CBI Transaction"). As a result, Greenstar no longer holds any Canopy Notes. Following closing of the CBI Transaction and the creation of the Exchangeable Shares, we maintain our intention to negotiate an exchange with Greenstar to purchase the CBI Notes in exchange for Exchangeable Shares.

On June 29, 2023, we entered into the June 2023 Exchange Agreements with certain Noteholders in connection with the June 2023 Exchange Transaction to acquire and cancel $12.5 million aggregate principal amount of the Canopy Notes from such Noteholders in exchange for cash, including accrued and unpaid interest owing under the Canopy Notes, and the issuance of approximately 2.43 million Canopy Growth common shares.

On July 13, 2023, we entered into the Redemption Agreements with certain Noteholders, pursuant to which approximately $193 million aggregate principal amount of the outstanding Canopy Notes held by such Noteholders were redeemed by us on the applicable closing date for: (i) an aggregate cash payment of approximately $101 million; (ii) the issuance of an aggregate 9.04 million Canopy Growth common shares; and (iii) the issuance of approximately $40.4 million aggregate principal amount of Debentures. Following the Redemption, we settled the remaining aggregate principal amount owing under the outstanding Canopy Notes and, as of the maturity date, there were no Canopy Notes outstanding. As of September 30, 2023, all conversions pursuant to the Paydown. The second payment pursuantDebentures have been completed and the amount outstanding under the Debentures was $nil.

On September 18, 2023, we entered into subscription agreements (the “Subscription Agreements”) with certain institutional investors (the “Investors”). Pursuant to the Paydownterms of the Subscription Agreements, we issued 2.29 million units of the Company (the "Units") to the Investors at a price per Unit of US$10.90 for aggregate gross proceeds of $33.7 million (US$25.0 million) (the “Unit Offering”). Each Unit is requiredcomprised of one Canopy Growth common share and one common share purchase warrant (a “Warrant”). Each Warrant entitles the holder to acquire one Canopy Growth common share at a price per share equal to US$13.50 for a period of five years from the date of issuance. The Unit Offering closed on September 19, 2023. The Investors also held an over-allotment option to acquire up to an additional 2.29 million Units at a price per Unit of US$10.90 for aggregate gross proceeds of approximately US$25.0 million at the discretion of the Investors at any time on or before November 2, 2023 (the “Over-Allotment Option”). The Over-Allotment Option was not exercised by the Investors and expired on November 2, 2023.

On January 18, 2024, we entered into subscription agreements (the "January 2024 Subscription Agreements") with certain institutional investors (the "January 2024 Investors"). Pursuant to the terms of the January 2024 Subscription Agreements, we issued 8.16 million units of the Company (the "January 2024 Units") to the January 2024 Investors at a price per January 2024 Unit of US$4.29 for aggregate gross proceeds of approximately $47.1 million (US$35.0 million) (the "January 2024 Unit Offering"). Each January 2024 Unit is comprised of (a) one Canopy Growth common share and (b)(i) one Series A common share purchase warrant (a "Series A Warrant") or (ii) one Series B common share purchase warrant (a "Series B Warrant" and, together with the Series A Warrants, the "January 2024 Warrants"). Each January 2024 Warrant entitles the holder to acquire one Canopy Growth common share from the Company at a price per share equal to US$4.83. The Series A Warrants are currently exercisable and will remain exercisable until January 19, 2029, and the Series B Warrants will be made no later than April 17, 2023. Weexercisable for a period commencing on July 19, 2024 until July 19, 2029. The January 2024 Unit Offering closed on January 19, 2024.

In addition to the above, we continue to review and pursue selected external financing sources to ensure adequate financial resources. These potential sources include, but are not limited to: (i) obtaining financing from traditional or non-traditional investment capital organizations; (ii) obtaining funding from the sale of our common shares or other equity or debt instruments; and (iii) obtaining debt financing with lending terms that more closely match our business model and capital needs. We may from time to time seek to retire our outstanding debt through cash purchases and/or exchanges for equity securities, and open market purchases, privately negotiated transactions or otherwise. Such repurchases or exchanges, if any, will depend on prevailing market conditions, our liquidity requirements, contractual restrictions and other factors. The amounts involved may be material.

 

There can be no assurance that we will gain adequate market acceptance for our products or be able to generate sufficient positive cash flow to achieve our business plans. In the nine months ended December 31, 2022, our purchases of and deposits on property, plant and equipment totaled $6.2 million, which were funded out of available cash, cash equivalents and short-term investments. We expect to continue funding these purchases with our available cash, cash equivalents and short-term investments. Therefore, we are subject to risks including, but not limited to, our inability to raise additional funds through debt and/or equity financing to support our continued development, including capital expenditure requirements, operating requirements and to meet our liabilities and commitments as they come due.68


 

Cash Flows

 

 

 

Nine months ended December 31,

 

(in thousands of Canadian dollars)

 

2022

 

 

2021

 

Net cash (used in) provided by:

 

 

 

 

 

 

Operating activities

 

$

(417,809

)

 

$

(419,125

)

Investing activities

 

$

342,125

 

 

 

(71,102

)

Financing activities

 

$

(145,921

)

 

 

(46,338

)

Effect of exchange rate changes on
   cash and cash equivalents

 

$

43,731

 

 

 

(2,942

)

Net decrease in cash and cash equivalents

 

$

(177,874

)

 

 

(539,507

)

Cash and cash equivalents, beginning of period

 

$

776,005

 

 

 

1,154,653

 

Cash and cash equivalents, end of period

 

$

598,131

 

 

$

615,146

 

The following table presents cash flows for the nine months ended December 31, 2023 and 2022:

 

 

Nine months ended December 31,

 

(in thousands of Canadian dollars)

 

2023

 

 

2022

 

Net cash (used in) provided by:

 

 

 

 

 

 

Operating activities1

 

$

(259,891

)

 

$

(417,809

)

Investing activities2

 

$

202,106

 

 

 

342,125

 

Financing activities

 

$

(473,524

)

 

 

(145,921

)

Effect of exchange rate changes on
   cash and cash equivalents

 

$

(2,953

)

 

 

43,731

 

Net decrease in cash and cash equivalents

 

$

(534,262

)

 

 

(177,874

)

Cash and cash equivalents, beginning of period3

 

$

677,007

 

 

 

776,005

 

Cash and cash equivalents, end of period4

 

$

142,745

 

 

$

598,131

 

1 Includes net cash used in operating activities from discontinued operations of $(53,930) and $(119,019) for the nine months ended December 31, 2023 and 2022, respectively.

 

2 Includes net cash used in investing activities from discontinued operations of $(2,600) and $(23,947) for the nine months ended December 31, 2023 and 2022 respectively.

 

3 Includes cash of our discontinued operations of $9,314 and $13,610 for March 31, 2023 and 2022, respectively.

 

4 Includes cash of our discontinued operations of $nil and $13,261 for December 31, 2023 and 2022, respectively.

 

 

Operating activities

 

Cash used in operating activities totaled $259.9 million in the nine months ended December 31, 2023, as compared to cash used of $417.8 million in the nine months ended December 31, 2022, relatively consistent with2022. The decrease in the cash used in operating activities is primarily due to: (i) the year-over-year decrease in our working capital spending, resulting from our previously-noted restructuring actions and cost savings programs, including the closure of $419.1 millioncertain of our Canadian facilities and other operational changes to implement cultivation-related efficiencies and improvements in the nine months ended December 31, 2021.Canadian adult-use cannabis business; and (ii) a reduction in the cash interest paid resulting from a reduction in our debt balances.

 

Investing activities

 

The cash provided by investing activities totaled $202.1 million in the nine months ended December 31, 2023, as compared to cash provided of $342.1 million in the nine months ended December 31, 2022, as compared to cash used of $71.1 million in the nine months ended December 31, 2021.2022.

70


 

In the nine months ended December 31, 2022,2023, purchases of property, plant and equipment were $6.2$3.2 million, primarily related to improvementsproduction equipment enhancements made at certain of our Canadian cultivation and production facilities, and at our Storz & Bickel facilities. Comparatively, in the nine months ended December 31, 2021,2022, we invested $36.6$6.2 million in improvements at certain of our Canadian cultivation and production infrastructure in the United Statesactivities, and an expansion ofat our Storz & Bickel facilities. The year-over-year decrease is primarily attributable to: (i) the substantial completion of the infrastructure projects that were in progress in fiscal 2022; and (ii) optimizing our capital expenditures as part of the previously-noted restructuring actions, particularly those actions that were initiated in the fourth quarter of fiscal 2022.

 

In the nine months ended December 31, 2023, our strategic investments in other financial assets were $0.5 million and related primarily to the Indiva Investment, as described under "Recent Developments" above. Comparatively, in the nine months ended December 31, 2022, our strategic investments in other financial assets were $67.2 million and related primarily to: (i) the upfront payment made as consideration for entering the Jetty Agreements ($29.2 million); and (ii) the payment of the Option Premium in the amount of $38.0 million (US$28.5 million) to acquirein connection with Acreage Debt Optionholder's acquisition of an option to purchase the Acreage Debt from the Lenders, pursuant to the option agreement entered into with the Lenders in connection with the Reorganization; see "Recent Developments" above for further details. Comparatively, in the nine months ended December 31, 2021, our strategic investments in other financial assets were $374.4 million and related primarily to the upfront payment made as consideration for entering into the Wana Agreements.

In the nine months ended December 31, 2022, we completed the Verona Acquisition, as described above under "Recent Developments". The net cash outflow associated with the Verona Acquisition was $24.2 million. Comparatively, in the nine months ended December 31, 2021, the net cash outflow relating to acquisitions totaled $14.9 million.Reorganization.

 

Net redemptions of short-term investments in the nine months ended December 31, 20222023 were $415.3$68.3 million, as compared to net redemptions of $340.2$415.3 million in the nine months ended December 31, 2021.2022. The year-over-year changedecrease in the net redemptions reflects the continued redemption of our short-term investments, largely to fund operations and investing activities as described above. As at December 31, 2023, we had short-term investments remaining of $43.4 million.

Net cash flow on sale of subsidiaries in the nine months ended December 31, 2023 was an outflow of $3.7 million and related to the completion of the This Works Divestiture, refer to Note 27 of the financial statements for details. Comparatively, in the nine months ended December 31, 2022 an inflow of $12.4 million resulted from the sale of certain wholly-owned subsidiaries.

69


 

Additional cash inflows during the nine months ended December 31, 20222023 include proceeds of $12.4 million from the sale of certain wholly-owned subsidiaries, and proceeds of $10.9$153.8 million from the sale of property, plant and equipment. Comparatively, additional cash inflows duringequipment, primarily in relation to facilities that have been recently sold in connection with the nine months ended December 31, 2021 relatedrestructuring actions associated with our Canadian cannabis operations and transition to proceeds of $10.3 million from the sale of certain wholly-owned subsidiaries, and proceeds of $25.7 million from the sale of property, plant and equipment.an asset-light model.

 

Finally, other investing activities resulted in a cash inflowoutflow of $2.3$9.2 million in the nine months ended December 31, 2022,2023, primarily related to completing the partial repaymentpurchase of the principal on a loan associatedremaining 45% of the common shares of Les Serres Vert Cannabis Inc., in connection with the sale of a wholly-owned subsidiary in fiscal 2022, partially offset by the cash outflow associated with the redemption of the first tranche of the BioSteel redeemable noncontrolling interest. Comparatively, other investing activities resulted in a cash outflow of $16.8 millionrestructuring actions related to our Canadian cannabis operations initiated in the nine months ended December 31, 2021, primarily related to the paymentfourth quarter of acquisition-related liabilities.fiscal 2023.

 

Financing activities

 

The cash used in financing activities in the nine months ended December 31, 20222023 was $145.9$473.5 million, as compared to cash used of $46.3$145.9 million in the nine months ended December 31, 2021.2022. In the nine months ended December 31, 2022,2023, we made repayments of long-term debt in the amount of $118.0$480.1 million. These repayments primarily related to the firstsecond payment made pursuant to the Paydown, which is described above in the contextJuly 2023 Paydown, the Second Quarter 2024 Paydowns, the Third Quarter 2024 Paydowns and settlement of the balance sheet actions completed in connection with the Reorganization (see "Recent Developments" above). Also, otherCanopy Notes.

Other financing activities resulted in a cash outflow of $29.1$27.2 million, primarilywhich related to fees paidto: (i) payments made in connection with terminating the Exchange Transactionfinance lease for the cultivation facility in Mirabel, Quebec and (ii) share issuance, debt issuance and debt extinguishment costs.

The cash used in financing activities was partially offset by proceeds from the Paydown (bothUnit Offering of which are described above). Comparatively, in the nine months ended December 31, 2021, we made repayments of long-term debt in the amount of $50.2 million, primarily related to the term loan assumed upon the completion of the acquisition of Supreme Cannabis on June 22, 2021.$33.7 million.

Free Cash Flow (Non-GAAP Measure)

 

Free cash flow is a non-GAAP measure used by management that is not defined by U.S. GAAP and may not be comparable to similar measures presented by other companies. Management believes that free cash flow presents meaningful information regarding the amount of cash flow required to maintain and organically expand our business, and that the free cash flow measure provides meaningful information regarding our liquidity requirements.

 

71The following table presents free cash flows for the three and nine months ended December 31, 2023, and 2022:


 

 

 

Three months ended December 31,

 

 

Nine months ended December 31,

 

(in thousands of Canadian dollars)

 

2022

 

 

2021

 

 

2022

 

 

2021

 

Net cash used in operating activities

 

$

(143,894

)

 

$

(167,380

)

 

$

(417,809

)

 

$

(419,125

)

Purchases of and deposits on property,
   plant and equipment

 

 

(1,868

)

 

 

(962

)

 

 

(6,176

)

 

 

(36,620

)

Free cash flow1

 

$

(145,762

)

 

$

(168,342

)

 

$

(423,985

)

 

$

(455,745

)

 

 

 

 

 

 

 

 

 

 

 

 

 

1Free cash flow is a non-GAAP measure, and is calculated as net cash provided by (used in) operating activities, less purchases of and deposits on property, plant and equipment.

 

 

 

Three months ended December 31,

 

 

Nine months ended December 31,

 

(in thousands of Canadian dollars)

 

2023

 

 

2022

 

 

2023

 

 

2022

 

Net cash used in operating activities - continuing
   operations

 

$

(33,348

)

 

$

(77,055

)

 

$

(205,961

)

 

$

(298,790

)

Purchases of and deposits on property,
   plant and equipment - continuing operations

 

 

(564

)

 

 

(1,868

)

 

 

(3,200

)

 

 

(6,176

)

Free cash flow1 - continuing operations

 

$

(33,912

)

 

$

(78,923

)

 

$

(209,161

)

 

$

(304,966

)

 

 

 

 

 

 

 

 

 

 

 

 

 

1Free cash flow is a non-GAAP measure, and is calculated as net cash provided by (used in) operating activities, less purchases of and deposits on property, plant and equipment.

 

 

Free cash flow in the third quarter of fiscalthree months ended December 31, 2023 was an outflow of $145.8$33.9 million, as compared to an outflow of $168.3$78.9 million in the third quarter of fiscalthree months ended December 31, 2022. The year-over-year decrease in the free cash outflow primarily reflects the decrease in cash used in operating activities, which is associated primarily with the year-over-year improvement in working capital spending.as described above.

 

Free cash flow infor the nine months ended December 31, 20222023 was an outflow of $424.0$209.2 million, as compared withto an outflow of $455.7$305.0 million in the nine months ended December 31, 2021.2022. The year-over-year decrease in the free cash outflow primarily reflects the decrease in purchases of property, plant and equipment associated with: (i) the substantial completion of the infrastructure projects that werecash used in progress in fiscal 2022; and (ii) optimizing our capital expendituresoperating activities, as part of the previously-noted restructuring actions, particularly those actions that were initiated in the fourth quarter of fiscal 2022.described above.

 

Debt

 

Since our formation, we have financed our cash requirements primarily through the issuance of common shares of the Company,Canopy Growth, including the $5.1 billion investment by CBI in the third quarter of fiscal 2019, and debt. Total debt outstanding as of December 31, 20222023 was $1.2 billion,$612.1 million, a decrease from $1.5$1.3 billion as of March 31, 2022.2023. The total principal amount owing, which excludes fair value adjustments related to the Notes,CBI Note, was $1.2 billion$626.6 million at December 31, 2022,2023, a decrease from $1.5$1.3 billion at March 31, 2022.2023, which excludes fair value adjustments related to the Canopy Notes. These decreases were due to: (i) the Exchange Transaction, which resulted in the acquisition and cancellation of $262.6 million of aggregate principal amount of the Notes from a limited number of holders of the Notes including Greenstar (collectively, the "Noteholders"); and (ii) the repayment of $126.3$125.6 million (US$94.493.8 million) of the principal amount outstanding under the Credit Agreement as part of the Paydown, as described under "Recent Developments" above,above; (ii) the conversion, into Canopy Growth common shares, of the remaining amount outstanding under the Convertible Debentures of $93.2 million; (iii) the June 2023 Exchange Transaction, which resulted in the

70


acquisition and cancellation of $12.5 million of aggregate principal amount of the Canopy Notes from the Noteholders, partially offset by the impactissuance of the strengtheningCBI Note in connection with the CBI Transaction; (iv) the July 13, 2023 Redemption Agreements, pursuant to which $193 million aggregate principal amount was redeemed for a combination of cash, shares and the Debentures with an aggregate principal amount of approximately $40.4 million; (v) the maturity of the U.S. dollar againstremaining Canopy Notes due in July 2023 where the Canadian dollar on amounts borrowed onremaining $31.9 million in aggregate principal was settled in cash; (vi) the Credit Facility (see below).Second Quarter 2024 Paydowns resulting in an aggregate principal reduction of $73.3 million; (vii) settlement of the $40.4 million of Debentures with Canopy Growth common shares; and (viii) the Third Quarter 2024 Paydowns resulting in an aggregate principal reduction of $65.4 million.

 

Credit Facility

 

The Credit Agreement provides for the Credit Facility in the aggregate principal amount of US$750.0 million.

The Credit Agreement also providedCompany had the ability to obtain up to an additional US$500.0 million of incremental senior secured debt pursuant to the Credit Agreement. As described above under "Recent Developments" above,“Recent Developments”, pursuant to the balance sheet actions completed in connection with the Reorganization, on October 24, 2022, we have entered into agreements with certain of our lenders party tounder the Credit Agreement pursuant to completewhich we agreed to purchase in the Paydown, which will result in us tenderingaggregate US$187.5 million of the principal amount outstanding under the Credit Agreement. OnFacility at a discounted price of US$930 per US$1,000 or US$174.4 million in the aggregate. The first payment, which was oversubscribed, in the amount of approximately $117.5 million (US$87.9 million) was made on November 10, 2022 to reduce the principal indebtedness under the Credit Facility by approximately $126.3 million (US$94.4 million) of principal was repaid pursuant to the Paydown.. The second payment pursuant to the Paydown is required to beof approximately $116.8 million (US$87.2 million) was made by no later thanon April 17, 2023. We also2023 to reduce principal indebtedness under the Credit Facility by approximately $125.6 million (US$93.8 million). Additionally, on October 24, 2022, we and certain of our lenders agreed to make certain amendments to the Credit Agreement with our lenders which, among other things, eliminatedresulted in: (i) a reduction to the minimum liquidity covenant to no less than US$100.0 million following completion of the second principal repurchase on April 17, 2023; (ii) certain changes to the application of net proceeds from asset sales; (iii) the establishment of a new committed delayed draw term credit facility in an aggregate principal amount of US$100.0 million; and (iv) the elimination of the additional US$500.0 million incremental term loan facility.

As described above under “Recent Developments”, on July 13, 2023, we entered into the Amended Credit Agreement. Pursuant to the Amended Credit Agreement we were required to make the July 2023 Paydown. In addition, pursuant to the Amended Credit Agreement we agreed to apply certain net proceeds from asset sales to prepay or repurchase principal indebtedness under the Credit Facility and receive principal reductions at, in certain circumstances, a discounted price of US$950 per US$1,000. The Amended Credit Agreement also includes, among other things, amendments to the minimum liquidity covenant such that the US$100,000 minimum ceased to apply concurrently with the July 2023 Paydown. The July 2023 Paydown was made on July 21, 2023.

As described above under “Recent Developments”, on each of August 11, 2023 and September 14, 2023, pursuant to the terms of the Amended Credit Agreement, we repurchased additional outstanding principal amounts under the Credit Facility using certain net proceeds from completed asset sales. The Second Quarter 2024 Paydowns resulted in an aggregate principal reduction of $73.3 million (US$54.5 million) for a cash payment of $69.6 million (US$51.8 million).

As described above under “Recent Developments”, on each of November 28, 2023 and December 27, 2023, pursuant to the terms of the Amended Credit Agreement, we repurchased and repaid, as applicable, additional outstanding principal amounts under the Credit Facility using certain net proceeds from completed asset sales (the "Third Quarter 2024 Paydowns"). The Third Quarter 2024 Paydowns resulted in an aggregate principal reduction of $65.4 million (US$48.5 million) for a cash payment of $63.2 million (US$46.9 million).

 

The Credit Facility has no amortization payments, matures on March 18, 2026, has a coupon of LIBOR2026. Borrowings under the Credit Facility are available by either prime rate advances or SOFR advances. Prime rate advances bear interest at the applicable prime rate plus 8.50%7.50% per annum and isare subject to a LIBORprime rate floor of 2.00%. SOFR advances bear interest at the adjusted term SOFR rate plus 8.50% per annum and are subject to an adjusted term SOFR rate floor of 1.00%. In the event that LIBOR can no longer be adequately ascertained or is no longer available, an alternative rate as permitted under the Credit Agreement will be used. Our obligations under the Credit Facility are guaranteed by our material wholly-owned Canadian and U.S. subsidiaries of Canopy Growth.subsidiaries. The Credit Facility is secured by substantially all of theour assets and our material wholly-owned Canadian and U.S. subsidiaries, including material real property, of the borrowers and each of the guarantors thereunder.property. The Credit Agreement contains representations and warranties, and affirmative and negative covenants, including a financial covenant requiring minimum liquidity of US$200.0 million at the end of each fiscal quarter; however, as a result of the amendments to the Credit Agreement, such minimum liquidity covenant has been reduced to US$100.0 million, which is to be reduced as payments are made in accordance with the Paydown.covenants.

 

Unsecured Senior Notes (the Canopy Notes)

 

In June 2018, we issued the Canopy Notes with an aggregate principal amount of $600.0 million. The Canopy Notes bear interest at a rate of 4.25% per annum, payable semi-annually on January 15th and July 15th of each year commencing January 15, 2019. The Canopy Notes maturematured on July 15, 2023. In June 2022, in connection with the 2022 Exchange Transaction, we entered into the 2022 Exchange Agreements with the Noteholders and agreed to acquire and cancel approximately $262.6 million of aggregate

71


principal amount of the Canopy Notes from the

72


Noteholders for an aggregate purchase price (excluding $5.4 million paid in cash to the Noteholders for accrued and unpaid interest) of $260.0 million which was paid in our common shares.

 

The Canopy Notes were issued pursuant to an indenture dated June 20, 2018, as supplemented on April 30, 2019 and June 29, 2022 (collectively, the “Canopy Notes Indenture”). As a result of a supplement to the Canopy Notes Indenture dated June 29, 2022 (the “Second Supplemental Indenture”), we irrevocably surrendered our right to settle the conversion of any Note with our common shares. As a result, all conversions of Canopy Notes following the execution of the Supplemental Indenture will be settled entirely in cash.

On April 13, 2023, we entered into the April 2023 Exchange Agreement with Greenstar in order to acquire and cancel $100.0 million aggregate principal amount of our outstanding Canopy Notes. Pursuant to the April 2023 Exchange Agreement, we agreed to acquire and cancel $100.0 million aggregate principal amount of the Canopy Notes held by Greenstar in exchange for: (i) a cash payment to Greenstar in the amount of the unpaid and accrued interest owing under the Canopy Notes held by Greenstar; and (ii) the CBI Note. As a result, Greenstar no longer holds any Canopy Notes.

On June 29, 2023, we entered into the June 2023 Exchange Agreements with certain Noteholders to acquire and cancel $12.5 million aggregate principal amount of the Canopy Notes from such Noteholders in exchange for cash, including accrued and unpaid interest owing under the Canopy Notes, and the issuance of approximately 2.43 million Canopy Growth common shares.

On July 13, 2023, we entered into the Redemption Agreements with certain Noteholders of our Canopy Notes, pursuant to which approximately $193 million aggregate principal amount of the Canopy Notes were redeemed on the applicable closing date for: (i) an aggregate cash payment of approximately $101 million; (ii) the issuance of approximately 9.04 million Canopy Growth common shares; and (iii) the issuance of approximately $40.4 million aggregate principal amount of Debentures. The Debentures were issued pursuant to a debenture indenture dated July 14, 2023 between us and Odyssey Trust Company, as trustee. The Debentures are convertible into Debenture Shares at the option of the holder at any time or times following the Shareholder Approval until the maturity date of January 15, 2024, at a conversion price equal to $5.50, subject to adjustment in certain events. Following the Redemption, we settled the remaining aggregate principal amount owing under the outstanding Canopy Notes and, as of the maturity date, there were no Canopy Notes outstanding.

As of September 30, 2023, all conversions pursuant to the Debentures have been completed and the amount outstanding under the Debentures was $nil.

Supreme Cannabis Convertible Debentures and Accretion Debentures

On October 19, 2018, Supreme Cannabis issued 6.0% senior unsecured convertible debentures (the “Supreme Debentures”) for gross proceeds of $100.0 million. On September 9, 2020, the Supreme Debentures were amended to effect, among other things: (i) the cancellation of $63.5 million of principal amount of the Supreme Debentures; (ii) an increase in the interest rate to 8% per annum; (iii) the extension of the maturity date to September 10, 2025; and (iv) a reduction in the conversion price to $0.285.$2.85.

In addition, on September 9, 2020, Supreme Cannabis issued new senior unsecured non-convertible debentures (the “Accretion Debentures”). The principal amount began at $nil and accretes at a rate of 11.06% per annum based on the remaining principal amount of the Supreme Debentures of $36.5 million to a maximum of $13.5 million, compounding on a semi-annual basis commencing on September 9, 2020, and ending on September 9, 2023. As of September 9, 2023, the principal amount of the Accretion Debentures was finalized as $10.4 million. The Accretion Debentures are payable in cash, but do not bear cash interest and are not convertible into Supreme Shares. The principal amount of the Accretion Debentures will amortize, or be paid, at 1.0% per month over the 24 months prior to maturity.

As a result of the arrangement (the “Supreme Arrangement”) we completed with Supreme Cannabis on June 22, 2021 pursuant to which we acquired 100% of the issued and outstanding common shares of Supreme Cannabis (the “Supreme Shares”), the Supreme Debentures remain outstanding as securities of Supreme Cannabis, which, upon conversion will entitle the holder thereof to receive, in lieu of the number of Supreme Shares to which such holder was theretofore entitled, the consideration payable under the Supreme Arrangement that such holder would have been entitled to be issued and receive if, immediately prior to the effective time of the Supreme Arrangement, such holder had been the registered holder of the number of Supreme Shares to which such holder was theretofore entitled.

In connection with the Supreme Arrangement, we, Supreme Cannabis and Computershare Trust Company of Canada (the “Trustee”) entered into a supplemental indenture whereby we agreed to issue common shares upon conversion of any Supreme Debenture. In addition, we may force conversion of the Supreme Debentures outstanding with 30 days’ notice if the daily volume weighted average trading price of our common shares is greater than $38.59$385.90 for any 10 consecutive trading days. We, Supreme

72


Cannabis and the Trustee entered into a further supplemental indenture whereby we agreed to guarantee the obligations of Supreme Cannabis pursuant to the Supreme Debentures and the Accretion Debentures. During the three and nine months ended December 31, 2023 principal payments on Accretion Debentures totaled $1,500 and $2,000, respectively.

Prior to September 9, 2023, the Supreme Debentures arewere not redeemable. Beginning on and after September 9, 2023, Supreme Cannabis may from time to time, upon providing 60 days prior written notice to the Trustee, redeem the Convertible Debentures outstanding, provided that the Accretion Debentures have already been redeemed in full.

 

Convertible Debentures

On February 21, 2023, we entered into the Convertible Debenture Agreement with an Institutional Investor pursuant to which the Institutional Investor purchased $135.2 million (US$100.0 million) aggregate principal amount of Convertible Debentures in a registered direct offering. The Convertible Debentures were convertible into our common shares at the option of the Institutional Investor at any time or times prior to the maturity date of February 28, 2028, at a conversion price equal to 92.5% of the volume-weighted average price of our common shares during the three consecutive trading days ending on the business day immediately prior to the date of conversion. No cash payment or any other property of Canopy Growth was made by us to the Institutional Investor in connection with, or as a result of, the issuance, conversion or repayment of the Convertible Debentures.

In the first quarter of fiscal 2024, $93.2 million in aggregate principal amount of the Convertible Debentures was converted for approximately 8.45 million Canopy Growth common shares. As of June 30, 2023, all conversions pursuant to the Convertible Debentures were completed and the amount outstanding under the Convertible Debentures was $nil.

Contractual Obligations and Commitments

 

Other than changes to our Canopy Notes pursuant to the June 2023 Exchange Transactions, the July 13, 2023 Redemption Agreements, the Second Quarter 2024 Paydowns, the Third Quarter 2024 Paydowns, and certain agreements entered into in connection with the Reorganization and the Reorganization Amendments, as described above under “Recent Developments”, there have been no material changes to our contractual obligations and commitments from the information provided in the MD&A section in our Annual Report.

 

Off-Balance Sheet Arrangements

 

We have no off-balance sheet arrangements that have, or are reasonably likely to have, a material current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors.

Critical Accounting Policies and Estimates

 

There have been no material changes to our critical accounting policies and estimates from the information provided in the MD&A section in our Annual Report.

 

Impairment of goodwill

 

First Quarter of Fiscal 2023

As a result of the continued decline in the price of our common shares in the first quarter of fiscal 2023, we determined there to be an indicator of impairment for the cannabis operations reporting unit in the global cannabis segment, which was a reportable segment in the first quarter of fiscal 2023. As a result, we performed a quantitative interim goodwill impairment assessment for the cannabis operations reporting unit as of June 30, 2022. We concluded that the carrying value of the cannabis operations reporting unit

73


was higher than its estimated fair value, and a goodwill impairment loss totaling $1.7 billion was recognized in the first quarter of fiscal 2023, representing the entirety of the goodwill assigned to the cannabis operations reporting unit.

The estimated fair value of the cannabis operations reporting unit was determined using the market valuation method, which was consistent with the methodology used for our annual impairment test conducted at March 31, 2022. The most significant assumptions used in applying this method were (i) the price of our common shares; and (ii) the estimated control premium associated with ownership of our common shares.

Second Quarter of Fiscal 2023

While we changed our reportable segments in the second quarter of fiscal 2023 (refer to "Segment Reporting" above), there were no changes to the composition of our reporting units to which goodwill remained assigned at September 30, 2022. In the second quarter of fiscal 2023, we determined there to be indicators of impairment for one of our other reporting units as slower growth rates resulted in updated long-term financial forecasts indicating lower forecasted revenue and cash flow generation. As a result, we performed a quantitative interim goodwill impairment test for the reporting unit as of September 30, 2022 and concluded that the carrying value of the reporting unit was higher than its estimated fair value, as determined using the income valuation method. We recognized a goodwill impairment loss totaling $2.3 million in the second quarter of fiscal 2023, representing the entirety of the goodwill assigned to the reporting unit.

Third Quarter of Fiscal 2023

We do not believe that an event occurred or circumstances changed during the third quarter of fiscal 20232024 that would, more likely than not, reduce the fair value of the remainingStorz & Bickel reporting unitsunit below theirits carrying value. Therefore, we concluded that the quantitative goodwill impairment assessment was not required for the remainingStorz & Bickel reporting unitsunit at December 31, 2022.2023. The carrying value of goodwill associated with all otherthe Storz & Bickel reporting unitsunit was $142.1 million$85,237 at December 31, 2022.2023.

 

We are required to perform theour next annual goodwill impairment analysis on March 31, 2023,2024, or earlier should there be an event that occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount.

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

 

Market risk is the potential economic loss arising from adverse changes in market factors. As a result of our global operating, acquisition and financing activities, we are exposed to market risk associated with changes in foreign currency exchange rates, interest

73


rates and equity prices. To manage the volatility relating to these risks, we may periodically purchase derivative instruments including foreign currency forwards. We do not enter into derivative instruments for trading or speculative purposes.

Foreign currency risk

 

Our Interim Financial Statements are presented in Canadian dollars. We are exposed to foreign currency exchange rate risk as the functional currencies of certain subsidiaries, including those in the United States and Europe, are not in Canadian dollars. The translation of foreign currencies to Canadian dollars is performed for balance sheet accounts using exchange rates in effect at the balance sheet date, and for revenues and expense using an average exchange rate for the period. Therefore, fluctuations in the value of the Canadian dollar affect the reported amounts of net revenue, expenses, assets and liabilities. The resulting translation adjustments are reported as a component of accumulated other comprehensive income or loss on the consolidated balance sheet.

 

A hypothetical 10% change in the U.S. dollar against the Canadian dollar compared to the exchange rate at December 31, 2022,2023, would affect the carrying value of net assets by approximately $5.1$66.6 million, with a corresponding impact to the foreign currency translation account within accumulated other comprehensive income (loss). A hypothetical 10% change in the euro against the Canadian dollar compared to the exchange rate at December 31, 2022,2023, would affect the carrying value of net assets by approximately $25.9$24.0 million, with a corresponding impact to the foreign currency translation account within accumulated other comprehensive income (loss).

 

We also have exposure to changes in foreign exchange rates associated with transactions which are undertaken by our subsidiaries in currencies other than their functional currency. As a result, we have been impacted by changes in exchange rates and may be impacted for the foreseeable future.

 

Foreign currency derivative instruments may be used to hedge existing foreign currency denominated assets and liabilities, forecasted foreign currency denominated sales/purchases to/from third parties as well as intercompany sales/purchases, intercompany principal and interest payments, and in connection with acquisitions, divestitures or investments outside of Canada. Historically, while

74


we have purchased derivative instruments to mitigate the foreign exchange risks associated with certain transactions, the impact of these hedging transactions on our financial statements has been immaterial.

Interest rate risk

 

Our cash equivalents and short-term investments are held in both fixed-rate and adjustable-rate securities. Investments in fixed-rate instruments carry a degree of interest rate risk. The fair value of fixed-rate securities may be adversely impacted due to a rise in interest rates. Additionally, a falling-rate environment creates reinvestment risk because as securities mature, the proceeds are reinvested at a lower rate, generating less interest income. As at December 31, 2022,2023, our cash and cash equivalents, and short-term investments consisted of $0.3 billion$99 million in interest rate sensitive instruments (March 31, 20222023$0.9$0.3 billion).

 

Our financial liabilities consist of long-term fixed rate debt and floating-rate debt. Fluctuations in interest rates could impact our cash flows, primarily with respect to the interest payable on floating-rate debt.

 

 

Aggregate Notional Value

 

 

Fair Value

 

 

Decrease in Fair Value - Hypothetical 1% Rate Increase

 

 

Aggregate Notional Value

 

 

Fair Value

 

 

Decrease in Fair Value - Hypothetical 1% Rate Increase

 

 

December 31, 2022

 

 

March 31, 2022

 

 

December 31, 2022

 

 

March 31, 2022

 

 

December 31, 2022

 

 

March 31, 2022

 

 

December 31, 2023

 

 

March 31, 2023

 

 

December 31, 2023

 

 

March 31, 2023

 

 

December 31, 2023

 

 

March 31, 2023

 

Unsecured senior notes

 

$

337,380

 

 

$

600,000

 

 

$

325,555

 

 

$

563,958

 

 

$

(1,552

)

 

$

(6,600

)

 

$

-

 

 

$

337,380

 

 

$

-

 

 

$

331,250

 

 

$

-

 

 

$

(1,552

)

Promissory note

 

 

100,000

 

 

 

-

 

 

 

85,486

 

 

 

-

 

 

 

(678

)

 

 

-

 

Fixed interest rate debt

 

 

41,639

 

 

 

43,386

 

 

N/A

 

 

N/A

 

 

N/A

 

 

N/A

 

 

 

39,480

 

 

 

135,573

 

 

N/A

 

 

N/A

 

 

N/A

 

 

N/A

 

Variable interest rate debt

 

 

838,407

 

 

 

893,647

 

 

N/A

 

 

N/A

 

 

N/A

 

 

N/A

 

 

 

487,108

 

 

 

840,058

 

 

N/A

 

 

N/A

 

 

N/A

 

 

N/A

 

Equity price risk

 

We hold other financial assets and liabilities in the form of investments in shares, warrants, options, put liabilities, and convertible debentures that are measured at fair value and recorded through either net income (loss) or other comprehensive income (loss). We are exposed to price risk on these financial assets, which is the risk of variability in fair value due to movements in equity or market prices.

 

For our Notes, a primary driver of its fair value is our share price. An increase in our share price typically results in a fair value increase of the liability.

Information regarding the fair value of financial instrument assets and liabilities that are measured at fair value on a recurring basis, and the relationship between the unobservable inputs used in the valuation of these financial assets and their fair value is presented in Note 2223 of the Interim Financial Statements.

7574


 

Item 4. Controls and Procedures.

 

Evaluation of Disclosure Controls and Procedures.

 

We maintain disclosure controls and procedures (as that term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) that are designed to ensure that information required to be disclosed in our reports under the Exchange Act is recorded, processed, and summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosures. Any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. An evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report was made under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer.

 

Based upon this evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of December 31, 2022,2023, our disclosure controls and procedures (a) arewere not effective as of such date due to the material weakness in our internal control over financial reporting related to information technology ("IT") general controls that were disclosed in Item 9A of the Annual Report.

Previously Reported Material Weaknesses

As previously disclosed in Item 9A of the Annual Report, we previously identified material weaknesses in our internal control over financial reporting relating to:

The accounting for sales recorded by the BioSteel segment, which resulted in material misstatements relating to revenue and trade receivables, particularly with respect to the timing and amount of revenue recognition. Specifically, we did not design and maintain effective controls to sufficiently assess the timing, amount, and appropriateness of revenue recognition. This included a lack of segregation of duties in the review of customer orders, inadequate controls over the review and approval of sales returns, and inadequate controls relating to revenue recognition policies and procedures. This also contributed to the failure to impair goodwill related to the BioSteel reporting unit on a timely basis as changes in the performance of BioSteel were not identified in a timely manner, and the failure to accurately record the redeemable noncontrolling interest; and
IT general control deficiencies that aggregated to a material weakness. These deficiencies specifically related to: (i) logical access management, including untimely periodic access review, access provisioning and modification, removal of user access and change management controls with respect to a payroll system implemented during the year; and (ii) untimely and inconsistent monitoring and oversight of third-party service organizations. Although we have identified no instances of any adverse effects due to these deficiencies, business processes that depend on the affected information systems or that depend on data from the affected information systems, could be adversely impacted.

Status of Remediation of Material Weaknesses in Internal Control over Financial Reporting

Management has developed a remediation plan to address the previously disclosed material weaknesses for which we implemented process and control improvements.

IT General Controls

Management continues to make progress in the remediation of all IT general control individual deficiencies that corresponded to the material weakness. The completed remediation actions include:

Improving the privileged access review process and performing a review of all in-scope systems for privileged user access;
Performing a review of the tools and improving the process relied upon to ensure that informationusers terminations or transfers are timely updated in systems;
Improving the access approval requirements to ensure all access requests are properly approved and documented prior to granting/modifying user access;
Adding a dedicated resource to support and perform key IT general controls, including privileged access review and review of third-party service organization control reports to assess their impact in relation to the control environment. Additionally, training on third-party service organization control reports review was delivered to relevant control owners; and

75


Improving the retention of evidence for testing and approval of system changes.
Training on strengthening Canopy Growth’s control environment was completed for all key stakeholders.

BioSteel business-to-business sales

Effective September 14, 2023, Canopy Growth no longer has a controlling interest in BioSteel Sports Nutrition Inc. ("BioSteel Canada"), and effective November 16, 2023, Canopy Growth no longer has a controlling interest in BioSteel Manufacturing, LLC ("BioSteel Manufacturing") and BioSteel Sports Nutrition USA LLC. Further, during November 2023, Canopy Growth completed the sale of substantially all of the assets of BioSteel Canada and BioSteel Manufacturing. As a result, the BioSteel segment is no longer considered part of management’s internal control over financial reporting and the material weakness previously identified in our internal controls is no longer applicable to Canopy Growth.

To remediate the existing material weakness on IT general controls, additional time is required to demonstrate the effectiveness of the remediation efforts. The material weakness cannot be disclosed by us in reports filed or submitted underconsidered remediated until the Exchange Act is timely recorded, processed, summarizedapplicable remedial controls operate for a sufficient period of time and reported and (b) include, without limitation,management has concluded, through testing, that these controls and procedures designed to ensureare operating effectively. We may also conclude that informationadditional measures may be required to be disclosedremediate the material weakness in our internal control over financial reporting, which may necessitate further action. Remediation actions are subject to ongoing senior management review as well as oversight by us in reports filed or submitted under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.Audit Committee of the Board.

 

Changes in Internal Control over Financial Reporting.

 

There have beenWe are taking actions to remediate the material weakness relating to our internal control over financial reporting as described above. Except as discussed above, there were no changes in our “internal control over financial reporting” (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the period covered by this Quarterly Report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

76


 

PART II—OTHER INFORMATION

Item 1. Legal Proceedings.

Other than as disclosed below, we are not aware of: (a) any legal proceedings to which we are a party, or to which any of our properties is subject, which would be material to us or of any such proceedings being contemplated, (b) any penalties or sanctions imposed by a court relating to securities legislation, or other penalties or sanctions imposed by a court or regulatory body against us that would likely be considered important to a reasonable investor making an investment decision, and (c) any settlement agreements that we have entered into before a court relating to securities legislation or with a securities regulatory authority.

 

None.On May 23, 2023, an ostensible shareholder commenced a putative class action (Turpel v. Canopy Growth Corporation, et al., Case No. 1:23-cv-043022-PAE) against the Company and two of its officers in the U.S. District Court for the Southern District of New York on behalf of persons and entities that purchased or otherwise acquired the Company’s securities between May 31, 2022 and May 10, 2023, alleging violations of U.S. federal securities laws. Two similar cases were subsequently filed, captioned as Kantner v. Canopy Growth Corporation, et al., Case No. 1:23-cv-06266-PAE and Allen v. Canopy Growth Corporation, et al., Case No. 1:23-cv-05891-PAE. On November 30, 2023, the U.S. District Court for the Southern District of New York consolidated the Turpel, Kantner and Allen actions (captioned as “In re Canopy Growth Securities Litigation, No. 23-cv-04302”) and appointed Chen Li as lead plaintiff. On January 22, 2024, the lead plaintiff filed a first amended complaint against the Company and certain of its current and former officers, alleging claims on behalf of persons and entities that purchased or otherwise acquired the Company’s securities between November 5, 2021 and June 22, 2023. The first amended complaint alleges that the Company made false or misleading statements and omissions regarding BioSteel’s revenue, performance and operations, and the Company’s internal controls over accounting and financial reporting in violation of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder. The lead plaintiff seeks an unspecified amount of damages, attorneys’ fees and costs, and other relief. The Company anticipates filing a motion to dismiss the first amended complaint on or before March 7, 2024.

On January 18, 2024, a follow-on derivative shareholder lawsuit, captioned Press v. Schmeling et al., was filed in the Supreme Court of the State of New York by ostensible shareholder Denise Press on behalf of Canopy Growth Corporation against the Company’s directors and certain of its officers based on substantially the same allegations as those alleged in the In re Canopy Growth Securities Litigation described above. The complaint asserts claims for breach of fiduciary duties, gross mismanagement, waste of corporate assets, unjust enrichment, and insider trading, and seeks damages, attorneys’ fees and costs, and equitable relief.

On June 27, 2023, an ostensible shareholder commenced a putative class action (Dziedziejko v. Canopy Growth Corporation et al., Court File No. CV-23-00701769-00CP) in the Ontario Superior Court of Justice against the Company, two of its officers, and the Company’s auditor on behalf of a putative class of all persons or entities who acquired Canopy’s securities in the secondary market between June 1, 2021 to June 22, 2023 and held some or all of those securities until the close of trading on May 10, 2023 or June 22, 2023.

The plaintiff alleges that the Company’s disclosures contained misrepresentations within the meaning of the Securities Act (Ontario), that certain officers authorized, permitted, or acquiesced in the release of the impugned disclosures, that the Company and one of its officers acted in a manner that was oppressive or unfairly prejudicial to the proposed class members by failing to remedy alleged deficiencies in the Company’s internal controls, and that all of the defendants are liable for damages to the putative class. The action seeks an unspecified amount of damages, interest, legal fees, and the costs of administering a plan of distribution of the recovery. The Company was also named in two other putative class proceedings that were commenced between May 2023 and July 2023 in the Ontario Superior Court of Justice regarding that the Company’s disclosures contained misrepresentations. However, on November 10, 2023, the Ontario Superior Court of Justice decided a carriage motion staying those actions (Leonard v. Canopy Growth Corporation et al., Court File No. CV-23-00702281-00CP and Twidale v. Canopy Growth Corporation et al., Court File No. CV-23-00700135-00CP), and allowing Dziedziejko v. Canopy Growth Corporation et al., Court File No. CV-23-00701769-00CP to proceed to a class certification hearing.

On June 15, 2023, an ostensible shareholder commenced a putative class action (Asmaro v. Canopy Growth Corporation et al., Court File No. VLC-S-S-234351) against the Company and two of its officers in the Supreme Court of British Columbia on behalf of a putative class of all persons and entities who purchased or otherwise acquired securities of the Company between August 6, 2021 and May 10, 2023. The lawsuit alleges that the Company’s disclosures contained misrepresentations within the meaning of the Securities Act (British Columbia), that certain officers authorized, permitted, or acquiesced in the release of the impugned disclosures, and that all of the defendants are liable for damages to the putative class. The plaintiff seeks an unspecified amount of damages.

In May 2023, in connection with the Company’s internal review of the financial reporting matters related to BioSteel, as previously disclosed in the Annual Report (the “BioSteel Review”), the Company voluntarily self-reported to the SEC that the timing and amount of revenue recognition in the BioSteel segment were under review. As a result of self-reporting the BioSteel Review, the

77


Company is the subject of an ongoing investigation by the SEC. Although the Company is fully cooperating with the SEC and continues to voluntarily respond to requests in connection with this matter, it cannot predict when such matters will be completed or the outcome and potential impact. Any remedial measures, sanctions, fines or penalties, including, but not limited to, financial penalties and awards, injunctive relief and compliance conditions, imposed on the Company in connection with this matter could have a material adverse impact on our business, financial condition and results of operations. See “Risk Factors—Risks Relating to the Restatement of the Prior Financial Statements—As a result of self-reporting the BioSteel Review, the Company is the subject of an investigation by the SEC and an ongoing informal inquiry by regulatory authorities in Canada, and it cannot predict the timing of developments, and any adverse outcome of these continuing matters could have a material adverse effect on the Company” under Item 1A of the Annual Report.

On December 29, 2023, a Request for Arbitration was made identifying the Company, one of its subsidiaries, and another entity as respondents. The Claimant seeks damages in the amount of USD $32,666,667 against the respondents based on alleged breaches of a Share Purchase Agreement (“SPA”), including breaches of the duty of good faith and honest performance in relation to certain milestone payments in the SPA.

The Company denies any alleged misconduct and liability for each of the claims asserted in the above-noted Court and Arbitral Proceedings, believes that the defendants/respondents have meritorious defenses to the claims, and expects to vigorously defend the claims, although the Company cannot predict when or how they will be resolved or estimate what the potential loss or range of loss would be, if any.

From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. We are not currently a party to any other legal proceedings other than described above, the outcome of which, if determined adversely to us, would individually or in the aggregate have a material adverse effect on our business, financial condition, results of operations or prospects. Please refer to “Risk Factors” under Item 1A of the Annual Report for further discussion.

 

Item 1A. Risk Factors.

 

For information regarding factors that could affect our results of operations, financial condition and liquidity, see the risk factors discussed in Part I, Item 1A in ourthe Annual Report. Except as set forth below, there have been no material changes to the risk factors previously disclosed in Part I, Item 1A in our Annual Report.

 

Cannabis is a controlled substance in the United States and therefore subjectThere can be no certainty that all conditions to the Controlled Substances Act.

We are indirectly involved in ancillary activities related to the cannabis industry in jurisdictions in the United States where local state law permits such activities and, by virtue of, among other transactions, the Acreage Amended Arrangement, the Floating Share Arrangement and the Wana Option, the Jetty Option, and our holding of securitiesAcreage Amending Agreement will be satisfied or waived, including, in the capitalcase of TerrAscend, we may be indirectly associated with the cultivation, processing or distribution of cannabis in the United States. In the United States, cannabis is regulated at both the federal and state levels. To our knowledge, there are to date a total of 38 states, and the District of Columbia, that have now legalized cannabis in some form, including California, Nevada, New York, New Jersey, Washington and Florida. Although several states allow the sale of cannabis at the state level, cannabis continues to be categorized as a controlled substance under the Controlled Substances Act (the “CSA”)and, as such, cultivation, distribution, sale and possession of cannabis violates federal law in the United States. The inconsistency between federal and state laws and regulations may result in a loss of the value of our investments and alliances in these businesses.

While state regulation in certain U.S. states may take a permissive approach to medical and/or adult-use of cannabis, the CSA may still be enforced by U.S. federal law enforcement officials against individuals and companies operating in those states for activity that is legal under state law. If the United States Department of Justice opted to pursue a policy of aggressively enforcing U.S. federal law against financiers or equity owners of cannabis-related businesses, then Acreage, TerrAscend, Wana and Jetty, for instance, could face (i) seizure of their cash and other assets used to support or derived from their business activities; and/or (ii) the arrest of its employees, directors, officers, managers and/or investors, who could face charges of ancillary criminal violations of the CSA for aiding and abetting and conspiring to violate the CSA by virtue of providing financial support to state-licensed or permitted cultivators, processors, distributors, and/or retailers of cannabis.

Based on the advice of our legal advisors, the transaction structure for the Reorganization was intended to (i) permit us to remain able to represent that we comply with U.S. federal criminal law, particularly direct or indirect violations of the CSA (collectively, “Applicable Federal Law”); and (ii) ensure that (a) we do not, directly or indirectly, violate Applicable Federal Law; (b) we will not directly violate U.S. federal law as we do not cultivate, distribute, sell, or possess cannabis in the United States; (c) we do not violate indirect federal law (such as aiding and abetting, conspiracy, or Racketeer Influenced and Corrupt Organizations (RICO) Act) because we do not control or profit from companies that cultivate, distribute, sell, or possess cannabis in the United States; and (d) we do not violate anti-money laundering laws because no funds will flow from entities that cultivate, distribute, sell, or possess cannabis in the United States to us. In particular, based on the advice of our legal advisors, this will not be impacted in the event that Canopy USA acquires Acreage, Wana or Jetty, exercises the Cultiv8 Option or converts the TerrAscend Exchangeable Shares into common shares of TerrAscend. While we believe, based on the advice of our legal advisors, that we currently comply, and will continue to comply (in the event that Canopy USA acquires Acreage, Wana or Jetty, exercises the Cultiv8 Option or converts the TerrAscend Exchangeable Shares into common shares of TerrAscend), with all applicable laws and regulations, there is a risk that our interpretation of laws, regulations, and guidelines, may differ from those of others, including those of shareholders, government authorities, securities regulators, and stock exchanges. However, in this regard, please see the disclosure under the heading “—If Canopy USA acquires Wana, Jetty or the Fixed Shares of Acreage without structural amendments to our interest in Canopy USA, the listing of our common shares on the Nasdaq may be jeopardized.” In the event of an aggressive enforcement policy, the United States Department of Justice could allege that we and the Board, and potentially our shareholders, “aided and abetted” violations of U.S. federal law as a result of the Acreage Amended Arrangement, the Floating Share Arrangement, obtaining approval of the Wana Option,Amendment Proposal by the Jetty Option, or other transactions involving us. In these circumstances, we may lose our entire investment and directors, officers and/or our shareholders may be required to defend any criminal charges against them at their own expense and, if convicted, be sent to federal prison. Conversely, in the event Canopy USA acquires Acreage, Wana or Jetty, exercises the Cultiv8 Option or converts the TerrAscend Exchangeable Shares into common shares of TerrAscend prior to federal permissibility of cannabis in the U.S., Canopy

77


USA will not be in compliance with Applicable Federal Laws; however, based on the advice of our legal advisors, we do not believe this will have a material adverse effect on us if we continue to hold the Non-Voting Shares.

Violations of any federal laws and regulations could result in significant fines, penalties, administrative sanctions, convictions or settlements arising from civil proceedings initiated by either the federal government or private citizens, or criminal charges, including, but not limited to, disgorgement of profits, cessation of business activities or divestiture. This could have a material adverse effect on us, including our reputation and ability to conduct business, the listing of our securities on the TSX, the Nasdaq or other exchanges, our financial position, operating results, profitability or liquidity or the market price of our listed securities. Overall, an investor’s contribution to and involvement in our activitiesExercise Outside Date, which may result in federal civil and/or criminal prosecution, including forfeiture of his or her entire investment

We are subject to certain restrictions of the TSX and the Nasdaq, which may constrain our ability to expand our business in the United States.

Our common shares are currently listed on the TSX and the Nasdaq, and accordingly, so long as we choose to continue to be listed on these exchanges, we must comply with the TSX and the Nasdaq requirements or guidelines when conducting business, especially when pursuing opportunities in the United States.

On October 16, 2017, the TSX provided clarity regarding the application of Sections 306 (Minimum Listing Requirements) and 325 (Management) and Part VII (Halting of Trading, Suspension and Delisting of Securities) of the TSX Company Manual (collectively, the “TSX Requirements”) to issuers with business activities in the cannabis sector. In TSX Staff Notice 2017-0009 (the “TSX Staff Notice”), the TSX notes that issuers with ongoing business activities that violate U.S. federal law regarding cannabis are not in compliance with the TSX Requirements. The TSX reminded issuers that, among other things, should the TSX find that a listed issuer is engaging in activities contrary to the TSX Requirements, the TSX has the discretion to initiate a delisting review. Although we believe that we currently comply with all applicable laws and regulations, including the TSX Requirements, there is a risk that our interpretation may differ from the TSX and failure to comply with the TSX Requirements could result in a delisting of our common shares from the TSX or the denial of an application for certain approvals, such as to have additional securities listed on the TSX, which could have a material adverse effect on the trading price of our common shares and could have a material adverse effect on our business, financial condition and results of operations.

While the Nasdaq has not issued official rules specific to the cannabis or hemp industry, stock exchanges in the United States, including the Nasdaq, have historically refused to list certain cannabis-related businesses, including cannabis retailers, that operate primarily in the United States. Failure to comply with any requirements imposed by the Nasdaq could result in the delisting of our common shares from the Nasdaq or denial of any application to have additional securities listed on the Nasdaq, which could have a material adverse effect on the trading price of our common shares. In this regard, please see the disclosure under the heading "–If Canopy USA acquires Wana, Jetty or the Fixed Sharesacquisition of Acreage without structural amendments to our interest in Canopy USA, the listing of our common shares on the Nasdaq may be jeopardized."

Federal law in the United States may impose restrictions on our ability to bank with certain institutions, repatriate funds to Canada or pay dividends to shareholders.

The U.S. federal prohibitions on the sale of cannabis may result in us or Canopy USAnot being restricted from accessing the U.S. banking system, and we may be unable to deposit funds in federally insured and licensed banking institutions. Banking restrictions could be imposed due to institutions not accepting payments and deposits. We are at risk that any of our bank accounts could be closed at any time. Such risks increase our costs and our ability to handle any revenue received. In addition, activities in the U.S., and any proceeds derived thereof, may be considered proceeds of crime due to the fact that cannabis remains federally illegal in the U.S. This may restrict our ability to declare or pay dividends, effect other distributions or subsequently repatriate such funds back to Canada.

We may be subject to heightened scrutiny by regulatory authorities.

Any future investments, joint ventures or operations in the United States, may become the subject of heightened scrutiny by regulators, stock exchanges and other authorities in Canada. As a result, we may be subject to significant direct and indirect interaction with public officials. There can be no assurance that this heightened scrutiny will not in turn lead to the imposition of certain restrictions on our ability to invest in the United States or any other jurisdiction, in addition to those described herein.

78


If Canopy USA acquires Wana, Jetty or the Fixed Shares of Acreage without structural amendments to our interest in Canopy USA, the listing of our common shares on the Nasdaq may be jeopardized.

Our listings on the TSX and the Nasdaq prohibit us from investing in, or acquiring, state regulated, but federally illegal, businesses in the United States cannabis market until a change in United States federal law occurs or we delist our common shares from the TSX and the Nasdaq and list on an alternative exchange that does not prohibit investments in United States cannabis businesses. While we believe that we currently comply with all applicable laws and regulations, as well as the applicable cannabis related policies of the TSX and the Nasdaq, our interpretation may differ from those of the stock exchanges now or in the future, and therefore, the TSX or the Nasdaq could allege that we violate the exchanges cannabis-related policies.

Canopy Growth consolidates the financial results of Canopy USA and is expected to consolidate the financial statements of Acreage, Wana and Jetty once those acquisitions have been completed by Canopy USA. On December 7, 2022, we received a letter from Nasdaq Regulation requesting certain information and stating, among other things, its position that companies that consolidate “the assets and revenues generated from activities in violation under federal law cannot continue to list on the Nasdaq.” We expect to continue our dialogue with Nasdaq Regulation regarding its position. Representatives of the Nasdaq have expressed that the exchange was comfortable with the formation of Canopy USA, the transfer of our U.S. cannabis investments and the holding of Non-Voting Shares. Representatives of the Nasdaq have also indicated that Nasdaq Rule 5205(c) requires the Nasdaq to determine compliance with the listing standards based on a company’s financial statements. The Company disagrees with the Nasdaq’s application of Nasdaq Rule 5205(c) since Nasdaq Rule 5205(c) merely refers to a company’s initial listing and continued listing qualifications expressly enumerated in the Nasdaq Rules and does not address the matter of the legality of the revenues reported within a company’s financial statements. Accordingly, the Company intends to continue its dialogue with Nasdaq Regulation as it believes that the “qualifications” referenced in Nasdaq Rule 5205(c) cannot refer to a standard that does not exist within the Nasdaq Rules nor, intuitively, can accounting treatment form the basis for a conclusion with respect to compliance with laws.

The Company is hopeful that another exchange will seek to determine the Company’s compliance with its listing requirements on the basis of applicable laws. In the event that neither the Nasdaq nor another exchange is comfortable with financial consolidation of Canopy USA and the Nasdaq initiates a delisting process, the Company intends to vigorously appeal such a decision.completed.

 

There is significant judgment in applying the guidance with respect to consolidation of a variable interest entity under U.S. GAAP, particularly given the highly-structured, nuanced and novel nature of Canopy Growth’s interest in Canopy USA. No precedent has been identified bycan be no certainty, nor can the Company with respect to the accounting treatment under U.S. GAAP. Canopy USA was structured to ensureprovide any assurance, that Canopy Growth does not currently have the ability to direct or manage the operations of Canopy USA. The Protection Agreement provides for stringent negative covenants in favor of Canopy Growth that limit a wide variety of corporate and operational decisions of Canopy USA without the consent of Canopy Growth. In the aggregate, given the disproportionality of economics to stated power over the operations and strategy of Canopy USA, the limited exposure to the economics of Canopy USA for shareholders other than Canopy Growth, the negative covenantsall conditions precedent contained in the ProtectionFloating Share Arrangement Agreement and the factAcreage Amending Agreement will be satisfied or waived, including that the third-party investorscurrent Exercise Outside Date of March 31, 2024 is extended or in Canopy USA had pre-existing business relationships with Canopy Growth, based on the current structure of our interest in Canopy USA, consolidation of Canopy USA by Canopy Growth was deemed to most appropriately result in compliance with the requirements of U.S. GAAP despite Canopy Growth’s inability to direct or manage the operations of Canopy USA. In addition, we believe that consolidating the financial statements of Canopy USA under U.S. GAAP provides investors of the Company with a more fulsome, accurate and detailed understanding of the financial position and profit and loss for the Company overall despite Canopy Growth’s inability to direct or manage the operations of Canopy USA. However, in the event that financial consolidation of Canopy USA is not acceptable to either the Nasdaq or another exchange and the Company is unsuccessful in an appeal with respect to a delisting on the Nasdaq, the Company intends to amend the structure of its interest in Canopy USA and the terms of the Protection Agreement and Canopy USA’s Limited Liability Company Agreement such that we would not be required to consolidate the financial results of Canopy USA into our financial statements. Such changes may include: (1) reducing Canopy Growth’s economic interest in Canopy USA on an as-converted basis to no greater than 90%, (2) reducing the number of managers on Canopy USA’s board of managers from four to three, including, reducing Canopy Growth’s nomination right to a single manager, (3) modifying the terms of the Protection Agreement and Canopy USA’s Limited Liability Company Agreement in order to eliminate certain negative covenants and (4) modifying the terms of the agreements with third-party investors in Canopy USA to, among other things, eliminate their right to guaranteed returns. Accordingly, the Company does not believe there is any circumstance in which the Amendment Proposal will result in a delisting from the Nasdaq unless there is a concurrent listing on another exchange. Nonetheless, there can be no assurance that we will be able to successfully amend the structure of our interest in Canopy USA, as well as the terms of the Protection Agreement and Canopy USA’s Limited Liability Company Agreement such that we would not be required to consolidate the financial results of Canopy USA into our financial statements. In addition, there can be no assurance that the SEC will agree with the Company’s proposed accounting treatment of Canopy USA. Moreover, there can be no assurance that we will remain listed on the Nasdaq or any other exchange on which our common shares are currently listed on, which would result in an increased interest rate pursuant to the Credit Agreement and could have a material adverse effect on the trading price of our common shares, as well as our

79


business, financial condition and results of operations. In the event of a delisting from a stock exchange, there is no assurance that we will be abledefault pursuant to satisfy the conditions required to list on an alternative stock exchange.

The anticipated benefits of the strategy involving Canopy USA may not be realized.

Achieving the benefits anticipated through Canopy USA depends in part on the ability of Canopy USA to effectively capitalize on its scale, to realize the anticipated capital and operating synergies, to profitably sequence the growth prospects and to maximize the potential of its growth opportunities. The ability to realize these benefits from the acquisitions of Acreage Wana and Jetty by Canopy USA will depend, in part, on successfully consolidating certain functions and integrating operations, procedures and personnel in a timely and efficient manner, as well as on Canopy USA’s ability to realize the anticipated growth opportunities and synergies. The integration of Acreage, Wana and Jetty by Canopy USA will require the dedication of substantial effort, time and resources on the part of Canopy USA’s management which may divert management’s focus and resources from other strategic opportunities available to Canopy USA and from operational matters during this process.Debt. In addition, the integration process could result in disruptionFloating Share Arrangement is subject to certain conditions precedent which, among other things, includes the receipt of existing relationships with suppliers, employees, customers and other constituencies of each company.approval from the Company’s shareholders on the Amendment Proposal by the Exercise Outside Date. There can be no certainty, nor can the Company provide any assurance, that Canopy USA’s managementthese conditions will be able to integrate the operations of each of the businesses successfullysatisfied or, achieve any of the synergies or other benefits thatif satisfied, when they will be satisfied. If such conditions precedent are anticipated.

Operational and strategic decisions with respect to the integration of Acreage, Wana and Jetty have not yet been made andsatisfied, it may present challenges. It is possible that the integration process could result in the lossacquisition of key employees, the disruption of the respective ongoing businesses or inconsistencies in standards, controls, procedures and policies that adversely affect the ability of management to maintain relationships with clients, suppliers, employees or to achieve the anticipated benefits. The performance of Canopy USA could be adversely affected if Canopy USA cannot retain key employees. As a result of these factors, it is possible that certain benefits expected from the formation of Canopy USA mayAcreage not be realized. Any inability of Canopy USA’s management to successfully integrate the operations could have a material adverse effect on our business, financial condition and results of operations.being completed.

Canopy USA may divert the attention of our management, impact our ability to attract or retain key personnel or impact third party business relationships.

The attention of our management may be diverted from the day-to-day operations of Canopy Growth in connection with the transactions that may be entered into between us and Canopy USA. These disruptions could be exacerbated by delays in completing certain transactions and could result in lost opportunities or negative impacts on performance, which could have a material and adverse effect on our current and future business, operations, financial condition and results of operations or prospects. As a result of the uncertainty, certain of our officers and employees may experience uncertainty about their future roles, which may adversely affect our ability to attract or retain key management and personnel.

In addition, third parties with which we currently have business relationships, including banks, industry partners, customers and suppliers, may experience uncertainty associated with our U.S. strategy, including with respect to maintaining current or future relationships with us. While we believe, based on the advice of our legal advisors, that we currently comply with all applicable laws and regulations and that we will remain in compliance in the event that Canopy USA acquires Acreage, Wana or Jetty, exercises the Cultiv8 Option or converts the TerrAscend Exchangeable Shares into common shares of TerrAscend, there is a risk that our interpretation of laws, regulations, and guidelines, may differ from those of others, including those of our banks, industry partners, customers and suppliers. Such uncertainty could have a material and adverse effect on our current and future business, operations, results of operations, financial condition and prospects.

We have not received audited financial statements with respect to Jetty.

The current financial information regarding Jetty that management has reviewed was prepared from Jetty’s internal management accounts. These internal management accounts and other information provided by Jetty has not been audited, reviewed, compiled, examined or subject to any procedures by an independent public accountant, and Canopy Growth has not independently verified the management accounts or the related financial information provided by Jetty. In addition, actual results for such periods may not be indicative of future results.

While the Company understands that Jetty is working to produce audited financial statements, the Company has not received such audited financial statements to date. These audited financial statements may include financial results that are different than or less positive than the unaudited financial information for Jetty that has been provided to the Company.

80


 

Acreage’s financial statements express doubt about its ability to continue as a going concern.

 

Acreage’s publicly available audited financial statements as of and for three years ended December 31, 2021 and its publicly available financial statements as of and for the nine months ended September 30, 20222023 filed with the SEC on November 14, 2023 (“Acreage’s September 30, 20222023 Interim Financial Statements”) express doubt about Acreage’s ability to continue as a going concern. In particular, Acreage’s September 30, 20222023 Interim Financial Statements state: “[Acreage] had an accumulated deficit as of September 30, 2022,2023, as well as a net loss and negative cash flow from operating activities for the nine months ended September 30, 2022.2023. Additionally, subsequent to quarter end [Acreage] was temporarily in default of the [Hempco Debenture, pursuant to which a subsidiary of Acreage owed approximately $46.8 million to a subsidiary of Canopy Growth as of September 30, 2023][. . .] These factors raise substantial doubt about [Acreage]’s ability to continue as a going concern for at least one year from [November 9, 2022, which is the date Acreage filed its quarterly report on Form 10-Q with the SEC and issued itsissuance of these financial statements].statements.” In the event that Acreage is unable to continue as a going concern, the Acreage Amended Arrangement and the Floating Share Arrangement may not be completed. In the event that the Acreage Amended Acreage Arrangement and the Floating Share Arrangement are completed and Acreage is unable to continue as a going concern, this would have a negative impact on Canopy USA’s business, financial results and operations and have an adverse impact on the Company’s United States strategy, and, ultimately, the Company’s financial results and operations.

 

The Exchangeable Shares have different rights from the common shares and there may never be a trading market for the Exchangeable Shares.78


 

If the Amendment Proposal is approved, shareholders will have the option to convert their common shares into Exchangeable Shares. There are important differences between the rightsIn view of the common sharesforegoing, Acreage’s continuation as a going concern is dependent upon its continued operations, which in turn is dependent upon, among other things, Acreage’s ability to meet its financial requirements. There is no assurance that Acreage will be successful in its plans to fund its operations and debt obligations as they become due and payable. Accordingly, in the event Acreage cannot satisfy its debt obligations as they become due, we may lose the Option Premium. In addition, Acreage may be required to terminate or significantly curtail its operations or enter into arrangements with third parties that may require Acreage to relinquish rights to certain aspects of its business and/or dispose of certain assets, which may ultimately result in Acreage not being able to satisfy the conditions in the Amended Acreage Arrangement and the Exchangeable Shares. While each ExchangeableFloating Share is convertible into a common share,Arrangement and the Exchangeable Shares willacquisition of Acreage not carry voting rights, rights to receive dividends or other rights upon dissolution. For example, holders of Exchangeable Shares will not be able to exercise voting rights at meetings of shareholders and will not receive distributions if dividends are declared by our Board. The differences between the rights of holders of the Exchangeable Shares and common shares are significant and may materially and adversely affect the market value of your investment.being completed.

Presently, there are no plans to list the Exchangeable Shares on a securities exchange or in the over-the-counter market, and there is not expected to be a market for trading of the Exchangeable Shares. Thus, persons holding Exchangeable Shares will likely have no ability to sell their Exchangeable Shares and will likely have to exchange them for common shares in order to have any liquidity.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

 

None.

 

Item 3. Defaults Upon Senior Securities.

 

None.

 

Item 4. Mine Safety Disclosures.

 

Not applicable.

 

Item 5. Other Information.

 

On February 9, 2023, the Company announced a seriesResignation of comprehensive steps to align its Canadian cannabis operations and resources in response to unfavorable market realities. These actions were approved on February 8, 2023, and include:Robert Hanson

 

TransitioningOn February 6, 2024, Robert Hanson provided notice to an asset-light model by: (i) exiting cannabis flower cultivation in the Company's Smiths Falls, Ontario facility; (ii) ceasing the sourcingCompany of cannabis flowerhis decision to resign from the Company's Mirabel, Quebec facility; and (iii) consolidating cultivation at the Company's existing facilities in Kincardine, Ontario and Kelowna, British Columbia;
Moving to an adaptive third-party sourcing model for all cannabis beverages, edibles, vapes, and extracts which will enableBoard of the Company, to selecteffective the same date. Mr. Hanson served as a member of the Corporate Governance, Compensation and bring to market new product formats withoutNominating Committee of the required investment in research and development and production footprint;
As aBoard. Mr. Hanson’s resignation from the Board was not the result of the aforementioned changes,any disagreement with the Company intendson any matter relating to consolidate flower, pre-rolled joints, softgel, and oil manufacturing in the Company’s current beverage production facility in Smiths Falls, Ontario and reduce headcount across the business; and
operations, policies or practices.
The Company intends to close the 1 Hershey Drive facility in Smiths Falls, Ontario and the Company is in active discussions with respect to restructuring the joint-venture entity which holds the cultivation facility in Mirabel, Quebec.

 

81Appointments of Luc Mongeau and Willy Kruh


 

AsOn February 7, 2024, on the recommendation of the Corporate Governance, Compensation and Nominating Committee the Board voted to increase the size of the Board to eight members and appoint each of Mr. Luc Mongeau and Mr. Willy Kruh to the Board effective immediately. Each of Mr. Mongeau and Mr. Kruh shall serve as a resultdirector of these actions, the Company expects to incur pre-tax chargesuntil the next annual general meeting of approximately $425 - $525 million, consisting of approximately $400 - $485 million of non-cash asset impairments relating to the impacted production sites in the fourth quartershareholders or until his earlier death, resignation, or removal. Mr. Kruh will serve as a member of the Company’s fiscal year ending March 31, 2023. The remaining charges of up to $25 - $40 million are cash charges primarily attributable to employee severance, contractAudit Committee and existing obligation terminations, outside services and other related cash shutdown costs, which are expected to be substantially recorded in the fourth quarterMr. Mongeau will serve as a member of the Company’s fiscal year ending March 31, 2023Corporate Governance, Compensation and the first half of the Company’s fiscal year ending March 31, 2024.Nominating Committee.

 

The chargesBoard has determined that each of Mr. Mongeau and Mr. Kruh is independent under applicable Nasdaq listing rules. There is no arrangement or understanding between either of Mr. Mongeau and Mr. Kruh and any other person pursuant to which he was appointed as a director of the Company. There are no family relationships between each of Mr. Mongeau and Mr. Kruh and any director or executive officer of the Company expectsor its subsidiaries. Neither Mr. Mongeau nor Mr. Kruh have a direct or indirect material interest in any transaction that would require disclosure under Item 404(a) of Regulation S-K.

In accordance with the Company’s customary practice, the Company has entered into its standard form of indemnification agreement with each of Mr. Mongeau and Mr. Kruh, which requires the Company to incur inindemnify each director against certain liabilities that may arise as result of his status or service as a director. The Company’s Form of Director and Officer Indemnity Agreement is filed as Exhibit 10.1 to its Form 10-K for the fiscal year ended March 31, 2022, which was filed with the SEC on May 31, 2022.

In connection with these actions are preliminary estimatesthe appointments to the Board, each of Mr. Mongeau and are subject toMr. Kruh will be compensated in accordance with the Company’s director compensation program as described in the Company’s filings with the SEC.

Rule 10b5-1 Trading Arrangements

During the three months ended December 31, 2023, no director or officer (as defined in Rule 16a-1(f) of the Exchange Act) informed us of the adoption or termination of a number“Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement”, as each term is defined in Item 408(c) of assumptions and risks, and actual results may differ materially. The Company may also incur other material charges not currently contemplated due to events that may occur as a result of, or in connection with, these actions.Regulation S-K.

79


 

Item 6. Exhibits.

 

Exhibit

Number

Description

 

 

 

3.1

 

Certificate of Incorporation and Articles of Amendment of Canopy Growth Corporation (incorporated by reference to Exhibit 3.1 to the Company’s Annual Report on Form 10-K for the year ended March 31, 2020, filed with the SEC on June 1, 2020).

 

 

 

3.2

 

Amendment to Articles of Canopy Growth Corporation (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed with the SEC on December 18, 2023).

3.3

Bylaws of Canopy Growth Corporation (incorporated by reference to Exhibit 3.2 to the Company’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2021, filed with the SEC on November 8, 2021).

 

 

 

10.1

 

ConsentFifth Amendment to Arrangement Agreement, dated October 24, 2022December 29, 2023, by and between CBG Holdings LLC, Greenstar Canada Investment Limited Partnership andamong Canopy Growth Corporation, Canopy USA, LLC and Acreage Holdings, Inc. (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed with the SEC on October 26, 2022)January 2, 2024).

 

 

 

10.210.2*

 

Voting Support Agreement dated October 24, 2022 bySecond Amended and between CBG Holdings LLC, Greenstar Canada Investment Limited Partnership and Canopy Growth Corporation (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K, filed with the SEC on October 26, 2022).

10.3

Floating Share Arrangement Agreement dated October 24, 2022 by and among Canopy Growth Corporation, Canopy USA, LLC and Acreage Holdings, Inc. (incorporated by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K, filed with the SEC on October 26, 2022).

10.4+

Amendment No. 1 to CreditRestated Protection Agreement, dated as of October 24, 2022, between Canopy Growth Corporation, 11065220 Canada Inc., the lenders party thereto and Wilmington Trust, National Association (incorporated by reference to Exhibit 10.4 to the Company’s Current Report on Form 8-K, filed with the SEC on October 26, 2022).

10.5

Letter Agreement, dated October 24, 2022, by and among 11065220 Canada Inc., AFC Gamma Inc., Viridescent Realty Trust, Inc. and AFC Institutional Fund LLC (incorporated by reference to Exhibit 10.5 to the Company’s Current Report on Form 8-K, filed with the SEC on October 26, 2022).

10.6*+

Protection Agreement, dated October 24, 2022,January 25, 2024, by and among Canopy USA, LLC, 11065220 Canada Inc. and Canopy Growth Corporation

10.7*+

Limited Liability Company Agreement of Canopy USA, LLCCorporation.

 

 

 

31.1*

Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

 

 

 

31.2*

Certification of Principal Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

 

 

 

32.1**

Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 

 

32.2**

Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 

 

101.INS

XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document

101.SCH

 

Inline XBRL Taxonomy Extension Schema Document

82


101.CAL

Inline XBRL Taxonomy Extension CalculationWith Embedded Linkbase Document

101.DEF

Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB

Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE

Inline XBRL Taxonomy Extension Presentation Linkbase DocumentDocuments

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

* Filed herewith.

** This exhibit shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that Section. Such exhibit shall not be deemed incorporated into any filing under the Securities Act or the Exchange Act.

+ Portions of this exhibit are redacted pursuant to Item 601(b)(10)(iv) of Regulation S-K.

The agreements and other documents filed as exhibits to this report are not intended to provide factual information or other disclosure other than with respect to the terms of the agreements or other documents themselves, and you should not rely on them for that purpose. In particular, any representations and warranties made by us in these agreements or other documents were made solely within the specific context of the relevant agreement or document and may not describe the actual state of affairs as of the date they were made or at any other time.

8380


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

CANOPY GROWTH CORPORATION

Date: February 9, 20232024

By:

/s/ David Klein

David Klein

Chief Executive Officer

(Principal Executive Officer)

 

Date: February 9, 20232024

By:

/s/ Judy Hong

Judy Hong

Chief Financial Officer

(Principal Financial Officer)

 

8481